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ABSTRACT 
Psoriatic arthritis (PsA) is a chronic heterogenous inflammatory arthritis with five 
phenotypes. The two least studied phenotypes are investigated in this thesis, including: 
psoriatic spondyloarthropathy (PsSpA) and psoriatic arthritis mutilans (PAM). The aims of 
this thesis were to determine the prevalence, clinical characteristics and radiographic 
characteristics of PsSpA and PAM in a cohort of PsA patients, and serum-soluble bone-
turnover biomarkers of these phenotypes. Comparisons were made with PsA patients 
without axial disease (pPsA), and ankylosing spondylitis (AS) patients. 
 
A prospective single-centre cross-sectional study was conducted of PsA and AS patients. 
Serum on psoriasis-only patients (PsC) and healthy controls (HC) were also obtained. 
Multivariate clinical, radiographic, genetic and serum biomarker comparisons were made 
between these five groups of subjects. 
 
The study enrolled 201 PsA and 201 AS patients, who were then reclassified as 118 
PsSpA, 127 pPsA and 157 AS cases, alongside 200 PsC and 50 HC subjects. Several 
clinical biomarkers, imaging biomarkers, serum-soluble biomarkers and genetic 
biomarkers were identified that differentiate PsSpA from pPsA and AS. PsSpA affected a 
significant proportion of PsA patients, and was not a milder version of AS. PsSpA 
involvement was as disabling and clinically impactful as AS. PAM was found to be 
associated with PsSpA, and clinical biomarkers of PAM occurrence and radiographic 
progression were identified.  
 
In conclusion, this thesis indicates that PsSpA is on a spectrum of musculoskeletal 
disease, in between pPsA and AS; with PsSpA comprising a continuum itself, and with a 
phenotype expression related to disease duration. These findings may prompt the 
inception of an international-consensus classification system for PsSpA, for which there is 
a great clinical need. Given that PsSpA has its own discrete clinical and biomarker 
signature, its clinical management and research should be tailored from that of pPsA and 
AS. Ultimately this may further the effort for stratified and personalised medicine. 
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1 CHAPTER I: INTRODUCTION 
 
This thesis aims to determine biomarkers of psoriatic arthritis (PsA) phenotypes. In 
particular, I will investigate serum-soluble bone-turnover biomarkers of both occurrence 
and severity of two subsets of PsA: psoriatic spondyloarthritis (PsSpA) and psoriatic 
arthritis mutilans (PAM).  
 
The aims will be achieved through a review of the current literature, followed by the 
enrolment and clinical assessment of a cohort of patients as part of a prospective cross-
sectional single-centre observational study. 
 
PsA, PsA subsets, related conditions including ankylosing spondylitis (AS), and the 
systems that have been devised and employed to classify these clinically overlapping 
conditions will be described briefly in this chapter. Biomarker research is currently very 
topical in rheumatology research globally; so the importance and utility of biomarkers in 
PsA will also be outlined here. More detailed descriptions of each sub-study are provided 
in related chapters, that combine the thesis. 
 
1.1 PSORIATIC ARTHRITIS 
PsA is a chronic inflammatory musculoskeletal disease usually accompanied by 
cutaneous psoriasis. PsA has clinical, radiological and immuno-pathogenic features 
distinct to other forms of arthritis.  
 
Psoriasis is a chronic inflammatory skin condition characterised by red scaly patches 
commonly on the elbows, knees, trunk and scalp. There are several potential reports of 
cutaneous psoriasis in the historical literature, but it is difficult to know for certain since 
psoriasis can be confused with leprosy. For example, the Ebers papyrus found in Luxor in 
1873, and written in the 15th century B.C., cites numerous skin diseases, and uses the 
term šuf.t (translated as ‘scale’) [1]. The Charaka Samitha, a book from Indian ayurvedic 
medicine, describes a disease named ‘khusta’, which has been proposed as being either 
psoriasis or leprosy [2]. Hippocrates in the 5th century B.C., used the word ‘psora’ for itchy 
lesions of the eyelids and genitals, and for which he recommended tars and climate as 
treatment [3]. The most convincing earliest report of psoriasis came in the 1st century A.D. 
series of books by A. Cornelius Celsus, De re Medica Libri Octo [4]. He described 
psoriasis as impetigo appearing on the skin of the extremities and nails, and managed 
with medications containing pitch and sulphur. 
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The association of inflammatory arthritis and cutaneous psoriasis is accredited to a report 
in 1822 by a French dermatologist, Jean-Louis Alibert, working at the Hospital of St. Louis 
in Paris dedicated to skin diseases [5] (Figure 1.1). The condition was later termed 
'Psoriasis Arthritique' in 1860 by another French dermatologist in Paris, Pierre-Antoine-
Ernest Bazin [6] (Figure 1.1). Only in 1964, with the advent of rheumatoid factor (RF) 
testing, and the observation that RF was rarely present in PsA patients, was the condition 
first recognised by the Arthritis and Rheumatism Association of North America [7], 




Figure 1.1. Founding fathers of the study of psoriatic arthritis 
Jean-Louis Alibert (1768-1837) [left], and Pierre-Antoine-Ernest Bazin (1807-1878) [right] 
 
 
1.1.1 Epidemiology of PsA 
 
PsA affects women and men equally [8-11], and tends to present between the ages of 30 
and 50 (median 48) years [11]. In the U.K. population, the prevalence of psoriasis is 
estimated to be 2 per 100 of the population [12], and the prevalence of PsA to be 1 - 2.5 
per 1000 of the population [9, 13]. The prevalence of PsA among psoriasis cases in two 
large primary care cohorts in the U.K. was 13.8% [10]. The incidence of PsA in the 
general population is estimated to be 6 cases per 100,000 per year [9, 13-15]. A 
prospective study of 313 psoriasis patients without arthritis (PsC) followed over four years, 
found an annual incidence of newly diagnosed arthritis of 1.87 (95% CI 0.71, 3.03) cases 
per 100 psoriasis cases per year [16]. Predictors of incident arthritis in PsC patients 
included the severity of psoriasis, the presence of nail lesions, and the presence of scalp 
and inter-gluteal lesions [16]. 
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1.1.2 Presentation of PsA 
 
PsA patients characteristically present with inflammatory early-morning musculoskeletal 
stiffness lasting at least thirty minutes, pain affecting peripheral joints (commonly hands, 
wrists, knees, ankles and feet), enthesitis (inflammation of tendon, ligament or joint 
capsule attachment to bone), tenosynovitis (inflammation of the sheath around tendons), 
inflammatory spinal pain (termed spondylitis), and dactylitis (inflammation of the joint, 
tendons, enthesis and subcutaneous tissues) [8]. Peripheral joints are often affected in an 
asymmetric manner [17].  
 
Five distinct patterns of PsA presentation were originally described by Moll and Wright, 
based upon clinical and radiographic characteristics [18]:  
• symmetric polyarthritis (five or more affected joints; 15% prevalence)  
• asymmetric oligoarthritis (four or fewer affected joints; 70% prevalence) 
• distal interphalangeal joint (DIPJ) predominant (affecting the joint at the end of 
fingers; 5% prevalence) 
• psoriatic spondyloarthropathy (PsSpA; 5% prevalence) 
• psoriatic arthritis mutilans (PAM; 5% prevalence)  
 
Patients can migrate between subsets, or have two subsets concomitantly during the 
course of their disease [19]. Oligoarthritis and polyarthritis are the most common subsets 
of PsA [20], whilst PAM is the rarest albeit most destructive form of PsA. Peripheral PsA is 
characterised radiologically by articular (pertaining to the joint) bone destruction (erosion), 
articular cartilage destruction (joint space narrowing), and articular new bone formation 
(osteoproliferation). 
 
Cutaneous psoriasis usually precedes the onset of arthritis in PsA (70%), but in 15% of 
individuals the arthritis precedes psoriasis, and in a further 15% of individuals psoriasis is 
present at the time of arthritis onset, but not detected by the clinician [8, 21]. PsA patients 
are prone to psoriatic nail disease (dystrophy) that is indistinguishable from that seen in 
those with psoriasis-only [22]. Of note, the prevalence of psoriatic nail dystrophy is more 
common in PsA (especially in those with DIPJ arthritis) than in psoriasis alone [23].  
  
Other extra-articular manifestations can include uveitis and inflammatory bowel disease 
(IBD). Uveitis presents as a painful red eye, and is likely related to inflammation of the 
entheseal structure within the eye. IBD is a chronic inflammatory condition of the 
gastrointestinal system manifesting as bloody diarrhoea and weight loss, with ulcerative 
colitis and Crohn’s disease being the two most common forms. 
  20  
1.1.3 Investigation and diagnosis of PsA 
 
There are no diagnostic criteria or laboratory tests specific to PsA. A diagnosis of PsA is 
usually made on the basis of an inflammatory arthritis accompanying psoriatic skin and / 
or nail disease, in a characteristic distribution, accompanied by enthesitis and / or 
tenosynovitis usually in the absence of rheumatoid factor.  
 
The Classification for Psoriatic Arthritis (CASPAR) criteria were devised in 2006 to aid the 
classification of participants enrolled in research studies (Table 1.1) [24]. The CASPAR 
criteria comprise a stem mandating inflammatory peripheral / axial arthritis or enthesitis, 
accompanied by at least three of the following features: psoriasis (current psoriasis 
scoring two points, previous psoriasis scoring one point, or family history of psoriasis 
scoring one point); dactylitis; psoriatic nail dystrophy; negative rheumatoid factor serology; 
and / or osteoproliferation on peripheral radiographs. The sensitivity and specificity of the 
CASPAR criteria are 91.4% and 98.7%, respectively [24]. 
 
 
Table 1.1. ClAsification criteria for Psoriatic Arthritis (CASPAR) criteria  
(from Taylor et al. 2005 [24]) 
 
A patient must have inflammatory articular disease (joint, spine, or entheseal) with ≥3 points from the following 
5 categories:  
i) Evidence of current psoriasis, a personal history of psoriasis, or a family history of psoriasis.  Current 
psoriasis is defined as psoriatic skin or scalp disease present today as judged by a rheumatologist or 
dermatologist.*  
(A personal history of psoriasis is defined as a history of psoriasis that may be obtained from a patient, family 
physician, dermatologist, rheumatologist, or other qualified health care provider. A family history of psoriasis is 
defined as a history of psoriasis in a first- or second-degree relative according to patient report). 
ii) Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current 
physical examination. 
iii) A negative test result for the presence of rheumatoid factor by any method except latex but preferably by 
enzyme-linked immunosorbent assay or nephelometry, according to the local laboratory reference range. 
iv) Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a 
rheumatologist. 
v) Radiographic evidence of juxta-articular new bone formation, appearing as ill-defined ossification near joint 
margins (but excluding osteophyte formation) on plain radiographs of the hand or foot.   
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1.1.4 Management of PsA 
 
Patients with mild PsA are managed with non-steroidal anti-inflammatory drugs (NSAIDs), 
simple analgesia, physiotherapy, occupational therapy, education and support. Moderate 
to severe PsA cases require more intensive therapy with synthetic (e.g. methotrexate, 
sulfasalazine, and leflunomide) and / or biologic (anti-tumour necrosis factor-alpha drugs, 
anti-TNF; and interleukin 23 / 12 inhibitors) disease modifying anti-rheumatic drugs 
(DMARDs) [25, 26].  
 
1.1.5 Prognosis of PsA 
 
As there is no cure for PsA, long-term pharmacologic and physical therapies are required 
to slow and / or halt the progression of disease [25]. Two years after the diagnosis of PsA, 
47% of cases are reported to have peripheral radiographic erosions, and 56% require the 
use of DMARDs [8]. In another study, over a period five year from presentation, the 
majority of cases showed progression in the number of joints affected and 68% had 
peripheral radiographic erosions [19]. In a study from Toronto (Canada) of 391 PsA cases, 
18% achieved remission with use of DMARDs; remission lasted a mean of 2.9 (standard 
deviation, SD 1.7) years, but the majority (52%) of patients had a relapse within a mean of 
1.8 (SD 1.3) years [27]. Predictors of severe peripheral disease in PsA include: female 
sex [28, 29]; high acute phase response at diagnosis or during disease course [19, 30]; 
high number of actively inflamed joints at presentation [29, 31, 32]; and a delay in 
receiving specialist care of greater than two years [33]. 
 
There is emerging evidence that patients with PsA are at increased risk for cardiovascular 
disease and / or death. One study reported a significant increased risk of myocardial 
infarction (standardised prevalence ratios, SPR 2.57; 95% CI 1.73, 3.80), angina (SPR 
1.97; 95% CI 1.24, 3.12), and hypertension (SPR 1.90; 95% CI 1.59, 2.27), in patients 
with PsA compared with the general population, particularly in those with more severe 
cutaneous psoriasis, diabetes, and dyslipidaemia [34]. The risk of cardiovascular-related 
death in PsA compared with the general population is less certain, with conflicting reports. 
Conflicting data exist concerning the association between PsA and increased mortality [9, 
35, 36]. There was no significant difference in mortality risk in a cohort of 453 patients with 
PsA followed in a single-centre in Bath (UK) compared with the general population of the 
UK (standardised mortality ratio 81.82; 95% CI 57.61, 112.78) [35]. 
 
Work disability is high in patients with PsA. A recent systematic literature review found 
that levels of unemployment range between 20 to 50% and work disability ranges from 16 
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to 39%, and can be in the form of absenteeism (unable to attend work due to symptoms 
related to PsA) and presenteeism (present at work but not working to full capacity due to 
symptoms related to PsA) [37]. Several factors have been shown to be associated with 
work disability in PsA, including longer disease duration, worse physical function, high 
joint count, low educational level, female gender, erosive disease and manual work [37]. 
The same systematic review identified some evidence that work disability is worse in 
those with PsA than those with psoriasis alone [37]. A large prospective multi-centre UK 
study of work disability reported that reduced effectiveness at work in PsA patients was 
associated with measures of disease activity, whilst unemployment was associated with 
employer factors, age and disease duration [38]. 
 
1.2 SPONDYLOARTHRITIS 
Spondyloarthritis (SpA) is the term encompassing a family of conditions with shared 
clinical manifestations, and is characterised by inflammatory axial disease, extra-articular 
manifestations, and often peripheral arthritis. Axial structures include the spine, sacroiliac 
joints (SIJs) and pelvis. Inflammatory axial disease manifests as inflammatory back pain 
and stiffness that is worse in the morning, exacerbated by rest, and improved by both 
activity and NSAIDs. SpA is characterised by inflammation of the SIJ(s) that bridge the 
sacrum (tail bone) and ilium of the pelvis (resulting in sacroiliitis), and / or the vertebral 
bodies (resulting in spondylitis). Sacroiliitis is inflammation of the lower third of the SIJ, 
where it is primarily a synovial joint. Spondylitis is inflammation of the interface between 
vertebral bodies and adjacent structures, such as intervertebral discs, ligaments and joint 
capsules. Inflammation of the SIJ(s) can results in osteoproliferation, with bridging of bone 
across the joint (ankylosis) leading, in severe cases, to fusion of the joints. Inflammation of 
the entheses can result in osteoproliferation at the corner of vertebral bodies, resulting in 
fine bone growths termed syndesmophytes (Figure 1.2). Both SIJ ankylosis and vertebral 
syndesmophytes result in pain, stiffness and restricted range of movement.  
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Figure 1.2. Vertebral syndesmophyte morphology 
Bridging (right) and non-bridging (left) para-marginal syndesmophytes of the vertebra 




Conditions within the continuum of SpA include: PsA, ankylosing spondylitis (AS), reactive 
arthritis, spondyloarthritis (SpA) associated with inflammatory bowel disease (IBD), 





Figure 1.3. The spectrum of spondyloarthritis 
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1.3 ANKYLOSING SPONDYLITIS 
Ankylosing spondylitis (AS) is the prototypical SpA. AS usually presents in the second to 
fourth decade of life, and the prevalence of AS is approximately three times higher in 
males [40]. It has a strong genetic component, with up to 95% of patients carrying variants 
of the human leucocyte antigen (HLA)-B27 [41].  
 
1.3.1 Presentation of AS 
 
AS presents with inflammatory axial pain, early morning stiffness that can wake from 
sleep, restricted range of movement, sacroiliitis manifesting as alternating buttock pain, 
usually spondylitis manifesting as spinal pain, occasional peripheral oligoarthritis, and 
extra-articular manifestations such as enthesitis, uveitis (painful inflammation of the eye) 
and IBD [41, 42].   
 
1.3.2 Investigation and diagnosis of AS 
 
The modified New York (mNY) criteria for diagnosing AS were devised in 1984 [43]. 
These criteria comprise a stem requiring the exclusion of spinal fracture, intervertebral 
disc disease and fibromyalgia as the cause of axial symptoms. A patient must then have 
plain radiographic sacroiliitis (grade ≥3 unilaterally or ≥2 bilaterally) and ≥1 of the following 
three clinical criterion: insidious onset inflammatory low back pain and stiffness of at least 
three months duration that improves with exercise and is not relieved by rest; limitation of 
motion of the lumbar spine in both the sagittal and frontal planes; and / or limitation of 
chest expansion relative to normal values correlated for age and sex [43].  
 
1.3.3 Management of AS 
 
AS is a chronic progressive condition, without cure, and managed primarily with 
physiotherapy, occupational therapy, hydrotherapy, NSAIDs, and anti-TNF therapy [40, 
42].  
 
Predictors of severe disease in AS include: axial syndesmophytes at presentation; high 
acute phase response at presentation; reduced range of movement of the lumbar spine; 
poor NSAID response; dactylitis or oligoarthritis; tobacco smoking; onset before the age of 
16 years; and early hip involvement [44-47]. 
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1.4 PSORIATIC SPONDYLOARTHRITIS 
Psoriatic spondyloarthritis (PsSpA) is a more precise term for SpA accompanying 
psoriasis. PsSpA shares clinical features of both PsA and AS. PsSpA patients have 
predominantly axial symptoms, but a significant proportion have concomitant peripheral 
arthritis and enthesitis.  
 
Some propose that isolated radiographic features alone may be sufficient to classify a 
patient as PsSpA [48], arguing that PsSpA patients often do not have a history of 
inflammatory axial symptoms [49]; in essence a symptomatically-silent form of 
radiographic-PsSpA.  
 
The association between psoriasis and AS was first reported in 1928 by Zellner [50]. After 
a number of case series supporting this association, Fletcher and Rose coined the term 
'psoriasis spondylitica' in the Lancet journal in 1955 [51]. In 1961 Wright reported that 
radiographic sacroiliitis was more common in PsA patients compared with RA patients 
[52]. Later the same year, Dixon et al. published a paper demonstrating a higher 
prevalence of radiographic sacroiliitis in PsA patients compared with a group of controls 
[53]. Three years later, Kaplan et al. added to the canon of knowledge with the 
observation that facet joint narrowing / sclerosis and anterior ligamentous calcification in 
the cervical spine were common in patients with psoriasis, even in those without 
peripheral arthritis [54]. They observed that changes were indistinguishable from AS, and 
that the lumbar spine and SIJs were not always affected. In 1965, Bywaters et al. 
proposed that PsSpA patients demonstrate para-marginal syndesmophytes (PMS; thorn-
like and angulated), which are different in shape and location to the marginal 
syndesmophytes (MS; slim and vertical) seen in AS, and may therefore help distinguish 
PsSpA and AS radiographically [55]. 
 
Example plain radiographs from healthy individuals are shown in Figure 1.4, and 
pathological plain radiographs from patients with PsA and AS are shown in Figures 1.5, 
1.6 and 1.7. 
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Figure 1.4. Normal radiographs of the axial skeleton  
Cervical spine (lateral view) [top-left image], lumbar spine (antero-posterior and lateral 
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Figure 1.5. Plain radiographs of the lateral cervical spine  
Showing syndesmophytes in PsSpA (left & middle images; broad-based thorn-like & 
diagonal orientation) and AS (right image; narrow slim vertical orientation). The right image 
also shows multi-level flowing facet joint fusion in AS (diagonal arrow). 
 
 
Figure 1.6. Plain radiographs of the lateral lumbar spine  
Showing syndesmophytes in PsSpA (left & middle images; broad-based thorn-like & 
diagonal orientation) and AS (right image; narrow slim vertical orientation). 
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Figure 1.7. Plain radiographs of the sacroiliac joints (SIJs)  
Showing: bilateral SIJ sclerosis and erosions in PsSpA [upper image]; and bilateral 
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1.4.1 Classification of PsSpA and AS 
 
The classification of PsSpA has been somewhat neglected, and there is no internationally-
recognised consensus on the best classification to use either in clinical practice or for 
research studies. As is discussed below, this is not due to a lack of effort or recognition of 
the importance to do so, but is in large part due to a lack of research investigating the 
clinical, radiographic and biomarker characteristics of PsSpA, and how they compare with 
AS. Only through further research will it be possible to devise a robust classification 
system, for the benefit of patients clinically and for research. 
 
The CASPAR classification criteria are used to classify PsA patients for research studies 
[24], and the 1984 modified New York (mNY) diagnostic criteria are used to diagnose AS 
[43]. However, no classification or diagnostic criteria exist for PsSpA, who are left to be 
captured by one, but sometimes neither of these two classification systems. The CASPAR 
classification system was devised using PsA cohorts with a predominantly peripheral 
phenotype (pPsA) [24]. Relatively little clinical and radiographic data was available in 
terms of the presence or absence of axial disease. As a result the CASPAR criteria 
perform well classifying pPsA patients (sensitivity 98.2%, specificity 99.1%) but did not 
have the remit to capture PsSpA patients [24]. It was assumed that such PsSpA patients 
would be captured by the mNY diagnostic criteria for AS. However, clinical experience 
and research studies show that PsSpA cases have a different clinico-radiographic 
expression to AS and may therefore not fulfil mNY criteria for AS [56-59]. Some PsSpA 
cases experiencing significant clinical impact from their axial disease therefore remain 
unclassified. This may have an impact on a patient’s management, especially once they 
have more active disease refractory to first and second-line treatment. For example, some 
PsA patients are denied escalation of therapy to anti-TNF therapy because they have 
predominantly axial symptoms, and do not fulfil the peripheral-weighted PsA criteria for 
anti-TNF, that requires them to have at least three tender or at least three swollen joints. 
Conversely, some AS patients are denied escalation of therapy to anti-TNF therapy 
because they have predominantly peripheral symptoms and do not fulfil the axial-weighted 
AS criteria for anti-TNF that require them to have a BASDAI of at least 4/10 and pain 
score of at least 4/10. In such circumstances exceptional funding for anti-TNF can be 
sought  on named individual basis, but this may result in variability in the provision of anti-
TNF between hospital and geographic regions.  
 
Taylor et al. reviewed the differences between PsA, AS, enteropathic SpA (eSpA), and 
SpA related to reactive arthritis (reSpA) [57]. They proposed that both symptoms and 
radiographics (spine and SIJs) must be considered together to capture the totality of axial 
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manifestations in PsA. Unfortunately, studies of axial disease in PsA have classified 
PsSpA using a variety of systems. Some have classified patients as PsSpA based upon 
isolated unilateral grade ≥2 sacroiliitis, whilst other studies have used a more stringent 
classification in keeping with that used to classify AS patients: radiographic sacroiliitis of 
grade ≥3 unilaterally, or grade ≥2 bilaterally. Some studies have classified patients as 
PsSpA based upon symptomatic back pain with restricted range of movement, one 
isolated syndesmophyte, or a combination of clinical and radiographic features [48]. Some 
studies have used the European Spondyloarthropathy Study Group (ESSG) criteria [60]. 
The ESSG criteria require: inflammatory spinal pain or synovitis (asymmetric or 
predominantly in the lower limbs), together with at least one of the following: positive 
family history, psoriasis, inflammatory bowel disease, urethritis, or acute diarrhea, 
alternating buttock pain, enthesopathy, or sacroiliitis as determined from radiography of 
the pelvic region. Whilst the ESSG criteria have a sensitivity of 87% and a specificity of 
87% for SpA [60], they have not shown good specificity or sensitivity for PsSpA [24, 57]. 
 
If the classification employed for PsSpA is that of the 1984 modified New York criteria, 
which requires radiographic sacroiliitis, then PsSpA cases with vertebral spondylitis but no 
sacroiliac changes, would be overlooked. Taylor et al. (2004) have proposed vertebral 
spondylitis without sacroiliitis to be a feature of PsSpA distinguishing it from AS [56]. 
 
One cannot robustly compare the severity of PsSpA and AS if the classification systems 
for each are not the same and restricted in certain ways. A study classifying PsSpA as 
unilateral sacroiliitis of grade ≥2 and / or ≥1 syndesmophyte of the spine, whilst classifying 
AS as bilateral sacroiliitis grade ≥2, or unilateral sacroiliitis grade ≥3, will by the entry 
criteria show PsSpA cases to be less radiographically severe than AS, and possibly 
clinically less severe as well. The most sensitive, specific and / or accurate classification 
system for PsSpA may be determined once we know: the proportion of psoriatics with 
unilateral grade 2 sacroiliitis demonstrating symptomatic and / or metrological evidence of 
axial disease; the proportion of such patients progressing to develop more extensive 
sacroiliitis or spondylitis; and the prevalence of grade 2 sacroiliitis in an otherwise healthy 
population [48]. This information may help determine whether unilateral grade 2 sacroiliitis 
is a ‘pre-PsSpA’, or simply an acceptable normal variant within the general population 
[48]. 
 
The different systems that have been used in studies to classify PsA patients as PsSpA, 
with decreasing order of stringency, are summarised in Table 1.2. 
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Table 1.2. Classification systems for psoriatic spondyloarthritis 
Study Classification criteria for psoriatic spondyloarthritis 
Helliwell et al. 1998 
[58] 
Cutaneous psoriasis and fulfilling 1984 modified New York diagnostic criteria for 
AS [43] (sacroiliitis of grade ≥2 bilaterally or grade ≥3 unilaterally; with decreased 
range of movement in two planes and inflammatory back pain). 
Chandran et al. 2010 
[61] 
Radiographic sacroiliitis (grade ≥2 bilaterally, or grade ≥3 unilaterally), with 
inflammatory spinal pain and / or limited spinal mobility. 
Leung et al. 2011 
[62] 
Radiographic sacroiliitis of grade ≥2 bilaterally, or grade ≥3 unilaterally. 
Gladman et al. 1993 
[49] 
Inflammatory back pain / stiffness; and / or sacroiliitis on clinical examination 
(Gaenslen test, Patrick-FABER test, or direct compression); and / or grade ≥2 
sacroiliitis; and / or ≥1 paramarginal syndesmophyte.  
Hanly et al. 1988 [63] Either inflammatory pain / stiffness of the spine, and / or clinical sacroiliitis disease 
(Gaenslen test, Patrick-FABER test, or direct compression), and / or sacroiliitis of 
grade ≥2 unilaterally. 
Fernandez-Sueiro et 
al. 2009 [64] 
Spinal symptoms (defined as a combination of inflammatory back pain plus back 
stiffness), and radiographic sacroiliitis grade ≥2 unilaterally. 
Battistone et al. 1999 
[65] 
Radiographic sacroiliitis grade ≥2 unilaterally. 
Lubrano et al. 2009 
[12]  
Meet CASPAR criteria for PsA [24], and the presence of clinical (axial 
inflammatory pain according to the Calin criteria [13]) and / or radiographic axial 
disease. 
Queiro et al. 2002 
[66] 
Spondyloarthritis according to the European Spondyloarthropathy Steering Group 
(ESSG) criteria, plus radiographic sacroiliitis. ESSG criteria require: inflammatory 
spinal pain or synovitis, together with at ≥1 of the following: positive family history, 
psoriasis, inflammatory bowel disease, urethritis, or acute diarrhea, alternating 
buttock pain, enthesopathy, or sacroiliitis as determined from radiography of the 
pelvic region [60].  
 
 
1.4.2 Prevalence of PsSpA in PsA cohorts 
 
The prevalence of PsSpA in PsA cohorts varies markedly from 25 to 70%, and is likely 
related to a number of factors. As described above, a number of different classification 
systems for PsSpA have been employed; some less stringent than others. Most of the 
studies have recruited participants of Caucasian ancestry, and only a few studies have 
recruited non-Caucasian patients, resulting in confounding; HLA-B27 variants are known 
to vary in populations of different ancestry, and HLA-B27 is important in the aetiology of 
PsSpA [62, 67]. Study design and sampling methods might also explain the wide estimate 
of prevalence. PsSpA is known to manifest several years after PsA onset, and studies 
have reported cohorts with quite different disease duration at assessment [49, 68]. 
Another reason is selection bias, e.g. specialist cohorts in tertiary referral centres having 
more severe or complex disease, compared with secondary-care centres. 
 
A study of 75 PsA patients from Bath (U.K.) published in 1994 found a high prevalence of 
cervical spine involvement: 45% of those examined and 36% of patients with radiographs 
[68]. Eighty five percent had a pattern of disease comprising of ankylosis, 
syndesmophytes and / or ligamentous ossification. ‘Silent’ radiographic cervical 
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spondylitis without clinical (symptomatic or examination) evidence of disease was present 
in 12% of cases.  
 
1.4.2.1 Prevalence of PsSpA in PsA cohorts using the 1984 mNY criteria for AS 
 
Studies classifying PsA cases as PsSpA using the mNY criteria for AS, have relatively 
consistent estimates of PsSpA prevalence. In a prospective cohort study by Chandran et 
al. (2010) of 206 PsA cases with a mean disease duration of 6.6 years at their first clinic 
visit, 50/206 (24%) were deemed to have PsSpA [61]. PsA patients were classified as 
PsSpA if they had radiographic sacroiliitis (grade ≥2 bilaterally, or grade ≥3 unilaterally), 
with inflammatory spinal pain and / or limited spinal mobility. In a cross-sectional study of 
125 PsA cases attending a tertiary referral hospital in Hong Kong (2011), a similar 
proportion (29/125; 24%) were classified as PsSpA using the same radiographic criteria, 
although did not include clinical criteria [62]. 
 
An earlier study by Hanly et al. of 220 PsA cases in Toronto (Canada), demonstrated a 
prevalence of PsSpA of 52/220 (24%) at entry to the cohort [63]. In addition, they found 
that the prevalence increased to 194/377 (52%) as the cohort was followed over a mean 
of 57 months [49]. 
 
1.4.2.2 Prevalence of PsSpA in PsA cohorts using less stringent criteria 
 
When less stringent criteria are used, especially those based on more subjective patient-
reported or clinical-examination rather than more robust imaging criteria, the estimated 
prevalence of PsSpA in PsA cohort varies more markedly. In a study of 130 PsA cases 
the prevalence of PsSpA was 40%, and the prevalence of sacroiliitis was 21% [69]. The 
definition of PsSpA was not detailed in the manuscript, and the paper was published in 
1977, prior to the advent of the 1984 modified New York criteria for AS. In addition, fewer 
than half the cohort (51/130) had a complete set of axial radiographs for review. Similarly, 
in a study of 498 PsA cases from Naples (Italy) published in 1988 [70], the prevalence of 
PsSpA was only 43/498 (11%) cases, defined clinically on the basis of Bennett and 
Wood’s suggestion [71]. The disease duration of these PsA patients was not stated, which 
is important, as others have shown that the prevalence of axial disease in PsA increases 
with increasing disease duration [49, 68]. 
 
A multi-centre study recruiting patients from North America as part of a randomised 
placebo-controlled trial comparing the efficacy of sulfasalazine for SpA, published a post-
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hoc analysis in 1999 of 221 PsA cases [65]. Pelvic radiographs, performed in all patients 
but interpretable in 202/221, were assessed by a blinded musculoskeletal radiologist for 
sacroiliitis using a less stringent definition (grade ≥2 unilaterally). Sacroiliitis was identified 
in 78% (157/202) of PsA cases. The prevalence of sacroiliitis decreased to 55% (112/202) 
when a more stringent definition was used (grade ≥3 unilaterally, or grade ≥2 bilaterally). 
Comparisons were made with other clinical parameters, using the less stringent definition 
of sacroiliitis, and likely explain the relatively low frequency of HLA-B27 positivity (17.2% 
of cases). However, a relatively high frequency of current inflammatory axial night pain 
(85%) was reported. The estimated prevalence of sacroiliitis of 55% is likely higher than 
reported by other studies because these PsA patients had more established disease 
(mean disease duration of 12 years) than those in other studies. 
 
In a cross-sectional Spanish study of 100 PsA and 103 AS cases, patients were classified 
as having PsSpA based on grade ≥2 unilateral sacroiliitis in the presence of spinal 
symptoms (defined as a combination of inflammatory back pain plus back stiffness) [64]. 
Using this less stringent criteria for PsSpA, 46/100 (46%) were classified as PsSpA, and 
54/100 as pPsA. Four PsA cases (4/100; 4%) were classified as having ‘pure-PsSpA’, 
without current peripheral arthritis. However, since a history of peripheral arthritis was not 
assessed by the investigators, the concept of ‘pure-PsSpA’ in this study was not robust 
and is therefore not a reliable estimate. 
 
1.5 PSORIATIC ARTHRITIS MUTILANS 
Psoriatic arthritis mutilans (PAM) is the rarest, albeit most destructive subtype of PsA. 
PAM is characterised by severe destruction of the joint and adjacent bone through erosion 
(small-scale destruction of bone) and subsequent osteolysis (large-scale destruction of 
bone along its length). As a result of lost bone stock and soft-tissue laxity, fingers and toes 
can shorten, giving rise to thick transverse folds of skin, and digits that can be elongated 
with traction [72] (Figures 1.8, 1.9 and 1.10). The prevalence of PAM is estimated to be 5 
per 100 PsA cases [14, 18, 73, 74]. The clinical and radiographic characteristics of PAM 
are discussed in more detail in Chapter 7 of this thesis. 
 
Given the significant bone destruction (resorption) and paradoxical osteoproliferation seen 
in PAM, I hypothesise that serum-soluble biomarkers of bone resorption and / or formation 
may associate with this extreme subphenotype of PsA. Since PAM is a rare subphenotype 
within PsA, and from clinical experience appears to be active for a relatively short period 
of time, followed by a protracted inactive ‘burnt-out’ state, it can be difficult to capture and 
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investigate. Most research cohorts of PsA around the world are relatively small, perhaps 
<200 cases, so few PAM cases are available for research. As a result, studies of PAM to 
date have been cross-sectional, with no longitudinal data [73-82]. Additionally, the natural 
clinical and / or radiographic history of PAM have never been described.  
 
 
Figure 1.8. Psoriatic arthritis mutilans - clinical images  
(Ventral [upper image] and dorsal [lower image] views of the hands of a patient with 
psoriatic arthritis mutilans demonstrating classical digit deformity and shortening, with 
secondary transverse fold of skin and soft-tissue) 
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Figure 1.9. Psoriatic arthritis mutilans of the hands - radiographic images  
(Characterised by osteolysis, erosion and joint space narrowing resulting in loss of bone 
stock, shortened and deformed digits, and the characteristic pencil-in-cup deformity 
affecting both thumbs) 
 
Figure 1.10. Psoriatic arthritis mutilans of the feet - radiographic images 
(Characterised by osteolysis, erosion and joint space narrowing resulting in loss of bone 
stock, shortened and deformed digits. Classical pencil-in-cup deformity affecting several 
toes are seen, and several phalanges have been entirely resorbed) 
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1.6 SERUM-SOLUBLE BIOMARKERS IN PSORIATIC ARTHRITIS 
Relatively little is known about the utility of serum-soluble bone and cartilage-turnover 
biomarkers in PsA, PsSpA or PAM. Given that PsA is characterised by osteoproliferation 
and bone / cartilage destruction, it seems plausible that biomarkers of their turnover may 
have value in monitoring disease activity, contributing to a diagnosis, and / or indicating 
prognosis. As in other diseases, serum-soluble biomarkers may potentially inform 
stratified medicine approaches. However, identifying and monitoring biomarkers in PsA is 
difficult due to the heterogeneity of PsA disease. In PsA, bone loss can occur in the form 
of bone erosion, osteolysis, and bone mineral density loss [83]. Bone formation can occur 
in the form of osteoproliferation, ankylosis and / or syndesmophytes.  
 
Several bone and cartilage turnover biomarkers might be of interest in PsA. Some directly 
cause bone resorption by virtue of their enzymatic or cytokine properties, e.g. matrix 
metalloproteinase-3 (MMP-3) enzymatically degrades the extra-cellular matrix of bone and 
cartilage [84]. Osteoprotegerin (OPG) is a glycoprotein secreted by osteoblasts and 
stromal cells, acting as a decoy receptor to receptor activator of nuclear factor-kappa B 
ligand (RANKL), thereby inhibiting osteoclastogenesis, resulting in reduced bone 
resorption. Others are by-products of bone resorption, thereby acting as markers of the 
process, e.g. cross-linked telopeptide of collagen-1 (CTX-1) is the product of excess 
metalloproteinase degradation of type 1 collagen. There are several by-products of 
cartilage turnover: C2C and C1-2C are neoepitopes that are released when type 2 
cartilage is degraded by collagenases; C-propeptide of type II collagen (CPII) is released 
during pro-collagen 2 synthesis; and CPII:C2C is the ratio of cartilage degradation versus 
by-product formation [85]. 
 
Serum-soluble bone-turnover biomarkers have shown some utility in AS. Low levels of 
sclerostin have been shown to be associated with syndesmophyte formation in AS [86], 
and MMP-3 appears to correlate with radiographic progression [87]. MMP-3 and OPG 
have been shown to be elevated in PsA patients [88]. Dickkopf 1 (Dkk-1) suppresses 
bone formation by interfering with the Wnt pathway, and blockade of Dkk-1 has been 
shown to lead to sacroiliac joint fusion in mouse models [89].  
 
A full systematic literature review of serum-soluble bone and cartilage-turnover 
biomarkers in PsA, PsSpA and PAM is presented in Chapter 2 of this thesis, and will 
therefore not be repeated here. 
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1.7 GENETICS OF PSORIATIC ARTHRITIS 
PsA has a strong genetic component to its aetiology, and is likely a polygenic disease. It is 
known to aggregate in families, being 55-fold more frequent if a first degree relative is 
affected by PsA [90]. Human leucocyte antigen (HLA) -B27 [66], HLA-Cw*06:02 [91], 
interleukin 12B (IL12B) [92, 93], interleukin 23 receptor (IL23R) [92, 94], interleukin 23A 
(IL23A) [95], late cornified envelope gene cluster [96], TRAF3IP2 [97], and TNIP1 [95] 
genes among others, have shown association with PsA.  
 
Unlike other gene polymorphisms, HLA-B27 [98-100] and interleukin 13 (IL13) [101] 
polymorphisms have shown association with PsA, independently of psoriasis. Three 
haplotypes containing HLA-B*27:05 or HLA-B*39:01 were significantly increased in 
frequency in PsA but not psoriasis cases [100]. A similarly designed study in an 
independent cohort confirmed several HLA alleles to be significantly associated with PsA 
compared with psoriasis: HLA-B*08 (OR 1.61; 95% CI 1.12, 2.30; p=0.009), HLA-B*27 
(OR 5.17; 95% CI 2.95, 9.04; p<0.0001), and HLA-B*38 (OR 1.65; 95% CI 1.06, 2.57; 
p=0.03) [102]. Conversely, HLA-C*06:02 is more associated with psoriasis than PsA 
(frequency 57.5 vs. 28.7%; p=9.9x10-12) [100]. The same study showed that HLA-C*06 is 
associated with more penetrant psoriasis and delayed musculoskeletal phenotype 
(interval ten years between skin and articular manifestations) [100]. In contrast HLA-B 
alleles (especially HLA-B*27) are associated with coincident skin and musculoskeletal 
manifestations (interval one year), and almost equivalent penetrance of musculoskeletal 
and psoriasis [100]. 
 
AS is strongly associated with HLA-B27, but its role in PsA has not been precisely defined 
[79, 103]. As in AS, the exact mechanism of the association between HLA antigens and 
PsA has not been established. HLA polymorphisms may result in altered antigen 
presentation to T-cells, misfolding of the HLA-molecule resulting in altered morphology, 
altered intracellular peptide handling by aminopeptidases, or simply be in linkage 
disequilibrium with a pathogenic susceptibility gene at another locus [104]. Allotypes of 
HLA-B*38:01 and HLA-B*08 encoding P2 pockets that bind side chains opposite in charge 
from those encoded by the HLA-B*27 and HLA-B*39 molecules may exert a ‘protective’ 
role [100]. 
 
1.7.1 Genetic markers of PsA phenotypes 
 
In 1974 Brewerton et al. first reported an association between HL-A 27(W27) and PsA 
[105]. In a cross-sectional study of 70 PsA cases, 56% of patients with isolated axial PsA 
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were HLA-B27 positive, compared with 24% of polyarthritic-axial PsA and 31% with 
oligoarthritic-axial PsA [66]. HLA-B27 positive cases tended to be younger at psoriasis 
onset and arthritis onset, and were more likely to be male, have bilateral sacroiliitis, and 
have uveitis. A separate study published recently of 282 PsA patients compared HLA-B 
and HLA-C sequencing data with clinical phenotype in PsA [106]. Enthesitis (OR 3.7; 95% 
CI 1.9, 7.1; p<0.001), dactylitis (OR 2.5; 95% CI 1.2, 5.0; p=0.009) and symmetric 
sacroiliitis (atypical for PsA) (OR 10.6; 95% CI 3.8, 29.0; p<0.0001) were more common in 
patients carrying variants of HLA-B*27:05:02. Joint fusion (OR 2.0; 95% CI 1.2, 3.4; 
p=0.006), joint deformities (OR 2.0; 95% CI 1.2, 3.7; p=0.004), and dactylitis (OR 1.8; 
95% CI 1.1, 2.9; p=0.03) were more common in patients carrying the HLA-B*08:01:01-
C*07:01:01 haplotype and its component alleles. Asymmetrical sacroiliitis (OR 0.45; 95% 
CI 0.21, 0.98; p=0.04) was less frequent in patients carrying HLA-C*06:02:01 variants. 
HLA-B*44:02:01 was associated with a lower frequency of joint fusion (OR 0.21; 95% CI 
0.07, 0.60; p=0.002), and dactylitis (OR 0.37; 95% CI 0.20, 0.70; p=0.003). Of note for the 
aims of this thesis, signals were present for osteolysis (a marker of PAM) to be more 
frequent in patients carrying HLA-C*02:02:02 variants (OR 3.1; 95% CI 1.2, 8.1; p=0.02). 
 
1.7.2 Prevalence of HLA-variants in PsSpA 
 
Several studies report that HLA-B27 is associated with PsSpA, especially with 
radiographic sacroiliitis [66, 107-110], as shown in Table 1.3. 
 
 
Table 1.3. Association between HLA-B27 and sacroiliitis in spondyloarthritis  
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Lambert et al. performed HLA-typing on 82 PsA patients in Yorkshire [110]. The 
prevalence of HLA-B27 was 28% in the whole PsA cohort, 60% in PsA cases with some 
form of spinal disease, 71% in PsSpA cases fulfilling the New York criteria for AS, and 5% 
in a control group (details not specified, but likely a general population control group). The 
prevalence of HLA-B27 positivity in patients with sacroiliitis alone was 78%, 36% in those 
with syndesmophytes alone, and 75% in those with both sacroiliitis and syndesmophytes. 
HLA-B27 positivity prevalence was not increased in those with peripheral arthritis only 
(11%). The prevalence of HLA-B13 was lower in those with PsSpA (though not statistically 
significant). The overall prevalence of HLA-BW17 was increased, especially in those with 
syndesmophytes (though not statistically significant). Gladman et al. found a similar 
prevalence of HLA-B27 positivity in males and females with PsSpA [111]. However, this 
finding was not corroborated by a later study by Queiro et al. [66], who found males 
PsSpA patients to be more likely HLA-B27 positive. HLA-B27 variants were prevalent in 
8% of patients with PsA in a Korean study, but sub-analyses in PsSpA cases were not 
performed  [67]. 
 
Mazzanti et al. argue that HLA-B27 is not a true marker of PsSpA [103]. They sub-
categorised 66 PsA patients into nine groups on the basis of the presence of: peripheral 
arthritis; axial disease fulfilling the modified New York criteria for AS or; axial disease with 
or without peripheral involvement; and bilateral or unilateral sacroiliitis. Only the group 
with sacroiliitis, spondylitis, no peripheral arthritis and not fulfilling the modified New York 
criteria showed an increased prevalence of HLA-B27 positivity. However, in this atypical 
group, only two patients had a true ankylosing pattern of spondylitis. Surprisingly, only 1/9 
cases in the group with axial disease fulfilling the modified New York criteria was HLA-B27 
positive. The authors therefore concluded that HLA-B27 is not a true marker of PsSpA 
[103]. 
 
1.7.3 Contribution of HLA-variants to disease expression in PsSpA 
 
In a prospective cohort study by Hanly et al. of 52 PsSpA cases, over a mean follow-up of 
57 months, HLA-B27 status did not appear to influence disease progression [63]. In the 
same PsA cohort, results published seven years later showed that of 194 PsSpA (from a 
cohort of 498 PsA) cases carrying HLA-B27 in the presence of HLA-DR7, had more 
severe disease [98]. In an Italian study published in 1992, predictors of radiographic 
cervical spine disease patterns were considered in a cohort of 57 PsA cases; 40/57 with 
PsSpA [112]. Multivariate analysis showed that the best predictors of radiographic cervical 
spondylitis were the presence of HLA-B39 and HLA-DR4 variants, and the absence of the 
HLA-DR5 variants [112]. 
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Queiro et al. studied the influence of HLA-B27 variants on PsSpA susceptibility and 
disease expression, using a retrospective cross-sectional single-centre study in northern 
Spain [66]. Axial disease was defined as grade >2 sacroiliitis, or inflammatory back pain 
plus syndesmophyte, facet fusion, or aseptic disciitis. Of 70 consecutive PsSpA patients, 
identified from a previous study of the entire PsA cohort (mean age 48 years, mean 
arthritis duration 12 years), 16/70 cases were classified as pure axial, 29/70 mixed axial 
and oligoarthritis, and 25/70 mixed axial and polyarthritis. HLA-B27 positivity was more 
likely in the PsA cases (24/70; 34%), compared with 7% in a ‘control’ group (details not 
given, but likely a general population comparator) (OR 6.4; p<0.0004). HLA-B27 positivity 
was significantly more likely in pure-axial (9/16; 56%), compared with mixed axial-
oligoarthritis (9/29; 31%), or mixed axial-polyarthritis (6/25; 24%) (p=0.02 across groups). 
Univariate analyses showed that HLA-B27 positive cases were significantly more likely 
than HLA-B27 negative cases to have bilateral sacroiliitis (75% vs. 28%; p=0.002), an 
earlier age of onset of psoriasis (26 vs. 33 years; p=0.03), an earlier age of onset of 
arthritis (32 vs. 40 years; p=0.01), male:female preponderance (7:1 vs. 1:1; p=0.002), and 
uveitis (33 vs. 11%; p=0.03). HLA-B27 negative patients developed significantly more 
peripheral erosions than HLA-B27 positive patients (p=0.05). No statistically significant 
differences were found between HLA-B27 positive and negative cases in terms of 
inflammatory spinal (neck or back) pain, radiographic cervical involvement, presence of 
marginal syndesmophytes, presence of paramarginal syndesmophytes, forward lumbar 
flexion (as measured by the Schober test), distal interphalangeal joint disease, nail 
dystrophy, psoriasis onset before arthritis, family history, or disability (as measured by the 
spinal health assessment questionnaire; HAQ-S). Syndesmophytes were present in 44% 
of cases, peripheral erosions in 44%, enthesitis in 43%, and psoriatic nail disease in 55%. 
Univariate analyses showed that the mixed axial-polyarthritis group faired significantly 
worse than the other two groups in terms of disability (p-value not stated), ESR 
(p=0.0001), and more peripheral erosions (p=0.0001).   
 
1.7.4 HLA-variants in PsSpA compared with AS 
 
The association of HLA-B27 with PsSpA has not been consistent, and is usually weaker 
than with AS. This might be because some studies have misclassified classical AS cases 
with coincidental psoriasis as PsSpA, and not considered the radiographic and clinical 
features thought to differentiate the two conditions; spondylitis without sacroiliitis in 
PsSpA, younger age at axial disease onset in AS, and more positive family history in AS. 
In a study of 66 PsA and 40 AS cases from Toronto (Canada) in 1993, AS cases 
compared with PsA cases had a significantly higher frequency of both HLA-B27 (83 vs. 
27%; p=0.0001) and HLA-Cw02 (47 vs. 16%; p=0.01), and a significantly lower frequency 
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of both HLA-Cw06 (0 vs. 22%; p=0.002) and HLA-B17 (6 vs. 17%; p=0.02) [49]. The 
authors therefore proposed that HLA-B27 status should be obtained in psoriasis-only 
patients, in order to identify cases likely to develop arthritis, and in whom closer 
monitoring would be prudent [113]. However, in the U.K. this does not currently form part 
of the National Institute for Health and Care Excellence (NICE) Quality Standards for 
Psoriasis (QS40) [114]. The authors also proposed that HLA-B27 testing should be 
performed in all PsA patients in order to identify PsA patients with asymptomatic PsSpA, 
or likely to develop PsSpA [113]. One might argue that it would be more sensitive and 
specific to simply perform protocolised baseline and interval clinical and radiographic 
assessments on patient with PsA. 
  
1.7.5 Genetic markers of PsA severity 
 
Relatively little is known about the genetic predictors of more severe disease in PsA. HLA 
variants appear to be markers for disease progression in PsA. There are reports that HLA-
B27, B39 and DQw3 pose a higher risk of progressive clinical damage [115]. HLA-DR7 
may confer some protection against disease progression [115]. Multivariate modeling of a 
cohort of 292 PsA cases followed for fourteen years in Canada showed that HLA-B27 in 
the presence of HLA-DR7, and HLA-DQw3 in the absence of HLA-DR7, are predictors of 
disease progression; defined as progression to a higher number of damaged joints. [98]. 
HLA-B39 was associated with progression in early disease, whilst HLA-B22 was 
associated with a lower risk of disease progression [116]. Examination of an independent 
cohort of 480 PsA patients in the United Kingdom indicated that PsA cases carrying the 
HLA-Cw6 - HLA-DRB1*07 haplotype were prone to 41% fewer damaged and (95% CI 23 
to 55%; p=0.02) and 31% fewer involved joints (95% CI 16 to 44%; p=0.001) compared 
with those who do not carry these variants [117]. Variants of HLA-Cw6 and HLA-DRB1*07 
were not independently associated with disease severity; a finding replicated for HLA-
Cw0602 in an independent cohort [118]. HLA-DRB1*03, HLA-DRB1*04 and shared 
epitope alleles did not predict disease severity. HLA-B*27:05:02-C*02:02:02 (OR 9.78; 
95% CI 1.23, 78.1), and HLA-B*08:01:01-C*07:01:01 (OR 2.35; 95% CI 1.36, 4.06) have 
been associated with more severe disease, as measured using propensity scores [106].  
 
The presence of peripheral radiographic erosions have been associated with a 
polymorphism of the IL23R gene [93], HLA-C*01:02:01 [106], the HLA-B*27:05:02-
C*01:02:01 haplotype [106], interleukin-4 receptor (IL4R) I50V gene [119], TNF-alpha 
gene [120], and TNF-beta gene [120]. A pilot study by our group, published in 
Rheumatology (Oxford) 2013, confirmed that patients carrying a variant of the IL12B gene 
are significantly more likely to have PsA (OR 1.70; 95% CI 1.3, 2.2; p<0.001), and a trend 
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for peripheral erosive disease to be less frequent in cases carrying a variant of the 
interleukin-23 receptor (IL23R) gene (OR 0.47; 95% CI 0.18, 1.20; p=0.16) [93]. However, 
a variant of the endoplasmic reticulum aminopeptidase 1 (ERAP1) gene was not 
associated with axial radiographic disease in PsA even after stratifying for HLA-B27 and 
HLA-C*0602 status, suggesting that spinal involvement in PsA may be genetically 
different from that in AS, which is in keeping with previous observations that the clinical 
and radiographic pattern of axial disease also differ. Variants of the TNF-alpha and TNF-
beta genes have also been investigated, but similarly did not show association with either 
a history of inflammatory back pain or radiographic sacroiliitis / spondylitis [120].   
 
1.8 SUMMARY 
In summary, relatively little is known about the clinical, radiographic, serum and genetic 
biomarker characteristics of two subphenotypes of PsA; PsSpA and PAM. Estimates of 
the prevalence of PsSpA and PAM in PsA cohort have markedly varied, in part due to a 
lack of an international consensus classification for PsSpA and PAM, and due to the 
scarcity of large well-characterised PsA cohorts. The demographic, articular and extra-
articular manifestations, functional and metrology impairments that PsSpA experience has 
yet to be established, in particular how they compare to pPsA and AS. Only a few 
moderate-sized studies have described sites, patterns, severity and morphological 
features of axial radiographic disease in PsSpA, and even fewer have made comparisons 
with AS. Furthermore, the reliability of some of these studies has been reduced by the 
stringency of the classification systems for PsSpA used, case selection and sample size. 
The association of HLA-B27 variants with PsSpA has yet to be fully established. Other 
genetic variants have not been thoroughly tested for association with PsSpA or PAM. 
Studies investigating PAM have been cross-sectional, likely underpowered, and had 
limited imaging data. No longitudinal study has been published describing the distribution 
of joints affected by PAM, or the natural radiographic history of PAM. Serum-soluble bone-
turnover biomarkers have been investigated in AS, and shown some utility for clinical and 
research purposes. However, only a few small studies with variable study designs have 
investigated serum biomarkers in PsA, and no study has investigated in PsSpA or PAM.  
 
It is hoped that through a better understanding of the clinical, radiographic and serum-
biomarker features of these two phenotypes of PsA, patients can be better classified and 
managed using the principles of stratified medicine, and a better understanding of their 
pathogenesis can be attained, thereby elucidating therapeutic targets.  
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2 CHAPTER II: SERUM-SOLUBLE BONE AND 
CARTILAGE TURNOVER BIOMARKERS IN PSORIATIC 
ARTHRITIS AND PSORIATIC 
SPONDYLOARTHROPATHY: A SYSTEMATIC REVIEW 
 
2.1 ABSTRACT 
Background: Psoriatic arthritis (PsA) is an inflammatory disease of joints. Therefore, 
serum soluble biomarkers specific for chronic joint and bone inflammation may predict 
future disease severity and response to therapy, thereby informing stratified medicine 
approaches. The objectives of this systematic review were to determine if serum-soluble 
bone and cartilage turnover biomarkers are: (i) associated with PsA or psoriatic 
spondyloarthropathy (PsSpA); (ii) associated with disease activity, disease severity, or 
clinical phenotype.  
Methods: A search was conducted of several databases (Medline, EMBASE, and 
Cochrane Controlled Trials Register) and conference proceeding sites using the following 
MeSH, EMTree or key term stems: Arthritis, Psoriatic; Psoriatic spondylarthritis; Biological 
markers; Bone turnover markers; osteoprotegerin (OPG), matrix metalloproteinase (MMP-
3), sclerostin, dickkopf 1 (Dkk-1), bone alkaline phosphatase (ALP), osteocalcin (OC), 
macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear factor-kappa 
B ligand (RANKL), collagen type II, extracellular matrix proteins, glycoproteins, 
procollagen, amino-terminal propeptide of procollagen type III (PIIINP), cross-linked 
telopeptide of collagen-1 (CTX-1), tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), bone morphogenetic protein (BMP), and cartilage oligomeric matrix protein 
(COMP). Two reviewers independently assessed abstracts for inclusion in the review, and 
extracted data from papers meeting study eligibility criteria. One reviewer (Deepak Jadon) 
critiqued the papers and results. 
Results: The search identified 155 unique studies, and ten of these met the eligibility 
criteria of the systematic review. MMP-3, Dkk-1, M-CSF, CTX-1, and TRAIL were 
associated with PsA, with equivocal results for OPG and ALP. MMP-3, Dkk-1, M-CSF, 
CPII:C2C, and possibly OPG associated with PsA independently of psoriasis. C1-2C was 
associated with both tender and swollen joint counts, and BMP-4 with patient global 
assessment of disease, pain score and BASDAI. Bone ALP was associated with disease 
activity. M-CSF and RANKL were associated with several plain radiographic features. 
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Conclusions: Whilst several studies have investigated serum-soluble bone and cartilage 
biomarker associations with PsA, no studies have investigated association specifically 
with PsSpA. Studies to date have had small samples sizes and may have been 
underpowered to detect associations. Studies have used inconsistent clinical end-points 
and laboratory methods, making comparison between studies difficult. We have identified 
several candidate biomarkers that warrant further investigation for association with PsA 
and PsSpA in the first instance, and subsequently for association with hard end-points 
such as radiographic outcome. 
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2.2 INTRODUCTION 
The following systematic review was published as a paper in The Journal of 
Rheumatology in January 2014 (J Rheumatol. 2015;42:21-30) [121]. There is some 
repetition in this chapter of the content of that paper. The manuscript was written by 
Deepak Jadon (DJ). Raj Sengupta (RS) and Alison Nightingale (AN) helped in the 
screening of eligible papers and data extraction, respectively. All co-authors contributed to 
the review inception, design, and internal peer review of the final draft written by DJ. 
 
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder with 
characteristic patterns of peripheral and axial joint inflammation, and extra-articular 
manifestations that can include skin psoriasis, psoriatic nail disease, enthesitis, dactylitis 
or uveitis. As such, candidate serum soluble biomarkers specific for chronic joint and bone 
inflammation may predict future disease severity and response to therapy, thereby 
informing stratified medicine approaches. However, identifying and monitoring biomarkers 
in PsA is difficult due to the heterogeneity of PsA disease. In PsA, bone loss can occur in 
the form of bone erosion, osteolysis, and bone mineral density loss [83]. Bone formation 
can occur in the form of osteoproliferation, ankylosis and syndesmophytes.  
 
Several bone and cartilage turnover biomarkers might be of interest in PsA. Some directly 
cause bone resorption by virtue of their enzymatic or cytokine properties, e.g. matrix 
metalloproteinase-3 (MMP-3) enzymatically degrades the extra-cellular matrix of bone and 
cartilage [84]. Osteoprotegerin (OPG) is a glycoprotein secreted by osteoblasts and 
stromal cells, acting as a decoy receptor to receptor activator of nuclear factor-kappa B 
ligand (RANKL), thereby inhibiting osteoclastogenesis, resulting in reduced bone 
resorption. Others are by-products of bone resorption, thereby acting as markers of the 
process, e.g. cross-linked telopeptide of collagen-1 (CTX-1) is the product of excess 
metalloproteinase degradation of type 1 collagen. There are several by-products of 
cartilage turnover: C2C and C1-2C are neoepitopes that are released when type 2 
cartilage is degraded by collagenases; CPII is released during pro-collagen 2 synthesis; 
and CPII:C2C ratio of cartilage degradation versus by-product formation [85]. 
 
Although there have been several editorial review articles, there have been no systematic 
reviews published on the clinical and prognostic value of serum soluble bone-turnover 
biomarkers in PsA. The objectives of this systematic review were to determine if serum-
soluble bone and cartilage turnover biomarkers are: (1) associated with PsA or psoriatic 
spondyloarthropathy (PsSpA); (2) associated with disease activity, disease severity, or 
clinical phenotype in PsA cases vs. healthy controls, and PsA vs. PsC cases.
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2.3 METHODS 
Methods of analysis and eligibility criteria were specified in advance and documented in 
an a priori protocol. This study aligns with the ‘meta-analysis of observational studies in 
epidemiology (MOOSE) guidelines [122].  
 




(i) Cohort, case-control, cross-sectional studies and randomised controlled trials published 
in the form of a journal paper, journal abstract or conference abstract that compared the 
serum concentration of bone and cartilage-turnover biomarkers in PsA cases to that in 
healthy controls, with or without an additional psoriasis (PsC) comparator group. 
 
(ii) Study participants with PsA must have fulfilled Classification for Psoriatic Arthritis 
(CASPAR) criteria [24] for PsA, or Moll and Wright criteria for PsA [18], or PsSpA [123]. 
 
(iii) The following bone and cartilage-turnover biomarkers were included (as defined in key 
indexing terms below; MeSH, EMTree or key terms): osteoprotegerin (OPG), matrix 
metalloproteinase (MMP-3), sclerostin, dickkopf 1 (Dkk-1), bone alkaline phosphatase 
(ALP), osteocalcin (OC), macrophage colony-stimulating factor (M-CSF), receptor 
activator of nuclear factor-kappa B ligand (RANKL), collagen type II, extracellular matrix 
proteins, glycoproteins, procollagen, amino-terminal propeptide of procollagen type III 
(PIIINP), cross-linked telopeptide of collagen-1 (CTX-1), tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), bone morphogenetic protein (BMP), and cartilage 
oligomeric matrix protein (COMP). 
 
(iv) Outcome variables were: (i) peripheral and / or spinal involvement: clinical symptoms, 
radiographic disease (ii) disease severity, as measured by axial and / or peripheral 
radiographic disease (iii) disease activity: tender joint counts, swollen joint counts, Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis 
Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), 
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Exclusion criteria 
 
We excluded studies without a healthy control (HC) group. We excluded studies where 
participants were using biological agents, since tumour necrosis factor inhibitors [88, 124, 
125], but not conventional DMARDs [88, 126], have been reported to directly influence 
serum bone and cartilage turnover biomarkers [127], thereby confounding results when 




The search date was 1 February 2014. The search was repeated on 1 July 2015 prior to 
submission of this thesis, and no additional papers were identified. The following 
databases were searched using key indexing terms: Medline (1950 - present); EMBASE 
(1974 - present); Cochrane Controlled Trials Register (1993 - present). The following 
MeSH, EMTree or key term stems were used: Arthritis, Psoriatic; Psoriatic 
spondylarthritis; Biological markers; Bone turnover markers. No language restrictions 
were applied to publications. 
 
The reference lists of all papers fulfilling inclusion criteria and all review articles were 
scrutinised for any references not identified in the original database search, but still 
meeting the inclusion criteria. Two key authors (Dr. Vinod Chandran, VC; Professor Oliver 
Fitzgerald, OF) were contacted to determine if any important unpublished papers or not 
indexed (e.g. conference proceedings) should be screened. 
 
2.3.3 Study selection 
 
Two reviewers (DJ, RS) independently assessed abstracts for inclusion in the review. 
Where there was disparity in opinion, the full paper was obtained and consensus for 
inclusion or exclusion reached (DJ, RS). An assessment was made at this point for 
potential publication bias, or selective reporting within studies. Two reviewers (DJ, AN) 
independently extracted data from the papers onto a standardised data-extraction Excel 
spread-sheet, that was initially pilot-tested. The papers were critically appraised using the 
Critical Appraisal Skills Programme toolkit [128] for cohort and cross-sectional studies, 
including sources of bias, both at study and outcome level. DJ and AN reached 
consensus on data for use in the subsequent analyses. 
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2.3.4 Synthesis of results 
 
The primary summary measure was odds ratios (OR) for serum biomarker levels in PsA 
vs. healthy controls, or PsA vs. PsC, including p-values for the analyses. The secondary 
summary measures were odds ratios or Spearman Rho correlation co-efficient for clinical 
outcomes in PsA vs. healthy controls, or PsA vs. PsC, including 95% confidence intervals 
(95% CI) and p-values for the analyses. 
 
We initially intended to combine the results of different studies mathematically as a meta-
analysis, including tests for heterogeneity. However, due to the differing methods used in 
the included studies (cohorts, laboratory techniques using enzyme-linked immunosorbent 
assay or immunoassays with different reference ranges, statistical analyses) and a lack of 
homogeneity in the reporting of results it was not possible to combine the results of 
different studies statistically. Therefore we have reported the results of the studies 




155 unique studies were identified; ten of these met the eligibility criteria and were 
included in the systematic review.  Two papers [129, 130] that met inclusion criteria were 
unobtainable from several libraries (including the British Library) or on contacting the first 
authors, and insufficient detail of results were provided in the abstract to allow inclusion in 
the systematic review. Four papers were excluded because they did not have a healthy 
control group for comparison with the PsA group [131-134]. Eight papers were excluded 
because the PsA cases were using biological agents, and either didn’t have a healthy 
control comparator group or did not provide pre-biological initiation biomarker data [88, 
124, 125, 127, 134-137]. The remaining 131 articles were excluded because they did not 
fulfil several eligibility criteria. No further articles were identified on scrutinising the 
reference list of included articles, or by recommendation of two key authors (VC, OF). 
 
Figure 2.1 details the flow of study selection in the systematic review, and Table 2.1 




  49  
 
Figure 2.1. Study selection in the systematic review 









155 abstracts screened by DJ & RS 
Medline 
 
Searched using pre-specified MeSH terms. 




Searched using pre-specified EMTree terms. 




Searched using pre-specified key-terms. 
Results = 5 
 
131 abstracts excluded because 
they did not meet inclusion 
criteria. 
174 Articles retrieved 
for abstract review 
10 articles (all full papers) met inclusion criteria for the systematic review. 
 
19 duplicate articles excluded 
‘Reference list’ of 20 full 
papers reviewed. Zero articles 
identified that were not 
identified by the original 
database searches. 
22 full papers obtained and reviewed by DJ & RS. 
4 papers excluded because no 
healthy control group for 
comparison.  
8 papers excluded because 
patients on Biologicals.  
2 key authors contacted. No 
additional articles 
recommended. 
2 papers met inclusion criteria, 
but unable to source full article, 
despite contacting the authors. 
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Table 2.1. Characteristics of the ten studies meeting eligibility criteria of the systematic review 











Matching Male : 
female  
ratio 
Chandran et al. 2010 
(10) 
Rheumatology (Oxf) Canada Prospective  
single 
centre  
OPD Age & sex 
matching 
CASPAR 26 26 26 - 46.9 13.4 Age & sex 12:14 















Grcevic et al. 2010  
(27) 
The Journal of 
Rheumatology 
Croatia Prospective  
single 
centre  
OPD n/s Moll & Wright 25 23 - 27 AS  
49 RA 
17OA 
53.5 9.9 Age 11:12 





Japan Prospective  
dual-centre 
OPD n/s Bennett 11 16 15 9 RA 51.8 - Age & sex 11:5 
Hofbauer et al. 2006 
(24) 
Rheumatology (Oxf) Germany Prospective  
single 
centre  
OPD n/s CASPAR 90 116 - - 52 - - 59:57 
Grisar et al. 2002 (26) The Journal of 
Rheumatology 
Austria Prospective  
 
OPD n/s ESSG 41 23 - 30 AS  
10 ReA 
45.2 - n/s 17:6 
Ribbens et al. 2001 
(28) 
Annals of the 
Rheumatic Diseases 
Belgium Prospective  
single 
centre  
OPD n/s Moll & Wright 96 18 - 126 RA  
37 OA  
28 AS  
9 else 
46 - Sex 9:9 










Moll & Wright 50 32 17 - 45 - Age & sex 21:11 







OPD n/s Baker 1963 16 12 - 40 OA  
30 RA 
50.6 7.5 - 10:2 




Italy Prospective  
single 
centre  
IPD n/s n/s 25 25 - 25 RA 50.3 11.3 Age & sex Females 
only 
 
HC: healthy control PsA: psoriatic arthritis PsC: cutaneous psoriasis without arthritis AS: ankylosing spondylitis  RA: rheumatoid arthritis  
OA: osteoarthritis ReA: reactive arthritis Steroids: corticosteroids  n/s: not stated   OPD: outpatient department 
IPD: inpatient department CASPAR: Classification criteria for psoriatic arthritis  ESSG: European spondyloarthropathy study group 
 
(Table reproduced from Jadon et al. J Rheumatol 2015) [121] 
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2.4.1 Comparison of biomarkers levels in PsA cases vs. healthy controls 
 
The results of comparisons between biomarkers levels in PsA cases vs. healthy controls 
are shown in Table 2.2. The serum concentration of several biomarkers (MMP-3, Dkk-1, 
M-CSF, CTX-1, and TRAIL) was significantly higher in PsA vs. healthy controls. whereas 
the serum concentration was not significantly different in PsA vs. healthy controls for 
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Table 2.2. Comparison of biomarkers levels in PsA cases and healthy controls 






























96,18,0   p<0.05 39.5 vs. 19.2 ng/ml 
Shibata 
2009 
Higher 11,16,15 14.9 1.90, 
397.40 





Higher 12,38,10   p<0.01 charted pg/ml 
RANKL Chandran 
2010 





Equal 12,38,10   p>0.05 charted pmol/L 
M-CSF Dalbeth 
2010 
Higher 12,38,10   p<0.01 charted pg/ml 
CTX-1 Grisar 
2002 






















90,116,0   p=0.38 5.09 vs. 5.4 pmol/l 
Dalbeth 
2010 
Equal 12,38,10   p>0.05 charted pg/ml 
BMP-2 Grcevic 
2010 
Equal 25,23,0   p>0.05 n/s n/s 
BMP-4 Grcevic 
2010 
Equal 25,23,0   p>0.05 n/s n/s 
BMP-6 Grcevic 
2010 
Equal 25,23,0   p>0.05 n/s n/s 
ALP Grisar 
2002 











50,32,17   p>0.05 136 vs. 125 U/l 
OC Grisar 
2002 
Equal 41,23,0   p>0.05 20.7 vs. 17.8 ng/ml 
Magaro 
1989 
Equal 25,25,0   p>0.05 4.83 vs. 7.25 ng/ml 
Franck 
2000 






50,32,17   p<0.05 2.28 vs. 4.11 ng/ml 
PIIINP Sharif 
1996 











Higher 11,16,15   p<0.01 12.7 vs. 8.9 U/l 
C1-2C Chandran 
2010 
Equal 26,26,26 0.46 0.001, 
217.74 
p=0.81 0.6 vs. 0.5 mcg/ml 
CPII:C2C Chandran 
2010 







Higher 90,116,0   p<0.01 66.1 vs. 50 pg/ml 
 
OR: odds ratio   95% CI: 95% confidence interval   n/s: not stated 
HC: healthy control  PsA: psoriatic arthritis   PsC: cutaneous psoriasis without arthritis   
Dkk-1: Dickoppf 1  OPG: osteoprotegerin   MMP-3: matrix metalloproteinase-3  
ALP: bone alkaline phosphatase BMP:  bone morphogenetic protein M-CSF: macrophage colony-stimulating factor     
OC: osteocalcin   C1-2C: collagen 2 neoepitope  CTX-1: cross-linked telopeptide of collagen 1 
TRAIL: tumor necrosis factor-related apoptosis-inducing ligand    RANKL: receptor activator of nuclear factor-kappa B ligand  
PIIINP: amino-terminal propeptide of procollagen type III    COMP: cartilage oligomeric matrix protein 
CPII:C2C : ratio of procollagen 2 to collagen 2 neoepitope 
 
(Table reproduced from Jadon et al. J Rheumatol 2015) [121] 
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2.4.2 Comparison of biomarker levels in PsA cases vs. PsC cases 
 
The results of comparisons between biomarkers levels in PsA cases vs. PsC cases are 
given in Table 2.3. The serum concentration of MMP-3, Dkk-1, M-CSF, and CPII:C2C was 
significantly higher in PsA vs. PsC. The results for OPG were equivocal. 
 
Table 2.3. Comparison of biomarkers levels in PsA and PsC cases 







































12,38,10   p<0.05 charted pg/ml 
RANKL Chandran 
2010 
















12,38,10   p>0.05 charted pmol/L 
M-CSF Dalbeth 
2010 




















































Equal 26,26,26 0.02 <0.001, 
16.44 





Higher 26,26,26 4.76 1.35, 16.77 p=0.02 4.76 vs. 
3.28 
ratio 
          
OR: odds ratio   95% CI: 95% confidence interval   n/s: not stated 
HC: healthy control  PsA: psoriatic arthritis   PsC: cutaneous psoriasis without arthritis   
Dkk-1: dickopff 1  OPG: osteoprotegerin   MMP-3: matrix metalloproteinase-3   
OC: osteocalcin  C1-2C: collagen 2 neoepitope   M-CSF: macrophage colony-stimulating factor  
RANKL: receptor activator of nuclear factor-kappa B ligand   COMP: cartilage oligomeric matrix protein   
CPII:C2C : ratio of procollagen 2 to collagen 2 neoepitope 
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2.4.3 Association of biomarker levels with demographic parameters 
 
Franck et al. [138] demonstrated two biomarkers to be higher in males vs. female PsA 
patients: ALP (mean serum concentration 137 U/l in males vs. 91 U/l in females; p<0.05) 
and OC (mean serum concentration 3.62 ng/ml in males vs. 2.28 ng/ml in females; 
p<0.05). However, Hofbauer et al. [139] did not corroborate the findings for OC, 
demonstrating OC levels to be no different in male and female PsA patients (23.7 ng/ml in 
males vs. 23.1 ng/ml in females; p=0.82). However, the study populations of the two 
studies differed with Hofbauer et al. excluding patients using DMARDs or corticosteroids 
and took fasting blood samples whereas Franck et al. took un-fasted samples and 
included patients using DMARDs and corticosteroids. Similarly, the association between 
OPG levels and sex were conflicting, with higher levels in females vs. males in the study 
by Hofbauer et al. (6.7 in females vs. 2.09 pmol/L in males; p=0.001) [139] but no 
difference by sex in the smaller study by Dalbeth et al. (mean serum concentrations or p-
values not stated) [126]. No correlation has been reported between sex and Dkk-1 [126], 
M-CSF [126], RANKL [126], PIIINP [140], [139], or cross-laps [139]. 
 
No association has been reported for PIIINP and age of PsA patient at the time of 
sampling (p=0.925) [126, 140], Dkk-1, RANKL, M-CSF or OPG (p-values or correlation 
coefficients not stated) and body weight in kilograms [126].  
  
2.4.4 Association of biomarker levels with clinical parameters 
 
Three studies investigated for association between PsA disease duration and serum 
biomarkers [138, 140, 141] . However, none of the studies defined whether duration was 
analysed as a continuous or categorical variable. Disease duration was positively 
associated with serum CTX-1 concentrations (r=0.670; p=0.009) [141], but not with OPG 
[141], ALP [141], PIIINP [140], or OC [138, 141].  
 
Chandran et al. demonstrated a positive correlation between C1-2C and both tender joint 
counts and swollen joint counts [88]. However, p-values, Spearman Rho correlation co-
efficients, and tender or swollen joint counts per unit increase in C1-2C were not stated. 
Grcevic et al. reported a positive association between BMP-4 and both patient global 
assessment of disease (r=0.54; p=0.02), and pain score on a visual analogue scale 
(r=0.49; p=0.04) [142]. No such associations were found between the same parameters 
and either BMP-2 or BMP-6 [142]. 
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2.4.5 Association of biomarkers levels with laboratory parameters 
 
An association was demonstrated between C-reactive protein (CRP) levels and both CTX-
1 [141] and TRAIL [139] in PsA patients, but not with either MMP-3 [143]  or OPG [139]. 
Erythrocyte sedimentation rate (ESR) was positively associated with both CTX-1 [141] 
and OPG [139]. TRAIL was not associated with ESR levels [139]. Two studies 
consistently showed ALP to be positively associated with OC [138, 144]. Serum creatinine 
levels were not associated with Dkk-1, RANKL, M-CSF or OPG levels in the single study 
that tested for this correlation [126]. 
 
2.4.6 Association of biomarkers levels with composite indices  
 
Franck et al. reported an association between disease activity and both ALP (mean serum 
concentration in patients with ‘no disease activity’ 69 U/l vs 148 U/l in patient with ‘high’ 
disease activity; p<0.005) and OC (mean serum concentration in patients with ‘no disease 
activity’ 2.2 ng/ml vs. 3.92 ng/ml in patient with ‘high’ disease activity; p<0.05) although 
the number of patients in these groups were very small (4 vs. 98, respectively) and no 
definition of ‘no’ vs. ‘high’ diseases activity was stated. [138]. Disease Activity Score 28-
joints using CRP (DAS28-CRP) was not associated with Dkk-1, M-CSF, RANK-L, OPG 
[126], BMP-2, BMP-4 or BMP-6 [142]. BMP-4 associated with BASDAI in the one study 
that tested this correlation (r=0.46; p=0.04) [142]. No association was demonstrated 
between BASDAI and either BMP-2 or BMP-6 [142]. COMP positively correlated with the 
Psoriasis Area and Severity Index (PASI) in one study (analyses not stated in paper) [88]. 
No association was demonstrated between DAS28-CRP and Dkk-1, M-CSF, RANKL, 
OPG, BMP-2, BMP-4, or BMP-6 [126]. No association was demonstrated between BASFI 
and BMP-2, BMP-4, or BMP-6 [142]. 
 
2.4.7 Association of biomarkers levels with radiographic parameters 
 
Four studies [88, 126, 139, 142] investigated the association between biomarker levels 
and radiographic parameters with two studies providing the majority of the data [88, 126] 
(Table 4). Joint space narrowing was associated with RANKL (p<0.05) and M-CSF 
(p<0.01), but not with Dkk-1 or OPG in the one study testing these associations [126]. 
Similarly, osteolysis (defined as pencil-in-cup deformity) was associated with both RANKL 
(p<0.05) and M-CSF (p<0.05), but not with Dkk-1 or OPG in the one study testing these 
associations [126]. Osteoproliferation was not associated with RANKL, M-CSF, Dkk-1 or 
OPG in the one study testing these associations [126]. Two studies tested for association 
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between peripheral radiographic erosions and serum biomarkers. M-CSF was positively 
associated with peripheral erosions (p<0.001) [126], but the remaining biomarkers were 
not (MMP-3, Dkk-1, RANKL, OPG, COMP, C2C, C1-2C, CPII) [88, 126]. The modified van 
der Heijde score for PsA (VDH) is a composite score encompassing joint space narrowing 
and erosions in peripheral radiographs [145]. Dalbeth et al. demonstrated an association 
between the VDH and both M-CSF (p<0.01) and RANKL (p<0.05), but not with Dkk-1 or 
OPG.  
 
Three studies [88, 126, 142] tested for association between radiographic sacroiliitis and 
several biomarkers: no associations were found with MMP-3, RANKL, OPG, BMP-2, 
BMP-4, BMP-6, COMP, C2C, C1-2C, CPII; and results were equivocal for Dkk-1 and M-
CSF [88, 126, 142]. 
 
No association was found between bone mineral density (BMD) at the hip, lumbar spine 
or femur and several biomarkers, including Dkk-1, RANKL, M-CSF, OPG, or TRAIL (Table 
4) [139].  
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2.5 DISCUSSION 
A summary of biomarkers that are associated with  PsA and its clinical parameters are 
shown in Figure 2.2.. The following biomarkers were associated with PsA: MMP-3, Dkk-1, 
M-CSF, CTX-1, TRAIL, and the results were equivocal for OPG and ALP. MMP-3, Dkk-1, 
M-CSF, CPII:C2C, and possibly OPG, were associated with PsA independently of PsC. 
ALP was associated with male sex in PsA. CTX-1 was associated with disease duration, 
C1-2C with both tender and swollen joint counts, and BMP-4 with both patient global 
assessment of disease and pain score. CRP was associated with both CTX-1 and TRAIL, 
ESR associated with both CTX-1 and OPG, and ALP associated with OC. Disease activity 
was associated with ALP and possibly OC; BASDAI associated with BMP-4, and skin 
score (PASI) correlated with COMP. The following biomarkers were associated with 
radiographic features: M-CSF with the PsA-modified van der Heijde composite score, joint 
space narrowing, peripheral radiographic erosions, and osteolysis; RANKL with the van 




Figure 2.2. Summary of serum bone and cartilage-turnover biomarkers associated with PsA 
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2.5.1 Disparity in study findings 
 
There are several potential reasons for disparity in study results. Firstly, most of the 
studies have been cross-sectional, rather than prospectively conducted cohort studies. A 
study by Young-Min et al. of early RA demonstrated biomarkers associations with swollen 
/ tender joint counts and disease activity score only when longitudinal data were analysed, 
and not when cross-sectional baseline data was analysed [146]. Studies have 
investigated differing clinical parameters, used differing collection protocols (overnight 
fasted in two studies [139, 144]) and laboratory techniques, making comparison difficult. 
Several studies had small samples [140-142, 144, 147, 148] and were likely to be 
underpowered. 
 
We acknowledge that there may be publication bias towards studies with positive results. 
However, we suspect that due to several biomarkers being reported in each study, with a 
mixture of both positive and negative findings, that selective reporting bias may be less of 
a problem. 
 
Whilst it is common practice in studies of metabolic bone disease to test bone markers in 
the morning and in a fasted state, few PsA studies have undertaken testing in this 
manner. Clowes et al. investigated the effect of feeding vs. fasting on several markers in 
twenty women, and demonstrated little effect on bone biomarkers, except in the case of 
serum CTX [149]. Other factors influencing serum levels: circadian rhythm [150], sex, oral 
contraceptive pill use, menstrual cycle, growth, diet, meal composition and timing of 
sample post-ingestion [149]. Standardisation of diet prior to sampling may improve 
measurement variability, but at the expense of feasibility. 
 
Conflicting reports of associations between serum biomarker concentrations and 
demographic parameters may be, in part, attributable to uncontrolled confounding due to 
a lack of matching or adequate adjustment for age and sex within the study design and 
analysis. Dalbeth et al. did not adjust for the higher proportion of women in their HC vs. 
PsA group [126]. Hofbauer et al. had entirely men in their HC group, since this was a 
‘convenience sample’ derived from participants in a coronary artery study [139]. They also 
reported higher OPG serum concentration in females compared with males, due to a lack 
of adjustment for sex; oestrogen is known to stimulate OPG production. Ribbens et al. 
sex-matched their participants, and since corticosteroid use alters MMP-3 levels, analyses 
were made in non-corticosteroid using patients only [147].  
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Sharif et al. did not state the source of their HC group, which appears much younger than 
the PsA cohort [140]. Significant differences in mean age, sex, and disease duration of the 
patients in all three disease groups were noted. Whilst Shibata et al. [148] matched for 
age in their study, further inspection demonstrates that the HC group was much younger 
than both the PsA and PsC groups [148].  
 
2.5.2 Priorities for future research 
 
Biomarker identification in PsA may help identify PsC patients with subclinical arthritis, 
and aid both prognostication and stratified medicine approaches. Biomarkers may 
facilitate monitoring of disease activity and treatment response, so that non-efficacious 
treatment is switched, rather than waiting several years for radiographic progression. Our 
knowledge of the pathogenesis of PsA, and how it overlaps with AS and RA, may be 
improved through such research. Biomarkers may guide the development of new drugs, 
both to obtain proof of principle in an early stage of drug development, and avoid reliance 
on slow structural damage outcomes requiring lengthy clinical trials [137]. Serum 
biomarkers may offer a more economic and readily available alternative to imaging. All 
such knowledge is important for the individual patient, public health and health policy.  
 
Despite the theoretical advantages, “novel” biochemical markers have not translated to 
the bedside. This may be in part due to a lack of longitudinal prospective studies and 
robust evidence of superiority over existing biomarkers e.g. CRP. PsA is a heterogenous 
disease with several subphenotypes, varied clinical course, and often comorbidities that 
can confound the interpretation of results [151].  
 
There is a need for longitudinal studies to identify biomarkers that correlate with or predict 
long-term clinical, radiographic, functional outcomes and treatment response. Research 
will be most valuable if it identifies biomarkers that fulfil the Outcome Measures in 
Rheumatology Clinical Trials (OMERACT) filter: truth; discrimination and feasibility [152]. 
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3 CHAPTER III: AIMS AND OBJECTIVES 
 
3.1 AIMS 
The aims of this thesis are to determine the prevalence and characteristics of psoriatic 
spondyloarthritis (PsSpA) and psoriatic arthritis mutilans (PAM) in a cohort of psoriatic 






3.2.1 OBJECTIVE 1: Prevalence and characteristics of PsSpA in PsA 
 
1a) To determine the prevalence and characteristics of axial involvement in a PsA cohort, 
using patient reported outcome measures (PROMs), clinical examination indices and 
radiographic indices. 
 
1b) To compare the pattern of axial involvement in a PsA cohort with that of an AS cohort, 
using PROMs, clinical examination indices and radiographic indices. 
 
 
3.2.2 OBJECTIVE 2: Prevalence, characteristics and natural radiographic history of 
PAM 
 
2a) To determine the prevalence of PAM in a cohort of PsA cases. 
 
2b) To compare the clinical characteristics of PAM  and non-PAM cases in a cohort of 
PsA cases using PROMs, clinical history and radiographic indices. 
 
2c) To determine the natural radiographic history of PAM. 
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3.2.3 OBJECTIVE 3: Serum-soluble bone-turnover biomarkers of PsSpA 
 
3a) To investigate four potential serum-soluble bone-turnover biomarkers 
(osteoprotegerin, OPG; Dickkopf 1, Dkk-1; matrix metalloproteinase 3, MMP-3; and 
macrophage colony stimulating factor, M-CSF) as predictors of PsSpA occurrence, by 
comparison with PsA, AS, psoriasis-only (PsC) cases and healthy controls (HC). 
 
3b) To investigate four potential serum-soluble bone-turnover biomarkers (OPG, Dkk-1, 
MMP-3 and M-CSF) as predictors of disease severity in patients with PsSpA. 
 
3c) To investigate four potential serum-soluble bone-turnover biomarkers (OPG, Dkk-1, 
















  63  
4 CHAPTER IV: STUDY DESIGN AND GENERAL 
METHODS  
 
1.1 STUDY DESIGN 
A single-centre prospective observational study was conducted at the Royal National 
Hospital for Rheumatic Diseases (RNHRD) in Bath, U.K.. Consecutive PsA patients were 
recruited from those attending a dedicated PsA clinic (seeing 600 unique PsA cases per 
year), and consecutive AS patients were recruited from those attending a dedicated AS 
clinic (seeing 500 unique AS cases per year). This study was named the Axial Disease in 
Psoriatic Arthritis (ADIPSA) study. The study data collection proforma is included in 
Appendix 1. The patient information sheet (PIS) and consent form are included in 
Appendix 2. 
 
4.1.1 Study eligibility criteria 
 
Study inclusion criteria  
 
Either: 
(i) psoriatic arthritis (PsA) patients fulfilling the Classification of Psoriatic Arthritis 
(CASPAR) criteria for PsA [24], or 
(ii) ankylosing spondylitis (AS) patients fulfilling the 1984 modified New York diagnostic 





(i) Patients younger than 18 years of age. 
(ii) Patients with severe mechanical spinal disease (e.g. spinal canal stenosis, disc 
prolapse) that would significantly complicate the assessment of inflammatory spinal 
disease. 
(iii) Patients with other concomitant inflammatory arthritis (e.g. rheumatoid arthritis, crystal 
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4.2 STUDY RECRUITMENT 
Recruitment of study participants commenced on 1st August 2012, and completed on 10th 
October 2013. Axial radiographic scoring and laboratory testing were performed after all 
participants were recruited. 
 
All patients had previously given consent to be screened and approached for research 
studies. Four weeks in advance of scheduled PsA and AS outpatient clinics, patients 
meeting the stated eligibility criteria were identified by DJ for potential study enrolment, 
using the existing PsA and AS clinical research databases. 
 
Three weeks prior to their routine outpatient clinic attendance, 250 consecutive PsA 
patients and 250 consecutive AS patients were posted a ‘Study Invitation Letter’ and 
‘Patient Information Sheet’ (PIS) that included detailed information about the study 
rationale, design and personal implications of the study. Patients interested in taking part 
returned the enclosed ‘Study Interest Reply Slip’. Patients identified by DJ were also 




On the day of routine outpatient clinic appointment, invited patients were approached by 
their routine clinician for further face-to-face counselling with DJ. Confirmation of eligibility 
and completion of informed written consent for study enrolment were performed. 
 
Completion of patient-reported outcome measure (PROM) questionnaires, clinical 
measurements and blood sampling took take place immediately. 
 
Patients were given further opportunity to discuss the study either by telephone or in 
person with DJ if they wished. The right of a patient to refuse consent without giving 
reasons was respected. The patient was free to withdraw from the study at any time 




As only one researcher (DJ) was available to identify eligible patients, recruit patients and 
perform the clinical assessment, it was not possible to blind the assessor as to the 
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patient’s underlying diagnosis of PsA or AS. However, during axial radiographic scoring, 
the patients’ rheumatological diagnosis was undisclosed. 
 
4.3 PATIENT REPORTED OUTCOME MEASURES 
All participants independently completed the following patient reported outcome measures 
(PROMs): Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [154], Bath 
Ankylosing Spondylitis Functional Index (BASFI) [155], Stanford Health Assessment 
Questionnaire (HAQ) [156]. The Ankylosing Spondylitis Disease Activity Score (ASDAS) 
[157] was derived from the completed BASDAI, BASFI and C-reactive protein blood test. 
All PROMs were checked after completion by DJ to ensure no missing data. 
 
Patients were questioned by DJ for the presence or absence of inflammatory axial 
symptoms (current or ever), using the Assessment of Spondyloarthritis International 
Society (ASAS) definition [123]. Current or previous dactylitis, peripheral enthesitis 
(including plantar fasciitis and greater trochanteric pain), and extra-articular manifestations 
(EAMs) were also queried, including: chest wall pain, uveitis and IBD. A standardised 
description was made as follows: 
• Inflammatory pain: Insidious onset pain with stiffness that is worse first thing after 
waking or after sitting down for an hour; it improves later in the day with some 
activity / exercise; it lasts for >30 min each time; improved by NSAIDs.  
• Chest wall pain: Pain and / or swelling either side of the breast bone. 
• Enthesitis: Pain and / or swelling where ligaments join bone e.g. tennis elbow, 
golfer's elbow, Achilles tendon, front of knee cap.  
• Plantar fasciitis: Pain on the sole of the foot near the heel base. 
• Dactylitis: When a finger or toe swells up along its entire length "like a sausage", 
with a shiny stretched skin appearance. 
• Uveitis: Red painful eye that affects vision. Lasts for a week or more. Often needs 
steroid eyedrops to settle.  
• IBD: A formal diagnosis of Crohn's disease or ulcerative colitis, presenting as 
bloody diarrhoea, even at night, weight loss, and lasting for several months. 
 
An enquiry was made of a family history in first-degree relatives of SpA (PsA, AS or 
undifferentiated SpA), psoriasis, uveitis and / or IBD.  
 
The data collection proforma is included in Appendix 1.  
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4.3.1 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
 
The BASDAI is a PROM of musculoskeletal disease activity (mainly axial, but some 
peripheral), that was originally devised in 1994 for use in AS [154]. It consists of 10 cm 
visual analogue scores (VAS) to answer six questions, pertaining to the five major 
symptoms of AS over the preceding week: fatigue; spinal pain; joint pain or swelling; 
areas of localised tenderness; and morning stiffness (Appendix 1). To give each symptom 
equal weighting, the mean of the two scores relating to morning stiffness is taken. The 
resulting 0 to 50 score is divided by five, to give a final score range for the BASDAI of 0 to 
10. A BASDAI score of greater than or equal to four, is considered to indicate active 
disease [158, 159]. A score of less than four is considered to indicate inactive disease [158, 
159].  Clinical response is regarded as a reduction in BASDAI of 2 units or more [158, 159]. 
The minimum clinically important difference (MCID) for the BASDAI is considered to be 
one unit [160]. Absolute values for BASDAI in AS compared with age and sex-matched 
healthy controls have been determined as reference centile charts [161]. In AS the 
BASDAI has shown to be feasible, reliable, have good score distribution, and good 
sensitivity to change [154, 162]. The BASDAI has subsequently been validated for use in 
PsSpA [163, 164], and this is discussed in more detail in Chapter 5. 
 
4.3.2 Bath Ankylosing Spondylitis Functional Index (BASFI) 
 
The BASFI is a PROM designed to determine the degree of functional limitation in 
patients with AS, and was conceived in 1994 [155]. It consists of 10 cm visual analogue 
scores (VAS) to answer ten questions relating to functional ability during the preceding 
week. Eight questions consider activities related to functional anatomy, and two questions 
assess the patient’s ability to cope with everyday life (Appendix 1). The resulting 0 to 100 
score is divided by ten, to give a final score range for the BASFI of 0 to 10. A BASFI score 
of greater than or equal to five, is considered to indicate poor functional ability [155, 165]. 
A score of less than five is considered to indicate good functional ability [155, 165].  
Clinical response is regarded as a reduction in BASFI of 2 units or more [155, 160]. The 
MCID for the BASDAI is considered to be 0.7 unit [160]. Absolute values for BASFI in AS 
compared with age and sex-matched healthy controls have been determined as reference 
centile charts [161].  Further details for the BASFI are given in Chapter 5. In AS the BASFI 
has shown to be feasible, reliable, have good score distribution, and good sensitivity to 
change [155, 162]. The BASFI has subsequently been validated for use in PsSpA [64], 
and this is discussed in more detail in Chapter 5. 
 
  67  
4.3.3 Ankylosing Spondylitis Disease Activity Score (ASDAS) 
 
The ASDAS is a composite score comprising PROMs and one objective laboratory 
measure of inflammation, the C-reactive protein (CRP). The ASDAS comprises three 
questions from the BASDAI and one question from the BASFI. It was originally devised for 
AS as an indicator of musculoskeletal (axial mainly, but also including peripheral) disease 
activity. Its main strength over the BASDAI is thought to be its inclusion of an objective 
biochemical marker of inflammation, the CRP [157]. The ASDAS comprises four grades of 
disease activity; inactive (score ≤1.2), moderate (score 1.3 to 2.0), high (score 2.1 to 3.4) 
and very high (score ≥3.5) [166]. A clinically important improvement is regarded as a 1.1 
unit change, and a major improvement as a ≥2 unit change [157]. The ASDAS has 
subsequently been validated for use in PsSpA [163, 164], and this is discussed in more 
detail in Chapter 5. 
 
4.3.4 Health Assessment Questionnaire (HAQ) 
 
The HAQ was originally devised for use in RA to measure physical function. It was 
subsequently validated for use in PsA [167-170]. Twenty questions relating to a patient’s 
ability to perform activities related to daily living over the last week are asked in eight 
domains: dressing and grooming; rising; eating; walking; hygiene; reach; grip; and 
activities (Appendix 1). Each question is graded by the patients on a 0-3 Likert scale from 
“no difficulty” to “unable to do”.  The score range of the final HAQ is continuous from 0 to 
3, and is graded as follows: 0 to 1, mildly disabled; >1 to 2, moderately disabled; >2 to 3, 
severely disabled [162, 167]. The MCID for the HAQ in PsA is considered to be 0.35 
[171]. The HAQ was modified for use in SpA by including two spinal domains (HAQ-S) 
[172], and for use in PsA by the addition of a skin domain (HAQ-SK) [167, 173]. However, 
the HAQ, HAQ-S and HAQ-SK have been shown to perform similarly [174]. Additionally, 
use of the same version of the HAQ across all rheumatological conditions may allow for 
more reliable comparison across diseases. Therefore in this study, the original HAQ was 
used. 
 
4.4 CLINICAL EXAMINATION 
All patients were examined and scored by DJ using the following clinical examination 
indices: Bath Ankylosing Spondylitis Metrology Index (BASMI) [175], chest expansion, 
Leeds Enthesitis Index (LEI) [176], 68 tender joint count (TJC) [177], 66 swollen joint 
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count (SJC) [177], Psoriasis Area and Severity Index (PASI) [178], and modified Nail 
Psoriasis Severity Index (mNAPSI) [179]. 
 
DJ was trained to perform the BASMI and chest expansion from AS specialist 
physiotherapists in the RNHRD who regularly perform it, alongside a review of the papers 
reporting the inception and application of the tools. DJ was trained to perform the PASI, 
TJC, SJC and mNAPSI from the PsA specialist nurses who regularly perform it as part of 
clinical and observational trials, alongside a review of the papers reporting the inception 
and application of the tools. 
 
4.4.1 Bath Ankylosing Spondylitis Metrology Index (BASMI) 
 
The BASMI is a clinical examination index designed to determine the degree of axial 
range of movement (metrology) limitation in patients with AS, and was conceived in 1994 
[175]. It is performed by a trained health professional and measures five key metrology 
domains: cervical rotation (with a value ≤70 degrees considered to be limited); ear tragus 
to wall distance (a marker of abnormally forward neck position); lumbar side-flexion (with a 
value ≤10 cm considered to be limited); modified Schober’s (a measure of forward lumbar 
flexion; with a value ≤5 cm considered to be limited); and inter-malleolar distance (a 
marker of hip disease) (Appendix 1). For cervical rotation, lumbar side flexion and tragus 
to wall, a mean of the left and right measurements are taken. The absolute values of each 
of the five domains are graded for metrology limitation, to give a final score range for the 
BASMI of 0 to 10. The MCID for the BASMI is considered to be one unit [160]. Absolute 
values for BASMI in AS compared with age and sex-matched healthy controls have been 
determined as reference centile charts [161]. In AS the BASMI has shown to be feasible, 
accurate, reliable, and have good sensitivity to change [162, 175]. The BASMI has 
subsequently been validated for use in PsSpA [62, 64, 180], and this is discussed in more 
detail in Chapter 5. 
 
4.4.2 Chest expansion 
 
Chest expansion is measured by the health professional at the level of the nipple using 
two hands clasped against the chest wall during full exhalation. As the patient inhales, the 
expanded distance between the examiner’s thumbs is recorded in centimeters. Normal 
chest expansion is ≥5 cm, but can be adjusted for the height and sex of the patient. Chest 
expansion tends to be reduced in patients with AS due to arthritis of the thoracic joints, but 
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the inter-rater reliability of the method has been variable in clinical studies [175]. The 
validity of chest expansion measurement in PsSpA has not been established. 
 
4.4.3 Leeds Enthesitis Index (LEI) 
 
The LEI measures six peripheral sites for the presence or absence of enthesitis as a 
binary outcome, and was both devised and validated for use in PsA [176]. The sites (three 
on each side of the body) are the: lateral epicondyle of the humerus (outer edge of the 
elbow); medial femoral condyle (inner edge of the knee); and Achilles tendon insertion at 
the calcaneum. The examiner applies moderate pressure (enough to blanche the finger 
nail) to these six sites to potentially elicit tenderness. The total score range is 0 to 6. 
Higher count represents greater enthesitis burden, but the score range has not been 
further sub-categorised in PsA [181]. 
 
4.4.4 Psoriasis Area and Severity Index (PASI) 
 
The PASI was devised and validated for use in psoriasis [178]. The examiner grades the 
head, arms, trunk and legs according to four domains: surface area affected; erythaema 
(redness); desquamation (scaling); and infiltration (elevation of the plaque above the 
adjacent skin surface). The calculation of the final PASI is somewhat complex and is 
therefore detailed in Figure 4.1. The PASI score range is 0 to 72, but most patients are 
clustered between 0 and 15, and few patients have PASIs at the upper end of the scale; 
patients with very severe psoriasis usually have a PASIs of ≤40 [182]. A reduction in PASI 
score of ≥50% is regarded as a clinically significant end-point in the assessment of 
psoriasis, but an improvement of ≥75% is often the primary end-point in clinical trials 
[183]. However, there is evidence that PASI-75 calculation (delta-PASI) may under-
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4.4.5 Modified Nail Psoriasis Severity Index (mNAPSI) 
 
The mNAPSI was devised and validated for use in psoriasis [179]. It scores all ten 
fingernails for: onycholysis (lifting of the distal nail; graded 0-3); pitting (small depressions 
in the nail; graded 0-3); crumbling (graded 0-3); leuconychia (excess whitening of the nail; 
graded 0-1 as present / absent); splinter haemorrhage (fine black lines of the nail; graded 
0-1 as present / absent); hyperkeratosis (thickening of the nail; graded 0-1 as present / 
absent); and red spot lunula (red discolouration of the proximal nail bed; graded 0-1 as 
present / absent), as detailed in Figure 4.2. These individuals scores are added to give the 
final mNAPSI score range of 0 to 140. Higher scores represent worse nail disease, but 
have not been further sub-categorised for severity as yet. The toe nails are not scored, as 
they are frequently affected by fungal nail disease, that can mimic psoriatic nail disease. 
The patient and clinician also grade their overall impression of the nail disease using a 0 







x 0.1 =   + +  =
x 0.2 =   + +  =
x 0.3 =   + +  =
x 0.4 =   + +  =
Extent          Total            {            SEVERITY                   }             Total         Total Extent x





.PASI (PsA Skin Index)=extent x severity
                       (max 72)
PASI     (Psoriasis Area Severity Index)
ADIPSA Study                                                                      Page 9 of 12                 V2 (24.04.2012)
1.25mm elevationVery thick scaleDeep red or purple4 – very severe
1mm elevationThick white scaleVery red3 – severe
0-0.75mm elevationModerate scaleDarker pink or red2 – moderate
0-0.5mm elevationFine white scalePink or light red1 – slight
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Figure 4.2. Modified Nail Psoriasis Severity Index (mNAPSI) 
 
4.4.6 Tender and swollen joint counts 
 
A selection of 68 peripheral and root (hip, shoulder and costal) joints commonly affected in 
PsA are usually evaluated in cross-sectional and longitudinal clinical studies of PsA [177]. 
Sixty eight of these joints are assessed for tenderness (tender joint count; TJC) and 66 for 
swelling (swollen joint count; SJC) by the examiner (Appendix 1). Tenderness is elicited 
by the application of enough pressure to blanche the examiner’s finger nail. The hip joint 
can not reliably be examined for swelling, and both hips are therefore excluded from the 
SJC. Whilst this method has shown good intra-rater reliability [177], the inter-reliability is 
poorer [184]. 
 
4.5 AXIAL RADIOGRAPHIC ASSESSMENT 
The most recent axial radiographs of the cervical (lateral), lumbar (lateral and 
anteroposterior) and pelvis (including SIJs) making a complete set were scored using the 
two most validated axial radiographic scoring tools for PsA; the Psoriatic Arthritis 
Spondylitis Radiology Index (PASRI) [185] and the modified Stoke Ankylosing Spondylitis 
Spinal Scoring tool (mSASSS) [186]. These scoring tools and their validation for use in 
mNAPSI         (modified Nail Psoriasis Severity Index)
R1    R2     R3      R4       R5             L1        L2      L3        L4       L5
CUMULATIVE TOTAL (Range 0-140)
Onycholysis     (0-3)
Pitting         (0-3)
Crumbling       (0-3)
Leukonychia     (0-1)
Splinter haem   (0-1)
Hyperkeratosis  (0-1)
Red spot Lunula (0-1)
Global assessment of nails - PATIENT
Global assessment of nails - RESEARCHER
0 100
0 100
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this study, along with the full methods for scoring are described in more detail in Chapter 
6. 
 
Where possible, radiographs taken at the same time-point were scored as a set. Where 
radiographs were taken at different time-points, the most recent time-point was taken as 
the date of radiographic assessment, on the condition that the interval between the 
earliest and latest radiograph was ≤5 years. All but six cases had radiographs taken within 
five years of study recruitment. The remaining six patients had one region of the spine 
radiographed between 5-7 years prior to study enrolment. 
 
4.5.1 Definition of inflammatory radiographic axial disease 
 
In keeping with previous publications, inflammatory radiographic axial disease (RAD) was 
defined as: the presence of modified New York criteria unilateral grade ≥3, or bilateral 
grade ≥2 sacroiliitis on AP pelvic radiograph; and / or ≥1 marginal / paramarginal 
syndesmophyte(s) of the cervical or lumbar spine [93, 187]. 
 
4.6 BLOOD SAMPLING  
Each patient had a blood sample taken for serum-soluble biomarker testing and high-
sensitivity CRP testing using commercially available enzyme-linked immunosorbent assay 
(ELISA) kits. Each patient also had a blood sample taken for deoxyribonucleic acid (DNA) 
extraction at the Bath Institute for Rheumatic Diseases (BIRD) laboratory, followed by 
HLA-B and HLA-C -sequencing by Professor Robert Winchester’s team at Columbia 
University, New York, USA. Full details of methods used to test for serum-soluble 
biomarkers are given in Chapter 7. 
 
4.7 DATA-HANDLING 
All data were collected and stored confidentially in Case Report Files (CRFs) at the 
RNHRD. All information collected during the course of the study will be kept strictly 
confidential. Information will be held securely on paper and electronically at the RNHRD, 
under the auspices of the RNHRD Data Protection Officer, in accordance with the Data 
Protection Act 1998. Operationally this included: 
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(i) Consent from patients to record personal details including name, date of birth, address 
and telephone  number, National Health Service (NHS) identification number, hospital 
identification number, General Practitioner name and address. 
(ii) Appropriate storage, restricted access and disposal arrangements for patient personal 
and clinical details. 
(iii) Consent from patients for access to their medical records by responsible individuals 
from the research staff, the sponsor or from regulatory authorities, where it is relevant to 
study participation. 
(iv) Consent from patients for the data collected for the study to be used to evaluate safety 
and develop new research. 
 
In accordance with the principles of Good Clinical Practice and U.K. Clinical Trial 
Regulations guidelines, at the end of the study, data will be securely archived for a 
minimum of ten years. Arrangements for confidential destruction will then be made. Any 
patient withdrawing consent for their data to be used, will have their records confidentially 
destroyed.  
 
4.8 STATISTICAL ANALYSIS & POWER CALCULATION 
4.8.1 Power calculation 
 
The target for study recruitment was 200 PsA and 200 AS cases. The power calculations 
for each element of the study (clinical, radiographic, serum biomarker and genetic 
biomarker) are described separately in the corresponding chapter of this thesis.  
 
4.8.2 Statistical analysis 
 
The statistical analyses specific to each study within this thesis are described in the 
relevant chapters. 
 
Data were analysed using STATA 12.1 (2011 Texas, USA). Some data were analysed 
using ‘R’ (GNU Project, The R Foundation, Vienna, Austria) when help was sought from 
academic colleagues at the University of Bath (Dr. Gavin Shaddick, Reader of 
Mathematics, Department of Mathematical Sciences; and Ms Amelia Jobling, PhD 
Student, Department of Pharmacy and Pharmacology). 
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Univariate analyses were performed using the continuity-corrected Chi-squared test for 
categorical variables, independent Student’s t-test for normally distributed continuous 
data, the Mann-Whitney U test for non-normally distributed continuous data, Poisson 
regression for non-normally distributed continuous data comprised of integers, and zero-
inflated Poisson regression for non-normally distributed continuous data with an excess of 
zero-values. Negative binomial regression and zero-inflated negative binomial regression 
were considered as an alternative to Poisson regression where the mean did not 
approximate the variance of the data. 
 
Multivariate analyses were performed using logistic regression for categorical variables, 
linear regression for normally distributed continuous data, Poisson regression for non-
normally distributed continuous data, and zero-inflated Poisson regression for non-
normally distributed continuous data with an excess of zero-values. Negative binomial 
regression and zero-inflated negative binomial regression were considered as an 
alternative to Poisson regression where the mean did not approximate the variance of the 
data. A reverse step-wise regression approach was used, setting the alpha-level at 0.1 to 
determine inclusion or exclusion of covariates in the model. This allowed adjustment for 
potentially significant covariates including: sex, age at clinical assessment, age at spinal 
radiographic assessment, disease duration at clinical assessment, disease duration at 
radiographic assessment, Biologic agent use, synthetic DMARD use, smoking and body 
mass index; whilst minimising noise and maximising the statistical power of the analyses. 
 
Data are presented as mean, median, inter-quartile range (IQR), standard deviation (SD), 
odds ratio (OR), adjusted OR (ORadj), incidence risk ratio (IRR), adjusted IRR (IRRadj), 
95% confidence interval (95% CI), and p-value as appropriate to the data. The alpha-level 
for statistical significance was set at 0.05. 
 
4.8.3 Missing data handling 
 
Patients uncertain how to complete the PROMs correctly were given support by DJ to 
ensure correct and full completion. No missing data were therefore expected for the 
PROMs or clinical examination. 
 
If an entire region of radiographic data was missing, e.g. no cervical spine images 
available, those patients were omitted from that component of the analyses. However, 
available radiographs were still scored as data remained valuable for specific sub-
analyses e.g. associations with osteoproliferation as a binary outcome measure. As per 
methods used by Wanders et al. [188] and later by Lubrano et al. [185]: if >3 scoring sites 
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(e.g. lower border of T12 vertebrae) were missing, the radiographs were excluded; if ≤3 
scoring sites were missing, the mean of the other scoring sites were used as a substitute 
for the missing sites. 
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5 CHAPTER V: CLINICAL CHARACTERISTICS OF AXIAL 
DISEASE IN PSORIATIC ARTHRITIS, AND A 
COMPARISON WITH ANKYLOSING SPONDYLITIS 
 
5.1 ABSTRACT 
Background: Few studies have characterised psoriatic spondyloarthritis (PsSpA) using a 
robust classification system, and only four studies have compared the clinical 
characteristics of PsSpA and ankylosing spondylitis (AS). The objectives of this chapter of 
the thesis were to: (i) determine the prevalence of PsSpA in a cohort of SpA cases 
(psoriatic arthritis, PsA; and AS) with psoriasis; (ii) compare the sociodemographic and 
treatment characteristics of PsSpA, peripheral-only PsA (pPsA) and AS cases; (iii) 
compare patient-reported outcome measures (PROMs) and clinical examination indices in 
PsSpA, pPsA and AS cases.  
Methods: A prospective single-centre cross-sectional observational study was conducted, 
recruiting consecutive PsA and AS cases. Participants completed PROMs, were 
examined, and their axial radiographs were scored. Univariate and multivariate analyses 
were performed. 
Results: The 402 enrolled cases (201 PsA and 201 AS) were reclassified based on 
radiographic axial disease and psoriasis into three more precise groups: 118 PsSpA, 127 
pPsA, and 157 AS cases. The prevalence of PsSpA in this SpA cohort was 118/245 
(48.16%). The modified New York diagnostic criteria for AS were fulfilled by 48/201 
(23.88%) of PsA cases, and the Classification of Psoriatic Arthritis (CASPAR) criteria were 
fulfilled by 49/201 (24.38%) of AS cases.  
Symptomatically-silent but radiographically-evident PsSpA was present in 30/118 
(25.42%). pPsA compared with PsSpA cases: were less likely to be HLA-B27 positive 
(odds ratio, OR 0.12; 95% CI 0.05, 0.25; p<0.001), and have inflammatory bowel disease 
(adjusted OR, ORadj 0.12; 95% CI 0.03, 0.55; p=0.01); had older age at arthritis symptom 
onset (median 37.98 vs. 31.27 years; p=0.01); had lower psoriatic nail disease severity 
(mNAPSI; adjusted incidence risk ratio, IRRadj 0.90 per unit increase; 95% CI 0.83, 0.97; 
p=0.01), in particular nail onycholysis severity (IRRadj 0.84 per unit increase; 95% CI 0.74, 
0.95; p=0.01). Male PsA cases were no more likely to be classified as PsSpA than female 
patients. 
AS and PsSpA cases had similarly high disease activity (as measured by ASDAS, 
BASDAI, and PaGA). Axial metrology as measured by the BASMI was no different in AS 
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compared with PsSpA cases, although tragus to wall distance (adjusted mean difference 
2.00 cm; 95% CI 0.58, 3.42; p=0.006), and modified Schober test (adjusted mean 
difference -0.65 cm; 95% CI -1.14, -0.15; p=0.01) were poorer in AS compared with 
PsSpA cases. Disability (HAQ) was no different across the three disease groups. Function 
was poorer in AS compared with PsSpA cases (BASFI, IRRadj 1.17 for every 0.7 unit 
increase in score; 95% CI 1.06, 1.26; p=0.002). 
Conclusions: A significant proportion of PsA cases have PsSpA, and it is often 
asymptomatic. Up to one quarter of PsA and AS cases may be classified as the other 
disease using the currently available classification systems. Several predictors of PsSpA 
occurrence in PsA were identified. Measures of disease activity, metrology and disability 
were equally poor in PsSpA and AS cases. All three groups were equally likely to proceed 
to anti-TNF therapy, at a similar interval from diagnosis. PsSpA should no longer be 
regarded as a clinically-milder form of AS. 
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5.2 INTRODUCTION 
5.2.1 Clinical characteristics of psoriatic spondyloarthritis 
 
Ten studies have compared the sociodemographic and clinical characteristics of psoriatic 
spondyloarthritis (PsSpA) and peripheral-only PsA (pPsA; without axial disease) [61-64, 
67-69, 111, 189, 190]. From the literature, the prevalence of PsSpA in PsA cohorts is 
estimated to be 24 - 40 per 100 PsA cases [63, 69, 111]. There are no estimates of 
asymptomatic (no clinical symptoms or signs) radiographic PsSpA, but one study found 
asymptomatic radiographic cervical spondylitis to be present in 41% of PsSpA cases 
[190]. Clinical predictors for PsSpA occurrence in PsA include: male sex [58, 63, 69], 
HLA-B27 positivity [61], psoriatic nail dystrophy [61], higher number of radiographically 
damaged joints [61], high erythrocyte sedimentation rate (ESR) [61], and longer 
disease duration, such that axial disease in PsA is a late-onset feature [68, 111]. The 
latter clinical predictor may explain much of the variation in estimated prevalence of 
PsSpA in PsA cohorts; many studies have investigated PsA cases with relatively recent 
onset disease, allowing insufficient time for the PsSpA phenotype to have fully expressed. 
There are conflicting reports for both early-age at psoriasis onset [67], and later-age [69] 
at psoriasis onset being a clinical predictor of PsSpA in PsA. The following are reported as 
being more common in PsSpA compared with pPsA patients: chronic inflammatory back 
pain [69], uveitis [69], inflammatory bowel disease (IBD) [68], and peripheral joint 
ankylosis [68]. The following have been reported to be higher (i.e. poorer) in PsSpA 
compared with pPsA patients: peripheral joint counts [68], ESR [61, 62], C-reactive protein 
(CRP) [62], and axial metrology as measured by the Bath AS Metrology Index (BASMI) 
[62, 64] or by axial region [62, 69, 189]. Reports of composite indices pertaining to 
function (Bath AS Functional Index; BASFI) [62, 64], disease activity (Bath AS Disease 
Activity Index; BASDAI) [62], and disability (Health Assessment Questionnaire; HAQ) [62, 
64, 68]  have had conflicting results; with some reporting either no difference or poorer 
scores in PsSpA compared with pPsA patients. No differences between PsSpA and pPsA 
patients have been reported in terms of the occurrence of enthesitis [62], or skin severity 
(Psoriasis Area and Severity Index; PASI) [62]. In terms of prognosis, in one study male 
PsSpA cases had more advanced disease as measured by the proportion with grade 4 
sacroiliitis and lumbar forward-flexion [111]. 
 
Certain themes for similarities and differences between PsSpA and pPsA emerge, but 
many features are investigated by only one study, and are therefore never corroborated 
nor challenged. Some studies have used convenience samples as part of a retrospective 
study, with incomplete clinical and radiographic data [65]. Several studies have not or only 
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partially adjusted for confounders. Some of the earliest studies from the 1960s and 1970s 
have not statistically compared the features of PsSpA and AS, providing descriptive 
analyses only [59, 191]. One of the major reasons for disparity in study results, is that 
there is no international consensus on how to classify cohorts of PsA and ankylosing 
spondylitis (AS) cases as PsSpA, pPsA and classical AS with coincidental psoriasis. 
Studies have therefore markedly varied in their case definition, and classification systems 
employed have often not been sufficiently stringent. Case definition is the fundamental 
first stage in studies comparing clinical characteristics and outcome across groups. 
Without a robust and consistent case definition, comparisons are simply unreliable and as 
described in the literature review above, are often not reproducible in independent studies. 
Knowledge on how to best classify PsSpA has improved over time through progressively 
more clinical experience, awareness of its occurrence as an entity, inception and 
validation of clinical indices, growth of radiographic repositories to allow better powered 
studies to be conducted, newer more sensitive and specific imaging techniques, and the 
expansion of genetic testing available for these cohorts.  
 
The studies reporting these results are summarised in turn below, along with a critique of 
their study methods, reliability of results, and where possible an explanation for any 
disparity between study results. This will allow the methods and results of this chapter of 
the thesis to be put into context of the existing literature comparing the clinical 
characteristics of PsSpA and pPsA. 
 
5.2.2 Clinical features of PsSpA compared with pPsA 
 
In 1977 Lambert and Wright reported the largest detailed description of axial disease in 
PsA [69]. They described spinal disease in 130 PsA patients, and noted a prevalence of 
PsSpA of 40%, although only 51/130 (39%) had complete axial radiographs for 
assessment. Whilst the criteria to classify cases as PsSpA were not stated, they are likely 
to have been strict given that 86% of PsSpA patients, but only 27% of PsA cases with 
peripheral-only and without radiographic axial disease (pPsA) fulfilled the New York 
criteria for AS. Compared with the pPsA group, the PsSpA group had proportionally more 
males (male:female ratio, 0.6:1.0 vs. 1.2:1.0, respectively; p<0.05), less prevalent nail 
dystrophy (mean 43 vs. 86%, respectively; p<0.05), and patients had developed psoriasis 
at a later age (mean 35 vs. 24 years, respectively; p<0.05). Chronic back pain (100 vs. 
37%, respectively; p<0.05), restriction of neck movement (83 vs. 32%, respectively; 
p<0.05), lumbar movement (71 vs. 5%, respectively; p<0.05), chest expansion (71 vs. 
11%, respectively; p<0.05), uveitis (14 vs. 5%, respectively), higher values of erythrocyte 
sedimentation rate (ESR, a measure of biochemical inflammation), and HLA-B27 positivity 
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(71 vs. 18%, respectively; p<0.05) were more common in the PsSpA than in the pPsA 
groups. Of note, pPsA patients rarely had axial symptoms or signs.  
 
In a cohort study from Toronto (Canada) by Hanly et al. published in 1988, of 220 PsA 
cases followed-up for at least 30 months. 52/220 (24%) were identified as PsSpA clinically 
or radiographically at study enrollment [63]. Clinical criteria for PsSpA classification were 
moderately stringent: inflammatory pain / stiffness of the cervical / lumbar spine, with 
evidence of clinical sacroiliac disease (Gaenslen test, Patrick-FABER test, or direct 
compression). Radiographic criteria included the presence of sacroiliitis (unilateral grade 
≥2). A slight male predominance in the PsSpA group was noted (male:female ratio 30:22). 
A subsequent report in 1992, from the now larger Toronto cohort of 498 PsA cases, 
showed a higher prevalence of PsSpA of 194/498 (39%) cases [111]. This might indicate 
that the prevalence of PsSpA rises with increasing disease duration, and that axial 
disease in PsA is late-onset feature. The primary objective of the study was to compare 
males and females with PsSpA. No differences in the degree of damage, type of 
peripheral arthritis, or medication use were noted between male and female PsSpA cases. 
However, male PsSpA cases appeared to have more advanced disease as measured by 
the proportion with grade 4 sacroiliitis (16 vs. 5%; p=0.04) and finger to floor distance 
(11.2 vs. 6.7 cm; p=0.03). These differences were not explained by HLA- differences in 
males and females.   
 
In a study of 75 PsA cases from Bath, cases with radiographic cervical spondylitis, 
compared to those without, had more frequent sacroiliitis (50 vs. 7%; p<0.001), higher 
peripheral joint counts (1.88 vs. 1.31; p<0.001), peripheral joint ankylosis (49 vs. 0; 
p<0.001), and more disability as measured by the HAQ (p<0.001) [68]. IBD was found to 
be particularly frequent in those with PsSpA, emphasising the overlap of PsSpA and AS. 
IBD was present in 7/23 (30%) PsSpA, 3/15 (20%) oligoarthritic, and 0/26 polyarthritic 
PsA cases [192]. However, the prevalence of IBD in PsSpA cases appears to be 
significantly lower than that reported in non-psoriatic SpA [192]. In another study, this time 
from Finland in 2002, investigating cervical spondylitis in 160 PsA cases, 65/160 had 
cervical radiographs, and 12/65 were noted to have radiographic cervical disease. 
Cervical rotation was measured in 40/65 of these PsSpA cases, and was limited to less 
than 45 degrees on either side in 20/40 (50%) of cases [189].    
 
A study from Spain by Queiro et al. identified 14 symptomatically-silent PsSpA cases 
(radiographic axial disease in the absence of inflammatory lumbar or buttock pain) from a 
cohort of 70 PsSpA cases (20%) [190]. However, the criteria for radiographic axial 
disease was not detailed. An association between symptomatic disease and longer 
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duration of arthritis (p=0.04) was demonstrated, but no adjustment was made for sex or 
age at assessment. Sacroiliitis was present in 11/14, facet joint disease (erosion / fusion) 
in 2/14, and aseptic disciitis in 1/14. This study also indicated that radiographic cervical 
disease in particular may be asymptomatic; of 29/70 (41%) cases with radiographic 
cervical disease, only 17/29 (59%) had pain and rigidity at that level, whilst 12/29 (41%) 
were asymptomatic (without clinical symptoms or signs). 
 
The same group published a study six years later proposing that the phenotype of PsSpA 
varies according to the age at PsSpA onset [193]. Seventy patients from a SpA clinic were 
diagnosed with PsSpA according to the European Spondyloarthropathy Steering Group 
(ESSG) for SpA criteria plus radiographic sacroiliitis, and prospectively followed. Patients 
were divided into two groups: young-onset PsSpA (disease onset <40 years of age; 
n=39), and late-onset PsSpA (disease onset ≥40 years of age; n=31). Young-onset cases 
tended to have a higher frequency of bilateral sacroiliitis (62 vs. 29%; p=0.01) and be 
HLA-B27 positive (51% vs. 13%; p=0.001). Late-onset PsSpA cases had a higher 
frequency of unilateral sacroiliitis (71 vs. 38%; p=0.01), silent axial disease (32% vs. 10%; 
p=0.02), and polyarthritis (45 vs. 23%; p=0.02). No differences were found between the 
two groups in terms of composite outcome measures: BASDAI, BASFI, BASMI, 
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), or BASRI. Importantly, no 
multivariate modeling was performed in this study to adjust for the differing disease 
duration, age at assessment, or sex in the two groups. The difference in sacroiliitis 
frequency in the two groups may simply be a cohort effect; with young-onset PsA cases 
having had disease for longer, therefore more time to develop to sacroiliitis. Given that the 
ESSG criteria [60] have not shown good specificity or sensitivity for axial disease in PsA 
[24, 57], one might argue that: the young-onset PsSpA cases were in fact patients with 
classical AS with coincidental psoriasis, with the classical bilateral sacroiliitis and higher 
prevalence of HLA-B27 variants; and that the late-onset PsSpA cases were the ‘true’ 
PsSpA cases, with polyarthritic often symptomatically-silent unilateral sacroiliitis. 
 
Lubrano et al. conducted a multi-centre study in Italy of 77 ‘PsSpA’ cases  recruited 
consecutively from the outpatient department (mean age 49 years, and mean disease 
duration 14 years) [186]. PsSpA was defined on the basis of meeting CASPAR criteria, 
and the presence of clinical (axial inflammatory pain according to the Calin criteria [194]) 
and / or radiographic axial disease). The classification criteria used in this study were less 
stringent, and resulted in half the cohort (37/75) being classified as PsSpA on the basis of 
axial symptoms but no radiographic axial disease. If aligned with the classification criteria 
used by most other studies, only 40/77 cases were in fact PsSpA. As a result of the 
classification criteria employed, only 19/60 (32%) were HLA-B27 positive, and little further 
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can be gleaned from the study’s secondary objectives of describing the clinical and 
radiographic features of PsSpA. 
 
A cross-sectional study of 125 PsA cases attending a tertiary-referral hospital in Hong 
Kong, 29/125 (23%) classified PsA cases as PsSpA on the basis of radiographic 
sacroiliitis (grade ≥2 bilaterally, or grade ≥3 unilaterally) and 96/125 (77%) as pPsA [62]. 
Multivariate analyses were not conducted, and no adjustments were made for the longer 
disease duration in the PsSpA cases compared with pPsA cases. Univariate analyses 
showed no difference between the two groups in terms of proportion of males, tender joint 
counts, swollen joint counts, current dactylitis, enthesitis burden as measured by the 
MASES, BMI, or psoriasis severity as measured by the PASI. Compared with pPsA 
cases, the PsSpA cases had higher CRP (9.6 vs. 17.4 mg/L; p=0.02) and ESR (28.4 vs. 
43.6 mm/h; p=0.01) levels. However, no adjustment was made for BMI which is known to 
influence CRP levels. 
 
5.2.3 Risk factors for axial disease in PsA 
 
Risk factors for axial involvement in 206 PsA cases were investigated in a prospective 
cohort study by Chandran et al., published in 2010 [61]. PsA patients were classified as 
PsSpA using stringent criteria: sacroiliitis (grade ≥2 bilaterally or grade ≥3 unilaterally), 
and inflammatory spinal pain and / or limited spinal mobility. Multivariate analyses showed 
that the risk of having PsSpA, rather than pPsA, was significantly increased by higher 
radiographically damaged peripheral joint count (OR 1.12; 95% CI 1.07, 1.17; p<0.0001), 
HLA-B27 positivity (OR 5.75; 95% CI 2.22, 14.90; p=0.0003), and an elevated ESR (OR 
1.02; 95% CI 1.01, 1.04; p=0.003).  
 
In the same study, of the 156 PsA patients without evidence of PsSpA at their first clinic 
visit, 28/156 developed PsSpA during a median follow-up period of 6.4 (range 0.5 to 31) 
years [61]. The risk of developing PsSpA during follow-up was increased by the presence 
of nail dystrophy (relative risk, RR 7.07; 95% CI 1.56, 43.04; p=0.01), the presence of 
periostitis (RR 5.67; 95% CI 2.11, 15.27; p<0.0001), higher radiographically damaged 
peripheral joint count (RR 1.11; 95% CI 1.05, 1.17; p<0.0001), elevated ESR (RR 1.03; 
95% CI 1.01, 1.05; p=0.001). After ten years of follow-up, it was estimated that 15% would 
develop PsSpA.  The findings were similar when the criteria for PsSpA were relaxed to 
radiographic criteria alone. Male sex, number of radiographically damaged joints, and 
elevated ESR increased the odds of having PsSpA at the first clinic visit, and developing it 
during follow-up. These risk factors align with the currently accepted theory for the 
pathogenesis of SpA: psoriatic nail dystrophy is thought to indicate inflammation of the 
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synovial entheseal complex; and periostitis is thought to be a precursor to 
osteoproliferation [195]. 
 
Jenkinson et al. reported disease duration to be longer in PsA cases with cervical 
spondylitis, than in those without (18.7 vs. 6.6 years; p<0.001) (n=75), implying that the 
prevalence of cervical spondylitis rises with increasing disease duration [68]. Radiographic 
cervical spondylitis was not related to sex, age at arthritis onset, arthritis severity, skin 
psoriasis severity as measured by the PASI, psoriatic nail dystrophy severity as measured 
by the Bath Nail Score, or any of the other four subgroups of PsA. It is difficult to 
generalise these risk factors for cervical spondylitis to PsSpA affecting the whole spine, 
nonetheless, this study identifies potential risk factors to explore further in PsSpA. 
 
Most studies of PsSpA have been performed in Caucasian populations. In a Korean 
population, Baek et al. demonstrated an earlier age of psoriasis onset (median age 22 vs. 
31 years; p=0.03), and an earlier age of arthritis onset (median age 29 vs. 44 years; 
p=0.01) in PsSpA cases compared with pPsA cases [67]. The authors reported the 
prevalence of HLA-B27 positivity in PsA cases to be 8%, which is comparable to other 
general PsA cohorts, but unfortunately did not report the prevalence of HLA-B27 in their 
PsSpA cases. This would have been particularly interesting given the unique non-
Caucasian ancestral origin of this PsA cohort. In addition, comparisons between PsSpA 
and pPsA cases were not adjusted for HLA-B27 status, which would certainly have 
influenced the results. 
 
5.2.4 Prognosis of PsSpA 
 
In two studies, both using the Toronto cohort, PsSpA cases did not have a poorer 
prognosis than pPsA cases [30, 196]. However, males PsSpA cases were found to have 
more advanced disease than females, as measured by grade 4 sacroiliitis and finger to 
floor distance, even after adjustment for HLA-B27 status, age and disease duration [111]. 
 
The prospective Toronto cohort was used to evaluate disease course in PsSpA patients at 
study entry, five-year and ten-year follow-up [187]. Of 297 cases at study entry (mean age 
43 years, arthritis duration 8 years), 56% had axial symptoms, 43% had radiographic 
sacroiliitis, and 13% had syndesmophytes. The frequency of patient-reported spinal pain, 
spinal stiffness, and clinical-sacroiliitis decreased significantly at both five and ten-year 
follow-up. However, there was a significant increase in the number of patients with 
clinician-measured restricted cervical mobility at both five and ten-year visits. This 
highlights the disparity between patients-reported and clinician-measured clinical indices, 
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and their potential reliability for use in longitudinal studies of PsSpA. Of those cases 
without sacroiliitis at baseline, 37% developed sacroiliitis (grade ≥2) at five-years, and 
52% developed sacroiliitis at ten-years follow-up. Of those cases who presented with 
grade two sacroiliitis at baseline, 47% progressed to a higher grade at five-years, and 
52% at ten-years follow-up. 25% of cases progressed from grade three to four sacroiliitis 
at ten-years follow-up. Of the patients without cervical, thoracic, or lumbar 
syndesmophytes at baseline: 11, 16, and 14% developed syndesmophytes in these 
regions at five-year follow-up, respectively; and 14, 21, and 20% at ten-years follow-up, 
respectively [187]. 
 
There have been no clinical trials specifically recruiting PsSpA cases. A very limited 
amount of data is available from a handful of biological studies of general PsA cohorts that 
have performed sub-analyses in those with PsSpA [197]. The impact of anti-TNF and 
NSAIDs therapy on structural progression in the related condition AS, also remains 
inconclusive [198]. 
 
5.2.5 Patient reported outcome measures in PsSpA: Utility and validation 
 
Some patient reported outcome measures (PROMs) have been used and at least partially 
validated in axial PsSpA. These were briefly discussed in Chapter 4, and are discussed in 
more detail below. 
 
5.2.5.1 Health Assessment Questionnaire Disability Index (HAQ) 
 
In a Spanish study of 46 PsSpA, 54 pPsA, and 103 AS patients, the Health Assessment 
Questionnaire Disability Index (HAQ) was a good measure for disability related to 
peripheral arthritis, but less so for disability related to axial arthritis [64]. However, it did 
not differentiate between the PsSpA and pPsA groups. Although used widely in clinical 
practice for PsA, the results of this single study indicate that the HAQ may not be an 
effective tool for evaluating both peripheral and spinal disability in PsSpA. The HAQ was 
modified for use in SpA by including two spinal domains (HAQ-S) [172], and for use in 
PsA by the addition of a skin domain (HAQ-SK) [167, 173]. However, the HAQ, HAQ-S 
and HAQ-SK have been shown to perform similarly [174]. Additionally, use of the same 
version of the HAQ across all rheumatological conditions may allow for more reliable 
comparison across diseases. 
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5.2.5.2 Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) 
 
In the same Spanish study, PsSpA cases reported higher BASFI scores than pPsA cases 
[64]. The BASFI showed good correlation with radiographic structural damage, as 
measured by the Bath AS Radiology Index (BASRI). Therefore, the authors proposed that 
the BASFI may be a useful tool for measuring function in PsSpA.  
 
BASDAI performed similarly in evaluating disease activity in PsSpA, pPsA, and in AS 
(Cronbach’s alpha 0.65, 0.78, and 0.79, respectively) [199]. The analysis of convergent 
validity showed that in pPsA and PsSpA patients, the BASDAI was significantly correlated 
with other subjective disease activity parameters. For responsiveness, no association was 
found between changes in the BASDAI and changes in disease activity either in pPsA or 
in PsSpA. A study from Wellington (New Zealand) by Taylor et al., showed BASDAI 
performs similarly for PsSpA and pPsA, but does not correlate well with external indicators 
of disease activity, such as treatment decisions [200]. 133 PsA patients identified from a 
disease-register, completed a postal questionnaire, and 86/133 consented to be 
examined. BASDAI correlated highly with patient perception of disease activity (Spearman 
r=0.739), but PsSpA and pPsA performed no differently. BASDAI was not associated with 
high or low disease activity as measured by other means: physician PGA, HAQ, Short 
Form-36 (SF-36), joint counts or acute phase reactants. 
 
A prospective cross-sectional study comparing 1072 AS, 147 PsSpA, and 45 enteropathic 
SpA (eSpA) patients (with similar disease duration, but younger age in the AS group) 
found that BASDAI, BASFI, and quality of life (as measured by the AS Quality of Life 
score; ASQoL) were no different across the three groups [201]. In another study, twenty 
nine PsSpA cases were compared with 96 pPsA cases. The two groups were no different 
in terms of HAQ, BASDAI, BASFI, global pain (patient reported on a 100mm VAS), global 
health (patient reported on a 100mm VAS), or quality of life (SF-36) [62]. 
 
5.2.5.3 Ankylosing Spondylitis Disease Activity Score (ASDAS)  
 
The discriminative ability and correlation of the Ankylosing Spondylitis Disease Activity 
Score using CRP (ASDASCRP) and BASDAI with disease activity in PsSpA was tested in a 
study by Eder et al. in a large prospective cohort of PsA cases, and published in 2010 
[163]. Patients were categorised into high and low disease activity states based on the 
patient’s global assessment score (PaGA), physician’s (PhGA) global assessment score, 
and physician’s decision to change treatment. In 201 PsSpA patients enrolled, ASDAS 
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and BASDAI showed good correlation with disease activity as reflected by the PaGA 
(correlation coefficient for BASDAI r=0.84, ASDAS r=0.81) and the PhGA (BASDAI 
r=0.53, ASDAS r=0.55). Both scores showed good discriminative ability between high and 
low disease activity states. However, there were no significant differences between areas 
under the curve for the models that compared ASDAS with BASDAI for each definition of 
disease activity state. BASDAI and ASDAS were therefore deemed to have similar good-
moderate discriminative ability and correlation with different constructs of disease activity 
in PsSpA.  
 
Subsequently in 2014, Kilic et al. compared the discriminative ability of ASDAS and 
BASDAI in 54 PsSpA cases from the Erciyes Spondyloarthritis Cohort and Anatolian 
Group for the Assessment in Rheumatic Disease cohorts [164]. ASDAS (both CRP and 
ESR versions) and BASDAI showed similar good discriminative ability between high and 
low disease activity, as reflected by the area under the curve analysis. The cut-off values 
for inactive disease (1.59) and high disease activity (2.03) were relatively similar to the 
cut-off values used in AS.  
 
5.2.6 Clinical examination in PsSpA: Utility and validation 
 
Some clinical examination indices have been used and at least partially validated in 
PsSpA, and will be discussed now. The International Spondyloarthritis Inter-observer 
Reliability Exercise (INSPIRE) study first demonstrated that the BASMI and its 
components (occiput to wall distance, tragus to wall distance, cervical rotation, Schober 
test) and chest expansion, all originally devised for use in AS, are also reliable in PsSpA 
[180]. These findings were corroborated in a more recent study of 46 PsSpA, 54 pPsA 
and 103 AS patients in Spain [64]. PsSpA patients demonstrated poorer metrology 
compared with pPsA cases, but of note, only minor differences were demonstrated 
between PsSpA and AS cases. The modified Schober test, lumbar side flexion, and 
cervical rotation were the more suitable measurements for assessing axial PsA.  
 
The usefulness of various spinal mobility measurements in predicting PsSpA were 
evaluated in a cross-sectional study of 125 PsA cases in Hong Kong [62]. 29/125 (23.2%) 
were classified as PsSpA (based on sacroiliitis of grade ≥2 bilaterally, or grade ≥3 
unilaterally) and 96/125 as pPsA. The BASMI differentiated PsSpA and pPsA. 
Components of the BASMI; tragus-to-wall distance, modified Schober test, and lumber 
side-flexion showed good sensitivity and specificity in predicting PsSpA. In the logistic 
regression model, lumber side flexion (independently) and modified Schober test best 
differentiated PsSpA and pPsA. 
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5.2.7 Comparison of PsSpA and AS 
 
Only four studies have compared the sociodemographic and clinical characteristics of 
PsSpA and AS [49, 58, 64, 201]. The following are reported to be more common in PsSpA 
compared with AS: enthesitis [201], peripheral arthritis [201], and dactylitis [201]. Spinal 
pain and / or stiffness has been shown to be more frequent in AS compared with PsSpA 
patients [49, 201]. The following are reported to be poorer or have higher scores in AS 
compared with PsSpA: metrology [201] as measured by the BASMI [64], occiput to wall 
distance [64], Schober test of lumbar forward-flexion [49, 58, 64], and chest expansion 
[64] although not consistently [58]. Radiographic severity as measured by the Bath AS 
Radiology Index (BASRI) in one study was higher in AS compared with PsSpA [201], but 
no different as measured by five radiographic indices in another study [202]. Several 
composite indices are reported to be no different in AS and PsSpA cases: disease activity 
(BASDAI) [201], function (BASFI) [201], and quality of life [201]. 
 
In these studies certain themes for similarities and differences between PsSpA and AS 
emerge. However, on closer inspection it is noted that these studies have used various 
classification systems for their cases, for some clinical characteristics no other studies 
have attempted to replicate results in an independent cohort, different sampling methods 
and study design have been used, and the disease duration in some PsA cohort may 
simply be to short to have allowed full expression of the PsSpA phenotype. The studies 
reporting these results are summarised in turn below, along with a critique of their study 
methods, reliability of results, and where possible an explanation for any disparity 
between study results. This will allow the methods and results of this chapter of the thesis, 
investigating and comparing the clinical characteristics of PsSpA and AS, to be put into 
context of the existing literature. 
 
5.2.7.1 Clinical features in PsSpA and AS cases 
 
In 1974, an expert in the field of PsA, Professor John Moll drew on the literature and his 
clinical experience, and wrote that PsSpA is probably a specific entity, as an alternative 
expression of PsA, but that in most cases there are no clinical or radiological differences 
from classical AS [203]. This has been supported, but also contested by researchers and 
commentators. Only four studies have directly compared PsSpA with AS cases in terms of 
clinical characteristics [49, 58, 64, 201], however, all but one have had a small sample 
size. 
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In 1993, Gladman et al. compared 66 PsSpA and 40 AS in terms of clinical, radiographic 
and HLA-status [49]. The criteria for classifying the PsA patients as PsSpA were relatively 
weak: the presence of inflammatory back pain / stiffness; and / or sacroiliitis on clinical 
examination; and / or grade ≥2 sacroiliitis; and / or ≥1 paramarginal syndesmophyte. The 
proportion of PsSpA patients earning their classification by each of the four routes was not 
reported, and a patient could have been classified as PsSpA on the basis of symptoms 
alone or clinical-examination sacroiliitis alone, without any radiographic evidence of 
disease. Even if radiographic disease was present, grade 2 sacroiliitis is relatively easy to 
attain, might not be pathological, and tends to have only moderate inter-rater reliability. In 
this study, clinical examination was performed by several different assessors, and intra- 
and inter-rater reliability testing not reported. Nonetheless, the authors reported that after 
adjusting for the pronounced differences in sex, age at assessment, and disease duration 
between the two groups, the AS patients were noted to have a higher frequency of 
inflammatory spinal (neck and / or lumbar) pain, inflammatory spinal stiffness (p<0.0002), 
and limitation of lumbar spinal movements (p<0.0006).  
 
In a study by Helliwell et al. comparing 34 PsSpA, 91 AS, 31 eSpA, and 7 reSpA patients, 
all fulfilling modified New York criteria for AS, the PsSpA and AS cases were no different 
in terms of male:female ratio (approximately 3:1) [58]. Given that the ratio of males to 
females in general PsA cohorts is usually 1:1, and although the findings in this paper were 
not adjusted for age or disease duration, it does infer that males are more likely to 
experience PsSpA. A significant difference in lumbar forward flexion (using the modified 
Schober’s method) was found across the groups, and poorest in AS. Chest expansion 
was no different across groups. The results of this thesis chapter will be less directly 
comparable with the study by Helliwell et al. because our cases were not required to fulfill 
mNY criteria for AS; which require inflammatory spinal pain, radiographic sacroiliitis, and 
reduced range of movement in two planes. Simply through study eligibility criteria, our 
PsSpA cases may therefore be less severe than those reported by Helliwell et al. 
 
Perez-Alamino et al. compared 2,044 consecutive SpA patients meeting ESSG criteria for 
SpA, to determine differential characteristics of axial involvement in PsSpA, AS and 
enteropathic SpA (eSpA) in a cohort of Ibero-American cases [201]. A total of 1,264 
patients met the 1984 modified New York criteria for AS, and were further subclassified as 
1072 AS, 147 PsSpA, and 45 eSpA. Median disease duration was comparable across the 
groups, but AS patients were significantly younger (p=0.01), and had a higher proportion 
of males (p=0.01). Analyses were therefore adjusted for sex, age and disease duration. 
AS patients had more prevalent inflammatory back and / or sacroiliac pain (p=0.05) than 
PsSpA patients. The frequency of dactylitis, enthesitis, and peripheral arthritis was higher 
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in PsSpA patients than in AS patients (p=0.05). Compared with PsSpA patients, patient 
with AS have more severe axial involvement in terms of metrology, radiographic severity 
as measured using the BASRI total, and prevalence of IBP.  Other clinical indices were no 
different between the two groups: disease activity, function, and quality of life. In 
summary, PsSpA appears to be as disabling as primary AS for two reasons: the disease 
progresses for a long time period, and brings with it the burden of peripheral arthritis. 
 
5.2.7.2 Examination indices in PsSpA and AS 
 
In a prospective cross-sectional study comparing 1072 AS, 147 PsSpA, and 45 eSpA 
patients (with similar disease duration, but younger age in the AS group), AS patients had 
more limited spinal mobility than the other two groups (p=0.0001) [201]. Another study 
comparing AS and PsSpA patients showed significantly worse occiput to wall distance, 
chest expansion and a lower modified Schober score in the AS patients [64]. 
 
5.2.7.3 Prognosis in PsSpA and AS 
 
In a study with the primary objective to compare the reliability of four radiographic scoring 
methods for PsSpA (n=40) and AS (n=18), the two groups were found to differ in terms of 
severity score [202]. The PsSpA and AS cases were no different in terms of sex, age at 
radiograph or disease duration. Acknowledging the small sample size, and this being a 
secondary outcome analysis, axial disease severity was no different in PsSpA and AS 
cases as measured by the PASRI (p=0.12), mSASSS (p=0.49), BASRI-spine (p=0.26) or 
RASSS (p=0.70). 
 
The clinical course of PsSpA was observed to be less disabling than that of AS in one 
study [70]. Whether clinical and radiographic severity differences between AS and PsSpA 
exist, as reported by some studies [58, 111, 204], is determined by the PsSpA 
classification criteria employed. Thresholds for classification of PsSpA have been very low 




Through a robust clinical and radiographic case classification system, this thesis chapter 
aims to investigate areas of limited knowledge and features of PsSpA important to 
patients. Comparisons will be made with the existing literature, to either corroborate or 
challenge the results of previous studies, and where possible explain any disparity. 
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5.3 STUDY OBJECTIVES 
The objectives of this study chapter were to:  
 
(i) determine the prevalence of PsSpA in a cohort of SpA (PsA and AS) cases with 
psoriasis. 
 
(ii) compare the sociodemographic and treatment characteristics of PsSpA, pPsA and AS 
cases. 
 
(iii) compare patient reported outcome measures in PsSpA, pPsA and AS cases. 
 
(iv) compare clinical examination indices in PsSpA, pPsA and AS cases. 
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5.4 METHODS 
A comprehensive description of general methods for this component of the Axial Disease 
in PsA (ADIPSA) study are detailed in Chapter 4 (Study Design and General Methods). 
Specific methods for this component of the study are described below. To avoid repetition, 
some items pertaining to radiographic methods, are provided in more detail in Chapter 6. 
 
5.4.1 Patient reported outcome measures 
 
All participants completed the following patient reported outcome measures (PROMs): 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [154], Bath Ankylosing 
Spondylitis Functional Index (BASFI) [155], Stanford Health Assessment Questionnaire 
Disability Index (HAQ) [156]. The Ankylosing Spondylitis Disease Activity Score (ASDAS) 
[157] was derived from the completed BASDAI, BASFI and C-reactive protein blood test. 
To ensure no missing data all PROMs were checked after completion by DJ. 
 
Patients were also questioned by DJ for the presence or absence of inflammatory axial 
symptoms (current or ever), using the ASAS definition [123]. Current or previous extra-
articular manifestations (EAMs) were also queried, including: dactylitis, peripheral 
enthesitis (including plantar fasciitis and greater trochanteric pain), chest wall pain, uveitis 
and IBD. An enquiry was made of a family history in first-degree relatives of SpA, 
psoriasis, uveitis and / or IBD.  
 
5.4.2 Clinical examination 
 
All patients were examined and scored by DJ using the following clinical examination 
indices: Bath Ankylosing Spondylitis Metrology Index (BASMI) [175], chest expansion, 
Leeds Enthesitis Index (LEI) [176], 68 tender joint count (TJC) [177], 66 swollen joint 
count (SJC) [177], Psoriasis Area and Severity Index (PASI) [178], and modified Nail 
Psoriasis Severity Index (mNAPSI) [179]. 
 
DJ was trained to perform the BASMI and chest expansion from AS specialist 
physiotherapists in the RNHRD who regularly perform them, alongside a review of the 
papers devising these tools. DJ was trained to perform the PASI, TJC, SJC and nail score 
from the PsA specialist nurses who regularly perform it as part of clinical and 
observational trials, alongside a review of the papers devising these tools. 
 




As only one researcher (DJ) was available to perform the clinical assessment, it was not 
possible to blind the assessor as to the patient’s underlying diagnosis of PsA or AS.  
 
5.4.4 Radiographic assessment and re-classification of the cohort 
 
Detailed methods for radiographic assessment and scoring are provided in Chapter 6 of 
this thesis, and will therefore not be repeated here. In brief, the most recent axial 
radiographs of the cervical (lateral), lumbar (lateral and anteroposterior) and pelvis 
(including SIJs) making a complete set were scored using the two most validated axial 
radiographic scoring tools for PsA; the Psoriatic Arthritis Spondylitis Radiology Index 
(PASRI) [185] and the modified Stoke Ankylosing Spondylitis Spinal Scoring tool 
(mSASSS) [186]. Where possible, radiographs taken at the same time-point were scored 
as a set. Where radiographs were taken at different time-points, the most recent time-
point was taken as the date of radiographic assessment, on the condition that the interval 
between the earliest and latest radiograph was ≤5 years. 
 
PsA patients (all fulfilling CASPAR criteria) were reclassified as either PsSpA or PsA 
using a radiographic definition. In keeping with previous publications, inflammatory 
radiographic axial disease (RAD) in psoriatic patients was defined as: the presence of 
New York criteria sacroiliitis (unilateral grade ≥3, or bilateral grade ≥2) on AP pelvic 
radiograph; and / or ≥1 syndesmophyte (marginal or paramarginal) of the cervical or 
lumbar spine. The entire study cohort were then reclassified into three more precise 
groups: psoriatic cases with RAD were reclassified as PsSpA; psoriatic cases without 
RAD were reclassified as peripheral-only PsA without axial disease (pPsA); and the 
remaining patients were all classified as AS, since by study eligibility criteria, all fulfilled 
modified New York diagnostic criteria for AS (radiographic and clinical). This 
reclassification is described in more detail in Figure 5.1 in the Results section of this 
chapter. 
 
5.4.5 DNA extraction and testing methods 
 
Each patient had a blood sample taken for deoxyribonucleic acid (DNA) extraction at the 
BIRD laboratory using a standard salting technique. Extracted DNA was aliquoted and 
diluted in 100 mcl of deionised water and stored at -20 degrees Celsius for analysis later. 
Extracted DNA samples were forwarded as one batch to Professor Robert Winchester 
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(Department of Medicine, Columbia University Medical School, New York, USA) for HLA-
B and HLA-C sequencing. HLA-B27 data are presented in this thesis, to allow HLA-B27 
positivity prevalence to be compared across the three disease groups, and to allow HLA-
B27 to be used a covariate in the regression models of clinical and radiographic outcome. 
 
5.4.6 Statistical methods 
5.4.6.1 Sample size calculation 
 
Using an estimated prevalence of axial inflammatory pain in AS cases of 99% and 75% in 
PsSpA cases, the sample required to detect a difference between the two groups, with a 
power of 0.90 (setting the alpha level at 0.05) would be 48 PsSpA and 48 AS cases. 
 
Based upon the mean HAQ in SpA cited by previous studies, and the minimum clinically 
important difference (MCID) for the HAQ in PsA estimated to be 0.35 [171], the sample 
size required to detect a difference in HAQ of 0.35 between PsSpA and AS cases 
(assuming a standard deviation of 0.3, an alpha level of 0.05, and a study Power of 0.90) 
would be 15 PsSpA and 15 AS cases. 
 
5.4.6.2 Statistical analysis 
 
Data were analysed using STATA 12.1 (2011 Texas, USA).  
 
Univariate analyses were performed using the continuity-corrected Chi-squared test for 
categorical variables, independent Student’s t-test for normally distributed continuous data 
(e.g. age at clinical assessment, age at recent axial radiographs, and BMI), the Mann-
Whitney U test for non-normally distributed continuous data (disease duration at clinical 
assessment, recent axial radiographs, and to first anti-TNF agent use), Poisson 
regression for non-normally distributed continuous data comprised of integers (e.g. 
BASDAI, Patient Global Assessment of axial disease activity, BASFI, and BASMI), and 
zero-inflated Poisson regression for non-normally distributed continuous data with an 
excess of zero-values (e.g. HAQ, tender joints counts, swollen joint counts, mNAPSI, nail 
onycholysis score, PASI and LEI). Negative binomial regression and zero-inflated 
negative binomial regression were considered as an alternative to Poisson regression 
where the mean did not approximate the variance of the data. 
 
Multivariate analyses were performed using logistic regression for categorical variables, 
linear regression for normally distributed continuous data (e.g. tragus to wall distance, 
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Schober test, lumbar side flexion, inter-malleolar distance, chest expansion), Poisson 
regression for non-normally distributed continuous data (e.g. BASDAI, Patient Global 
Assessment of axial disease activity, BASFI, and BASMI), and zero-inflated Poisson 
regression for non-normally distributed continuous data with an excess of zero-values 
(e.g. HAQ, tender joints counts, swollen joint counts, mNAPSI, nail onycholysis score, 
PASI and LEI). Negative binomial regression and zero-inflated negative binomial 
regression were considered as an alternative to Poisson regression where the mean did 
not approximate the variance of the data. A reverse step-wise regression approach was 
used, setting the alpha-level at 0.1 to determine inclusion or exclusion of covariates in the 
model. This allowed adjustment for potentially significant confounders including: sex, age 
at clinical assessment, age at spinal radiographic assessment, disease duration at clinical 
assessment, disease duration at radiographic assessment, anti-TNF use at any time point 
during disease course (although it was found that all patients who had ever used an anti-
TNF agent, were still using at the time of assessment), synthetic DMARD use (at any time 
point during disease course), smoking (current and ex-smokers were grouped together, 
and compared with never smokers) and body mass index (most recently recorded). It is 
acknowledged that indices such as BMI change over time, and that both smoking and 
medication use as a binary outcome does not capture the various durations and doses 
used by the patients. Univariate and multivariate reduced-models are presented in the 
tables as indicated. 
 
Data are presented as mean, median, inter-quartile range (IQR), standard deviation (SD), 
odds ratio (OR), adjusted OR (ORadj), incidence risk ratio (IRR), adjusted IRR (IRRadj), 
95% confidence interval (95% CI), p-value, and adjusted p-value as appropriate to the 
data. The alpha-level for statistical significance was set at 0.05.  
 
5.4.6.3 Missing data handling 
 
Patients uncertain how to correctly complete the PROMs were given support by DJ to 
ensure correct and full completion. No missing data were therefore expected for PROMs. 
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5.5 RESULTS 
5.5.1 Demographic, lifestyle and treatment characteristics of the cohort 
 
The study enrolled 402 SpA patients (201 PsA and 201 AS), and all completed clinical 
assessment. A full set of axial radiographs (cervical, lumbar and pelvis) were available on 
392/402 cases, with an incomplete series of axial radiographs in 10/402 cases. Of these: 
118/402 (29.35%) cases were classified as PsSpA based upon psoriasis (current or 
previous) and radiographic axial disease (RAD); 127/402 (31.60%) cases were classified 
as peripheral PsA (pPsA) based upon psoriasis (current or previous), peripheral arthritis 
and without RAD; and 157/402 (39.05%) cases were classified as AS based upon mNY 
criteria but no psoriasis (current or history of) (Figure 5.1).  
 
Only ten PsA patients had an incomplete series of axial films to determine RAD, and were 




pPsA: peripheral PsA PsSpA: psoriatic spondyloarthropathy   AS: ankylosing spondylitis   mNY: modified New York criteria for AS 
Figure 5.1. Classification of the study cohort 
 
5.5.1.1 Prevalence of PsSpA 
 
The prevalence of PsSpA amongst the PsA cases was 74/201 (36.82%; 95% CI 30.14, 
43.89 using Fisher Exact Clopper-Pearson). The prevalence of PsSpA in all SpA (PsA 
and AS) cases with psoriasis was 118/245 (48.16%; 95% CI 41.76, 64.61 using Fisher 
Exact Clopper-Pearson). 
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5.5.1.2 Fulfilment of CASPAR and modified New York classification criteria  
 
Of 201 cases clinically coded as PsA according to hospital case-notes, as many as 
48/201 (23.88%) also fulfilled modified New York criteria for AS, whilst 153/201 (76.12%) 
did not. 
 
Of 201 cases clinically coded as AS according to hospital case-notes: 49/201 (24.38%) 
fulfilled CASPAR criteria for PsA; 46/201 indeterminate, though likely to fulfil CASPAR 
(score +1; RF is usually negative in AS, and the absence of peripheral radiographs 
suggests that the patient did not have peripheral arthritis to indicate having imaging and 
therefore likely would not have radiographic osteoproliferation); 3/201 were unlikely to fulfil 
CASPAR (score +2; no peripheral radiographs available); and 103/201 did not fulfil 
CASPAR. Thus, at least 49/201 (24.38%) AS patients fulfil CASPAR criteria for PsA. 
 
5.5.1.3 Demographic characteristics of the pPsA, PsSpA and AS cases 
 
The proportion of male cases in the PsSpA group was 74/118 (62.71%), 66/127 (51.97%) 
in the pPsA group, and 118/157 (75.16%) in the AS group (Table 5.1). There was a 
significantly higher proportion of males in the AS group compared with the PsSpA group 
(OR 1.80; 95% CI 1.07, 3.03; p=0.03), but not in the pPsA group compared with the 
PsSpA group. Male PsA cases were no more likely to be classified as PsSpA than female 
patients (ORadj 0.65; 95% CI 0.39, 1.08; p=0.09) (adjusted for age at radiographic 
assessment, disease duration at radiographic assessment, HLA-B27 status, synthetic 
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Table 5.1. Sociodemographic and treatment characteristics of the pPsA, PsSpA and 
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(mean difference) 
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     >1 anti-TNF used  




















*continuity adjusted Chi2 test   ^ two-tailed Student’s t-test 
pPsA: peripheral PsA    PsSpA: psoriatic spondyloarthropathy AS: ankylosing spondylitis  
DMARD: disease modifying anti-rheumatic drug anti-TNF: anti-tumour necrosis factor drug  HLA: human leucocyte antigen 
n: number / proportion    95% CI: 95% confidence interval  mean diff: mean difference 
 
 
Peripheral psoriatic arthritis mutilans (PAM) was evident clinically and radiographically in 
19 cases; 8/127 in the pPsA group, and 11/118 in the PsSpA group. 
 
5.5.1.4 Age and disease duration characteristics of the PsA, PsSpA and AS cases 
 
The mean age at clinical assessment was 58.13 (SD 11.71) years for pPsA, 58.09 (SD 
11.42) years for PsSpA, and 53.44 (SD 13.61) years for AS cases (Table 5.2). At clinical 
assessment, AS cases were a mean 4.63 years younger than PsSpA cases (95% CI -
7.68, -1.58; p=0.003) (Table 5.2), but there was no significant difference between the 
mean ages of PsSpA and pPsA cases. 
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Table 5.2. Clinical characteristics of the pPsA, PsSpA and AS cases (continuous variables) 
























(58.13) (11.71) (58.09) (11.42) (53.44) (13.61) -0.03 -2.95, 2.88 0.98* -4.63 -7.68, -1.58 0.003* 
Arthritis 
onset 
37.98  28.37, 46.32 31.27 21.06, 46.24 20.00 16.00, 26.00 -  0.01^ -  - 
Arthritis 
diagnosis 
39.99 29.70, 48.73 35.99 27.27, 52.00 29.00 23.00, 38.00 -  0.33^ -  - 
Psoriasis 
onset 
27.00 16.00, 41.00 31.50 17.50, 41.50   -  0.68^ -  - 
Psoriasis 
diagnosis 















13.00 6.00, 23.00 15.50 7.00, 26.00 19.00 10.00, 29.00 -  0.41^ -  0.13^ 
To first 
anti-TNF 
13.00 4.00, 23.00 16.00 9.00, 27.00 16.00 8.00, 26.00 -  0.07^ -  0.62^ 
 
* two-tailed Student’s t-test ^ Mann-Whitney-U test  
pPsA: peripheral PsA  PsSpA: psoriatic spondyloarthropathy  AS: ankylosing spondylitis  anti-TNF: anti-tumour necrosis factor drug  
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Compared with pPsA cases, PsSpA cases tended to have a younger age at arthritis 
symptom onset (median 31.27 vs. 37.98 years; p=0.01), but were no different in terms of 
age at arthritis diagnosis (p=0.33), psoriasis onset (p=0.68) or psoriasis diagnosis 
(p=0.20) (Table 5.2).  
 
The mean age at the most recent axial radiograph (most often the pelvis film) was 56.80 
(SD 12.21) years in pPsA, 56.36 (SD 11.56) years in PsSpA, and 51.48 (SD 13.67) years 
in AS cases. AS cases were a mean 4.88 years younger than PsSpA cases (95% CI -
7.95, -1.81; p=0.002) at the most recent axial radiograph (Table 5.2). 
 
The year of arthritis diagnosis was known for all 402 SpA cases. It was extracted from the 
case notes and corroborated by the patient. The disease duration, as measured from year 
of diagnosis to the year of clinical assessment, was a median 15.00 (IQR 7.00, 26.00) 
years in pPsA, 18.00 (IQR 9.00, 27.00) years in PsSpA, and 22.00 (IQR 10.00, 31.00) 
years in AS cases, with no statistically significant differences between the PsSpA and AS 
groups, or pPsA and PsSpA groups (Table 5.2). Similarly, the disease duration to the 
most recent axial radiograph was no different across the three groups: median 13.00 
(6,00, 23.00) years in pPsA, 15.50 (IQR 7.00, 26.00) years in PsSpA, and 19.00 (IQR 
10.00, 29.00) years in AS (Table 5.2).  
 
5.5.1.5 HLA-B27 characteristics of the pPsA, PsSpA and AS cases 
 
All but two of the 402 SpA cases were of self-reported (patient questioned by DJ) 
Caucasian ethnicity. One case was Indian and the other Persian. 
 
HLA-B27 variants (primarily HLA-B2705) were present in 9/127 (7.09%) pPsA, 47/118 
(39.83%) PsSpA and 140/157 (89.17%) AS cases (Table 5.1). AS cases were more likely 
to be HLA-B27 positive than PsSpA cases (OR 12.44; 95% CI 6.67, 23.22; p<0.001). 
pPsA cases were less likely to be HLA-B27 positive than PsSpA cases (OR 0.12; 95% CI 
0.05, 0.25; p<0.001). 
 
Quantification and assessment of strand length was performed on four DNA samples at 
the Department of Pharmacy and Pharmacology (University of Bath) under the 
supervision of a post-doctoral student, Dr. Benoit Roux. DNA quantification was 
performed using the ‘Qubit 2.0 Fluorometer (Invitrogen, by Life technologies)’ using the 
manufacturers instructions. Concentrations were very high (Table 5.3). 
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Table 5.3. DNA concentrations and total quantity in ADIPSA samples 
Sample ID Concentration 
(ng/µl) 
Quantity per 100mcl stored sample 
(µg) 
ASINP004 439 43.9 
ASINP005 710 71.0 
ASINP006 610 61.0 
ASINP010 428 42.8 
 
Gel electrophoresis was performed on the same four random samples of DNA, using a 
standard operating procedure. Very little DNA fragmentation was detected, with the 
majority of DNA remaining as long strands (Figure 5.2). The first and last lanes are the 
DNA ladder, with the strand lengths detailed in the standards on the right; lanes 2 - 5 are 
the four samples (ASINP004, 5, 6, 10, respectively); lane 6 is a negative control 
comprising of fragmented DNA. 
 
 
Figure 5.2. Gel electrophoresis to determine DNA fragmentation in the ADIPSA samples  
(The first and last lanes are the DNA ladder, with the strand lengths detailed in the 
standards on the right; lanes 2 - 5 are the four patient samples; lane 6 is a negative control 
comprising of fragmented DNA). 
 
 
5.5.1.6 Lifestyle characteristics of the pPsA, PsSpA and AS cases 
 
A history of tobacco smoking (current or ex-smoker) was present in 61.47% of pPsA, 
51.82% of PsSpA and 45.86% of AS patients; with no difference between PsSpA and 
pPsA cases, or PsSpA and AS cases (Table 5.1).  
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The mean body mass index (BMI) in the pPsA group was 29.69 (SD 5.36), 29.52 (SD 
5.16) in the PsSpA group, and 27.92 (SD 4.96) kg/m2 in the AS group; with a lower BMI in 
AS compared with PsSpA group (mean difference -1.60; 95% CI -2.21, -0.84; p=0.01), but 
no significant difference between PsSpA and pPsA cases (Table 5.1). 
 
5.5.1.7 Acute-phase response in the pPsA, PsSpA and AS cases 
 
A multivariate reverse-stepwise Poisson regression was used to compare high sensitivity 
CRP concentrations in pPsA, PsSpA and AS groups, adjusted for: sex, age at sampling, 
disease duration as sampling, anti-TNF use ever, DMARD use ever and BMI. CRP 
concentration was lower in PsSpA compared with pPsA cases (IRRadj 0.79 for every 1 unit 
increase in concentration; 95% CI 0.74, 0.84; p<0.001). CRP concentration was no 
different in PsSpA compared with AS cases (IRRadj 1.06 for every 1 unit increase in 
concentration; 95% CI 0.99, 1.12; p=0.07).  
 
5.5.1.8 Treatment characteristics of the pPsA, PsSpA and AS cases 
 
Anti-TNF therapy had been used during disease course by 47/127 (37.01%) of pPsA, 
53/118 (44.92%) of PsSpA, and 59/157 (37.58%) of AS cases (Table 5.1), with no 
differences demonstrated between the groups. Similarly, no difference was found between 
the groups in the likelihood of using more than one anti-TNF agent during their disease 
course (Table 5.1). The interval between diagnosis and commencement of the first anti-
TNF agent was a median 13.00 (IQR 4.0, 23.00) years in the pPsA, 16.0 (IQR 9.0, 27.0) 
years in PsSpA, and 16.0 (IQR 8.0, 26.0) in the AS group; with no statistically significant 
difference between groups (Table 5.2). 
 
pPsA cases had commonly used methotrexate (65/127; 51.18%), sulfasalazine (48/127; 
37.80%) and less commonly leflunomide (12/127; 9.45%) (Table 5.1). PsSpA cases had 
commonly used methotrexate (38/118; 32.20%), sulfasalazine (36/118; 30.51%) and more 
rarely leflunomide (10/118; 8.47%). pPsA cases were more likely to have used a synthetic 
DMARD during the course of their disease than PsSpA cases (OR 2.33; 95% CI 1.39, 
3.85; p=0.001). AS cases were less likely to have used a synthetic DMARD (methotrexate 
8/157; sulfasalazine 17/157; leflunomide 1/157) than PsSpA cases (OR 0.24; 95% CI 
0.14, 0.42; p<0.001).    
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5.5.1.9 Summary  
 
The PsSpA and pPsA groups were different to each other in terms of HLA-B27 status, and 
synthetic DMARD use. The PsSpA and pPsA groups were no different to each other in 
terms of age at clinical assessment, age at axial radiographic assessment, disease 
duration at clinical assessment, disease duration at axial radiographic assessment, 
disease duration at first anti-TNF use, anti-TNF agent use, sex ratio, smoking history, or 
body mass index. The PsSpA and AS groups were different to each other in terms of 
proportion of males, HLA-B27 status, synthetic DMARD use, age at clinical assessment 
and age at axial radiographic assessment. The PsSpA and AS groups were no different to 
each other in terms of disease duration at clinical assessment, disease duration at axial 
radiographic assessment, disease duration at first anti-TNF use, anti-TNF agent use, or 
smoking history. However, synthetic DMARD use has not been shown in the literature to 
have axial disease-modifying effects in either PsA or AS. These univariate analyses 
guided the choice of covariates to include in the reverse-stepwise multivariate models. 
 
5.5.2 Patient reported outcome measures in pPsA, PsSpA and AS cases 
5.5.2.1 Inflammatory axial symptoms  
 
A history (current or ever) of inflammatory axial symptoms was present in 77/127 
(60.63%) pPsA, 88/118 (74.58%) PsSpA, and 156/157 (99.36%) AS cases (Table 5.4). Of 
particular note, 30/118 (25.42%) PsSpA cases, with radiographic axial disease by 
classification, did not report a history of inflammatory axial symptoms. Whilst some of this 
may be explained by patient recall error, this estimate of ‘symptomatically-silent’ axial 
disease in PsSpA is significant, and far exceeds the estimate in AS of 1/157. This finding 
may also in part be explained by PsA patients being more likely than AS patients to be 
attending clinic for peripheral arthritis, giving the opportunity for imaging of the axial 
skeleton and subsequent detection of symptomatically-silent radiographic axial disease. 
 
The sites most commonly affected by a history of inflammatory pain: in PsSpA cases were 
the cervical (71/118; 60.17%) and lumbar (70/118; 59.32%) spine; and in AS cases were 
the lumbar (149/157; 94.90%), cervical (132/157; 84.08%) spine and buttocks (132/157; 
84.08%).  
 
Multivariate analyses showed that AS cases were far more likely than PsSpA cases to 
have a history of inflammatory axial symptoms (ORadj 28.45; 95% CI 3.65, 221.74; 
p=0.001), even when analysed by axial site: thoracic spine (ORadj 2.20; 95% CI 1.23, 3.92; 
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p=0.01), lumbar spine (ORadj 6.75; 95% CI 2.82, 16.16; p<0.001) spine, and buttock(s) 
(ORadj 3.19; 95% CI 1.67, 6.07; p<0.001) (Table 5.4). 
 
Multivariate analyses showed that whilst pPsA cases were not less likely than PsSpA 
cases to report a history of inflammatory axial symptoms (adjusted OR 0.69; 95% CI 0.38, 
1.25; p=0.22), a difference was noted when analysed by axial site: thoracic spine 
(adjusted OR, ORadj 0.48; 95% CI 0.26, 0.88; p=0.02), and buttocks (ORadj 0.38; 95% CI 
0.20, 0.71; p=0.003) (Table 5.4). This indicates that a history of inflammatory axial 
symptoms of the thoracic spine and buttocks has a role in identifying PsSpA cases from a 
PsA cohort, but also detects some false-positive cases (pPsA cases) based on a 
radiographic definition of RAD. Whether these cases are false-positives based on a 
magnetic resonance imaging (MRI) definition of axial disease remains to be determined.  
 
 
Table 5.4. Axial inflammatory symptoms in pPsA, PsSpA and AS cases 
 Site Condition n %  Comparison Adjusted  
OR 
95% CI p-value 
History of 
inflammatory 
axial symptoms  
Spine / 
buttock(s) 












PsSpA 88/118 74.58 
AS 156/157 99.36 












PsSpA 71/118 60.17 
AS 132/157 84.08 












PsSpA 50/118 42.37 
AS 114/157 72.61 












PsSpA 70/118 59.32 
AS 149/157 94.90 












PsSpA 55/118 46.61 


















PsSpA 65/118 55.08 
AS 53/157 33.76 
 
pPsA: peripheral PsA  PsSpA: psoriatic spondyloarthropathy AS: ankylosing spondylitis  
n: proportion   OR: odds ratio   95% CI: 95% confidence interval  
 
* Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: disease duration at assessment, and HLA-B27 status) 
** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: disease duration at assessment, HLA-B27 status, and 
synthetic DMARD use ever) 
*** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, age at assessment, HLA-B27 status, and 
synthetic DMARD use ever) 
**** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, and age at assessment). 
 
Current inflammatory axial symptoms were present in 54/127 (42.52%) of pPsA, 65/118 
(55.08%) of PsSpA, and 53/157 (33.76%) of AS cases (Table 5.4). Multivariate analyses 
demonstrated that AS cases were significantly more likely than PsSpA cases to report 
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current inflammatory axial symptoms (ORadj 2.76; 95% CI 1.62, 4.71; p<0.001), and pPsA 
cases to be less likely than PsSpA cases (ORadj 0.57; 95% CI 0.34, 0.96; p=0.03). 
 
5.5.2.2 Personal history of extra-articular manifestations  
 
Multivariate analyses showed that pPsA cases were less likely to have a clinical history of 
IBD than PsSpA cases (ORadj 0.12; 95% CI 0.03, 0.55; p=0.01), but no different in terms 
of a clinical history of dactylitis, enthesitis, chest wall pain, or uveitis (Table 5.5).  
 
AS cases were less likely to have a clinical history of dactylitis compared with PsSpA 
cases (ORadj 0.18; 95% CI 0.07, 0.42; p<0.001), but were no different in terms of a clinical 
history of enthesitis, chest wall pain, uveitis and IBD (Table 5.5).  
 
Table 5.5. Extra-articular manifestations in pPsA, PsSpA and AS cases 
Clinical 
history of 
 n %  Comparison Adjusted  
OR 
95% CI p-value 












PsSpA 37/118 31.36 
AS 8/157 5.10 












PsSpA 56/118 47.46 
AS 58/157 36.94 
Chest wall 
pain  












PsSpA 52/118 44.07 
AS 102/157 64.97 












PsSpA 31/118 26.27 
















PsSpA 13/118 11.02 
AS 15/157 9.55 
 
pPsA: peripheral PsA  PsSpA: psoriatic spondyloarthropathy AS: ankylosing spondylitis  
n: proportion  OR: odds ratio   95% CI: 95% confidence interval  
 
* Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, and HLA-B27 status) 
** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, and anti-TNF use ever) 
*** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: age at assessment, disease duration at assessment, 
and HLA-B27 status) 
**** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: HLA-B27 status, and smoking ever) 
***** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: age at assessment, disease duration at 
assessment, and synthetic DMARD use ever) 
 
5.5.2.3 Family history  
 
AS cases were more likely than PsSpA cases to have a family history of uveitis (ORadj 
2.27; 95% CI 0.94, 5.51; p=0.07), although this did not reach statistical significance (Table 
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5.6). The two groups were no different in terms of a family history of SpA and IBD.  PsA 
and PsSpA cases were no different in terms of a family history of SpA, psoriasis, uveitis 
and IBD (Table 5.6). 
 
Table 5.6. Family history of disease in pPsA, PsSpA and AS cases 
Family History of  n %   OR 95% CI p-value 












PsSpA 25/118 21.19 
AS 52/157 33.12 












PsSpA 58/118 49.15 
AS 20/157 12.74 












PsSpA 7/118 5.93 
AS 37/157 23.57 
Inflammatory 
bowel disease 












PsSpA 9/118 7.63 
AS 17/157 10.83 
 
pPsA: peripheral PsA  PsSpA: psoriatic spondyloarthropathy AS: ankylosing spondylitis  
n: proportion  OR: odds ratio   95% CI: 95% confidence interval  
 
* Reverse-stepwise logistic regression model adjusted for HLA-B27 status 
 
5.5.2.4 Composite measures 
 
Similar proportions of PsSpA and AS cases were found to be in each of the four ASDAS 
activity categories, with no statistically significant differences between the diseases (Table 
5.7). Of note, disease activity was generally high or very high in both PsSpA (64/118; 
54.24%) and AS (80/157; 50.96%) cases, with no statistically significant difference 
between the two diseases.  
 
Table 5.7. ASDAS in PsSpA and AS cases 
ASDAS 
category 
Disease n %  Comparison Adjusted 
OR 
95% CI p-value 
Inactive 
(≤1.2) 







0.59 * AS 25/157 15.92 
Moderate  
(1.3-2.0) 







0.51* AS 52/157 33.12 
High  
(2.1-3.4) 







0.21 * AS 54/157 34.39 
Very high 
(≥3.5) 







0.17 * AS 26/157 16.56 
 
PsSpA: psoriatic spondyloarthropathy AS: ankylosing spondylitis  ASDAS: AS Disease Activity Score 
n: proportion   OR: odds ratio   95% CI: 95% confidence interval  
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* Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: age at assessment, disease duration at assessment, 
anti-TNF use ever, and synthetic DMARD use ever) 
 
These data were corroborated when using other composite measures of disease activity, 
BASDAI and patient global assessment of axial disease activity (PaGA). A BASDAI of 
≥3.5 [205] and ≥4 [159] have been cited in the literature as indicating high disease activity 
in AS. The MCID cited for the BASDAI in AS is 1 unit [160]. The median BASDAI in 
PsSpA (3.60; IQR 2.2, 5.60) and AS (3.20; IQR 2.10, 5.40) cases suggests near active 
disease in both conditions, bearing in mind that data for each disease were negatively 
skewed (Figure 5.3). The BASDAI was statistically no different in PsSpA and AS cases; 
both had similarly active disease (adjusted IRR, IRRadj 1.03 for every 1 unit increase in 




Multivariate reverse-stepwise Poisson regression model (reduced model adjusted for: sex, HLA-B27 status, age at clinical 
assessment, disease duration at clinical assessment, and anti-TNF use) 
Figure 5.3. BASDAI in PsSpA and AS cases  
 
A PaGA of ≥4 cm is considered to indicate active disease in AS. The median PaGA in 
PsSpA (3.00 cm; IQR 2.00, 5.00 cm) and AS (3.00 cm; IQR 2.00, 6.00 cm) cases 
suggested active disease, with no differences between the two disease groups (IRRadj 
1.13 for every 1 cm increase in score; 95% CI 1.00, 1.28; p=0.15) (Figure 5.4). 
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Multivariate reverse-stepwise Poisson regression model (reduced model adjusted for: sex, age at clinical assessment, 
disease duration at clinical assessment, and anti-TNF use) 
Figure 5.4. Patient global assessment of axial disease activity in PsSpA and AS cases  
 
The MCID for the BASFI in AS is cited as 0.7 units [160]. Function as measured by the 
BASFI was poorer in AS (median 3.90 units; IQR 2.20, 5.60) compared with PsSpA 
(median 3.10 units; IQR 1.40, 5.20) cases, with a clinically and statistically significant 
difference in BASFI score between the two groups (IRRadj 1.17 for every 0.7 unit increase 
in score; 95% CI 1.06, 1.26; p=0.002) (Figure 5.5). Expressed in another way, for every 
0.7 unit increase in BASFI score, the probability of a test patient being categorised in the 
AS rather than PsSpA group, increases by 17%. 
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Multivariate reverse-stepwise Poisson regression model (reduced model adjusted for: age at clinical assessment, disease 
duration at clinical assessment, and anti-TNF use) 
 
Figure 5.5. BASFI in PsSpA and AS cases 
 
Disability was compared between the three diseases using the HAQ. The median HAQ 
score was 0.75 (IQR 0.25, 1.50) in pPsA, 0.63 (IQR 0.13, 1.25) in PsSpA, and 0.50 (IQR 
0.13, 1.13) in AS cases. The MCID for the HAQ in PsA has been cited as 0.35 units [171]. 
Using this value in a multivariate zero-inflated Poisson regression, no statistically 
significant differences were demonstrated between AS and PsSpA (IRRadj 1.04 for every 
0.35 unit increase in score; 95% CI 0.90, 1.19; p=0.61), or pPsA and PsSpA (IRRadj 1.09 
for every 0.35 unit increase in score; 95% CI 0.95, 1.26; p=0.21) (Figure 5.6). 
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Multivariate reverse-stepwise zero-inflated Poisson regression model (reduced model adjusted for: sex, age at clinical 
assessment, disease duration at clinical assessment, anti-TNF use, and smoking) 
 
Figure 5.6. HAQ scores in pPsA, PsSpA and AS cases 
 
 
5.5.3 Clinical examination indices in pPsA, PsSpA and AS cases 
5.5.3.1 Axial metrology in PsSpA and AS cases 
 
Axial metrology as measured by the BASMI was no different in AS (median score 3.0; IQR 
1.00, 5.00) compared with PsSpA (median score 2.0; IQR 1.00, 5.00) cases (IRRadj 1.07 
for every 1 unit increase in score; 95% CI 0.95, 1.21; p=0.26) (Figure 5.7).  
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Multivariate reverse-stepwise Poisson regression model (reduced model adjusted for: age at clinical assessment, disease 
duration at clinical assessment, and anti-TNF use) 
 
Figure 5.7. BASMI in PsSpA and AS cases 
 
 
As has been performed in previous studies [64, 189, 201], the components of the BASMI 
using their absolute values, rather than their BASMI grade, were also compared in PsSpA 
and AS cases (Table 5.8). Tragus to wall distance (adjusted mean difference 2.00 cm; 
95% CI 0.58, 3.42; p=0.006), and modified Schober test (adjusted mean difference -0.65 
cm; 95% CI -1.14, -0.15; p=0.01) were poorer in AS compared with PsSpA cases. 
However, lumbar side-flexion, inter-malleolar distance, cervical rotation (Table 5.8), and 
chest expansion (Figure 5.8) were no different in PsSpA and AS cases.  
 
BASMI scores were no different in pPsA compared with PsSpA cases. When analysed by 
the BASMI subdomains, the Schober test was paradoxically poorer in pPsA compared 
with PsSpA cases (adjusted mean difference –0.59 cm; 95% CI -1.08, -0.09; p=0.02), but 
the other domains were no different in the two groups (Table 5.8). These exploratory 
analyses imply that the BASMI may not be useful to differentiate PsA cases with and 
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Table 5.8. BASMI subdomains in PsSpA and AS cases 



















PsSpA 13.56 4.59 
AS 16.77 7.29 












PsSpA 5.13 1.92 
AS 4.30 2.10 












PsSpA 11.45 4.77 
AS 11.05 7.49 












PsSpA 91.00 19.10 
AS 94.21 20.69 
Poor cervical rotation  
     (≤70 degrees) 







OR 0.63, 2.06 




PsSpA 85/118 72.03% 
AS 110/157 70.06% 
 
PsSpA: psoriatic spondyloarthropathy AS: ankylosing spondylitis BASMI: Bath AS Metrology Index   
95% CI: 95% confidence interval   SD: standard deviation  OR: odds ratio  cm: centimetres 
     
* multivariate reverse-stepwise linear regression model (reduced model adjusted for: sex, HLA-B27 status, age at assessment, disease 
duration at assessment, and synthetic DMARD use) 
** multivariate reverse-stepwise linear regression (reduced model adjusted for: sex, HLA-B27 status, age at assessment, disease duration at 
assessment, anti-TNF use, and synthetic DMARD use) 
*** multivariate reverse-stepwise linear regression model (reduced model adjusted for: age at assessment, disease duration at assessment, 
synthetic DMARD use, and smoking) 
**** multivariate reverse-stepwise linear regression model (reduced model adjusted for: sex, and age at assessment) 
^ multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, HLA-B27 status, age at assessment, and disease 





Multivariate reverse-stepwise linear regression model (reduced model adjusted for: HLA-B27 status, and age at 
assessment) 
Figure 5.8. Chest expansion in PsSpA and AS cases 
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5.5.3.2 Peripheral examination indices in pPsA and PsSpA cases 
 
Nail disease severity, as measured by the mNAPSI was lower in pPsA than PsSpA cases 
(median 2.0 vs. 2.0, respectively; IRRadj 0.90 per unit increase in score; 95% CI 0.83, 
0.97; p=0.01) (Table 5.9). Similarly, a signal was detected for nail onycholysis to be less 
severe in pPsA cases than PsSpA cases (IRRadj 0.84 per unit increase in score; 95% CI 
0.74, 0.95; p=0.01) (Table 5.9). Nail onycholysis was tested as it is a more specific marker 
of synovial-entheseal complex disease, a process considered to be important in the 
pathogenesis of SpA [195]. Nail pitting scores and nail crumbling scores were no different 
in PsSpA compared with pPsA cases. 
 
Table 5.9. Peripheral examination measures in pPsA, PsSpA and AS cases 


















PsSpA 2.0 0.0, 7.0 
AS 0.0 0.0, 2.0 












PsSpA 0.0 0.0, 1.0 
AS 0.0 0.0, 0.0 
Enthesitis score  
(LEI)  












PsSpA 0.0 0.0, 1.0 
AS 0.0 0.0, 1.0 
Nail severity 
(mNAPSI) 







0.01 *** PsSpA 2.0 0.0, 10.0 
Nail onycholysis 
score 







0.01 *** PsSpA 1.0 0.0, 4.0 
Skin severity  
(PASI) 







0.08 **** PsSpA 0.9 0.0, 2.9 
 
pPsA: peripheral PsA    PsSpA: psoriatic spondyloarthropathy AS: ankylosing spondylitis  
mNAPSI: modified Nail Psoriasis Severity Index  PASI: Psoriasis Area and Severity Index  LEI: Leeds Enthesitis Index 
IRR: incidence risk ratio   95% CI: 95% confidence interval  IQR: interquartile range  
OR: odds ratio  
 
* Multivariate reverse-stepwise zero-inflated Poisson regression model (reduced model adjusted for: sex, age at assessment, disease 
duration at assessment, and anti-TNF use ever) 
** Multivariate reverse-stepwise zero-inflated Poisson regression model (reduced model adjusted for: sex, and anti-TNF use ever) 
*** Multivariate reverse-stepwise zero-inflated Poisson regression model (reduced model adjusted for: sex, HLA-B27 status, and smoking 
ever) 
**** Multivariate reverse-stepwise zero-inflated Poisson regression model (reduced model adjusted for: sex, HLA-B27 status, disease duration 
at assessment, and synthetic DMARD use ever) 
 
The median tender joint count was 3.0 (IQR 0.0, 10.0) in pPsA, and 2.0 (IQR 0.0, 7.0) in 
PsSpA cases, with a clinically and statistically significant difference between the two 
diseases on multivariate analyses (IRRadj 1.17 for every 1 joint increase; 95% CI 1.11, 
1.24; p<0.001) (Table 5.9). No differences were found between pPsA and PsSpA cases in 
terms of swollen joint count, peripheral enthesitis as measured by the Leeds Enthesitis 
Index, or skin psoriasis severity as measured by the PASI (Table 5.9). Similarly, the LEI 
was no different in AS compared with PsSpA cases (Table 5.9). All of these PROM and 
clinical examination results are summarised in Figure 5.9 and Figure 5.10. 
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Figure 5.10. A comparison of clinical characteristics in AS and PsSpA cases 
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5.6 DISCUSSION & CONCLUSIONS 
This study used a large cohort of SpA patients attending a single centre to compare the 
sociodemographic, lifestyle, treatment, patient-reported and clinical examination 
characteristics of pPsA, PsSpA and AS.  
 
To my knowledge, this is the first study to directly compare PsSpA with AS patients in 
terms of inflammatory axial symptoms by region, disability as measured by the HAQ, 
disease activity as measured by the ASDAS and PaGA, treatment in terms of anti-TNF 
and synthetic DMARD use, enthesitis burden as measured by the LEI, and personal 
history of chest wall pain and IBD. This is also the first study to compare PsSpA and pPsA 
patients in terms of psoriatic nail disease severity using the mNAPSI, occurrence of global 
and regional inflammatory spinal pain, and personal history of dactylitis. Importantly, for 
the purpose of future research and devising a classification system for PsSpA, we are the 
first to report the proportion of PsSpA patients with radiographic sacroiliitis, spondylitis or 
both, and how these correlate with clinical parameters and HLA-B27 status. 
 
5.6.1 Clinical characteristics in PsSpA compared with pPsA cases 
 
The prevalence of PsSpA in this PsA cohort (36.82%) is very similar to that reported by 
Lambert et al. of 40% [69] and Gladman et al. of 39% [111]. A study be Leung et al. 
reported a lower prevalence of 23%, but the disparity is likely explained by the shorter 
disease duration in their cohort of 9.2 (SD 6.7) years [62], compared with 18 (IQR 9, 27) 
years in this study. A previous study from Bath has shown that the prevalence of PsSpA 
rises with increasing disease duration [68]. 
 
The prevalence of PsSpA in all SpA (PsA and AS) cases with psoriasis was 118/245 
(48.16%), which is higher than the prevalence stated in the ‘PsA cohort’. The difference is 
explained by the set-up of clinical services in our hospital, which is similar to that in many 
other large secondary-care hospitals in the UK. Historically, patients initially presenting 
with psoriasis and predominantly peripheral symptoms have been cared for in the 
dedicated PsA clinic; whilst patients initially presenting with psoriasis and axial symptoms 
have been cared for in the dedicated AS clinic. The clinical diagnosis is therefore 
influenced by their initial predominant presentation. As described in the Results section: of 
201 cases clinically coded as PsA in hospital case-notes, 24% also fulfil modified New 
York criteria for AS; and of 201 cases clinically coded as AS in hospital case-notes, at 
least 24% also fulfilled CASPAR criteria for PsA. This finding is important for both 
clinicians and patients, and for both clinical and academic purposes. For the clinician, 
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these data would support the establishment of a specialist ‘SpA service’, whereby patients 
with pPsA, PsSpA, AS and other forms of SpA attending the same service, have access 
to the same medical and nursing expertise, specialist physiotherapy and occupational 
therapy services, and medications. For the patient, this would allow them to utilise 
services based on their need, rather than their ‘NHS diagnosis’, which as is demonstrated 
above, has its pitfalls. Such a ‘SpA clinic’ may also encourage and improve quality of 
research. SpA patients scattered in several general rheumatology clinics seeing clinicians 
without an academic interest in SpA may be disadvantaged by not having the same 
access to SpA-related research. In many hospitals in the UK, PsA patients are seen by 
one group of clinicians with a research interest in PsA, and AS patients are seen by 
another group of clinicians with an interest in AS. This has potentially impeded research of 
PsSpA, which bridges the two services. Given the overlap between PsA and AS, a ‘SpA 
clinic’ would serve to integrate and improve research of these overlapping diseases.  
 
Symptomatically-silent radiographic axial disease was present in a significant proportion 
(30/118; 25.42%) of PsSpA cases, which is similar to the prevalence of 20% reported by 
Queiro et al. [190]. Ten PsA patients had an incomplete series of axial films to determine 
RAD, and were therefore classified as pPsA. It was assumed that the absence of a 
complete set of radiographs implied no widespread axial symptoms. However, given that 
almost a quarter of PsSpA cases were shown in this study to have symptomatically-silent 
radiographic axial disease, it is possible that three or more of these cases may have had 
PsSpA. This is a significant proportion of patients with potentially sub-optimised treatment. 
Although one might argue that awareness of these asymptomatic patients is not 
necessary given that medical intervention is not required, one might repost that given the 
natural clinical history of such patients has yet to be determined, preventative early 
intervention through physiotherapy and medications may halt or slow disease progression 
to the symptomatic state. This would benefit patients and the health service. 
 
We did not find that male PsA patients are more likely to develop PsSpA than female 
patients. These results are in keeping with a study from Hong Kong of 125 PsA cases 
using stringent classification criteria [62], a study from Bath of 75 PsA cases with cervical 
spondylitis [68], and a large prospective cohort study from Toronto (Canada) of 206 PsA 
cases [61]. The latter study did however, suggest that PsSpA develops at an earlier stage 
(often at first clinic attendance) in male compared with female patients [61]. Two studies 
reported male PsA cases being more prone to PsSpA [63, 69], although the study by 
Hanly et al. classified PsSpA cases using less stringent criteria (sacroiliitis unilaterally of 
grade ≥2, or clinical sacroiliitis) [63].  
 
  116 
 
HLA-B27 was far less likely to be positive in pPsA than in PsSpA cases. This is discussed 
further in Chapter 6, including how HLA-B27 appears to relate to radiographic subsets of 
PsSpA.  
 
PsSpA cases in our cohort had a younger age at arthritis onset than pPsA cases. This 
was also shown in a study of PsA cases in Korea [67]. We did not find a younger age at 
psoriasis onset in the PsSpA compared with pPsA groups, as has been reported 
elsewhere [67, 69]. The disparity may be explained by recall bias in our PsA cases, who 
had a mean arthritis disease duration of 18 (IQR 7, 27) years, and with skin psoriasis 
onset approximately ten years prior to that. 
 
We found that psoriatic nail severity, especially nail onycholysis severity, was significantly 
higher in PsSpA compared with the pPsA cases, and may therefore be a clinical indicator 
of PsSpA occurrence; this might be especially useful in those with symptomatically-silent 
PsSpA. A similar association was noted by Chandran et al. who in a prospective 
longitudinal cohort also demonstrated a higher risk of developing PsSpA in PsA cases 
with nail dystrophy (RR 7.07; p=0.01) [61]. Nail onycholysis is a more specific marker of 
synovial-entheseal complex disease, a process considered to be important in the 
pathogenesis of SpA [195]. The nailbed is attached by ligaments and entheses to the 
distal interphalangeal joint (DIPJ), and it is therefore hypothesised that PsA-related DIPJ 
inflammation encompasses and is transmitted to the nailbed, manifesting as psoriatic nail 
disease [195]. The pathogenesis of PsSpA is considered to involve both entheses and 
synovial joints [195]. Therefore the same axial enthesitis may be manifesting as nail 
onycholysis in this study. The association between PsSpA and nail onycholysis 
demonstrated in this study aligns appropriately along a causal pathway and is biologically 
plausible, further strengthening the validity of the result. 
  
A significant proportion of our pPsA cases reported a past (60.63%) or current (42.52%) 
history of inflammatory axial symptoms. These findings differ to those of Lambert et al. 
who reported that their pPsA cases rarely had axial symptoms [69]. We used the ASAS 
criteria for ‘inflammatory spinal symptoms’ [123], but Lambert et al. did not state the 
criteria they used [69]. Taken together, this questions the sensitivity and specificity of the 
ASAS screening questions for use in PsSpA cases ultimately classified radiographically. 
However, further exploration is beyond the remit of this thesis. 
 
Our finding of higher peripheral joint counts in PsSpA compared with pPsA cases 
corroborates a previous study by Jenkinson et al. [68], but not a more recent smaller study 
of 125 PsA cases which found no difference between the groups [62]. However, the latter 
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study did not perform multivariate analyses, and no adjustments were made for the longer 
disease duration in the PsSpA cases compared with pPsA cases. 
 
A personal history of dactylitis, enthesitis, chest wall pain and uveitis, and a family history 
of SpA or psoriasis were not associated with developing PsSpA rather than pPsA in this 
study; in keeping with the results of another study [61]. Our results of PsSpA and pPsA 
cases showing no difference in terms of personal history of dactylitis, skin severity or 
enthesitis burden corroborate those of a recent study from Hong Kong [62], although 
enthesitis burden in that study was measured using a more detailed and sensitive clinical 
index, the MASES. These findings are somewhat surprising. Whilst both pPsA and PsSpA 
are both entheseal-related diseases, PsSpA is considered by some to be more so [206, 
207], and one might therefore expect PsSpA to present with a more entheseal-related 
disease e.g. peripheral enthesitis, chest wall pain and uveitis once adjusted for HLA-B27 
status. The cross-sectional design of this study, use of dichotomous outcome measures 
(e.g. chest wall pain and uveitis), and possible insensitivity of the LEI may explain these 
results. 
 
The higher frequency of IBD in PsSpA compared with pPsA cases is corroborated by a 
previous study [192], although the latter had a higher frequency (30%) compared to ours 
(11%). Our results align well with the research framework of ‘association, causality, and 
biological plausibility’. The pathogenesis of both SpA [208-210] and IBD [211-213] have 
been shown to be related to the interleukin-23 pathway. The higher prevalence of IBD in 
PsSpA compared with pPsA cases therefore potentially ties-in with the interleukin-23 
pathway and is biologically plausible. 
 
Disability, as measured by the HAQ, was no different in PsSpA and pPsA cases, which 
corroborates a smaller Spanish study of 46 PsSpA and 54 pPsA cases [64], and a small 
study from Hong Kong of 29 PsSpA and 96 pPsA cases [62]. A previous smaller study 
from Bath of 75 PsA cases published in 1994, demonstrated that PsA cases with 
radiographic cervical spondylitis have a higher HAQ than those without radiographic 
cervical spondylitis [68]. The difference may be due to that study only comparing PsA 
patients with cervical spondylitis or not, whereas this study assessed the entire axial 
skeleton. Very few of the questions in the HAQ relate to specifically to neck function, and 
it is therefore more appropriate to compare HAQ with axial disease of the entire skeleton, 
as we performed here. 
 
BASFI was higher in PsSpA than in the pPsA cases in this study, which corroborate the 
results of a smaller Spanish study [64], but not those of a small study from Hong Kong 
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which showed no difference in BASFI between the groups [62]. The Hong Kong study was 
probably underpowered to detect a difference as it compared only 29 PsSpA with 96 pPsA 
cases. Our findings are important since BASFI, unlike BASMI, BASDAI, ASDAS, and 
PaGA appears to distinguish PsA patients with and without axial disease. 
 
We found evidence of high disease activity (ASDAS, BASDAI and PaGA) in both PsSpA 
and AS cases, although with no difference between groups. These findings are 
corroborated by previous studies investigating BASDAI [62] and PaGA [62]. A cross-
sectional observational study comparing the utility of ASDAS and BASDAI in unselected 
established 201 PsSpA cases, with classification criteria similar to ours, also 
demonstrated moderate-high disease activity in their PsSpA cohort: mean ASDAS 2.4 
(SD 1.1), and mean BASDAI 3.5 (SD 2.4) [163]. Similarly, another validation study of 
ASDAS in PsSpA demonstrated moderate-high disease activity in their 54 PsSpA cases: 
mean BASDAI 3.96 (SD 2.65), mean PaGA 4.25 (SD 2.79), and mean ASDAS 2.68 (SD 
1.13) [164]. 
 
Metrology as measured by the BASMI, and its individual domains (apart from the Schober 
test, although in the opposite direction to expected) were no different in PsSpA and pPsA 
cases. Although it is beyond the remit of this thesis chapter to compare in more detail, this 
exploratory analysis does suggest that the BASMI and it domains may have little clinical 
utility to differentiate PsA cases with and without axial disease. 
 
5.6.2 Clinical characteristics in PsSpA compared with AS cases 
 
The proportion of males in our AS (75%) group was higher than in the PsSpA (63%) 
group. These results are different to a study by Helliwell et al., which showed 
approximately 75% males in both groups [58]. The disparity might be explained by the 
classification criteria used. All of their PsSpA cases fulfilled modified New York criteria for 
AS, and were subsequently sub-classified on the basis of their psoriasis. Only 65 of our 
118 PsSpA cases (55%) fulfilled modified New York criteria for AS, and may therefore 
more truly represent PsSpA rather than a mixture of PsSpA and AS cases with 
coincidental psoriasis. 
 
HLA-B27 was significantly more likely to be positive in AS than in PsSpA cases. This is 
discussed further in Chapter 6, in the context of the radiographic similarities and 
difference between PsSpA and AS. 
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Our findings of a higher prevalence of all-region axial inflammatory symptoms in AS 
compared with PsSpA cases, is corroborated by two previous studies [49, 201]. This is in 
large part explained by the 25% of radiographic-PsSpA cases who have never been 
symptomatic. 
 
AS cases in this study were less likely to have a personal history of dactylitis than PsSpA 
cases. This has been noted previously, in a study that also reported a higher frequency of 
enthesitis in PsSpA compared with AS cases [201]; a finding we did not corroborate. Our 
AS cases were no more likely than our PsSpA cases to have a personal history of uveitis, 
once adjusted for HLA-B27 status. This challenges the results of another study, which did 
not adjust for HLA-B27 status [49].  
 
AS cases compared with PsSpA cases in this study were more likely to have a family 
history of SpA. No such difference was reported in the only other study investigating this 
[201]. 
 
We found that function as measured by the BASFI was poorer in AS compared with 
PsSpA cases. A large prospective cross-sectional study comparing 1072 AS and 147 
PsSpA cases, found no difference in BASFI between the groups on multivariate analysis 
[201]. This disparity might be explained by differing classification systems being used. 
Perez-Alamino et al. classified PsSpA cases on the basis of SpA through ESSG criteria 
and concomitant psoriasis. The ESSG criteria have not shown good specificity or 
sensitivity for axial disease in PsA [24, 57]. In addition, both their AS (median 6 vs. 18 
years, respectively) and PsSpA (median 6 vs. 15 years, respectively) patients had much 
shorter disease duration than those in our cohort, permitting less time for differential 
functional impairment to develop between the two diseases. 
 
Disease activity as measured by the BASDAI were no different in AS and PsSpA cases, a 
finding corroborated by another study [201]. Metrology as measured by the BASMI was no 
different in AS compared with PsSpA cases in this study. This is supported by one other 
study comparing BASMI and its component domains [64], but challenges the poorer 
BASMI demonstrated in AS compared with PsSpA cases in another study [201]. Lumbar 
forward flexion was poorer in AS compared with PsSpA cases in our study, which 
corroborates the results of three studies [49, 58, 201], but challenges one study that 
reported no difference [64]. Tragus to wall distance was higher in in the AS cases 
compared with the PsSpA cases. A comparable measure, the ‘occiput to wall distance’ 
was similarly shown to be poorer (higher) in AS compared with PsSpA cases in two 
studies [64, 201].   
  120 
 
Cervical rotation was no different in our AS and PsSpA cases. This corroborates the result 
of one study [64], but refutes the results of another study where cervical rotation was more 
limited in AS compared with PsSpA [201]. Although the cohort in the Fernandez-Sueiro et 
al. [64] study was older than in the study by Perez-Alamino et al. [201], adjustments were 
made for age in the multivariate model, and both studies used similar definitions of 
restricted cervical rotation (less than or greater than seventy degrees of rotation). Inter-
malleolar distance was no different in AS compared with PsSpA cases our study or in one 
other study [64]. Chest expansion was no different in AS compared with PsSpA cases in 
our study, and in another study [58]. Such a difference was not found in another study 
[64], which may have been underpowered to detect what can be quite small differences in 
expansion. 
 
In summary, it appears that PsSpA and AS are no different in terms of disease activity 
and several domains of metrology, but AS patients have poorer function. Patients adapt to 
their disease over time and find novel ways to circumvent a physical limitation through the 
use of aids, using their body in a different way, pacing and carer-support. Given that the 
management of axial disease in PsA is sometimes considered after peripheral disease in 
PsA, it is important that PsSpA patients have as much access as AS patients to axial-
specific education, physiotherapy and occupational therapy, in order for them to optimise 
their remaining physical ability. Clinicians need to be pro-active to enable patients to 
achieve this. 
 
5.6.3 Classification of the study cohort using a stricter definition 
 
It might be argued that PsSpA should have been classified as psoriasis plus sacroiliitis 
(grade ≥2 bilaterally, or grade ≥3 unilaterally), and not permitted cases with spondylitis but 
no sacroiliitis to qualify as PsSpA. Using this classification system, this study would have 
79 PsSpA (instead of 118), 166 pPsA (instead of 127), and 157 AS cases. The prevalence 
of PsSpA in the psoriatic cohort would have been 79/245 (32.24%). I chose not use this 
classification system as there is evidence and expert clinical opinion that the radiographic 
expression of PsSpA and AS is different [57, 214]. Exclusion of spondylitis-only patients 
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5.6.4 Study critique 
 
This study had several strengths, especially the large sample size, the robust case 
classification system employed, and no missing PROM or clinical examination data. The 
latter is a rarity in clinical studies, and has both improved the study’s power and the 
reliability of the results. Covariate data were collected including anti-TNF use, synthetic 
DMARD use, smoking and BMI to include in the multivariate regression models; thereby 
allowing for some adjustment for potential confounders. The findings of this study are 
generalisable, because the RNHRD is a secondary referral centre, rather than a centre 
receiving high volumes of specialist tertiary-centre referrals. 
 
All PsA and AS clinic attendees were invited to participate in the study, thereby minimising 
selection bias. However, as the study was titled the ‘Axial Disease in PsA’ study and 
despite the patient information leaflet explicitly stating that all PsA patients were invited, it 
is possible that the study attracted PsA patients with axial symptoms more so than those 
without axial symptoms, thereby causing some selection bias. Some clinical indices such 
as BASDAI are known to vary somewhat over time, despite other indicators of disease 
activity being stable [215, 216]. BASFI and BASMI have been shown to have better test-
retest reliability [215, 216]. The study may have been improved by averaged clinical 
assessment at two time-points. However, this would have significantly impacted on study 
recruitment, inconvenience to the participants, and clinical assessor’s time. Whilst recall 
bias is likely to have been present, particularly in patients without longer disease duration, 
its impact is likely to have been curtailed by a similar magnitude and direction of effect in 
each of the three disease groups. 
 
For clinical examination indices, the study might have been improved by having more than 
one clinical assessor, thereby reducing assessor bias and / or performance bias. At study 
inception, I intended to have three clinical assessors, but this later became impossible due 
to insufficient research staff. Having other clinical examination assessors may have 
enabled the diagnosis of participants to have been partially blinded, as their might be a 
bias for an unblinded assessor of AS patients to expect, for example, their axial metrology 
to be poorer than that in PsSpA patients. Such a bias would have made it more likely for 
BASMI to be higher in AS compared with PsSpA cases; a result not seen in this study. 
However, one might also argue that having one assessor for clinical examination is a 
strength of this study, given that inter-rater reliability for clinical assessment in PsA has 
been shown to be notoriously poor [184].  
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In this study, smoking was defined as a history (past or present) of tobacco consumption, 
and was therefore present in 61.47% of pPsA, 51.82% of PsSpA and 45.86% of AS 
patients, with no significant difference between groups. These ‘lifetime prevalence’ values 
are much higher than estimates of ‘point prevalence’ of smoking in the general UK 
population, which as published by the Office of National Statistics is 19.16% (95% CI 
18.27, 20.06%) for all persons aged over 16 years in year 2013 [217]. The disparity may 
in part be related to: ‘point’ compared with ‘lifetime’ prevalence, the latter also comprising 
ex-smokers. Age, sex and socio-demographics of the two study populations may also 
contribute to the disparity. However, it may also implicate smoking in the aetio-
pathogenesis of PsA and AS.  
 
One must also consider the presence of uncontrolled confounding or unmeasured 
confounders. Despite our best attempts with the data collected, time-varying variables 
such as smoking, BMI and medications have not been fully adjusted for in these analyses. 
For example, a ‘history of smoking’ encompasses patients who are both ex-smokers and 
current smokers, and smokers of varying duration, dose (cigarettes per day or ounces of 
tobacco) and form (filtered cigarettes, self-rolled cigarettes, pipes). BMI changes over 
time, often rising with increasing age, and this study has used the most recently recorded 
BMI within the last one year. For these two uncontrolled confounders, the direction and 
magnitude of their confounding is unlikely to be significantly different across the three 
disease groups, and therefore their effect on the results of this study may be minimal. 
Medication use is another time-varying variable that may differ across the three groups in 
terms of agent, dose and duration. We only included synthetic DMARD and anti-TNF use 
as dichotomous covariates in the analyses. Whilst we have some data on anti-TNF start 
and end date, and exact anti-TNF and synthetic DMARDs used, there is some missing 
data, medications have differential efficacy, patients don’t necessarily take their 
medications compliantly, and such longitudinal data analyses would require complex 
mathematical modelling considered to be somewhat beyond the remit of this thesis.  
 
We also acknowledge that there are unmeasured confounders, of which some we may not 
even be aware. For example, functional ability (as measured by the BASFI) is somewhat 
influenced by the use of aids and patients’ personal and environmental adaptations. If 
axial disease in AS, is more likely than axial disease in PsSpA to have drawn the 
clinician’s attention and prompted a referral for education and occupational therapy 
services, it is possible that functional impairment in AS may be more compensated for in 
AS than in PsSpA. The higher BASFI this study has demonstrated in AS compared with 
PsSpA cases may therefore be even higher if this unmeasured confounder had been 
adjusted for. For similar reasons, AS compared with PsSpA patients may have been more 
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likely to have been referred for specialist axial physiotherapy. This unmeasured 
confounder may have differentially improved AS compared with PsSpA patients’ 
metrology, resulting in no apparent difference in BASMI between the two disease groups. 
After adjustment for this confounder, AS patients may have demonstrated poorer 
metrology than PsSpA patients. Other potential unmeasured confounders include NSAID 
use, analgesia use, delay from symptom-onset to diagnosis. The latter may be different 
both within and between groups. For example, if the index of suspicion for axial disease in 
PsA is not high, then there may be greater delay in diagnosis in PsSpA than in AS, 
resulting in longer untreated axial disease in PsSpA and resultant poorer clinical 
outcomes. Similarly, given that AS is more common in males than females, the index of 
suspicion for AS in a female presenting with axial symptoms may be low, resulting in 
greater delay to diagnosis in female compared with male AS patients. This may translate 
into poorer clinical outcomes in female than in male AS patients. Furthermore, juvenile-
onset AS patients have poorer clinical outcomes than adult-onset AS patients [218, 219], 
although in this study we have grouped both sub-subsets of AS into one group for 




Through the robust classification of a large cohort of SpA cases, we have demonstrated 
that a significant proportion of PsA cases have axial disease, and that it is often 
asymptomatic. Occurrence of axial disease in PsA appears to be associated with HLA-
B27 positivity, younger age at arthritis onset, and with psoriatic nail disease severity, in 
particular nail onycholysis severity. Other indicators include axial inflammatory symptoms, 
and the occurrence of IBD. PsSpA appears not to be the clinically-milder ‘sister’ of AS. 
Measures of disease activity were high in both PsSpA and AS cases, with no difference 
between groups. All three disease groups have significant disability, with no difference 
between groups. Metrology was just as impaired in PsSpA as in AS. Up to one quarter of 
PsA and AS cases may be classified as the other disease using the currently available 
classification systems.   
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5.7 PUBLICATIONS ARISING FROM THE WORK OF THIS THESIS 
CHAPTER 
 
CONFERENCE ABSTRACT (oral presentation) 
 
Jadon D, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, McHugh 
N. 2015. Axial disease in psoriatic arthritis: A clinical and radiographic comparison with 
ankylosing spondylitis. American College of Rheumatology - Annual Congress 2015, San 
Francisco, USA. November 2015. 
 
 
CONFERENCE ABSTRACT (poster presentation) 
 
Jadon D, Sengupta R, Nightingale A, Lindsay M, Korendowych E, McHugh J. Axial 
Disease in Psoriatic Arthritis (ADIPSA) study: Prevalence and characteristics of 
inflammatory axial disease in psoriatic arthritis. 9th International Congress on 
Spondyloarthropathy, Gent, Belgium. October 2014.  
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6 CHAPTER VI: RADIOGRAPHIC CHARACTERISTICS OF 




Background: Only four studies have compared the radiographic characteristics of 
psoriatic spondyloarthritis (PsSpA) and ankylosing spondylitis (AS), and findings have not 
been entirely consistent. The objectives of this chapter of the thesis were to: (i) compare 
the pattern of radiographic axial disease in PsSpA and AS; (ii) compare the morphological 
(osteoproliferation and erosion) features of radiographic axial disease in PsSpA and AS; 
(iii) compare axial radiographic severity in PsSpA and AS. 
Methods: A prospective single-centre cross-sectional observational study was conducted, 
recruiting consecutive PsA and AS cases. Axial radiographs of the cervical spine, lumbar 
spine and pelvis taken for clinical-reasons in the five-years preceding study enrolment 
were read by two raters and scored using the modified Stoke Ankylosing Spondylitis 
Spinal Score (mSASSS) and the Psoriatic Arthritis Spondylitis Radiology Index (PASRI). 
Univariate and multivariate analyses were performed. 
Results: The 402 enrolled cases (201 PsA and 201 AS) were reclassified based on 
radiographic axial disease and psoriasis into three more precise groups: 118 PsSpA, 127 
pPsA, and 157 AS cases.  
Of the PsSpA cases: 45/118 (38.14%) had sacroiliitis with spondylitis; 34/118 
(28.81%) had sacroiliitis without spondylitis; and 39/118 (33.05%) had spondylitis without 
sacroiliitis. HLA-B27 positivity was significantly more likely in PsSpA cases with both 
sacroiliitis and spondylitis (adjusted odds ratio, ORadj 9.10; 95% CI 3.01, 27.47; p<0.001) 
compared with PsSpA cases with spondylitis-alone. The majority of PsSpA cases with 
spondylitis-alone were symptomatic (56.41%); although were less likely to be symptomatic 
than PsSpA cases with sacroiliitis with / without spondylitis (83.54%) (OR 0.26; 95% CI 
0.11, 0.61; p=0.002).  
Radiographic sacroiliitis was more likely in AS (147/157; 93.63%) compared with 
PsSpA (79/118; 66.95%) cases (adjusted OR, ORadj 3.78; 95% CI 1.63, 8.77; p=0.002). 
AS cases were more likely to have complete ankylosis of the SIJs (ORadj 2.96; 95% CI 
1.42, 6.15; p=0.004), but not SIJ sclerosis, erosion or partial ankylosis. Both PsSpA and 
AS cases tended to have bilateral (82.28 and 96.60%, respectively) symmetrical-grade 
(75.95 and 80.95%, respectively) sacroiliitis.  
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Bridging syndesmophytes were significantly more common in AS compared with 
PsSpA (ORadj 2.78; 95% CI 1.49, 5.18; p=0.001), and may therefore be more useful to 
distinguish PsSpA from AS than paramarginal syndesmophytes. There was no significant 
difference between AS and PsSpA cases in terms of the occurrence of cervical vertebrae 
spondylitis (ORadj 1.20; 95% CI 0.65, 2.25; p=0.56), lumbar vertebrae spondylitis (ORadj 
1.37; 95% CI 0.75, 2.50; p=0.30), or cervical facet joint fusion (ORadj 1.48; 95% CI 0.81, 
2.72; p=0.20).  
Radiographic axial disease was more severe in AS compared with PsSpA as 
measured quantitatively using the PASRI (adjusted incidence risk ratio, IRRadj 1.13 for 
every 1 unit increase in score; 95% CI 1.09, 1.19; p<0.001), mSASSS (IRRadj 1.09 for 
every 1 unit increase in score; 95% CI 1.04, 1.14; p<0.001) and osteoproliferative burden 
(IRRadj 1.31 for every 1 unit increase in score; 95% CI 1.09, 1.57; p=0.004), but not 
erosion burden. 
Conclusions: Spondylitis without sacroiliitis was both common and usually symptomatic 
in PsSpA, so must be considered in classification systems for PsSpA. HLA-B27 positivity 
is more specific to sacroiliitis than to spondylitis, implying different pathogenesis. 
Complete ankylosis of the SIJs and bridging syndesmophytes appear to distinguish AS 
from PsSpA radiographically. AS is radiographically more severe than PsSpA as 
measured by the mSASSS and PASRI scores, both globally and regionally.  
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6.2 INTRODUCTION 
Assessment of structural radiographic damage in psoriatic spondyloarthritis (PsSpA) is 
important since it can help classify cohorts, quantify disease burden, monitor disease 
progression, and has been shown to be a prognostic marker in several rheumatological 
conditions including ankylosing spondylitis (AS) [44]. 
 
Eleven studies have reported on the radiographic characteristics of PsSpA [49, 55, 58, 59, 
63, 68-70, 112, 189, 201]. From these studies, it seems that radiographic sacroiliitis in 
PsSpA is usually of symmetrical grade [69], but whether it is unilateral [70] or bilateral [59, 
69] remains to be determined in a cohort of PsSpA cases with long enough disease 
duration to ascertain this likely time-dependent variable. Vertebral syndesmophytes are 
reported in up to a quarter of PsSpA cases [69], with an unilateral asymmetrical random 
distribution along the spine [70]. Para-marginal shaped syndesmophytes may be more 
specific to PsSpA than AS [58, 59, 70], although in the cervical spine of PsSpA cases, 
marginal syndesmophytes are reported to be more common than para-marginal 
syndesmophytes [68]. According to four studies, vertebral spondylitis of the cervical and / 
or lumbar spine without concurrent sacroiliitis is common in PsSpA, with an estimated 
prevalence of 16 – 62%, albeit different definitions of sacroiliitis have been used [63, 69, 
70, 112]. Radiographic axial disease can manifest in PsSpA in other forms, such as (in 
order of decreasing frequency): facet joint space narrowing or fusion [68, 189], 
posterior ligament ossification [68], para-vertebral ossification [55], narrowing of the lower 
cervical disc space with subsequent fusion of the vertebral bodies [68], atlanto-axial 
subluxation [189], and atlanto-axial impaction [189]. Very little has been reported on the 
natural radiographic history of axial disease in PsSpA. Only one study has reported that 
syndesmophytes and sacroiliitis progress over time, although not necessarily 
accompanied by increasing spinal pain, SIJ tenderness or deterioration of thoracolumbar 
spinal metrology [63]. 
 
Some findings have been consistent in studies using independent cohorts, whilst others 
have not been replicated. This may be explained by the variety of classification systems 
for PsSpA employed, sampling methods, and differing disease durations between cohorts; 
a factor believed to influence the expression of PsSpA. Some studies have used 
convenience samples as part of a retrospective study design, with incomplete 
radiographic data and selective reporting of available data. Several studies have either not 
or only partially adjusted for confounders. Some of the earliest studies from the 1960s and 
1970s did not statistically compare radiographic features in PsSpA and AS, providing 
descriptive analyses only. The studies reporting these results are summarised in turn 
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below, along with a critique of their study methods, reliability of results, and where 
possible an explanation for any disparity between study findings. This will allow the 
methods and results of this thesis chapter to be put into context of the existing literature. 
 
6.2.1 Radiographic features of PsSpA 
 
Para-vertebral ossification is a phenomena typically seen in PsA, and was first reported in 
1965 by Bywaters and Dixon as a case series of four patients [55]. Sacroiliitis or 
syndesmophytes were not always present, but peripheral joint erosions and periosteal 
bone reaction often accompanied. 
 
In a study of 130 PsA patients by Lambert et al. (1977), 40% were classified as PsSpA 
and syndesmophytes were noted in 25% of cases [69]. However, the paper did not state 
the classification criteria used for PsSpA, and only 51/130 had complete sets of axial 
radiographs for review. Isolated anterior syndesmophytes of the cervical spine, without 
sacroiliitis, were noted in 60% of PsSpA cases. This group had a slight male 
preponderance, and more prevalent nail dystrophy, but were no more likely to have 
symptoms or signs of spinal disease than those with normal spine radiographs; 
suggesting symptomatically-silent radiographic PsSpA. Lateral syndesmophytes were 
most commonly found in the lumbar and lower thoracic spine; although that might be 
explained by the often poor visualisation of syndesmophytes on anteroposterior views of 
the cervical spine. Radiographic sacroiliitis was observed in 17% (22/130) of cases, with 
the majority having bilateral sacroiliitis (17/22; 77%). Bilateral sacroiliitis was of 
symmetrical-grade in the majority (12/22), and asymmetrical-grade in 5/22.  
 
In a cohort study by Hanly et al. (1988) of 220 PsA, 52/220 (24%) were classified as 
PsSpA using relatively weak criteria: either inflammatory pain / stiffness of the spine, and / 
or clinical sacroiliitis disease (Gaenslen test, Patrick-FABER test, or direct compression), 
and / or sacroiliitis of grade ≥2 unilaterally [63]. Sacroiliitis of grade ≥2 was noted in 
24/220 (11%) of PsA cases. Of 22 patients with syndesmophytes, only 13/22 had 
sacroiliitis (even using the less strict definition of grade ≥2 unilaterally) and 9/22 (41%) 
had normal SIJs. Although the classification criteria were less stringent, these data 
support the observation of Lambert et al. [69] that syndesmophytes without sacroiliitis are 
a common occurrence in PsSpA, thereby distinguishing PsSpA from AS. However, since 
AS patients are only classified as such by virtue of their sacroiliitis, perhaps a better 
comparison in this setting might be PsSpA with non-radiographic axial SpA. Unfortunately, 
no studies have investigated this. 
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In the same study, serial radiographs over a mean follow-up of 57 months showed a 
significant increase in the number of patients with syndesmophyte formation and 
sacroiliitis. There was no significant increase in the number of patients with spinal pain, 
SIJ tenderness, or change in thoracolumbar spine metrology [63]. The authors concluded 
that although PsSpA patients experience radiographic progression, it remains clinically 
silent and does not compromise spinal mobility. 
 
Of 57 consecutive PsA patients enrolled in a cross-sectional study in Italy by Salvarani et 
al, 40/57 (70%) demonstrated radiographic cervical spondylitis [112]. Two patterns of 
cervical spondylitis were noted: a pattern similar to that seen in AS (n=25/40); and a 
pattern similar to that seen in RA with erosion and / or subluxation (n=15/40). Isolated 
cervical spondylitis without lumbar spondylitis or sacroiliitis was present in 9/57 cases; all 
of whom had peripheral disease and all were HLA-B27 negative.   
 
In a study of 75 PsA patients from Bath (UK) in 1994, 43/75 (57%) cases had radiographic 
cervical spondylitis. Cervical spondylitis changes included: facet joint space narrowing or 
fusion in 21/43 cases; syndesmophytes in 7/43 cases; vertebral body fusion in 6/43 cases; 
and posterior ligament ossification in 4/43 cases [68]. When present, marginal 
syndesmophytes were noted in the majority of cases (8/13), compared with paramarginal 
syndesmophytes in only 5/13 cases. This indicates that marginal syndesmophytes are not 
exclusive to AS, and can be more frequent in PsSpA than paramarginal syndesmophytes. 
Narrowing of the lower cervical disc space with subsequent fusion of the vertebral bodies 
was relatively frequent (6/43). Atlanto-axial subluxation (n=3, but asymptomatic in 2/3) 
and sub-axial subluxation (n=1) were rare. Unlike in RA, odontoid peg erosion was not 
demonstrated in any PsA cases. 
 
In a study of 498 PsA cases, 43/498 were classified as PsSpA [70] on the basis of 
Bennett and Wood’s clinical suggestion [71]. All patients were later confirmed as having 
radiographic spondylitis and / or sacroiliitis (further details not provided in the paper). 
Three further subgroups were derived by the researchers: 22/43 with axial arthritis only; 
8/43 with mixed axial and DIPJ arthritis; and 13/43 with mixed axial and symmetrical 
polyarthritis. Neither, sacroiliitis nor HLA-B27 positivity were present in 8/13 cases with 
mixed axial-DIPJ disease. Psoriatic nail dystrophy was present in 13/43 (30%) of PsSpA 
cases, and particularly so in the group with mixed axial-DIPJ disease (at 40%). Only one 
case had a history of acute anterior uveitis. Of 17/43 patients with sacroiliitis, sacroiliitis 
was unilateral in 11/17, and bilateral in 6/17. Spinal disease was characterised by 
unilateral asymmetrical syndesmophytes, often para-marginal, and randomly distributed 
along spine. This was especially so in the mixed axial-polyarthritis group. One might 
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conjecture: the axial-only group were AS cases with coincidental psoriasis; the mixed 
axial-DIPJ group had diffuse idiopathic hyperostosis (DISH) rather than inflammatory axial 
disease; and the mixed axial-polyarthritis group were the ‘true’ PsSpA cases.   
 
A paper published in 2002, reports 160 consecutive PsA patients enrolled and assessed 
in a secondary-care teaching hospital in Finland [189]. Cervical radiographs were only 
available in 65/160 cases. In 12/65 (18%) cases, inflammatory radiographic cervical 
changes were observed. Facet joint ankylosis was the most frequent pathology (7/65; 
11%), followed by anterior atlanto-axial subluxation (5/65; 8%) and atlanto-axial impaction 
(3/65; 5%). The reliability of this study is however, severely diminished by the large 
amount of missing cervical radiographic data. 
 
No studies have explored whether the pathogenesis of osteoproliferation and / or erosion 
is a systemic process, nor whether it occurs in axial and peripheral sites concomitantly.  
 
6.2.2 Radiographic features of PsSpA compared with AS 
 
Only four studies have compared the axial radiographic characteristics of PsSpA and AS 
[49, 58, 59, 201]. Three of these studies had small (n=34, 39 and 66, respectively) sample 
sizes, and one was large with 147 PsSpA cases, although relied upon the European 
Spondyloarthropathy Study Group (ESSG) criteria for SpA [60] which have not shown 
good specificity or sensitivity for PsSpA [24, 57]. Several similarities and differences were 
found between AS and PsSpA in these studies. Sacroiliitis appears to be commonly 
bilateral in AS (even in early disease), but either unilateral or bilateral in PsSpA [59]. 
Sacroiliitis tends to be of symmetrical-grade in AS of recent onset, but of asymmetrical-
grade in recent-onset PsSpA [58, 59]. In terms of severity of sacroiliitis, whilst Gladman et 
al. (1993) demonstrated a higher frequency of grade 4 sacroiliitis in AS compared with 
PsSpA [49], Helliwell et al. (1998) did not corroborate this [58]. In AS syndesmophytes 
have been shown to be symmetrically distributed [58, 59], progressing cranially from the 
lumbar to the cervical spine [58, 59], with a primarily marginal shape and rarely 
paramarginal [59]. Whereas in PsSpA, the same two studies found that syndesmophytes 
progress in a more random fashion along the spine [58, 59], with both marginal and 
paramarginal syndesmophytes being equally common [58, 59]. Gladman et al. found a 
higher frequency of syndesmophytes in AS compared with PsSpA, although did not sub-
classify by shape [49]. The following axial radiographic features appear to be more 
common in PsSpA than AS, albeit data being from one study only [59]: pubic symphisitis, 
osteoporosis, lumbar hyperextension, thoracic kyphosis, frequency and severity of facet 
joint involvement. Acknowledging the frequently poor radiographic projection, Helliwell et 
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al. propose that lumbar facet joint fusion is also more common in AS than in PsSpA [58]. 
Data in terms of ligamentous ossification and vertebral squaring is somewhat conflicting, 
with McEwen et al. [59] reporting both to be more common in AS than PsSpA, but 
Helliwell et al. [58] reporting no difference. One study found that vertebral corner lesions, 
paravertebral ossification, and disciitis are no more common in AS than in PsSpA [58]. 
According to two studies, radiographic severity is worse in AS than in PsSpA as measured 
by the Bath AS Radiology Index (BASRI) total [201] and BASRI whole spine [58], 
particularly when comparing the lumbar spine [58]. However, another study with the 
primary objective to validate four different axial radiographic scoring indices in PsSpA, 
found that BASRI-spine, PASRI, mSASSS and RASSS scores to be no different in AS 
compared with PsSpA [202]. Finally, Helliwell et al. observed that in AS, BASRI scores 
were similar in the three spinal regions (cervical, thoracic and lumbar), whereas in PsSpA, 
BASRI scores were highest in the cervical followed by the thoracic then lumbar spine [58].  
 
The small sample sizes of these studies, variety of radiographic endpoints used, selective 
reporting of incomplete datasets, lack of confirmed or attempted replication of results in 
other studies, and different classification systems for PsSpA utilised, limits the reliability of 
the comparisons between PsSpA and AS listed above. The four studies are summarised 
in turn below, along with a critique of their study methods, reliability of results, and where 
possible an explanation for any disparity between study.  
 
Paramarginal syndesmophytes (also termed non-marginal syndesmophytes) were first 
reported in a study comparing 18 PsSpA, 19 AS, 19 reSpA, and 18 eSpA cases, and 
presented as an abstract at the 1964 American College of Rheumatology Annual Meeting 
[191]. It was noted that the radiographic features of AS and eSpA were similar, but 
different to the radiographic features of PsSpA and reSpA. The cohort was added to, and 
in 1971 McEwen et al. reported a North American multicentre study comparing the 
radiographic features of 39 PsSpA, 29 AS, 38 eSpA, and 34 reSpA [59]. None of the AS 
cases has clinical evidence of psoriasis. The method for classifying cases as PsSpA were 
not described in detail; other than they were SpA cases with psoriasis confirmed on 
clinical examination by a physician, and occasionally with biopsy. This was an entirely 
descriptive paper, with proportions of radiographic features cited for each condition, and 
no statistical comparisons made between groups. The majority (50%) of PsSpA cases had 
onset of SpA after the onset of psoriasis, and 18% synchronously. Axial radiographs 
comprising a set, were taken at different time-points during disease course, with 
significant variation. This paper preceded the advent of the 1984 modified New York 
criteria for AS; although the SIJs were scored using the New York grading system. Axial 
disease without peripheral radiographic involvement was present in 10% of PsSpA 
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compared with 34% of AS cases. All PsSpA cases had DIPJ disease, but in none of the 
AS cases. Both PsSpA and AS cases were prone to hip and shoulder joint radiographic 
damage. 
 
In AS cases, sacroiliitis was usually bilateral and of symmetrical-grade, even in early 
disease [59]. In PsSpA cases, sacroiliitis could be unilateral or bilateral, and 
asymmetrical-grade in early disease. The following were more common in AS than in 
PsSpA cases: pubic symphisitis; osteoporosis; lumbar hyperextension; thoracic kyphosis; 
more limited chest expansion;  frequency and severity of facet joint involvement; vertebral 
squaring; greater frequency of syndesmophytes; bilateral symmetrical-grades of 
syndesmophytes progressing cranially from the lumbar to the cervical spine in AS, whilst 
PsSpA cases having syndesmophytes progressing in a more random fashion along the 
spine; AS cases mainly having marginal syndesmophytes and rarely having paramarginal 
syndesmophytes, whilst PsSpA cases commonly having both marginal and paramarginal 
syndesmophytes; greater ligamentous ossification.  
 
In 1993, Gladman et al. compared 66 PsA and 40 AS cases in terms of clinical, 
radiographic and genetics [49]. The criteria for classifying the PsA patients as PsSpA was 
relatively weak: the presence of inflammatory back pain / stiffness; and / or sacroiliitis on 
clinical examination; and / or grade ≥2 sacroiliitis; and / or ≥1 paramarginal 
syndesmophyte. The proportion of PsSpA patients earning their classification by each of 
the four routes was not reported, and a patient could have been classified as PsSpA on 
the basis of symptoms alone or clinical-examination sacroiliitis alone, without any 
evidence of disease on radiographs. After adjusting for the pronounced differences in sex, 
age at assessment and arthritis duration between the two groups, the AS patients were 
noted to have a higher frequency of grade four sacroiliitis (p=0.007), and syndesmophytes 
(p=0.005).  
 
A medium-sized hospital-based study in Leeds (UK) of 34 PsSpA, 91 AS, 31 eSpA, and 7 
reSpA patients by Helliwell et al. in 1998 corroborated the findings of McEwen et al., 
including: symmetry of sacroiliitis in AS, symmetry of lumbar spinal involvement in AS, 
frequency and size of syndesmophytes [58]. However, this study also demonstrated less 
severe radiographic axial disease in PsSpA compared with AS cases, as measured by the 
BASRI-total, and more frequent lumbar facet joint fusion in AS than in PsSpA. All 163 
patients fulfilled the modified New York criteria for AS, and further subdivision was based 
on concomitant disorders e.g. psoriasis diagnosed by a dermatologist, IBD diagnosed by 
a gastroenterologist, and reactive arthritis diagnosed using the criteria of Calin et al. [220]. 
Radiographs had been taken in the previous twelve months, and although read in tandem 
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by two blinded readers, no intra- or inter-rater reliability testing was performed. The 
PsSpA and AS cases were no different in term of sex ratio, median age (46 vs. 46 years), 
or median disease duration (16 vs. 18 years).   
 
Severity of SIJ involvement (using the higher grade of the two SIJs) did not differ 
significantly between the groups [58]. However, AS, PsSpA and eSpA differed when 
compared for sacroiliitis grade-symmetry (p=0.02). Groups were no different in terms of 
pubic symphisitis, iliac enthesitis, ischial enthesitis, or hip involvement.  
 
Syndesmophyte morphology, as recorded by the percentage of paramarginal 
syndesmophytes, was not significantly different between PsSpA, AS and eSpA cases. 
However, the degree of syndesmophyte symmetry differed, especially when comparing 
the lumbar spines of PsSpA, AS, and eSpA groups (p=0.04) [58]. The asymmetry of 
syndesmophytes in PsSpA may simply be a function of the lower frequency of 
syndesmophytes in PsSpA compared with AS. In addition, the cervical spine was only 
assessed on the lateral view, therefore not allowing for assessment of left-right symmetry. 
The groups were no different in terms of vertebral squaring, vertebral corner erosions, 
paravertebral ossification, ligamentous calcification, disciitis, or spinal pseudarthrosis.  
 
6.2.3 Radiographic severity in PsSpA and AS cases 
 
Whilst two studies have used the BASRI to quantitatively compare radiographic severity in 
PsSpA and AS cases [58, 201], to date no study has with a key study objective compared 
radiographic severity, as measured by the mSASSS or PASRI scores, in PsSpA and AS 
cases. 
 
Regional variation in radiographic severity occurs between diseases, according to  a study 
by Helliwell et al. [58]. Compared with PsSpA cases the AS cases showed: more severe 
changes (as measured by the BASRI), particularly of the lumbar spine (p=0.02), with a 
higher percentage of grade three and four involvement; more lumbar facet joint 
involvement (p=0.03); and more complete ankylosis. The grading system was as follows: 
0 (normal); 1 (erosion of the superior anterior corner of a vertebra); 2 (≤3 
syndesmophytes); 3 (>3 syndesmophytes); 4 (complete ankylosis or facet joint fusion 
throughout the region). On this basis, and despite having similar disease duration to the 
AS group, the PsSpA group were considered to have less severe disease overall. 
 
Whilst the inter-regional pattern of severity differed across AS, PsSpA, eSpA and reSpA, it 
was not consistently so between groups. In AS the worst affected area was the lumbar 
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spine, but there was little difference between the spinal areas (grade 3-4 disease: lumbar 
55%; cervical 50%; thoracic 45%). In the PsSpA group the worst affected area was the 
cervical spine (grades 3 - 4 disease: cervical 47%; thoracic 36%; lumbar 25%). 
 
A recent large prospective cross-sectional study by Perez-Alamino et al. comparing 1072 
AS, 147 PsSpA, and 45 eSpA patients found that radiographic severity, as measured by 
the BASRI-total score, to be different across the three groups [201].  
 
A study with the primary objective to compare the reliability of four radiographic scoring 
methods for PsSpA (n=40) and AS (n=18), found that the two groups did not differ in 
terms of radiographic severity [202]. The PsSpA and AS cases were no different in terms 
of sex, age at radiograph or disease duration. Acknowledging the small sample size, and 
this being a secondary outcome analysis, axial disease severity was no different in PsSpA 
and AS cases as measured by the PASRI (p=0.12), mSASSS (p=0.49), BASRI-spine 
(p=0.26) or RASSS (p=0.70). 
 
6.2.4 Syndesmophyte morphology in PsSpA and AS 
 
Marginal syndesmophytes represent calcification in the outer fibres of the annulus fibrosis 
of the intervertebral disc, and are the predominant form in all of the SpAs [58]. 
Paramarginal syndesmophytes that are broader and bulkier have been observed to occur 
commonly but not exclusively, in patients with PsSpA. Axial syndesmophyte pathogenesis 
may parallel the periosteal osteoblastogenesis seen in pPsA, in the form of an 
enthesopathy at the attachment of the annulus fibrosis to the vertebrae. De Vlam et al. 
proposed that reduced spinal mobility secondary to facet joint fusion, more common in 
AS, is associated with marginal syndesmophyte formation. Whereas in PsSpA, 
preservation of facet joint mobility results in greater anterior tensile forces, and increased 
damage coupled with reparative osteoproliferation leading to the bulkier para-marginal 
syndesmophytes of PsSpA [221]. More detailed longitudinal pathological data on the 
origin and progression of syndesmophytes are needed. 
 
6.2.5 Radiographic scoring tool inception and design 
 
Three key scoring methods have been devised to assess radiographic axial disease in 
AS: the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) [222], the Bath 
Ankylosing Spondylitis Radiology Index (BASRI) [223], and the Radiographic Ankylosing 
Spondylitis Spinal Score (RASSS) [224]. The mSASSS and BASRI were later validated 
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for use in PsSpA [186]. The Psoriatic Arthritis Spondylitis Radiology Index (PASRI) is a 
modification of the mSASSS, designed to capture cervical facet joint fusion, which is 
thought to be more specific to PsSpA than AS [225].  
 
The mSASSS scores the superior and inferior corner of each vertebrae as follows: 0 = 
normal; 1 = erosion, sclerosis or squaring; 2 = non-bridging syndesmophyte; 3 = bridging  
syndesmophyte (Figure 6.1) [226]. This is done from the lower border of the second 
cervical vertebrae to the upper border of the first thoracic vertebrae (using a lateral 
cervical radiograph), then from the lower border of the twelfth thoracic vertebrae to the 
upper border of the first sacral vertebrae (using lateral and anteroposterior lumbosacral 
radiographs). The total score range is 0 to 72 (cervical 0 to 36; lumbar 0 to 36). Of note, 
the mSASSS does not score the facet joints or SIJs. 
 
 
Figure 6.1. Radiographic scoring of the vertebral corner using the mSASSS  
(Figure from Maksymowych et al. 2010 [227]) 
 
The PASRI scores the superior and inferior corner of each vertebrae using the same 
grading system as the mSASSS (Figure 6.1) [225]. This is done from the lower border of 
the second cervical vertebrae to the upper border of the sixth cervical vertebrae (using a 
lateral cervical radiograph), then from the lower border of the twelfth thoracic vertebrae to 
the upper border of the first sacral vertebrae (using lateral and anteroposterior 
lumbosacral radiographs). The facet joints between C2 and C3, C3 and C4, C4 and C5, 
and C5 and C6 are also scored as follows; 0 = non-fused; 1 = fused. In addition, the 
PASRI scores each SIJ using the New York grading system: 0 = normal; 1 = suspicion of 
sacroiliitis; 2 = sclerosis either side of the joint; 3 = erosions, joint space widening or 
partial ankylosis of the joint; 4 = complete ankylosis of the joint. The total score range is 0 
to 72 (cervical 0 to 24; lumbar 0 to 36; cervical facet joints 0 to 4; SIJs 0 to 8). 
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6.2.5.1 Radiographic scoring tool validation 
 
All four tools have now been validated for use in PsSpA [186, 202, 225].  
 
The PASRI was developed for use in PsSpA and validated in 73 PsSpA cases with 
established disease (54 males, mean age 49.4 years, mean disease duration 14.0 years) 
[225]. During development, the PASRI scored facet joints in both the cervical and lumbar 
spine. The lumbar facets were then removed because their visualisation and interpretation 
was not reliable. The construct validity of the PASRI was tested by examining the 
correlation with PROMs (Revised Leeds Disability Questionnaire, RLDQ; and BASFI), 
anthropometric measures, and comparison of these domains with the other two validated 
tool in PsSpA, the mSASSS and BASRI. The PASRI encompassed a greater range of the 
radiographic axial features of PsSpA. Correlation with anthropometric and patient reported 
outcomes was good for both the PASRI and BASRI, with both these measures outscoring 
the mSASSS. The PASRI had a score range that exceeded that of the mSASSS and 
BASRI. The PASRI had less complete data than the BASRI, as it scored more vertebral 
levels, so had more potential for poorly-visible levels. 
 
In 2009, the BASRI and mSASSS scores were first validated for use in PsSpA by Lubrano 
et al. in terms of construct validity, reliability, and feasibility [186]. Seventy seven PsA 
cases (58 males, mean age 49 years, mean disease duration 14 years) fulfilling CASPAR 
criteria and with clinical, functional and / or radiological axial involvement were studied. 
When compared with metrology (as measured by the BASMI), both the BASRI (Spearman 
rho=0.47; p<0.001), and mSASSS (Spearman rho=0.39; p<0.001) showed modest 
correlation. No correlation was found between mSASSS or BASRI and BASFI, BASDAI or 
HAQ. Test-retest analysis demonstrated good reliability of the scores. Both were feasible, 
although the BASRI was quicker to perform.  
 
All four tools appear to have face validity, as required by the Outcome Measures in 
Rheumatology (OMERACT) filter [152], given that they measure osteoproliferation and 
erosion at both SIJs and vertebrae; key features of PsSpA. The four scores have since 
been compared in terms of intra- and inter-rater reliability in PsSpA (n=40) and AS (n=18), 
as read in random order by each of four rheumatologists [202]. In PsSpA, the intra- and 
inter-rater intraclass correlation coefficients (ICC) were: 0.81 (95% CI 0.73, 0.88) and 0.67 
(95% CI 0.54, 0.79) for sacroiliitis grade; 0.92 (95% CI 0.87, 0.95) and 0.88 (95% CI 0.82, 
0.93) for PASRI; 0.91 (95% CI 0.86, 0.95) and 0.65 (95% CI 0.49, 0.80) for mSASSS; 
0.77 and 0.52 for BASRI-spine; and 0.90 and 0.68 for RASSS, respectively. In AS, the 
intra- and inter-rater ICC were: 0.91 and 0.80 for sacroiliitis grade; 0.99 and 0.93 for 
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PASRI; 0.98 and 0.86 for mSASSS; 0.96 and 0.86 for BASRI-spine; and 0.96 and 0.75 for 
RASSS, respectively [202]. All radiographic scoring tools had moderate to excellent intra- 
and inter-rater reliability when used in PsSpA. In particular, the PASRI had excellent intra- 
and inter-rater-reliability in PsSpA, and the inter-rater reliability of the PASRI was 
significantly better than the other three measures tested. The PASRI may therefore be the 
scoring method of choice for assessing structural damage in PsSpA. In AS, the PASRI 
had excellent intra- and inter-rater-reliability, whilst the mSASSS and RASSS had very 
good reliability. Of note, the reliability of sacroiliitis scoring was lower in PsSpA compared 
to AS. The authors noted that all four methods were less reliable in PsSpA compared with 
AS, especially in terms of sacroiliitis, and reasoned that this was because the PsSpA 
population were older than their AS population (53 vs. 45 years; p=0.05) and therefore 
had a higher prevalence of degenerative arthritis (87 vs. 50%; p=0.01) complicating 
radiographic interpretation [202]. 
 
These four radiographic scoring tools appear to have moderate sensitivity, but high 
specificity to detect 'true' change in PsSpA, with little difference between them to detect 
change, according to one study by Chandran et al. 2011 [228]. Axial radiographs of 105 
PsSpA patients (71 males, mean age 52 years, mean PsA duration 16 years; defined as 
sacroiliitis of grade ≥2 and inflammatory back pain and / or restricted spinal mobility) were 
retrieved for two time points at least two years apart. All radiographs were scored by three 
rheumatologists using the PASRI, mSASSS, BASRI-spine, and RASSS. The proportion of 
patients with worsening scores between the two time intervals (mean 3.5 years) was: 32% 
with the PASRI, 5% with the mSASSS, 29% with the BASRI-spine, and 3% with the 
RASSS. During this interval the mSASSS (p=0.02), PASRI (p=0.01) and BASRI-spine 
(p=0.02) showed statistically significant difference in mean scores. The sensitivity for any 
increase in score to detect true change was as follows: PASRI 0.52 (95%CI 0.32, 0.72); 
mSASSS 0.52 (95%CI 0.32, 0.72); BASRI-spine 0.48 (95%CI 0.28, 0.68); and RASSS 
0.44 (95%CI 0.25, 0.65). The specificity for any increase in score to detect true change 
was as follows: PASRI 0.74 (95%CI 0.63, 0.83); mSASSS 0.84 (95%CI 0.73, 0.91); 




Only four studies have compared the axial radiographic characteristics of PsSpA and AS 
[49, 58, 59, 201]. Radiographic findings across these studies are somewhat more 
consistent than the clinical findings (PROM and clinical examination) reported Chapter 5. 
This is likely to be a reflection of the more consistent classification methods used, and the 
more robust nature of radiographic outcome measures compared with several clinical 
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outcome measures. However, most of these studies had a small sample size (PsSpA, 
n=34 to 39; AS n=29 to 91) and may have been underpowered to detect a difference 
between the two diseases. Perez-Alamino et al. had a larger cohort, but the only 
radiographic outcome reported was the BASRI [201]. There is an unmet need to compare 
PsA and AS cases in terms of syndesmophyte morphology, radiographic severity, 
osteoproliferative and erosive burden. This will allow for the phenotypes of both diseases 
to be better compared in terms of serum and genetic biomarkers.
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6.3 STUDY OBJECTIVES 
Our study objectives were to:  
 
(i) compare the pattern of radiographic axial disease in PsSpA and AS. 
 
(ii) compare the morphological (osteoproliferation and erosion) features of radiographic 
axial disease in PsSpA and AS. 
 





  140 
 
6.4 METHODS 
PsSpA and AS patients were identified, recruited and clinically assessed for the Axial 
Disease in PsA (ADIPSA) study using the methods described in Chapter 4. 
 
6.4.1 Axial radiographic assessment 
 
The most recent axial radiographs of the cervical (lateral), lumbar (lateral and 
anteroposterior) and pelvis (including SIJs) making a complete set were scored using the 
two most validated axial radiographic scoring tools for PsA; the Psoriatic Arthritis 
Spondylitis Radiology Index (PASRI) [185] and the modified Stoke Ankylosing Spondylitis 
Spinal Scoring tool (mSASSS) [186]. 
 
Where possible, radiographs taken at the same time-point were scored as a set. Where 
radiographs were taken at different time-points, the most recent time-point was taken as 
the date of radiographic assessment, on the condition that the interval between the 
earliest and latest radiograph was ≤5 years. 
 
In keeping with previous publications, inflammatory radiographic axial disease (RAD) was 
defined as: the presence of New York criteria sacroiliitis (unilateral grade ≥3, or bilateral 
grade ≥2) on AP pelvic radiograph; and / or ≥1 syndesmophyte (marginal or paramarginal) 
of the cervical or lumbar spine. 
 
6.4.1.1 Axial radiographic scoring: Rate of progression pilot study 
 
Since the axial radiographs were not taken for research purposes, they were not taken at 
fixed time intervals. Studies of AS report a very slow rate of axial radiographic 
progression, of only 1.3 (SD 2.5) units/year using the mSASSS [229]. However, little has 
been published regarding progression in PsSpA; one study reported that 20% of patients 
without syndesmophytes at baseline, developed them after ten years [187]. No studies 
have reported PASRI progression in PsSpA. 
 
Therefore, a pilot study was undertaken to estimate the rate of axial radiographic 
progression in PsSpA, and guide the decision whether it is reasonable to compare current 
clinical data and historic radiographs. Sequential axial radiographs of a case-series of 22 
PsSpA patients attending the RNHRD over the last three decades with at least two 
sequential radiographs were scored. 
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6.4.1.2 Axial radiographic scoring: Reliability exercise 
 
Radiographs were scored by two raters (DJ and AN), but due to time constraints, not in 
duplicate. Therefore, a reliability exercise was performed to test whether DJ and AN score 
consistently with each other, and according the ‘gold-standard’ rater Dr. Graham 
Robinson (GR, Consultant Musculoskeletal Radiologist). 
 
Ten random cases were selected from the ADIPSA cohort (five PsA and five AS cases) 
for scoring independently by DJ, AN and GR using the PASRI and mSASSS scoring tools.  
 
6.4.1.3 Axial radiographic scoring 
 
Axial radiographs were anonymised for the patient’s rheumatological diagnosis prior to the 
scoring. Radiographs were scored by two raters (DJ and AN) using the PASRI and 
mSASSS. The absolute score served as a marker of disease severity, for comparison with 
clinical characteristics and serum-soluble biomarkers. Subdomains of these composite 
scores allowed for comparisons between different pathologies and serum-soluble 
biomarkers.  
 
All but a few radiographs were available for scoring on the RNHRD Picture Archiving 
Computer System (PACS), and both raters used the same monitor, viewing settings and 
office environment. Scoring data was entered into an electronic database designed by DJ. 
 
6.4.2 Statistical methods 
6.4.2.1 Power calculation 
 
200 PsA patients were compared with 200 AS patients. To date, no studies have defined 
the relationship between axial radiographic change and minimum clinically important 
difference (MCID) using the PASRI or mSASSS. Therefore it was not possible to perform 
a power calculation for this component of the study. However, it should be noted that the 
proposed sample size was more than double other published studies comparing PsSpA 
with AS radiographically [49, 58, 59]. 
 
Perez-Alamino et al. found a difference in BASRI-total in AS and PsSpA cases [mean 8.7 
(SD 4.0) in AS; mean 6.1 (SD 4.0) in PsSpA] [201]. A sample of size of 77 PsSpA and 77 
AS would be needed to detect a difference in BASRI-total between the two groups (with 
an alpha level of 0.05 and Power of 0.90). 
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6.4.2.2 Statistical analysis 
 
Data was analysed using STATA 12.1 (2011 Texas, USA).  
 
Intra-rater and inter-rater reliability testing was performed for axial radiographic 
assessments using intra-class correlation coefficients (ICC). 
 
Univariate analyses was performed using the continuity-corrected Chi-squared test for 
categorical variables, Poisson regression for non-normally distributed continuous data 
comprised of integers (e.g. PASRI, mSASSS, and vertebral osteoproliferation burden 
scores in AS compared with PsSpA cases), and zero-inflated Poisson regression for non-
normally distributed continuous data with an excess of zero-values (e.g. cervical vertebrae 
PASRI, lumbar vertebrae PASRI, cervical facet joint PASRI, and vertebral erosion burden 
scores in AS compared with PsSpA cases). Negative binomial regression and zero-
inflated negative binomial regression was considered as an alternative to Poisson 
regression when the mean did not approximate the variance of the data. 
 
Multivariate analyses was performed using logistic regression for categorical variables, 
Poisson regression for non-normally distributed continuous data (e.g. PASRI, mSASSS, 
and vertebral osteoproliferation burden scores in AS compared with PsSpA cases), and 
zero-inflated Poisson regression for non-normally distributed continuous data with an 
excess of zero-values (e.g. cervical vertebrae PASRI, lumbar vertebrae PASRI, cervical 
facet joint PASRI, and vertebral erosion burden scores in AS compared with PsSpA 
cases). Negative binomial regression and zero-inflated negative binomial regression was 
considered as an alternative to Poisson regression when the mean did not approximate 
the variance of the data. A reverse step-wise regression approach was used, setting the 
alpha-level at 0.1 to determine inclusion or exclusion of covariates in the model. This 
allowed adjustment for potentially significant covariates (derived from Chapter 5) 
including: sex, HLA-B27 status, age at axial radiographic assessment, disease duration at 
axial radiographic assessment, anti-TNF use, synthetic DMARD use, smoking and body 
mass index, to minimising noise and maximise statistical power. It is acknowledged that 
indices such as BMI change over time, and that both smoking and medication use as a 
binary outcome does not capture the various durations and doses used by the patients. 
Univariate and multivariate reduced-models are presented in the tables as indicated. 
 
Data are presented as mean, median, inter-quartile range (IQR), standard deviation (SD), 
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odds ratio (OR), adjusted OR (ORadj), incidence risk ratio (IRR), adjusted IRR (IRRadj), 
95% confidence interval (95% CI), and p-value as appropriate to the data. The alpha-level 
for statistical significance was set at 0.05.  
 
6.4.2.3 Missing data handling 
 
If an entire region of radiographs were missing, e.g. no cervical spine images available, 
then those patients were omitted from that component of the analyses. However, available 
radiographs were still scored as data remained valuable for specific sub-analyses e.g. 
associations with osteoproliferation as a binary outcome measure. As per methods used 
by Wanders et al. [188] and later by Lubrano et al. [185]: if >3 scoring sites (e.g. lower 
border of T12 vertebrae) were missing, the radiographs were excluded; if ≤3 scoring sites 
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6.5 RESULTS 
6.5.1 Rate of axial radiographic progression in PsSpA: An exploratory study 
 
Twenty two patients (14 males; mean age at baseline 42.24 years, defined as the first 
radiograph available) were selected: 12/22 had a diagnosis of PsA with / without axial 
symptoms; and 10/22 had a diagnosis of PsSpA (7/10 with peripheral symptoms, and 3/10 
without peripheral symptoms). Follow-up of the patients ranged from 2 to 31 years, and 
the interval between radiographs ranged from 2 to 33 years. 
 
The median mSASSS at baseline was 8.57 (range 0, 24) and 11.29 (range 1, 30) at the 
second time-point. During a median of 5.98 years (range 1.83, 11.00) the annual 
mSASSS progression was a median 0.61 units/year (range -0.67, 2.18). 
 
The median PASRI at baseline was 12.57 units (range 4, 30) and 15.00 units (range 2, 
34) at the second time-point. Over a median of 5.98 years (range 1.83, 11.00) the annual 
PASRI progression was a median 0.40 units/year (range -0.67, 1.64).  
 
In summary, the rate of mSASSS progression in PsSpA is approximately half-that 
reported in AS (0.6 vs. 1.3 units/year). This data suggests that it is reasonable to use films 
in this study that are up to ten years old. This explorative study has limitations, including: 
an assumption of linear progression; small sample size; differing time intervals between 
films, non-random patient selection (with a potential bias towards symptomatic patients, 
who might be the progressors); and time between symptom onset and baseline film were 
unknown. A large prospective longitudinal study using pre-defined imaging intervals is 
needed to fully understand radiographic progression of axial disease in PsSpA. 
 
6.5.2 Reliability of axial radiographic scoring 
 
There was excellent (>0.75) inter-rater reliability between DJ, AN and GR for both of the 
composite radiographic scoring tools (PASRI and mSASSS) and their regional 
subdomains (cervical, lumbar and SIJs), as measured by the intra-class correlation 
coefficient (ICC) [230]. Compared to the gold standard rater (GR), ICCs ranged between: 
0.98 (95% CI 0.90, 1.00) to 0.98 (95% CI 0.92, 1.00 ) for the PASRI; 0.98 (95% CI 0.90, 
0.99) to 0.99 (95% CI 0.96, 1.00) for the mSASSS; and 0.85 (95% CI 0.33, 0.96) to 0.90 
(95% CI 0.56, 0.98) for the SIJs (Table 6.1).  
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Table 6.1 Inter-rater reliability of axial radiographic scoring in PsSpA and AS across 
the three raters 




PASRI DJ vs. AN 0.99 0.97, 1.00 
PASRI DJ vs. GR 0.98 0.90, 1.00 
PASRI AN vs. GR 0.98 0.92, 1.00 
mSASSS DJ vs. AN 0.99 0.97, 1.00 
mSASSS DJ vs. GR 0.98 0.90, 0.99 
mSASSS AN vs. GR 0.99 0.96, 1.00 
SIJs DJ vs. AN 0.97 0.90, 0.99 
SIJs DJ vs. GR 0.90 0.56, 0.98 
SIJs AN vs. GR 0.85 0.33, 0.96 
C-spine vertebrae DJ vs. AN 0.98 0.91, 0.99 
C-spine vertebrae DJ vs. GR 0.99 0.94, 1.00 
C-spine vertebrae AN vs. GR 0.97 0.84, 0.99 
C-spine facet joints DJ vs. AN 0.99 0.94, 1.00 
C-spine facet joints DJ vs. GR 0.89 0.58, 0.97 
C-spine facet joints AN vs. GR 0.96 0.83, 0.99 
L-spine vertebrae DJ vs. AN 1.00 0.99, 1.00 
L-spine vertebrae DJ vs. GR 0.94 0.78, 0.99 
L-spine vertebrae AN vs. GR 0.95 0.82, 0.99 
 
DJ: Deepak Jadon   AN: Alison Nightingale   GR: Graham Robinson 
SIJs: sacroiliac joints   C-spine: cervical spine   L-spine: lumbar spine   
95% CI: 95% confidence interval  PASRI: Psoriatic Arthritis Spondylitis Radiology Index  
mSASSS: modified Stoke Ankylosing Spondylitis Spinal Score   
   
 
 
There was excellent (>0.75) intra-rater reliability by both DJ and AN with the PASRI, 
mSASSS and, and their regional subdomains (cervical, lumbar and SIJs), when the same 
ten cases were re-scored a month later by each rater. ICCs for DJ ranged between 0.99 
(95% CI 0.95, 1.00) for the cervical spine, to 1.00 (1.00, 1.00) for the SIJs and cervical 
facet joints; and for AN ranged between 0.88 (95% CI 0.53, 0.97) for cervical spine, to 
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Table 6.2. Intra-rater reliability of axial radiographic scoring in PsSpA and AS 
across the two raters 





PASRI DJ vs. DJ 1.00 0.99, 1.00 
mSASSS DJ vs. DJ 1.00 0.98, 1.00 
SIJs DJ vs. DJ 1.00 1.00, 1.00 
C-spine vertebrae DJ vs. DJ 0.99 0.95, 1.00 
C-spine facet joints DJ vs. DJ 1.00 1.00, 1.00 
L-spine vertebrae DJ vs. DJ 0.99 0.97, 1.00 
PASRI AN vs. AN 0.99 0.96, 1.00 
mSASSS AN vs. AN 0.98 0.93, 1.00 
SIJs AN vs. AN 0.99 0.94, 1.00 
C-spine vertebrae AN vs. AN 0.88 0.53, 0.97 
C-spine facet joints AN vs. AN 0.99 0.95, 1.00 
L-spine vertebrae AN vs. AN 1.00 0.98, 1.00 
 
DJ: Deepak Jadon    AN: Alison Nightingale   SIJ: sacroiliac joint   
C-spine: cervical spine    L-spine: lumbar spine   95% CI: 95% confidence interval 




In summary, the mSASSS and PASRI were reliable methods to score axial radiographic 
disease in PsSpA and AS. 
 
6.5.3 Axial radiographic characteristics of PsSpA and AS cases 
 
The study enrolled 402 SpA patients (201 PsA and 201 AS), and all completed clinical 
assessment. A full set of axial radiographs (cervical, lumbar and pelvis) were available on 
392/402 cases, with an incomplete series of axial radiographs in 10/402 cases. Only ten 
PsA patients had an incomplete series of axial films to determine RAD, and were 
assumed to have peripheral arthritis only, and therefore classified as pPsA. Of these: 
118/402 (29.35%) cases were classified as PsSpA on based upon psoriasis (current or 
previous) and radiographic axial disease (RAD); 157/402 (39.05%) cases were classified 
as AS based upon RAD but no psoriasis (current or history of); 127/402 (31.60%) cases 
were classified as peripheral PsA (pPsA) based upon psoriasis (current or previous), 
peripheral arthritis and without RAD.  
 
All the vertebral levels were visible for scoring in the PsSpA and AS cases; so there were 
no missing data. A comparison of the axial radiographic characteristics of the 118 PsSpA 
and 157 AS cases are presented below. 
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6.5.3.1 Socio-demographic and treatment characteristics of the PsSpA and AS 
cases 
 
A more detailed description is given in Chapter 5, but a summary for the purpose of this 
chapter is given here. There was a preponderance of males in the AS group compared 
with the PsSpA group (OR 1.80; 95% CI 1.07, 3.03; p=0.03). AS cases were a mean 4.88 
years younger than PsSpA cases at the most recent axial radiograph (51.48 vs. 56.36 
years, respectively; p=0.002). Disease duration from arthritis diagnosis to the most recent 
axial radiograph was no different in AS compared with PsSpA cases (19.00 vs. 15.50 
years, respectively; p=0.13). AS cases were more likely than PsSpA cases to be HLA-B27 
positive (89.17 vs. 39.83%; OR 12.44; 95% CI 6.67, 23.22; p<0.001). AS and PsSpA 
cases were no different in terms of a history of tobacco smoking (45.85 vs. 51.82%, 
respectively; p=0.34). BMI was lower in AS compared with PsSpA cases (mean difference 
-1.60 kg/m2; p=0.01). AS cases were far less likely to have used a synthetic DMARD than 
PsSpA cases (OR 0.24; 95% CI 0.14, 0.42; p<0.001). Anti-TNF therapy use during 
disease course was no different in AS compared with PsSpA cases (37.58 vs. 44.92%, 
respectively; p=0.22); nor was the interval between diagnosis and commencement of the 
first anti-TNF agent (16.0 years in PsSpA vs. 16.0 years in AS; p=0.62%). Multivariate 
regression models were used to adjust for differences between the AS and PsSpA 
groups. 
 
6.5.3.2 Axial radiographic pattern  
 
Radiographic sacroiliitis was more likely in AS (147/157; 93.63%) compared with PsSpA 
(79/118; 66.95%) cases (ORadj 3.78; 95% CI 1.63, 8.77; p=0.002) (Table 6.3). The ten 
cases in the AS group deemed not to have sacroiliitis were re-reviewed after the formal 
scoring exercise. Their classification as AS was deemed appropriate as the sacroiliitis was 
equivocal, and might justifiably have been scored as New York criteria sacroiliitis in a non-
research clinical setting. They remained in the AS cohort (n=157), and their PASRI and 
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Table 6.3. Axial radiographic characteristics in PsSpA and AS 
Domain  Clinical Parameter Disease Yes (%) Adjusted  
OR 
95% CI p-value 
Radiographic  Sacroiliitis 
 





0.002 * AS 147/157 (93.63) 
Spondylitis  
(cervical and / or 
lumbar) 





0.83 ** AS 109/157 (69.43) 
Sacroiliitis 
pattern 





0.001 *** AS 142/147 (96.60) 





0.65 **** AS 119/147 (80.95) 
Spondylitis 
pattern 





0.56 ***** AS 85/157 (54.14) 





0.20 ***** AS 60/157 (38.22) 





0.30 ****** AS 85/157 (54.14) 
 
* Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: HLA-B27 status) 
** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, age at radiographic assessment, disease 
duration at radiographic assessment) 
*** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: disease duration at radiographic assessment) 
**** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: age at radiographic assessment, and disease 
duration at radiographic assessment) 
***** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, HLA-B27 status, age at radiographic 
assessment, anti-TNF use ever, and synthetic DMARD use ever) 
****** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: HLA-B27 status, and age at radiographic 
assessment) 
 
Bilateral sacroiliitis was present in the majority of PsSpA cases (65/79; 82.28%), with 
unilateral sacroiliitis present in only 14/79 (17.72%) (Table 6.3). Similarly, bilateral 
sacroiliitis was present in the majority of AS cases (142/147; 96.60%), with unilateral 
sacroiliitis present in only 5/147 (3.40%). Despite this, AS cases were statistically more 
likely to have bilateral sacroiliitis than PsSpA cases (ORadj 6.14; 95% CI 2.08, 18.15; 
p=0.001).  
 
Symmetrical-grade sacroiliitis was present in the majority of PsSpA cases (60/79; 
75.95%), with asymmetrical-grade sacroiliitis present in only 19/79 (24.05%) (Table 6.3). 
Similarly, symmetrical-grade sacroiliitis was present in the majority of AS cases (119/147; 
80.95%), with asymmetrical-grade sacroiliitis present in only 28/147 (19.05%). Of note, AS 
cases were no more likely to have symmetrical-grade sacroiliitis than PsSpA cases (ORadj 
1.17; 95% CI 0.59, 2.32; p=0.65).  
 
There was no significant difference between AS (109/157; 69.43%) and PsSpA (84/118; 
71.19%) in terms of the occurrence of spondylitis (cervical and / or lumbar) (ORadj 0.94; 
95% CI 0.52, 1.69; p=0.83) (Table 6.3). Regional analysis showed that cervical vertebrae 
spondylitis was present in 52/116 (44.83%) PsSpA and 85/157 (54.14%) AS cases, with 
no difference between diseases (ORadj 1.20; 95% CI 0.65, 2.25; p=0.56) (Table 6.3). 
  149 
 
Similarly, cervical facet joint fusion was present in 29/118 (24.58%) PsSpA and 60/157 
(38.22%) AS cases, with no difference between diseases (ORadj 1.48; 95% CI 0.81, 2.72; 
p=0.20) (Table 6.3). Lumbar vertebrae spondylitis was present in 50/117 (42.74%) PsSpA 
and 85/157 (54.14%) AS cases, with no difference between diseases (ORadj 1.37; 95% CI 
0.75, 2.50; p=0.30) (Table 6.3). 
 
Of 118 cases classified as PsSpA: 45/118 (38.14%) had sacroiliitis with spondylitis; 
34/118 (28.81%) had sacroiliitis without spondylitis; and 39/118 (33.05%) had spondylitis 
without sacroiliitis (Figure 6.2). The majority of PsSpA cases with spondylitis but no 
sacroiliitis were symptomatic (22/39; 56.41%); although were less likely to be symptomatic 
than PsSpA cases with sacroiliitis with / without spondylitis (66/79; 83.54%) (OR 0.26; 




Figure 6.2. Pattern of radiographic axial disease in PsSpA cases 
 
 
All 39 cases with spondylitis but not sacroiliitis were enrolled from the PsA clinic. In that 
group, 4/39 had borderline unilateral grade 2 sacroiliitis. Spondylitis had been scored in 
this group on the basis of cervical non-bridging syndesmophyte(s) (n=18/39; 46.15%), or 
cervical bridging syndesmophyte (n=3/39; 7.69%), or lumbar non-bridging 
syndesmophyte(s) (n=23/39; 74.36%). 
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HLA-B27 was positive in 6/39 (15.38%) of PsSpA cases with spondylitis-alone, 11/34 
(32.35%) of cases with sacroiliitis-alone, and 30/45 (66.67%) of cases with both sacroiliitis 
and spondylitis. Logistic regression (adjusted for sex, age at radiographic assessment and 
disease duration at radiographic assessment) demonstrated that compared with PsSpA 
cases with spondylitis-alone, there is a significantly increased probability of HLA-B27 
positivity in PsSpA cases with both sacroiliitis and spondylitis (unadjusted OR 11.00; 95% 
CI 3.78, 32.00; p<0.001. Adjusted ORadj 9.10; 95% CI 3.01, 27.47; p<0.001), and a trend 
for the same when comparing spondylitis-alone with sacroiliitis-alone (unadjusted OR 
2.63; 95% CI 0.85, 8.13; p=0.09. Adjusted OR 2.60; 95% CI 0.80, 8.42; p=0.11). 
 
Peripheral hand and feet radiographs of all of the 201 PsA cohort had been scored by DJ 
during a previous study using the modified Van der Heijde scoring tool [231]. Peripheral 
joint ankylosis (≥1 joint) was observed in 12/127 (9.45%) pPsA cases and 11/74 (14.86%) 
PsSpA cases; 44 PsSpA cases derived from the AS cohort didn’t have peripheral 
radiographs for scoring. A logistic regression model included sex, HLA-B27 status, age at 
axial radiograph, disease duration at axial radiograph, anti-TNF use ever and synthetic 
DMARD use ever demonstrated that the odds of having peripheral joint ankylosis was no 
higher in the PsSpA compared with the pPsA group (ORadj 1.61; 95% CI 0.66, 4.20; 
p=0.29), although may be underpowered to detect a difference. 
 
6.5.3.3 Axial radiographic morphology 
 
AS cases were significantly more likely to have SIJ complete ankylosis (grade 4 
sacroiliitis) than PsSpA cases (43.31 vs. 15.25%; ORadj 2.96; 95% CI 1.42, 6.15; p=0.004) 
(Table 6.4). However, there was no statistically significant difference between AS and 
PsSpA cases in terms of the probability of SIJ joint partial ankylosis (29.30 vs. 21.19%; 
ORadj 1.08; 95% CI 0.56, 2.10; p=0.81), SIJ erosion (33.76 vs. 35.59%; ORadj 1.07; 95% 
CI 0.63, 1.81; p=0.80), and SIJ bilateral simple sclerosis (5.73 vs. 5.08%; ORadj 1.75; 95% 
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Table 6.4. Axial radiographic morphology in PsSpA and AS 
Site  Morphological feature Disease Yes (%) Adjusted  
OR 









Simple sclerosis bilaterally 
(Grade 2) 





0.34 * AS 9/157 (5.73) 
Erosion 
(Grade 3) 





0.80 ** AS 53/157 (33.76) 
Partial ankylosis 
(Grade 3) 





0.81 *** AS 46/157 (29.30) 
Complete ankylosis 
(Grade 4) 





0.004 **** AS 68/157 (43.31) 





0.53 ** AS 6/157 (3.82) 
Non-bridging 
syndesmophyte   





0.79 ***** AS 58/157 (36.94) 





0.001 ****** AS 36/157 (22.93) 
 
* Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: synthetic DMARD use ever) 
** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, and disease duration at radiographic 
assessment) 
*** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: HLA-B27 status, age at radiographic assessment, 
and disease duration at radiographic assessment) 
**** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, HLA-B27 status, and disease duration at 
radiographic assessment) 
***** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, and age at radiographic assessment) 
****** Multivariate reverse-stepwise logistic regression model (reduced model adjusted for: sex, age at radiographic assessment, anti-TNF 
use ever, and synthetic DMARD use ever) 
 
 
Bridging syndesmophytes were relatively common in both AS (22.93%) and PsSpA 
(10.17%) cases, but significantly more common in AS cases (ORadj 2.78; 95% CI 1.49, 
5.18; p=0.001) (Table 6.4). Non-bridging syndesmophytes were common in both AS 
(36.94%) and PsSpA (39.83%) cases, with no difference in frequency between groups 
(ORadj 0.93; 95% CI 0.57, 1.56; p=0.79). Vertebral erosion (also known as the Romanus 
lesion) was remarkably rare in both AS (3.82%) and PsSpA (2.54%) cases, with no 
significant difference in frequency between groups (ORadj 1.58; 95% CI 0.38, 6.57; 
p=0.53). 
 
6.5.3.4 Axial radiographic severity 
 
Axial radiographic severity was higher in AS than in PsSpA cases, as measured by the 
PASRI (median score 15 vs. 6, respectively; IRRadj 1.13 for every 1 unit increase in score; 
95% CI 1.09, 1.19; p<0.001) (Figure 6.3), and the mSASSS (median score 10 vs. 3, 
respectively; IRRadj 1.09 for every 1 unit increase in score; 95% CI 1.04, 1.14; p<0.001) 
(Figure 6.4).  
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Multivariate reverse-stepwise Poisson regression model adjusted (reduced model adjusted for: sex, HLA-B27 status, age at 
radiographic assessment, disease duration at radiographic assessment, anti-TNF use ever, synthetic DMARD use ever, and 
smoking ever) 
Figure 6.3. Axial radiographic severity as measured by the PASRI in PsSpA and AS cases 
 
 
Multivariate reverse-stepwise Poisson regression model (reduced model adjusted for: sex, HLA-B27 status, age at 
radiographic assessment, disease duration at radiographic assessment, anti-TNF use ever, synthetic DMARD use ever, and 
smoking ever) 
Figure 6.4. Axial radiographic severity as measured by the mSASSS in PsSpA and AS cases 
 
The same held true when analysed by axial region: cervical vertebral PASRI in AS and 
PsSpA (median score 2 vs. 0, respectively; IRRadj 1.57 for every 1 unit increase in score; 
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95% CI 1.35, 1.83; p<0.001) (Figure 6.5); and lumbar vertebral PASRI in AS and PsSpA 
(median score 4 vs. 0, respectively; IRRadj 1.42 for every 1 unit increase in score; 95% CI 
1.29, 1.58; p<0.001) (Figure 6.6). 
 
 
Multivariate reverse-stepwise zero-inflated Poisson regression model (reduced model adjusted for: sex, age at radiographic 
assessment, disease duration at radiographic assessment, anti-TNF use, synthetic DMARD use, and smoking ever) 
Figure 6.5. Cervical vertebrae radiographic severity (using PASRI) in PsSpA and AS cases 
 
Multivariate reverse-stepwise zero-inflated Poisson regression model (reduced model adjusted for: sex, HLA-B27 status, 
age at radiographic assessment, disease duration at radiographic assessment, anti-TNF use, synthetic DMARD use, and 
smoking ever) 
Figure 6.6. Lumbar vertebrae severity (using PASRI) in PsSpA and AS cases 
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Cervical facet joint PASRI was also higher in AS (median score 0; IQR 0, 3) compared 
with PsSpA (median score; IQR 0, 0) cases (IRRadj 1.47; 95% CI 1.08, 1.99; p=0.01) 
(multivariate reverse-stepwise zero-inflated Poisson regression model adjusted for: sex, 
age at radiographic assessment, disease duration at radiographic assessment, anti-TNF 
use ever, and synthetic DMARD use ever). 
  
The mSASSS scores the same number of levels in the cervical and lumbar spine, thereby 
allowing score comparisons to be made; whereas the PASRI scores a different number of 
levels in the cervical and lumbar spine. Using the mSASSS, the cervical spine was more 
severely affected than the lumbar spine in PsSpA (IRRadj 1.54; 95% CI 1.20, 1.74; 
p<0.001), but no different in AS. 
 
The burden of vertebral osteoproliferative disease as measured by the PASRI (bridging 
and / or non-bridging syndesmophytes) was higher in AS compared with PsSpA cases 
(median score 6 vs. 2, respectively; IRRadj 1.31 for every 1 unit increase in score; 95% CI 
1.09, 1.57; p=0.004) (Table 6.5). The burden of vertebral erosive disease was not 
statistically different in AS and PsSpA cases (IRRadj 0.99; 95% CI 0.43, 2.31; p=0.99). 
 
 
Table 6.5. Burden of osteoproliferation and erosion in PsSpA and AS cases 
Vertebral morphology 
using the PASRI 
Disease Median 
score 











0.99 ^ AS 0 0, 0 
Osteoproliferation burden  
(syndesmophytes) 





0.004 * AS 6 0, 30 
 
IQR: inter-quartile range     IRR: Incidence risk ratio  
PsSpA: psoriatic spondyloarthritis AS: ankylosing spondylitis PASRI: Psoriatic Arthritis Spondylitis Radiology Index 
 
^ Multivariate reverse-stepwise zero-inflated Poisson regression model, adjusted for: age at radiographic assessment, and smoking ever. 
* Multivariate reverse-stepwise Poisson regression model, adjusted for: sex, HLA-B27 status, age at radiographic assessment, disease 
duration at radiographic assessment, anti-TNF use ever, synthetic DMARD use ever, and smoking ever. 
 
 
There was a moderate-to-good [232] positive correlation that was statistically significant 
between the PASRI and mSASSS in: PsSpA cases (Spearman rank correlation 
coefficient, rs 0.62; p<0.0001), and in AS cases (rs 0.97; p<0.0001); although the strength 
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6.5.4 An exploratory analysis of axial radiographic severity in male and female cases 
 
The objective of this chapter of the thesis was to compare PsSpA and AS cases, rather 
than subgroups within each cohort. However, due to the findings of a few previous 
studies, exploratory analyses was performed to determine if axial radiographic severity 
was related to sex, adjusted for HLA-B27 status and other covariates. 
 
In the PsSpA cohort: PASRI was lower in female (median 5.5; IQR 4, 6) compared with 
male (median 7; IQR 4, 23) cases (IRRadj 0.62 per 1 unit increase in score; 95% CI 0.57, 
0.67; p<0.001); and mSASSS was lower in female (median 2.5; IQR 0, 6) compared with 
male (median 4; IQR 0, 18) PsSpA cases (IRRadj 0.60 per 1 unit increase in score; 95% CI 
0.54, 0.66; p<0.001). A zero-inflated Poisson regression adjusting for HLA-B27 status, 
age at axial radiograph, disease duration at axial radiograph, anti-TNF use ever, synthetic 
DMARD use ever and smoking was used for each analysis.    
 
The same was found in the AS cohort: PASRI was lower in female (median 8; IQR 6, 23) 
compared with male (median 18; IQR 7, 40) AS cases (IRRadj 0.67 per 1 unit increase in 
score; 95% CI 0.61, 0.73; p<0.001); and mSASSS was lower in female (median 0; IQR 0, 
20) compared with male (median 12; IQR 0, 36) AS cases (IRRadj 0.58 per 1 unit increase 
in score; 95% CI 0.53, 0.64; p<0.001). A Poisson regression adjusting for HLA-B27 status, 
age at axial radiograph, disease duration at axial radiograph, anti-TNF use ever, synthetic 
DMARD use ever and smoking was used for each analysis.    
 
6.5.5 An exploratory analysis of correlation between axial radiographics and metrology 
in both PsSpA and AS 
 
Given that two radiographic indices (mSASSS and BASRI)-spine have shown correlation 
with metrology in PsSpA in a previous study [204], we performed an exploratory analysis 
comparing metrology (BASMI and its subdomains) with radiographic indices (PASRI and 
mSASSS) in our cohort. These exploratory analysis showed moderate-to-good positive 
correlation that was statistically significant in: PsSpA between PASRI and BASMI 
(Spearman rank correlation coefficient, rs = 0.57; p<0.0001) (Figure 6.7), and between 
mSASSS and BASMI (rs = 0.56; p<0.0001); and in AS between PASRI and BASMI (rs = 
0.57; p<0.0001) (Figure 6.8), and between mSASSS and BASMI (rs = 0.57; p<0.0001). 
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Figure 6.7. Scatterplot of correlation between radiographics (PASRI) and metrology (BASMI) 
in PsSpA cases 
 
 
Figure 6.8. Scatterplot of correlation between radiographics (PASRI) and metrology (BASMI) 
in AS cases 
 
Further exploratory analyses for association between regional PASRI and corresponding 
regional BASMI showed a moderate-to-good positive / negative correlation that was 
statistically significant in PsSpA cases between: cervical-PASRI (vertebral and facet 
scores combined) and cervical rotation (rs = -0.54; p<0.0001), cervical-PASRI and tragus-
to-wall distance (rs = 0.64; p<0.0001), lumbar-PASRI and lumbar forward flexion as 
measured by the Schober test (rs = -0.56; p=<0.0001), and lumbar-PASRI and lumbar 
side-flexion (rs = -0.38; p<0.0001). Similarly, there was moderate-to-good positive / 
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negative correlation that was statistically significant in AS cases between: cervical-PASRI 
(vertebral and facet scores combined) and cervical rotation (rs = -0.56; p<0.0001), 
cervical-PASRI and tragus-to-wall distance (rs = 0.44; p<0.0001) lumbar-PASRI and 
lumbar forward flexion as measured by the Schober test (rs = -0.56; p<0.001), and lumbar-
PASRI and lumbar side-flexion (rs = -0.39; p<0.0001). 
 
 
6.5.6 Summary of the results 
 
The typical radiographic axial phenotype of AS and PsSpA are summarised in Figure 6.9. 
The axial radiographic similarities and difference between AS and PsSpA are summarised 
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6.6 DISCUSSION & CONCLUSIONS 
To our knowledge, this is the largest sample of PsSpA and AS cases with a detailed 
description of plain radiographic characteristics, and the first study to compare PsSpA and 
AS cases in terms of: inflammatory symptoms in PsSpA cases with and without sacroiliitis; 
symptoms in unilateral grade 2 sacroiliitis; prevalence of bridging and non-bridging 
syndesmophytes; radiographic severity as measured by the PASRI and mSASSS; 
cervical facet joint severity; vertebral osteoproliferative burden; and vertebral erosion 
burden. This is also the first study to investigate the influence of HLA-B27 variants on the 
radiographic expression of PsSpA in terms of sacroiliitis, spondylitis, or both.  
 
6.6.1 Radiographic axial disease in PsSpA  
 
Spondylitis in the absence of sacroiliitis was present in 33% (39/118) of our cohort of 
PsSpA cases. This is lower than the prevalence of 60% reported by Lambert at al., 
although that study did not state the classification system used for cases, and only 51 of 
their 130 PsA cases had complete sets of axial radiographs for review [69]. The missing 
radiographs are most likely to have been of the cervical or lumbar spine, given that those 
cases were often asymptomatic. Hanly et al., using a less stringent definition of sacroiliitis 
(of grade ≥2 unilaterally) demonstrated a 17% (9/52) prevalence of spondylitis without 
sacroiliitis [63]. This figure would have risen had they used a definition of sacroiliitis similar 
to ours. Salvarani et al. demonstrated a prevalence of cervical spondylitis without 
sacroiliitis and / or lumbar spondylitis of 16% (9/57) [112]. Unfortunately, the prevalence 
spondylitis without sacroiliitis was not reported.  
 
Taylor et al. (2004) proposed that vertebral spondylitis without radiographic sacroiliitis is a 
feature that may distinguish PsSpA from AS [56]. This has important implications when 
classifying PsSpA, when a requirement of sacroiliitis (as per AS classification), may 
incorrectly exclude genuine PsSpA cases with vertebral spondylitis but no sacroiliitis. We 
support this position given that a significant proportion (56%) of our PsSpA cases with 
spondylitis-alone had inflammatory axial symptoms. 
 
This is the first study to investigate the influence of HLA-B27 variants on the radiographic 
expression of PsSpA in terms of sacroiliitis, spondylitis, or both. When compared with 
PsSpA cases with spondylitis-alone, HLA-B27 variants were significantly more common in 
PsSpA cases with both sacroiliitis and spondylitis and with sacroiliitis-alone (trend for 
significance). This implies that sacroiliitis may be the results of abnormal HLA-B27-related 
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pathways, whereas spondylitis may involve pathways unrelated to HLA-B27. Whilst 
osteoproliferation is a shared feature of both sacroiliitis and spondylitis, there aetio-
pathogenesis may be different. 
 
Taken together, our data showing that a significant proportion PsSpA suffer with 
spondylitis-alone, the majority are symptomatic, and that it might not be appropriate to 
group sacroiliitis and spondylitis together given that they may have different pathogenesis, 
would argue against having the same the treatment criteria for PsSpA and AS. Requiring 
PsSpA patients to fulfill AS criteria for anti-TNF therapy, which mandates AS criteria 
sacroiliitis, seems strict. Similarly, requiring PsSpA patients with primarily axial disease to 
fulfill PsA criteria for anti-TNF therapy, which mandates significant peripheral arthritis, also 
seems strict. One might therefore advocate PsSpA-specific criteria for access to specialist 
therapies such as anti-TNF, whereby symptomatic PsSpA patients with spondylitis but no 
sacroiliitis can access anti-TNF therapy with equal opportunity. Clinical trials testing the 
efficacy of specialist therapies such as anti-TNF, specifically in PsSpA patients would be 
required to justify this. In addition, a new international-consensus classification system for 
PsSpA, perhaps recognising that spondylitis-alone is sufficient to classify a patient as 
having PsSpA, would improve the classification of cohorts in research studies and clinical 
trials, improve the quality of research, and raise the profile of PsSpA. 
 
6.6.2 Radiographic axial disease pattern in PsSpA compared with AS  
 
Bilateral sacroiliitis was the most common pattern in both PsSpA and AS cases in this 
study. These findings replicate the results of two other studies [59, 69], but challenges the 
predominantly unilateral sacroiliitis in PsSpA cases reported by Scarpa et al. [70]. The 
disparity may be related to Scarpa et al.’s cases being younger than ours (mean age 42 
vs. 56 years, respectively), so they may not have expressed their complete sacroiliitis 
phenotype. Another explanation is the classification system used by Scarpa et al. may 
have misclassified patients with either DISH or AS with coincidental psoriasis, as PsSpA.  
 
Bilateral sacroiliitis was usually symmetrical-grade in our PsSpA and the AS cases, which 
corroborates the findings of Lambert et al. [69]. McEwen et al. noted asymmetrical grade 
sacroiliitis in PsSpA cases with early disease, but did not comment on grade-symmetry in 
established PsSpA cases such as ours [59]. Helliwell et al. reported symmetrical 
sacroiliitis to be more common in their AS cases [58]. The PsSpA cases in that study were 
younger than ours (46 vs. 56 years, respectively), and so may not have expressed their 
complete sacroiliitis phenotype. Complete ankylosis of the SIJs (grade 4) was more 
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common in our AS compared with PsSpA cases; a finding corroborated by one previous 
study [49]. 
 
Cervical vertebrae spondylitis was noted in 21% (52/245) of our PsA cases, which is 
similar to the prevalence reported by Laiho et al. of 18% [189]. However, this prevalence 
is far lower than the 70% reported by Salvarani et al. [112], and the 57% reported by 
Jenkinson et al. [68]. Such a difference may have arisen if both those studies classified 
patients as cervical spondylitis on the basis of facet joint disease alone.  
 
AS and PsSpA cases in our cohort had a similar frequency of cervical facet joint disease. 
McEwen et al. noted a greater frequency of facet joint involvement in AS, but did not 
compare the groups statistically [59]. However, just as found in our cohort, McEwen et al. 
also reported a greater severity of facet joint involvement in AS compared with PsSpA.  
 
Just like Helliwell et al. [58], we found no difference between the groups in terms of the 
frequency of vertebral corner erosion, or vertebral squaring. Neither our study nor that by 
Jenkinson et al. [68] demonstrated RA-like odontoid peg erosion in the PsSpA cases. We 
found a greater frequency of bridging syndesmophytes in AS cases compared with PsSpA 
cases; but no difference in non-bridging syndesmophytes frequency. This is the first study 
to separately analyse bridging and non-bridging syndesmophytes in the two disease. 
Three other studies noted a greater frequency of syndesmophytes in AS, but did not sub-
analyse by bridging [49, 58, 59]. 
 
According to Helliwell et al., the percentage of paramarginal syndesmophytes is not 
significantly different between PsSpA and AS [58]. However, McEwen et al. noted AS 
cases rarely having paramarginal syndesmophytes, mostly marginal syndesmophytes; 
whilst PsSpA cases commonly having both types of syndesmophytes [59]. Jenkinson et 
al. [68] noted that in PsSpA cases, cervical marginal syndesmophytes were more 
common than paramarginal syndesmophytes.  
 
6.6.3 Radiographic axial disease severity in PsSpA and AS  
 
Axial radiographic severity as measured by the PASRI and / or mSASSS, was more 
severe in our AS cases compared with PsSpA cases; even when analysed by spinal 
region. As measured by the mSASSS, we also found that the cervical spine was more 
severely affected than the lumbar spine in PsSpA, but was no different in AS. Helliwell at 
al. measured axial radiographic severity using the BASRI-total, and support our findings 
both for the whole spine, and for the cervical versus lumbar spine [58]. A large prospective 
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cross-sectional study by Perez-Alamino et al. using the BASRI-total also supports our 
findings [201]. Only one study challenges our results, and found no difference in 
radiographic severity as measured by the PASRI, mSASSS or BASRI-spine [202]. 
However, that study had much fewer cases (PsSpA n=40, and AS n=18), their cases had 
shorter disease duration than ours, and the comparison was a secondary objective of the 
study, so the study most likely was underpowered to detect a difference in severity. 
Nonetheless, the burden of axial radiographic damage in PsSpA cases was still high and 
widespread, and is therefore still clinically impactful. In summary, axial disease in PsSpA 
is not mild, it is clinically important and should be actively treated. 
 
6.6.4 The significance of unilateral grade 2 sacroiliitis 
 
A study classifying PsSpA as unilateral sacroiliitis of grade ≥2, whilst classifying AS as 
bilateral sacroiliitis grade ≥2 or unilateral sacroiliitis grade ≥3, simply by the entry criteria 
will show PsSpA cases to be less radiographically severe than AS, and possibly clinically 
less severe as well. One author has proposed that three key pieces of information will 
help determine the best definition of PsSpA [48]. Firstly, the proportion of psoriatics with 
unilateral grade 2 sacroiliitis demonstrating symptomatic and / or metrological evidence of 
axial disease needs to be determined. Secondly, the proportion of such patients 
progressing to develop more extensive sacroiliitis or spondylitis needs to be ascertained. 
Thirdly, the prevalence of grade 2 sacroiliitis in an otherwise healthy population needs to 
be determined for comparison with the suspected PsSpA patients. This information may 
help determine whether unilateral grade 2 sacroiliitis is a ‘pre-PsSpA’, or simply an 
acceptable normal variant within the general population. In our cohort, of eight cases with 
unilateral grade two sacroiliitis, 5/8 reported a history of inflammatory lumbosacral pain. 
Unfortunately, data on progression of grade 2 sacroiliitis, or the prevalence in the general 
healthy population are not available in our study. 
 
6.6.5 Correlation between axial radiographics and metrology in PsSpA and AS 
 
This study is the first to compare mSASSS with BASMI, and PASRI with BASMI and 
BASMI-subdomains. We found moderate-to-good positive correlation that was statistically 
significant between PASRI and BASMI, and between mSASSS and BASMI,  
in both PsSpA and AS cases. Further analyses of BASMI subdomains showed moderate-
to-good correlation that was statistically significant between cervical-PASRI and cervical 
rotation, cervical-PASRI and tragus-to-wall distance, lumbar-PASRI and Schober test, in 
both PsSpA and AS cases. Our results indicate that the PASRI has construct validity, and 
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supports our choice to use it in this study as a radiographic outcome measure in both 
PsSpA and AS cases. Our data are supported by the results of a study from Toronto 
(Canada) published in 2007, of ten PsSpA and nine AS cases with similar disease 
duration to our cohort, as part of the International Spondyloarthritis Inter-observer 
Reliability Exercise (INSPIRE) study [204]. Spinal metrology were correlated with the 
mSASSS and BASRI-spine. Moderate-to-good correlation was demonstrated between 
mSASSS and cervical rotation, tragus-to-wall distance, modified Schober test, and lumbar 
side-flexion in the entire group (rs > ±0.54 for each measure; p<0.05 for each measure). 
The clinical-radiographic correlations were comparable in the PsSpA and AS groups, 
although, cervical rotation correlated better with mSASSS in PsSpA, than in AS.  
 
6.6.6 Other imaging modalities in PsSpA 
 
In a study from Oxford (U.K.) of 68 PsA patients, moderate-to-severe sacroiliitis on clinical 
examination (clinical-sacroiliitis) was demonstrated in 24/68 (35%) cases [233], and MRI-
sacroiliitis was present in 26/68 (38%) cases. However, there was no association between 
clinical-sacroiliitis and MRI-sacroiliitis, or between HLA-B27 status and MRI-sacroiliitis, 
MRI-sacroiliitis was associated with restricted spinal movements, and the duration of PsA. 
These data question the reliability of ‘clinically-demonstrated sacroiliitis’ using physical 
maneuvers. The correlation between radiographic-sacroiliitis and MRI-sacroiliitis in PsSpA 
has not been reported. 
 
A retrospective cross-sectional study of MRI scans of the lumbar spine and SIJs from 33 
PsSpA, 24 non-radiographic axial SpA (nr-axSpA), and 19 AS patients (of comparable 
age across groups) found that  total MRI scores for bone marrow oedema were higher in 
AS patients than in PsSpA and nraxSpA patients [234]. HLA-B27 positivity was no 
different in PsSpA and nraxSpA cases, but higher in AS patients. HLA-B27 negative 
PsSpA patients had lower MRI scores than both HLA-B27 positive PsSpA patients and AS 
patients, whereas MRI scores were similar in HLA-B27 positive PsSpA patients and AS 
patients. Based on this single study, it appears that HLA-B27 might be a predictor of 
disease severity (burden) in PsSpA, as measured by axial bone marrow oedema on MRI.  
 
It is not known whether the pathogenesis of osteoproliferation and / or erosion is systemic, 
nor whether it occurs in axial and peripheral sites concomitantly. To determine this, a 
prospective inception cohort study with concurrent spinal and peripheral imaging would be 
required. 
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6.6.7 Study critique 
 
This study had several strengths, in particular the large sample size, and the robust case 
classification system employed. Secondly, the quantitative radiographic scoring with 
detailed sensitive scores allowing the groups to be compared using continuous rather than 
binary outcome measures, improves the study’s power to detect a difference. The 
collection of morphology data embedded within the scoring tools, allowed comparison of 
morphologies and patterns of disease. The collection of covariate data including anti-TNF 
use, synthetic DMARD use, smoking and BMI to include in the multivariate regression 
models allowed for some adjustment for potential confounders, although we did not 
measure exposure to these covariates at the exact time of the radiographs; therefore 
treatment and smoking may not be entirely controlled for. As is discussed in detail in 
Chapter 5, based on the data we collected, it was not possible in analyses to fully adjust 
for time-varying variables such as smoking, BMI and medication. The differential 
magnitude and direction of effect of potential confounders such as anti-TNF use have yet 
to be determined in AS and PsSpA. There are conflicting reports of anti-TNF therapy both 
inhibiting [235, 236] and having no effect [237, 238] on the formation of vertebral 
syndesmophytes in AS. No data exist in PsSpA. Lastly, through education and practice 
we achieved very high inter- and intra-rater reliability for radiographic scoring. 
 
This study would have been improved by having the entire axial skeleton imaged on the 
day of the clinical assessment rather than using historical radiographs, a fixed interval 
between diagnosis and imaging, and sequential radiographs in each case, ideally from 
diagnosis. This could only have been achieved through a prospective inception cohort, 
with protocolised imaging at predefined intervals. Although the PsSpA patients were 4.88 
years older at imaging, we were fortunate that the disease duration to imaging was no 
different across the disease groups on univariate analyses. In addition, we made 
adjustments for age and disease duration at imaging in the multivariate regression 
models. We do acknowledge that such modelling can only in part, adjust for the 
differences between the groups. A more sensitive imaging method such as MRI may have 
detected subtle early imaging difference between the groups. Such a study would not 
have been affordable or time-feasible in this number of cases, and likely would have 
reduced study recruitment. As is described above, the utility of MRI in PsSpA has yet to  
be established. 
 
There are potentially a few unmeasured and therefore uncontrolled confounders in this 
study. For example, data on participation in regular physiotherapy was not collected in the 
patients groups. For reasons discussed in Chapter 5, AS patients may be more likely to 
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be referred for and perform regular physiotherapy. Higher participation may inhibit 
radiographic disease development and progression. Although the direction of confounding 
may be the same in PsSpA and AS, the magnitude of effect may be different. Another 
unmeasured potential confounder is NSAID use, which has been shown to inhibit 
vertebral syndesmophyte for in AS [239]. Whilst the direction of confounding might be the 
same in PsSpA and AS, the magnitude of effect and use of NSAIDs may be different in 




In this study of established PsSpA and AS cases, both groups tended to have bilateral 
symmetrical-grade sacroiliitis. Unilateral or asymmetrical-grade sacroiliitis reported in 
previous studies to be characteristic of PsSpA, may simply reflect an earlier stage in its 
radiographic phenotype expression. AS cases were more likely than PsSpA cases to have 
complete ankylosis of the SIJs, and / or bridging syndesmophytes. These two features 
may therefore be more useful than paramarginal syndesmophytes to distinguish PsSpA 
from AS. The frequency of cervical vertebral spondylitis, lumbar vertebral spondylitis, and 
cervical facet joint spondylitis was no different in AS and PsSpA cases. Radiographic axial 
disease appears to be more severe in AS compared with PsSpA as measured 
quantitatively using the PASRI, mSASSS and osteoproliferative burden, and 
morphologically as measured by complete ankylosis of the SIJs. PASRI and mSASSS 
showed good-to-moderate correlation with metrology in both disease. Spondylitis without 
sacroiliitis was both common and usually symptomatic in PsSpA, so must be considered 
in classification systems for PsSpA. Aetio-pathogenic differences may exist between 
sacroiliitis and spondylitis in PsSpA, given that the prevalence of HLA-B27 variants 
differed in subsets of PsSpA with and without these radiographic features. 
Taken together, these data indicate that PsSpA is on a spectrum of musculoskeletal 
disease, starting at pPsA, then PsSpA, then AS; with PsSpA being a continuum itself, and 
with a phenotype expression related to disease duration. Current qualification criteria for 
anti-TNF use may be unnecessarily disadvantaging PsSpA patients. Our findings could 
guide an internationally agreed classification system for PsSpA with the purpose of  
improving clinical care and research. 
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6.7 PUBLICATIONS ARISING FROM THE WORK OF THIS THESIS 
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Jadon D, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, McHugh 
N. 2015. Axial disease in psoriatic arthritis: A clinical and radiographic comparison with 
ankylosing spondylitis. American College of Rheumatology - Annual Congress 2015, San 
Francisco, USA. November 2015. 
 
  
CONFERENCE ABSTRACT (poster presentation) 
 
Jadon D, Sengupta R, Nightingale A, Lindsay M, Korendowych E, McHugh J. Axial 
Disease in Psoriatic Arthritis (ADIPSA) study: Prevalence and characteristics of 
inflammatory axial disease in psoriatic arthritis. 9th International Congress on 
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7 CHAPTER VII: PSORIATIC ARTHRITIS MUTILANS: 
PREVALENCE, CLINICAL CHARACTERISTICS, AND 
NATURAL RADIOGRAPHIC HISTORY 
 
7.1 ABSTRACT 
Objectives: The objectives of this thesis chapter were to: (i) determine the prevalence of 
psoriatic arthritis mutilans (PAM) in a cohort of psoriatic arthritis (PsA) cases; (ii) compare 
the clinical characteristics of PAM and non-PAM cases in a cohort of PsA cases using 
patient reported outcome measures (PROMs), clinical history and radiographic indices; 
(iii) determine the natural radiographic history of PAM. 
Methods: A retrospective cohort study was conducted of all PsA patients attending a 
teaching hospital. The most recent hand and feet radiographs were screened for PAM. 
Serial radiographs (earliest to most recent) were quantitatively scored for osteolysis, 
erosion, joint space narrowing, and osteoproliferation by two raters using validated scores. 
Results: Of 610 PsA cases, 36/610 (5.9%) had PAM. PAM cases were younger at 
diagnosis of PsA than non-PAM cases (p=0.04), had more prevalent psoriatic nail 
dystrophy (odds ratio, OR 5.43; 95% CI 2.21, 13.30; p<0.001), and more disability 
(adjusted incidence risk ratio, IRRadj 1.26 per 0.35 unit increase in HAQ score; 95% CI 
1.07, 1.49;  p=0.005). Radiographic axial disease (adjusted odds ratio, ORadj 2.31; 95% CI 
1.07, 4.97; p=0.03), and especially radiographic sacroiliitis (ORadj 2.99; 95% CI 1.33, 6.73; 
p=0.01) were more prevalent in PAM cases compared with non-PAM cases. PAM cases 
were more likely than non-PAM cases to have used a synthetic DMARD (OR 16.36; 95% 
CI 3.88, 68.96; p<0.001), but not an anti-TNF agent (OR 1.25; 95% CI 0.62, 2.54; p=0.54). 
29/33 PAM cases had initiated a synthetic DMARD, and 4/13 had initiated anti-TNF, prior 
to first demonstration of PAM.  
A median five radiographs were scored for each PAM case (IQR 3-7). PAM 
progressed from monoarticular (60%) to polyarticular (80%) involvement, with certain 
joints being more frequently affected (big toe IPJ, MTPJ2-5, and hand MCPJ1, DIPJ2, and 
PIPJ5). Osteolysis was initially rapid and progressive in the hands and feet, tapering later 
during disease course. Nail dystrophy predicted more severe osteolysis (p=0.03). 
Conclusion: Compared to non-PAM cases, PAM cases have earlier age at PsA 
diagnosis, more disability (HAQ), more prevalent nail dystrophy and radiographic axial 
disease / sacroiliitis. The rate of osteolysis is higher in earlier disease, and more severe in 
those with nail dystrophy. DMARDs and anti-TNF appear not to prevent PAM occurrence.
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7.2 INTRODUCTION 
The content of this chapter of the thesis was published as a peer-reviewed paper in The 
Journal of Rheumatology in July 2015 (J Rheumatol 2015;42:1169-76) [240]. Therefore 
there is some repetition in this chapter of the content of that paper. The paper was written 
by Deepak Jadon (DJ). Dr. William Tillett (WT; Consultant Rheumatologist, Royal National 
Hospital for Rheumatic Diseases, Bath) contributed to radiographic data collection, and 
complex longitudinal statistical modeling was performed by Dr. Gavin Shaddick (GS; 
Reader of Mathematics, Department of Mathematical Sciences, University of Bath, Bath). 
All co-authors contributed to the study inception, design, and internal peer review of the 
final draft of the paper written entirely by DJ. 
 
Five patterns of psoriatic arthritis (PsA) were described in 1973 by Moll et al.: asymmetric 
oligoarthritis, symmetric polyarthritis, distal interphalangeal joint-predominant arthritis, 
psoriatic spondyloarthritis (PsSpA), and arthritis mutilans [18]. The most extreme, albeit 
rarest form of PsA is psoriatic arthritis mutilans (PAM).  
 
PAM is a condition characterised by severe destruction of the joint and adjacent bone 
through erosion and subsequent osteolysis. As a result of soft-tissue laxity and loss of 
bone stock, fingers and toes can shorten, giving rise to thick transverse folds of skin, and 
digits that can be elongated with traction. Clinical and radiographic images of PAM were 
provided in Figures 1.8, 1.9 and 1.10 in Chapter 1 of this thesis. Two such cases were first 
described in 1913 by Marie et al., who compared the phenomena with the telescopic 
action of an opera glass (la main en lorgnette) [72]. Earlier in 1888, Bourdillon first 
reported a resorptive arthropathy associated with psoriasis [241]. Arthritis mutilans can 
occur in association with several diseases, including psoriatic arthritis (PAM) [18], 
rheumatoid arthritis [242, 243], chronic reactive arthritis, juvenile chronic arthritis and 
mixed connective tissue disease [244]. Its pathogenesis is unknown. 
 
Research of PAM has been impeded by the rarity of the subphenotype, and the lack of an 
agreed clinical or radiographic definition. Estimates of the prevalence of PAM in PsA 
cohorts range from 0.6 to 21 per 100 PsA patients [14, 18, 73, 74, 245, 246], but are likely 
to be closer to the 5 per 100 PsA patients as was originally described by Moll and Wright 
[18] and subsequently by others [14, 73, 74]. A recent population-based study estimated 
the prevalence of PAM in the adult Nordic population to be 3.69 per million inhabitants, 
and with similar sex distribution [82]. Studies to date have been cross-sectional, with no 
longitudinal data. Recent reports are mostly case series [75-77], with a few studies of 
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between 6 to 24 cases each [73, 74, 78-81], and only one large study of 59 cases [82]. 
The majority of studies simply note the occurrence of PAM in a general PsA cohort. To 
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7.3 STUDY OBJECTIVES 
The objectives of this thesis chapter were to:  
 
(i) determine the prevalence of PAM in a cohort of PsA cases. 
 
(ii) compare the clinical characteristics of PAM and non-PAM cases in a cohort of PsA 
cases using patient reported outcome measures (PROMs), clinical history and 
radiographic indices. 
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7.4 METHODS 
A retrospective cohort study was conducted of all PsA patients attending the dedicated 
PsA outpatient clinic at the Royal National Hospital for Rheumatic Diseases (RNHRD) in 
Bath, and enrolled in the Long-term Outcomes in Psoriatic Arthritis Study 1 (LOPAS1). 
Patients attending clinic had plain radiographs of hands and feet performed at intervals 
determined by usual clinical care; and dated from 1974 to 1 December 2013 (census). 
The case notes and clinical data collection proforma (from the LOPAS1 and Axial Disease 
in PsA study, ADIPSA) of PsA cases provided clinical data including: sex, date of birth, 
age at psoriasis symptom onset, age at psoriasis diagnosis, age at PsA arthritis symptom 
onset, age at PsA diagnosis, smoking history (never, ever, current), alcohol consumption 
(never, ever, current), nail dystrophy at any time during disease course, most recent 
Stanford Health Assessment Questionnaire (HAQ) [167], anti-cyclical citrullinated peptide 
antibody (ACPA) serology, synthetic disease modifying anti-rheumatic drug (DMARD) use 
(agent, date of initiation, date of cessation), biological therapy use in particular anti-tumour 
necrosis factor-alpha (anti-TNF) (agent, number of biologicals used, date of initiation, date 
of cessation), and corticosteroid use (in oral, intramuscular or intravenous form). 
 
7.4.1 Peripheral radiographic scoring methods 
 
As no existing plain radiographic score for PsA captures the various radiographic features 
of PAM, components of existing radiographic tools that have been validated for use in 
PsA, were used. Plain radiographs of hands and feet were quantitatively scored for 
osteolysis (see below), erosion (using the PsA-modified Sharp score; mSS [247, 248]), 
joint space narrowing (mSS), osteoproliferation (PsA Ratingen Score; PARS [249]), 
periostitis of the shaft and juxta-articular area (mSS), tuft resorption (mSS), and 
osteopaenia using the PsA-modified Steinbrocker score [250]. A new domain to score 
osteolysis was devised to aid the detection of PAM and capture progression; with a range 
of 0 to 12, and based upon lysis of bone from the articular surface of the epiphysis, 
through the metaphysis, to the diaphysis (Figure 7.1). With some variability according to 
the radiographic domain, the following joints were scored in the hands (all small joints of 
the fingers and thumb, the majority of carpal articulation, radio-carpal joints, and ulnar-
carpal joints) and feet (big toe interphalangeal joint, IPJ1; first to fifth metatarsophalangeal 
joints, MTPJ 1-5). The other toes’ interphalangeal joints were not scored due their poor 
visibility on radiographs likely to cause unreliable and difficult scoring (see radiographic 
data collection proforma, Appendix 4). 
 
  172 
 
Figure 7.1. Osteolysis score  
(Osteolysis is scored as blocks of bone. Either side of the joint, there are two blocks in the 
epiphysis, two blocks in the metaphysis, and two blocks in the diaphysis. Score range 0 to 
12) 
 
7.4.2 Reading strategy and reliability exercise 
 
Standard digital antero-posterior radiographs of the hands and feet were viewed and 
scored using the hospital’s Picture Archiving and Communication System (PACS). 
Historical hard-film plain radiographs, preceding the advent of PACS in our institution 
(February 2007), were digitised to HiPAX Image Viewer for scoring. All images were read 
on the same viewing monitor, preserved at the original 1:1 ratio. All radiographs included 
a ‘phantom phalanx’ as a reference for normal bone mineral density. 
 
The two readers (DJ and WT) underwent pre-study training in the precise definitions of 
radiographic findings of PsA [251], practice, supervision and discussion with an 
experienced Consultant musculoskeletal radiologist (Dr Graham Roinson, GR). To 
determine inter-rater reliability, ten random pairs of hand and feet radiographs were 
scored by both the readers, in random order. 
 
7.4.3 Identification of PAM cases 
 
In keeping with previous publications on PAM [78, 79, 246], plain radiographic PAM was 
defined as osteolysis affecting ≥50% of the visualised articular surface on both sides of 
the joint. A large erosion qualified as osteolysis once the epiphyseal plate was 
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encroached. PAM was therefore only called once the osteolysis score in an individual joint 
was ≥4 units. 
 
The most recent plain radiographs of hands and feet were evaluated for PAM (DJ). Group 
consensus (DJ, WT, GR and Professor Neil McHugh) was sought for uncertain cases. All 
available radiographs of PAM cases (earliest to most recent) were then randomised and 
scored by the two readers (DJ, WT). Radiographs were scored in chronological order. An 
assumption of non-regression of the score was made in advance to allow for variability in 
radiographic exposure and projection, and facilitate longitudinal statistical modelling. 
 
7.4.4 Axial radiographic scoring methods 
 
All cases had their most recent axial plain radiographs (cervical spine, lumbar spine, and 
sacroiliac joints, as available) scored for evidence of radiographic axial disease (RAD) by 
one reader (DJ) following education, practice and reliability testing as described in 
Chapter 6 of this thesis. In keeping with Chapter 6 of this thesis, radiographic axial 
disease was defined as: the presence of New York criteria unilateral grade ≥3, or bilateral 
grade ≥2 sacroiliitis on AP pelvic radiograph; or ≥1 marginal / paramarginal 
syndesmophyte(s) of the cervical, and / or lumbar spine. 
 
7.4.5 Statistical analysis 
 
Data were analysed using STATA 12.2 (2011 Texas, USA) by DJ, and more complex 
longitudinal modelling was performed by Dr. Gavin Shaddick (GS) using ‘R’ [252]. Inter-
rater reliability testing for peripheral radiographic scoring was determined using the intra-
class correlation coefficient (ICC).  
 
For univariate analyses continuity-corrected Chi-squared tests were used to test for 
differences between categorical variables, and independent t-tests or Mann-Whitney U-
tests used for normally and non-normally distributed continuous variables, respectively.  
 
Logistic regression models were used to compare the prevalence of radiographic axial 
disease in PAM and non-PAM, adjusted for sex and age at radiographic assessment. As 
the HAQ data had an excess of zeros and is not a truly continuous variable, univariate 
analyses were performed using a zero-inflated Poisson regression model, and multivariate 
analyses were performed using a revere-stepwise (alpha level set at 0.1 for significance) 
zero-inflated Poisson regression adjusted for sex and age at HAQ assessment. Univariate 
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and reduced-multivariate models are presented. Median, inter-quartile range (IQR), mean, 
standard deviation (SD), odds ratios (OR), adjusted OR (ORadj), incidence risk ratio (IRR), 
adjusted IRR (IRRadj), 95% confidence interval (95% CI), and p-value were calculated as 
appropriate to the data. The alpha-level for statistical significance was set at 0.05. 
 
Patterns and rates of deterioration of individual joints over time were examined for all 
patients by Dr. Gavin Shaddick (GS) using the following method (written by GS): Initial 
analysis consisted of plotting the data together with locally-weighted polynomial 
regression smoothers (lowess) [253]. Formal modelling of the changes in scores over time 
was performed using generalised additive mixed models (gamm) [254], using penalised 
splines to assess the complexity of the model required for each joint and allowing a 
random effect for each patient. For each joint, this complexity was expressed as the 
effective degrees of freedom (EDF) required to model the changes over time. For this part 
of the study GS undertook the analyses and DJ was involved in providing a clinical 
interpretation of the results. 
 
7.4.6 Ethical considerations 
 
Ethical approval for the study was given by the Local Regional Ethics Committee and 
informed written consent obtained from participants as part of the on-going prospective 
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7.5 RESULTS 
All 610 PsA cases fulfilling Classification Criteria for Psoriatic Arthritis (CASPAR) [24] in 
the LOPAS1 study [255] were screened for the presence or absence of plain radiographic 
PAM. PAM was present in 36/610 (5.9%) PsA cases, with 35/36 having serial 
radiographs. 483/610 had no evidence of PAM. 91/610 either had no radiographs of 
hands and feet, or only one of the two sites imaged, and therefore although unlikely, PAM 
could not be excluded. 
 
7.5.1 Inter-rater reliability of plain radiographic scoring 
 
The inter-rater reliability of peripheral plain radiographic scoring was very high: intra-class 
correlation coefficient, ICC 0.99 (95% CI 0.98, 1.00) for osteolysis; ICC 0.95 (95% CI 0.91, 
0.99) for erosion; ICC 0.97 (95% CI 0.95, 0.99) for osteoproliferation; and ICC 0.90 (95% 
CI 0.84, 0.93) for osteopaenia. The reliability of radiographic scoring between the two 
raters (DJ and WT) was therefore very high. 
 
7.5.2 Clinical characteristics of PAM and non-PAM cases 
 
The proportion of females in the PAM (19/36; 52.78%) and non-PAM (228/483; 47.20%) 
groups was statistically no different (odds ratio, OR 1.25; 95% CI 0.63, 2.46; p=0.52). 
PAM cases were significantly younger at PsA diagnosis than non-PAM cases (median 
age 33.00 vs. 40.00 years; p=0.04), but no different in terms of age at PsA arthritis 
symptom onset, psoriasis symptom onset, psoriasis diagnosis, or age at census (Table 
7.1).  
 
Psoriatic nail dystrophy at anytime during disease course was significantly more common 
in PAM cases than non-PAM cases (OR 5.43; 95% CI 2.21, 13.30; p<0.001) (Table 7.2).  
For the patients in whom ACPA serology was available, no difference was demonstrated 
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Table 7.1. Clinical characteristics of PAM and non-PAM cases (numerical variables) 
Clinical parameter PAM (n=36) Non-PAM (n=483) Unadjusted Adjusted 
Median IQR Median IQR IRR 95% CI p-value IRR 95% CI p-value 
Age at Psoriasis symptom onset 29.00 16.00, 45.00 28.00 18.00, 42.00 - - 0.86 ^ - - - 
Psoriasis diagnosis 30.00 16.00, 52.00 33.00 21.00, 47.00 - - 0.79 ^ - - - 
PsA symptom onset 32.00 23.00, 45.00 38.00 28.00, 49.00 - - 0.12 ^ - - - 
PsA diagnosis 33.00 24.00, 45.00 40.00 30.00, 51.00 - - 0.04 ^ - - - 
Census 67.37 51.56, 73.53 59.05 48.54, 67.73 - - 0.05 ^ - - - 
HAQ  
(n=34/36 PAM;  
439/483 non-PAM) 
Total score 1.25 0.38, 2.13 0.63 0.13, 1.38 1.32 ` 1.13, 1.56 ` 0.001 * 1.26 1.07, 1.49 0.005 ** 
   HAQ-dressing 
   HAQ-rising 
   HAQ-eating 
   HAQ-walking 
   HAQ-hygiene 
   HAQ-reach 
   HAQ-grip 

















































































      
Radiographic 
events 
Number of films scored per case 5.00 3.00, 7.00 - - - - - - - - 
Interval: earliest to most recent 
film (years) 
10.87 5.48, 16.51 - - - - - - - - 
Age at (years) Earliest film 47.37 37.45, 61.71 - - - - - - - - 
Recent film 64.54 49.71, 70.37 - - - - - - - - 
Census 67.37 51.56, 73.53 - - - - - - - - 
PAM first 
demonstrated 
(restricted to cases 
with PAM-onset 
during follow-up) 
Age (years) 49.70 42.92, 68.21 - - - - - - - - 
Years after diagnosis of PsA 12.50 6.00, 18.00 - - - 
 




PAM: psoriatic arthritis mutilans    PsA: psoriatic arthritis     HAQ: Health assessment questionnaire     IQR: inter-quartile range     
IRR: incidence risk ratio per 1 unit increase in HAQ-subscore ` incidence risk ratio per 0.35 unit increase in HAQ total-score    ^ Mann-Whitney U test     
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Table 7.2. Clinical characteristics of PAM and non-PAM cases (categorical variables) 




Unadjusted Adjusted * 
n % n % OR 95% CI p-value OR 95% CI  p-value 
Female sex 19/36 52.78 228/483 47.20 1.25 0.63, 2.46 0.52 - - - 
Nail dystrophy present 30/36 83.33 211/440 47.95 5.43 2.21, 13.30 <0.001 - - - 
ACPA Positive 0/16 0.00 8/226 3.54 - - 0.44 - - - 
Axial 
Disease 
Radiographic axial disease 16/29 55.17 129/366 35.25 2.42 1.11, 4.99 0.04 2.31 1.07, 4.97 0.03 
Radiographic spondylitis 
   Cervical-spine  
































    Symmetry 
       Unilateral 
       Bilateral 
    Grade 
       2 
       3 




















































































   Methotrexate 
   Sulfasalazine 
   Leflunomide 



















































DMARD initiated prior to PAM 
onset 
  Yes 
  No 











































Yes 13/36 36.11 150/483 31.06 1.25 0.62, 2.54 0.53 - - - 
Anti-TNF initiated prior to 
PAM onset 
  Yes 
  No 













































* logistic regression model adjusted for sex & age at most recent pelvic radiograph  PAM: psoriatic arthritis mutilans ACPA: anti-cyclical citrullinated peptide antibody DMARD: synthetic disease modifying anti-rheumatic drug  
Anti-TNF: anti-tumour necrosis factor     OR: odds ratio  95% CI: 95% confidence interval 
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Physical function, as measured by the HAQ total score was significantly more impaired in 
PAM (median HAQ 1.25; IQR 0.38, 2.13) cases compared with non-PAM (median HAQ 
0.63; IQR 0.13, 1.38) cases using a zero-inflated Poisson regression model adjusted for 
sex and age at HAQ assessment (adjusted incidence risk ratio, IRRadj 1.26 per 0.35 unit 
increase in HAQ score; 95% CI 1.07, 1.49; p=0.005) (Table 7.1). Differences in sub-
domains of the HAQ between the PAM and non-PAM cases were clinically significant, and 
approached statistical significance for the HAQ-rising domain (IRRadj 1.62 per 1 unit 
increase in subscore; 95% CI 0.98, 2.66; p=0.06), HAQ-reach domain (IRRadj 1.34 per 1 
unit increase in subscore; 95% CI 1.00, 1.79; p=0.05), and the HAQ-grip domain (IRRadj 
1.44 per 1 unit increase in subscore; 95% CI 0.99, 2.08; p=0.06) (Table 7.1). Other 
subdomains of the HAQ were statistically no different in PAM compared with non-PAM 
cases.  
 
PAM cases were significantly more likely to have radiographic axial disease than non-
PAM cases (ORadj 2.31; 95% CI 1.07, 4.97; p=0.03) (Table 7.2). PAM cases were 
significantly more likely to have radiographic sacroiliitis than non-PAM cases (ORadj 2.99; 
95% CI 1.33, 6.73; p=0.01). When sacroiliitis was present in PAM cases it tended to be 
bilateral (9/11; 81.82%) and of grade ≥3 (11/11; 100%) (Table 7.2). PAM cases were no 
more likely to have radiographic spondylitis than non-PAM cases (ORadj 1.46; 95% CI 
0.65, 3.28; p=0.36). When spondylitis was present in PAM cases it affected both the 
cervical (6/27; 22.22%) and lumbar spine (5/24; 20.83%), no differently in frequency to 
that seen in non-PAM cases (Table 7.2). 
 
During the course of their disease, PAM cases were significantly more likely than non-
PAM cases to have used a synthetic DMARD (OR 16.36; 95% CI 3.88, 68.96; p<0.001); 
including methotrexate (OR 5.20; 95% CI 2.32, 11.66; p<0.001), sulfasalazine (OR 4.71; 
95% CI 2.28, 9.73; p<0.001) and leflunomide (OR 6.94; 95% CI 2.98, 16.18; p<0.001) 
(Table 7.2). Of particular note, 29/33 (87.88%) of PAM cases had initiated a DMARD 
before PAM was first observed radiographically (a median of six years before), implying 
that DMARDs do not prevent the onset of PAM. Corticosteroids (in oral, intramuscular or 
intravenous form) had been used during disease course in 15/36 (41.67%) PAM cases. 
 
PAM cases were no more likely than non-PAM cases to have used an anti-TNF agent 
(OR 1.25; 95% CI 0.62, 2.54; p=0.53) (Table 7.2). In 4/13 PAM cases, anti-TNF had been 
initiated before the onset of radiographic PAM (5.67, 3.89, 3.72, and 1.08 years 
beforehand). In 6/13 PAM cases anti-TNF had been initiated after radiographic PAM 
onset, and 3/13 cases already had PAM at their earliest radiograph.  
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7.5.3 Radiographic characteristics of PAM cases 
 
The median number of films (pairs of hands and feet) scored per patient was 5 (IQR 3, 7) 
(Table 7.1). The median interval from baseline to most recent film (i.e. duration of 
radiographic follow-up) was 10.87 (IQR 5.48, 16.51) years. The median age of PAM cases 
at the earliest film was 47.37 (IQR 37.45, 61.71) years, and at the most recent film was 
64.54 (IQR 49.71, 70.37) years (Table 7.1).  
 
Whilst radiographic PAM was evident in the earliest film in 13/35 (37.14%) cases, the 
majority of cases (22/35; 62.86%) developed it during the course of their follow-up (Table 
7.3). In the 22 cases where PAM developed during the course of follow-up, the time from 
diagnosis of PsA to onset of radiographic PAM was a median of 12.50 (IQR 6.00, 18.00) 
years, at a median age of 49.70 (IQR 42.92, 68.21) years (Table 7.1). 
 
PAM was most commonly monoarticular (21/35; 60%) when first demonstrated, but 
progressed to being polyarticular at the most recent film (28/35; 80%) (Table 7.3). At the 
most recent film, the most frequently affected joint was the big toe interphalangeal joint 
(IPJ1) (8.81%), followed in equal frequency (6.92%) by the thumb metacarpophalangeal 
joint (MCPJ1), index finger distal interphalangeal joint (DIPJ2), little finger proximal 
interphalangeal joint (PIPJ5), and feet metatarsophalangeal joints 2 to 5 (MTPJ2-5) 
(Figure 7.2). 
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Figure 7.2. Eight joints most commonly affected by PAM at the most recent radiography  
(frequency in white box) 
 
 
Of note, 12/35 (34.29%) PAM cases had concurrent evidence of joint osteolysis and 
ankylosis within the same hand or foot (Table 7.3). Two of 35 PAM cases had proceeded 
to having surgery on the joint affected by PAM; due to impaired hand function in one case, 
and pain in the other case (Table 7.3). 
 
 
Table 7.3. Radiographic characteristics of PAM cases with serial radiographs 
 n % 
PAM present on earliest radiograph   13/35 37.14 
PAM pattern on earliest radiograph 
 
PAM pattern on most recent radiograph 
Mono-articular 21/35 60.00 
Polyarticular 14/35 40.00 
Mono-articular 7/35 20.00 
Polyarticular 28/35 80.00 
Concurrent joint ankylosis in hand / foot  12/35 34.29 
Surgery to joint affected by PAM   2/35 5.710 
 
PAM: Psoriatic arthritis mutilans    
 
7.5.4 Radiographic progression of PAM 
 
Serial radiographs were available for scoring in 35/36 PAM cases. For hands and feet 
combined, at the most recent film the median osteolysis score was 2.00 (IQR 0.00, 15.00) 
units, erosion score 9.00 (IQR 0.00, 26.00) units, joint space narrowing score 14.00 (IQR 
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0.00, 31.00) units, osteoproliferation score 3.00 (IQR 0.00, 6.00) units, and osteopaenia 
score 0.00 (IQR 0.00, 2.00) units.  
 
A significant change in osteolysis score over time was observed for all joints (p<0.008). 
After allowing for patient differences in a random effects model, there was a strong 
indication that different joints had different patterns of deterioration over time (p<0.001).  
 
Figure 7.3. shows curves from the generalised additive mixed model, including data from 
all 159 joints affected by PAM. The best fit regression curve, 95% confidence interval 
bands, and the effective degrees of freedom (EDF) for each curve are shown for the 
hands and feet joints separately. In the feet, there is an initial high rate of osteolysis, 
followed by a tapering rate, and eventually little further progression of osteolysis 
(EDF=3.1). However, in the hands the curve is more complex (EDF=4.3) with an initially 
high increase in osteolysis, followed by a tapering in the rate. For some patients there was 
indication of a second surge of osteolysis in some joints later during disease course, 
adjusted for the time since diagnosis. 
 
 
Figure 7.3. Rate of osteolysis progression over time  
[additive mixed model of all joints: smoothed regression line (black), 95% confidence 
interval (grey bands) and effective degrees of freedom (EDF)] 
 
 
PAM cases with a history of psoriatic nail dystrophy (30/36) had significantly higher overall 
osteolysis scores in topographically related joints (DIPJ / PIPJ / IPJ) of the hands, than 
PAM cases without nail dystrophy (6/36) (mean scores: 3.0 with nail dystrophy, 1.3 
without nail dystrophy; p=0.03) 
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7.6 DISCUSSION & CONCLUSIONS 
This study takes advantage of a large well-characterised cohort of PsA patients followed 
longitudinally in a single centre to estimate the prevalence of PAM in a PsA cohort, 
compare the clinical characteristics of PAM and non-PAM cases, and to investigate the 
natural radiographic history of PAM. To our knowledge, this is the largest sample of PAM 
cases with a detailed description of plain radiographic characteristics, and the first study to 
report on radiographic progression. 
 
A previous study by our group showed that nail dystrophy is more common in PsA 
patients with DIP joint disease, and is significantly associated with adjacent DIP joint 
disease (33). Here we demonstrate that psoriatic nail dystrophy is a clinical biomarker of 
both PAM occurrence, and of having more severe osteolysis in topographically adjacent 
joints (hand DIP, PIP and IP joints).  This has not previously been reported. Furthermore, 
PAM was most commonly seen in the weight-bearing joints of the feet (MTPJ 2-5, IPJ1) 
and hand joints involved in power / precision grip (DIPJ2, MCPJ1). Little is known about 
the pathogenesis or trigger for PAM. The concept of altered biomechanical loads or stress 
on the synovial-entheseal complex being involved in the pathogenesis of SpA, as 
proposed by McGonagle et al. [195, 206], is supported by our current findings in PAM.  
 
There has been debate as to whether involvement of a single joint is sufficient for a case 
to be defined as PAM [256]. Our data indicates that 7/35 (20%) have monoarticular PAM, 
even after several years of follow-up. Review of these seven cases in our outpatient clinic 
demonstrated clinical evidence of PAM, with shortened telescopic digits. We therefore 
propose that PAM can be monoarticular, although it is more frequently polyarticular and 
the notion is supported by data from other studies [18, 75, 80, 82]. 
 
We found that disability as measured by the HAQ, is worse in PAM compared with non-
PAM cases. This seems reasonable given the damage and deformity that PAM inflicts on 
the hands and feet. Closer inspection of the data shows that disability was often in HAQ 
subdomains pertaining to hand and / or foot function, such as HAQ-grip, HAQ-reach and 
HAQ-rising. No other studies have investigated disability in PAM compared with non-PAM 
patients. 
 
Several of our results corroborate those of the Classification of Psoriatic Arthritis 
(CASPAR) dataset [80], which showed that PAM cases are usually polyarticular, of long 
disease duration, and are more prone to spinal involvement compared to their non-PAM 
counterparts. In our cohort there was a higher prevalence of sacroiliitis, that tended to be 
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more severe than in non-PAM cases, and some increase in other features of spondylitis. 
However, we did not replicate the CASPAR findings of more frequent ACPA-positivity 
(albeit of low titre) in PAM compared with non-PAM cases. Joint surgery rates in our 
cohort of PAM cases were far lower than the 48% reported in that study. 
 
A further intriguing issue is the nature of the relationship between osteolysis and 
ankylosis. In our dataset, 12/35 (34.29%) cases had concurrent osteolysis and ankylosis 
in the same hand or foot. Occasionally, osteolysis progressed to joint ankylosis in the 
same joint, but more commonly we saw joint space narrowing progressing to ankylosis, 
suggesting that there are two separate pathological processes, although both may occur 
in the same patient. Axial osteoproliferation causing cervical myelopathy in PAM despite 
peripheral bone erosion has been described [257]. 
 
None of our PAM cases had improvement of osteolysis, erosion or osteoproliferation 
scores. Joint space narrowing, osteopaenia and periostitis scores fluctuated, with both 
regression and progression. There are emerging reports in the literature of improvement 
in erosion [258, 259] and joint-space narrowing [259] scores following anti-TNF use, 
implying filling-in or ‘healing’ of previous structural damage. However, a paper reporting 
the follow-up of three PAM cases treated with etanercept, demonstrated no improvement 
in deformities resulting from several years of progressive disease [76]. Furthermore, our 
data suggests that neither synthetic DMARDs nor anti-TNF prevent the onset of 
radiographic PAM. Our findings need to be interpreted with caution in a retrospective 
study where the radiographs were not taken at fixed time intervals, hence sensitivity to 
detect PAM onset is reduced, and the doses of some agents such as methotrexate were 
lower than those used nowadays. 
  
The sequence of pathological events leading to the frank osteolysis of PAM is of much 
interest, particularly as it could prompt the clinician to instigate more intensive disease 
modifying therapy. Magnetic resonance imaging has demonstrated higher bone 
proliferation and oedema scores in PAM compared with non-PAM cases, and has 
therefore been proposed as a potential radiological biomarker of progressing to PAM [78]. 
In our study we did not see osteopaenia or periostitis preceding the onset of erosions or 
osteolysis. Nor did we overtly see progressive erosions prior to the onset of osteolysis. 
However, we acknowledge that the varied time interval between radiographs may have 
reduced our sensitivity to track such changes. In our general observations we noted 
progressive joint space narrowing prior to the onset of osteolysis.  
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7.6.1 Study critique 
 
This study has particular strengths. This is the largest sample of PAM cases with a 
detailed description of plain radiographic characteristics, and is unique in being the first 
study to report on radiographic progression. Our large sample size for PsA cases, and 
relatively large sample size for PAM given its rarity, has increased the statistical power of 
our analyses to detect a difference between the PAM and non-PAM cases. Several of our 
analyses were adjusted for potential confounders, including sex and age at clinical / 
radiographic assessment. The findings of our study are generalisable to PsA cohorts in 
other centres in the UK, since the RNHRD takes unselected secondary-care referrals from 
the local community, spanning the spectrum of mild to severe PsA.  
 
We acknowledge that our study has limitations. Whilst it appears that 36/519 (6.94%; 95% 
CI 4.91, 9.47 using Fisher-exact Clopper-Pearson) of our cohort have PAM, we are aware 
that 91/610 PsA cases had insufficient or no radiographs to assess the presence or 
absence of PAM. The lack of radiographs may imply minimal disease activity at these 
sites, or may be due to non-clinical factors. Assuming that all 91 were non-PAM cases, 
the prevalence of PAM in our cohort falls to 36/610 (5.90%; 95% CI 4.17, 8.08 using 
Fisher-exact Clopper-Pearson). However, both estimates and their 95% confidence 
interval values are within the range of prevalence described by other authors [14, 18, 73, 
74, 245, 246], especially those using a radiographic rather than clinical definition of PAM.  
 
Since the interval between films was determined by clinical need, rather than predefined 
intervals, we were unable to determine the incidence of PAM onset. Since PAM was 
evident in the earliest available radiograph in 13/35 (37.14%) of cases, the initial rate of 
radiographic progression could not be determined in this subgroup of patients. To 
overcome this issue one would need to conduct a prospective inception cohort study with 
radiographs taken on all patients at protocolised regular time intervals. This would be 
difficult given the rarity of PAM, late-age at onset of PAM (median in this cohort of 49.70; 
IQR 42.92, 68.21 years), and natural radiographic history as demonstrated in this study 
characterised by much osteolytic damage happening in the first few years after onset. A 
very large inception cohort, followed over 20-40 years, and with longitudinal radiographs 
taken every 1-2 years would be required. This would be an enormous logistical, financial 
and ethical challenge. 
 
We did not adjust for anti-TNF use and synthetic DMARD use as the proportion of patients 
using these agents was too small to include in the regression models. In addition, we did 
not have detailed longitudinal data on medication use, and there is no evidence that these 
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agents either prevent PAM or alter its radiographic progression. We report in Table 7.2 the 
proportion of PsA cases who have ever used corticosteroids. These data have their 
limitations, in particular the varied routes of administration with differing efficacy, the 
variety of doses commonly used in clinical practice, and the significant potential for 
incomplete data give that some corticosteroids are administered in primary care and never 
documented in the hospital case-notes. We had dichotomous smoking data on all of the 
PAM cases, but data was incomplete on a third of non-PAM cases. Furthermore, as 
discussed previously in Chapters 5 and 7 of this thesis, as smoking is a time-varying 
variable, we elected not to report the smoking data or include it in the multivariate models.  
 
This study has potential unmeasured confounders, such as disease duration. As there 
was a significant proportion of incomplete data on disease duration (from diagnosis to 
census) in this cohort, we elected not to report or include it as a covariate in the 
regression models. More complete disease duration data would certainly have 
strengthened this study, especially when comparing PAM and non-PAM cases in terms of 
HAQ and axial radiographic disease, both of which are known to be dependent on disease 
duration. We attempted to adjust for this by including age at clinical / radiographic 
assessment in the regression models for HAQ and axial radiographic disease, 
respectively. The magnitude and direction of potential confounders should be similar in 
PAM and non-PAM cases, therefore have less impact on comparisons between the two 
groups. 
 
As will be discussed in chapter 9, the chronology of pathological events leading to 
osteolysis in PAM has never been described. The radiographic scoring conducted in this 
study included domains for osteolysis, erosion, joint space narrowing, osteoproliferation, 
periostitis, osteopaenia and tuft resorption. This thesis chapter only reports the natural 
history of PAM based on change in osteolysis score. Within the constraints of this study 
design and data available, the type of pathological changes that occur before the onset of 
osteolysis in a particular joint will be investigated. Anecdotal observations during 
radiograph scoring is of progressive joint space narrowing before onset of osteolysis, 
rather than progressive erosions or osteopaenia. However, after the onset of osteolysis, 
bone remodelling appeared to occur in the form of osteoproliferation, perhaps as a 
compensatory mechanism to correct abnormal joint loading and movement. Periostitis 
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7.6.2 Conclusions 
 
To conclude, PAM is a rare but severely destructive subphenotype of PsA. Further 
research is need to investigate the pathogenesis of PAM, serum-soluble and / or genetic 
biomarkers of PAM, and whether anti-TNF or anti-resorptive agents may offer therapeutic 
efficacy. 
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8 CHAPTER VIII: SERUM-SOLUBLE BONE-TURNOVER 
BIOMARKERS IN PSORIATIC DISEASE 
 
8.1 ABSTRACT 
Background: Psoriatic spondyloarthritis (PsSpA), peripheral-only psoriatic arthritis (pPsA) 
and ankylosing spondylitis (AS) are characterised by differing patterns and degrees of 
pathological new bone formation (osteoproliferation) and bone loss (resorption), which 
may be reflected by differing levels of serum-soluble bone-turnover biomarkers. Our study 
objectives were to investigate four potential serum-soluble bone-turnover biomarkers 
(Dkk-1, M-CSF, MMP-3 and OPG) as predictors of: (i) PsSpA occurrence, by comparison 
with pPsA, AS, psoriasis-only (PsC) cases and healthy controls (HC); (ii) axial 
radiographic disease severity / morphology in PsSpA and AS patients; (iii) psoriatic 
arthritis mutilans (PAM) occurrence in a cohort of PsA patients. 
Methods: A prospective cross-sectional study was conducted recruiting spondyloarthritis 
(SpA; pPsA, PsSpA and AS) patients from a single-centre, followed by clinical and 
radiographic assessment, and peripheral blood sampling. Serum samples were obtained 
from two other centres of clinically characterised PsC patients, and sex / age-matched HC 
subjects. Serum samples were tested with commercially available ELISA kits to determine 
concentrations of Dkk-1, M-CSF, MMP-3 and OPG. Statistical comparisons were made 
between serum concentrations and disease phenotypes. 
Results: OPG appears to be a biomarker of axial disease in patients with SpA; 
concentrations were significantly lower in SpA patients with axial disease than in those 
without (adjusted odds ratio, ORadj 0.20 per ng/ml increase in concentration; 95% CI 0.05, 
0.80; p=0.02), independently of having psoriasis.  
Dkk-1 appears to be a biomarker of axial disease in patients with SpA, with a 
pattern for increasing concentration along a spectrum of increasing axial involvement. 
Dkk-1 concentrations were significantly higher in SpA patients with axial disease than in 
those without (ORadj 1.22; 95% CI 1.05, 1.42; p=0.01), independently of having psoriasis, 
and significantly lower in PsSpA compared with AS (ORadj 0.85; 95% CI 0.74, 0.98; 
p=0.02). 
M-CSF appears to be a biomarker of arthritis. Compared with HC, M-CSF 
concentrations were significantly lower in pPsA (ORadj 0.14; 95% CI 0.06, 0.32; p<1x10-5), 
PsSpA (ORadj 0.07; 95% CI 0.03, 0.17; p<1x10-8), and AS (ORadj 0.37; 95% CI 0.16, 0.85; 
p<1x10-7). Similarly, M-CSF concentrations were significantly lower in PsA compared with 
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PsC (ORadj 0.44; 95% CI 0.24, 0.82; p=0.01) patients. However, M-CSF concentrations 
didn’t differentiate various forms of SpA, i.e. pPsA, PsSpA and AS.  
MMP-3 appears to be a biomarker of arthritis. Compared with HC, MMP-3 
concentrations were significantly higher in pPsA (ORadj 1.06; 95% CI 1.01, 1.10; p=0.02), 
PsSpA (ORadj 1.06; 95% CI 1.01, 1.11; p=0.02), and AS (ORadj 1.06; 95% CI 1.01, 1.11; 
p=0.01). Similarly, MMP-3 concentrations were significantly higher in PsA compared with 
PsC (ORadj 1.02; 95% CI 1.01, 1.03; p=0.0004) patients. However, MMP-3 concentrations 
didn’t differentiate various forms of arthritis, i.e. pPsA, PsSpA and AS.  
Only OPG significantly and positively correlated with radiographic severity (adjusted 
p=0.03) and osteoproliferation burden (adjusted p=0.01), as measured by the Psoriatic 
Arthritis Spondylitis Radiology Index (PASRI); although only in PsSpA cases.  
Concentrations of each of the four biomarkers were no different in PsA cases with 
and without PAM. 
Conclusion: OPG and Dkk-1 appear to be biomarkers of axial disease in patients with 
SpA (pPsA, PsSpA and AS), independently of cutaneous psoriasis status. Both M-CSF 
and MMP-3 appear to be biomarkers of arthritis, although don’t differentiate various forms 
of SpA. Only OPG has shown signals to be a biomarker of radiographic severity / 
morphology, but the clinical significance of this remains be determined. No biomarkers for 
the occurrence of PAM in PsA cases were found. The high concentration of Dkk-1 in AS 
and PsSpA compared with HC, supports previous reports that Dkk-1 may be dysfunctional 
in SpA. Since bone mineral density was not measured, it is difficult to determine if these 
serum biomarkers are reflecting SpA-related pathology in trabecular bone, or vertebral 
corners and sacroiliac joints. 
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8.2 INTRODUCTION 
Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic inflammatory 
conditions of the musculoskeletal system belonging to the family of spondyloarthritis 
(SpA). They are characterised by: bone loss (resorption) in the form of erosion and bone 
mineral density (BMD) loss; and new bone formation (osteoproliferation) in the form of 
sacroiliac joint (SIJ) ankylosis (bony bridging across the joint), syndesmophytes, and 
periostitis (inflammation of the bone cortex). AS is the prototypical SpA, and its 
pathogenesis has been studied in far more detail than either PsA or psoriatic 
spondyloarthritis (PsSpA). It is likely however, that AS and PsSpA share common 
pathogenic processes. In AS the primary site of inflammation is the enthesis and 
subchondral bone marrow, with bone marrow oedema, lymphocytic infiltrates, increased 
osteoclast density, and increased microvessel density being typical findings during acute 
inflammation [260]. In AS, joint fusion is thought to be the result of increased 
endochondral cartilage formation followed by bone formation (ossification), which allows 
bone formation and bridging of the joint space [261, 262]. After an initial phase of bone 
resorption, to counteract the now abnormal load bearing of the deformed joint, joints are 
thought to ‘respond’ through a marked anabolic remodelling of bony architecture and form 
syndesmophytes, which are bony appositions originating from the juxta-articular periosteal 
lining [263]. These bone appositions are formed via endochondral ossification, and take 
the form of bridging / non-bridging syndesmophytes and / or SIJ ankylosis. AS patients 
also suffer bone loss, especially in trabecular bone, resulting in osteoporosis and 
fractures. The prevalence of osteoporosis in AS is estimated between 19 - 62 per 100 AS 
cases, and vertebral fractures at 9 - 42 per 100 AS cases [264-266]. The risk of 
osteoporosis is also higher in PsA patients compared with the general population [267, 
268]. Markers of bone loss and formation may therefore vary with disease phenotype, 
pathological phase, disease activity and hold prognostic value. The paradox in SpA is that 
these diametrically opposite pathological processes of bone resorption and formation 
occur concurrently. The interpretation of circulating serum bone-biomarkers can therefore 
be challenging.  
 
The systematic review of bone and cartilage-turnover markers in PsA and PsSpA detailed 
in Chapter 4, identified four bone-turnover markers to be of interest in PsA, although data 
were limited. These four candidate biomarkers will therefore be investigated further in this 
chapter of the thesis, using the cohorts of PsSpA, pPsA and AS identified and 
characterised in Chapters 5 and 6 of this thesis. Three biomarkers promote bone 
resorption: macrophage colony stimulating factor (M-CSF), dickkopf 1 (Dkk-1), and matrix 
metalloproteinase 3 (MMP-3). Osteoprotegerin (OPG) promotes new bone formation by 
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inhibiting bone resorption. A more detailed description of the four biomarkers is given in 
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Figure 8.1. Metabolic bone pathways involving Dkk-1, OPG, M-CSF and MMP-3  
[original figure, compiled from various sources. Green cross indicates induction effect 
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8.2.1 Dickkopf 1 (Dkk-1) 
 
The dickkopf (Dkk) gene family encodes secreted proteins and consists of four main 
members in vertebrates (Dkk-1, -2, -3, and -4). Human dickkopf related protein 1 (Dkk-1) 
is a 40 kDa glycosylated protein [269, 270]. Dkk proteins contain two conserved cysteine-
rich domains separated by a linker region [269, 270]. The C-terminal domain contains a 
colipase fold with a conserved pattern of ten cysteine residues, and is necessary and 
sufficient for Wnt inhibition [271]. A distant Dkk family member is soggy (sgy) and is also 
known as Dickkopf-like protein 1 (DkkL1). The hallmark of the Dkk-1, Dkk-2 and Dkk-4 
family is their ability to modulate Wnt signaling. Mostly their effect is inhibitory, but there is 
evidence that Dkk-2 can also activate Wnt signaling [269, 270]. Dkk-1 is primarily an 
antagonist of the Wnt signaling pathway (Figure 8.1), and was discovered by its ability to 
block Wnt signaling during early Xenopus (aquatic frogs native to sub-Saharan Africa) 
embryogenesis, which is required for head induction [272], and later in many other cell 
types and vertebrate species [270]. Dkk-3 and sgy are divergent members of the Dkk 
family, which do not seem to function in Wnt signaling [270]. 
 
The Wnt family of growth factors are essential in numerous processes during 
embryological development, and in physiological and pathological processes [273]. In the 
normal state Wnt proteins bind to a co-receptor complex, which comprises low-density 
lipoprotein receptor-related protein 5 (LRP5) or LRP6, and a member of the Frizzled (Fz) 
family of proteins. This leads to an increase in intracellular beta-catenin levels through 
inhibition of the beta-catenin degradation complex. Beta-catenin triggers a series of 
events that lead to osteoblastogenesis, and ultimately new bone being formed and laid 
down (accretion) (Figure 8.1). Wnts can be inhibited and induced by several effectors 
acting intracellularly, e.g. modulating components of the signal transduction machinery, or 
extracellularly, e.g. modulating ligand receptor interactions [270]. Five families of extra-
cellular Wnt antagonists have been identified and include: the Dkk family of secreted 
proteins, the secreted frizzled-related protein (sFRP), Wnt inhibitory factor 1 (Wif1), Wise, 
and Xenopus Cerberus [270]. Wnts trigger three pathways that employ Wnt receptors of 
the frizzled seven transmembrane class: Wnt/b-catenin pathway (canonical pathway); the 
planar cell polarity pathway (PCP), which does not involve b-catenin but recruits small 
GTPases of the rho/cdc42 family to activate Jun kinase; and the Wnt/Ca2 þ cascade 
which may overlap with the PCP pathway [270]. Dkks specifically affect the Wnt / beta-
catenin cascade, by binding and modulating Wnt co-receptors LRP5 and LRP6, which are 
indispensable for routing the Wnt signal to the b-catenin pathway. Wnt engages a receptor 
complex composed of the Fz proteins, LRP5 and LRP6 [274]. Dkk-1 antagonises Wnt by 
forming ternary complexes of LRP5/6 with Kremen1 (Krm1) or Kremen2 (Krm2) [274]. 
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Internalisation of the Dkk-1/LRP6/Krm2 complex down-regulates Wnt signaling [274]. 
Krm1 and Krm 2 greatly potentiate the ability of Dkk-1 to block Wnt signaling. Krm2 forms 
a ternary complex with Dkk-1 and LRP6, and induces rapid endocytosis and removal of 
LRP6 from the plasma membrane, thereby blocking beta-catenin signaling [270]. While 
Dkk-1 acts as a pure inhibitor of Wnt / beta-catenin signaling, Dkk-2 can either activate or 
inhibit the pathway depending on its host cell and environment [270]. Dkk-1 and Dkk-2 






[a] Wnt forms ternary complexes with the Frizzled (Fz) and low-density lipoprotein receptor-related protein 5 
and 6 (LRP5 and LRP6) , which promotes stabilisation of beta-catenin, thereby activating the pathway. [b 
,c]Dkk-1 binding to LRP6 blocks signal transduction preventing Wnt-Fz binding [b] and / or LRP6 endocytosis 
in the presence of the Dkk-1 co-receptor Kremen (Krm) [c]. [d] Dkk-2 can activate Dkk-2 LRP6. [Figure taken 
from Neihrs et al. 2006]  
Figure 8.2. Model of Dkk-1 interaction with the Wnt/beta-catenin pathway.  
 
 
The Wnt/b-catenin pathway is pivotal in bone formation; increasing bone mass by various 
mechanisms including renewal of stem cells, osteoblast proliferation, promoting 
osteoblastogenesis and inhibiting osteoblast apoptosis and osteocyte apoptosis, as 
shown in Figure 8.2 [275]. During embryogenesis Dkk-1 antagonises Wnt-7a during limb 
development and keratinocytes [276, 277]. In children, Dkk-1 is expressed mainly by 
osteoblasts and osteocytes, when its homeostasis with Wnt determines bone formation 
[278]. Insufficient Dkk-1 activity secondary to the deletion of one Dkk-1 allele in a mouse 
model resulted in increased bone density [278]; whilst excess Dkk-1 activity resulted in 
decreased bone density [279]. There is emerging evidence that high Dkk-1 expression is 
pathogenic in erosive bone disorders such as SpA [121, 260, 280-286], rheumatoid 
arthritis (RA), Paget’s disease, and glucocorticoid-induced osteoporosis [89, 287, 288]. 
Dkk-1 levels have been investigated in PsA [121] and in AS [260, 280-286]. More details 
are given later in this Chapter. Pathological overexpression of Dkk-1 in human myeloma 
Wnt/b-catenin pathway (Cadigan and Liu, 2006), (2) the
planar cell polarity pathway (PCP), which does not
involve b-catenin but recruits small GTPases of the rho/
cdc42 family to activate Jun kinase (JNK) and which at
least in vertebrates appears to be triggered by Wnts
(Tada et al., 2002) and (3) the Wnt/Ca2þ cascade, which
is still controversial and may be partly overlapping with
the PCP pathway (Kohn and Moon, 2005). Of the
various pathways employed by Wnts, Dkks specifically
affects the canonical or Wnt/b-catenin cascade. Dkk1
for example does not interfere with PCP pathway in
Xenopus nor with a Xwnt5a-induced Ca2þ activation as
measured by CaMKII autophosphorylation (Semenov
et al., 2001). This is because Dkks bind and modulate
Wnt coreceptors of the lipoprotein receptor-related
protein 5/6 class, which are indispensable for routing
the Wnt signal to the b-catenin pathway (He et al.,
2004). Lrp5/6 are coreceptors that form a ternary
complex with Wnt and Fz proteins (Figure 2a).
In addition to Fz and Lrp6, there are two other Wnt
coreceptors, Ror2, an orphan tyrosine kinase possessing
a CRD domain, which is bound by Wnt5a and activates
JNK (Oishi et al., 2003; Mikels and Nusse, 2006), and
the tyrosine kinase Derailed/Ryk (Yoshikawa et al.,
2003). Their mechanism of signal transduction is still
poorly understood and possible effects of Dkks on them
are still unknown.
Wnt-independent functions of Dkks
An overwhelming body of evidence supports the
function of Dkk1 in Wnt/b-catenin s naling, but it
has been suggested that Dkk1 and -2 may have also
b-catenin-independent functions. For examp e, the
mesothelioma cell line H28 contains a homozygous
deletion of the b-catenin gene and yet Dkk1 over-
expression induces apoptosis and growth suppression
(Lee et al., 2004). Similarly in HeLa cells, there are no
significant changes in either cellular b-catenin localiza-
tion, expression of Wnt target genes or tcf-reporter
activity after ectopic expression of Dkk1 (Mikheev et al.,
2004). However, activation of Lrp6 by Wnts may have
effects which are b-catenin independent (Orme et al.,
2003) and still be Dkk1 modulated. Comparing Dkk1
to dominant-negative Lrp6 or to other receptor antago-
nists such as Wise may reveal Lrp6-independent
functions of Dkks.
JNK activation may be one such b-catenin-independent
effect of blocking Wnt-LRP6 signaling. Wnt11 (via the
PCP pathway) as well as Dkk1 and another secreted Wnt
antagonist crescent, all can activate JNK (Pandur et al.,
2002). Furthermore, inhibitors of JNK reduce apoptosis
induced by Dkk1 overexpression in H28 cells (Lee et al.,
2004). This suggests a crosstalk upstream of b-catenin
between the canonical and the Wnt/PCP pathway.
Taken together, while it cannot be ruled out that
Dkk1 and -2 may affect signaling cascades independent
of their ability to regulate LRP6, there is no convincing
evidence for this at present.
Dkk3 and sgy are divergent members of the Dkk
family which do not seem to function in Wnt signaling
(Glinka et al., 1998; Krupnik et al., 1999; Mao et al.,
2001a). It was suggested that an N-terminally truncated
Dkk3 encodes a substrate binding subunit, ‘p29’, of the
type II iodothyronine 50-deiodinase (D2) in rat (Leonard
et al., 2000). This suggestion has not been supported (a)
because of the seleno-nature of all other cloned
deiodinases that act without substrate binding subunits,
(b) because there is poor correlation between Dkk3/p29
and the D2 expression patterns in rat brain (Montero-
Pedrazuela et al., 2003) and (c) since Dkk3 knockout
mice have normal deiodinase and thyroid hormone
status (del Barco Barrantes et al., 2006). While Dkk3
mouse m tants are viable, they show changes in the
frequency of NK cells, immunoglobulin M, hemoglobin
and hematocrit levels, as well as lung ventil t on.
Furthermore, Dkk3-deficient mice display hyperactivity.
Little is known about Sgy (also called DkkL1), other
than that the protein is associated with spermatogenesis,
and that it localizes to the acrosome (Kaneko and
DePamphilis, 2000; Kohn et al., 2005).
Dkk receptors
Vertebrate Lrp5 and Lrp6 are closely related type I
transmembrane proteins, of about 180 kDa molecular
Figure 2 Model of Dkk interactions with the Wnt/b-catenin pathway. (a) Wnt forms a ternary complex with Fz and Lrp6, which
promotes stabilization of b-catenin, thereby activating the pathway. (b, c) Dkk1 binding to Lrp6 blocks signal transduction by
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cells is associated with increased bone erosion and osteolytic bone lesions [289]. In 
humans, LRP5 loss-of-function mutations lead to osteoporosis-pseudoglioma syndrome, 
characterised by low bone density [290], whilst LRP5 gain-of-function mutations are 
associated with high bone mass [291]. Dkk-1 has a physiological role in the skin 
complexion of the palm of the hand. Palmo-plantar fibroblasts secrete Dkk-1, which 
inhibits melanocyte growth and differentiation, explaining the lighter pigmentation of the 
palm compared with the dorsum of the hand [277].  
 
Diarra et al. used a neutralising monoclonal antibody (mAb) to mouse Dkk-1 (anti-Dkk-1) 
in a transgenic mouse model of RA [287]. They found that Dkk-1 plays a key role in the 
remodeling of joints by two mechanisms. In RA, Dkk-1 prevents compensatory bone-
formation following pathological bone degradation by osteoclast-forming inflammatory 
tissue. Secondly, through inhibition of the Wnt-pathway-related osteoblastogenesis, Dkk-1 
reduces OPG secretion by osteoblasts. Increased serum levels of OPG where 
demonstrated upon mAb inhibition of Dkk-1. A mutual inverse relationship between OPG 
and Dkk-1, exists, allowing Dkk-1 to have an indirect influence on osteoclastogenesis-
mediated bone resorption (Figure 8.1). Dkk-1 therefore has a dual action; regulating  
anabolic and catabolic pathways in both health and disease. These processes are 
summarised in Figures 8.3 and 8.4. 
 
Tumour necrosis factor-alpha (TNF-alpha) promotes destruction of bone by decreasing 
the number of osteoblasts that form bone (in part through the Dkk-1/Wnt pathway), and 
increasing the number of osteoclasts that resorb bone (in part through the OPG/RANKL 
and M-CSF pathways) (Figure 8.1 and Figure 8.4). TNF-alpha therefore has an overall 
bias toward bone resorption [292]. TNF-alpha also induces the expression of MMP-3, 
which degrades the extra-cellular matrix of bone and cartilage (Figure 8.1). 
 
Dkk-1 expression is also tightly linked to sclerostin expression. Sclerostin is another Wnt 
antagonist, and has been associated with syndesmophyte formation [293]. Wnt agonists 
such as R-spondin have been shown to induce bone spur formation along inflamed joints 
[294].  
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Wnt/β-catenin signaling regulates osteogenesis through multiple mechanisms, but leading ultimately to more 
bone formation and less bone resorption. (i) Wnts promote osteoblast differentiation, proliferation, and 
mineralisation activity. (ii) Wnts inhibit mesenchymal differentiation pathways such as adipocyte and 
chondrocyte differentiation. (iii) Wnts inhibit osteoblast apoptosis. (iv) Osteoblasts secrete OPG, and therefore 
Wnt-induced osteoblasts increase the ratio of OPG. RANKL is an inducer of osteoclastogenesis leading to 
increased bone resorption. However, since, OPG acts as a decoy receptor to RANKL, Wnt pathways lead to 
increased OPG:RANKL ratio, thereby inhibiting osteoclastogenesis, thus decreased bone resorption. (The 
‘green + signs’ indicate positive effects of Wnt; the ‘red – signs’ indicate inhibitory effects of Wnt. Dlx5, distal-
less homeobox 5; MSC, mesenchymal stem cell; Msx2, msh homeobox homolog 2; Osx, osterix; Runx2, runt-
related transcription factor 2.)  
Figure 8.3. Downstream cellular effects of Wnt/β-catenin signaling  








(a) In a physiological state, cortical bone formation and resorption next to joints are in balance. (b) 
Inflammatory arthritis such as rheumatoid arthritis leads to an imbalance between bone formation and 
resorption. Bone formation is hampered by TNF-mediated expression of DKK-1, which suppresses Wnt 
signals, whereas bone resorption is enhanced by expression of RANKL. (c) Blockade of DKK-1 relieves Wnt 
signaling from DKK-1–mediated suppression and induces bone formation resulting in osteophytes. Moreover, 
Wnt proteins induce OPG expression, which blocks RANKL-mediated bone resorption. 
Figure 8.4. Dkk-1 is critical for joint remodeling  
(Figure taken from Diarra et al. 2007 [287]) 
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and Wnt14 are expressed in calvarial tissue and osteoblast cultures 
(13), and Wnt1 and Wnt3a are induced by bone morphogenic pro-
tein 2 (BMP-2) in a mesenchymal precursor cell line (25). However, 
because Wnts function through autocrine and paracrine mecha-
nisms, analysis of those Wnts tha  specifically contribute to bone 
formation, as well as the frizzled receptors mediating their effects, 
will require in situ analysis of gene expression within bone and 
marrow and confirmation by genetic approaches.
8OUSFHVMBUFTPTUFPCMBTUPHFOFTJT
UISPVHIUIFDBOPOJDBMQBUIXBZ
One of the mechanisms whereby Wnt signaling increases bone 
formation is via stimulation of the development of osteoblasts, 
and there is considerable in vitro evidence supporting a role for 
Wnt/β-catenin (i.e., canonical) signaling in this process (Figure 2). 
For example, inhibition of GSK3 enzymatic activity with lithium 
chloride (LiCl; ref. 26) or small molecules (e.g., Chir99021 and 
LY603281-31-8) stimulates mesenchymal precursors to differen-
tiate into osteoblasts (24, 27, 28). This concept is supported by 
observations with Wnt3a, Wnt1, Wnt10b, and constitutively active 
β-catenin, all of which activate signaling through β-catenin and 
stimulate osteoblastogenesis, while Dkk1, which inhibits this 
pathway, reduces osteoblastogenesis (24, 28, 29). Importantly, 
activation of Wnt/β-catenin signaling also inhibits adipogenesis of 
mesenchymal precursors (30, 31), which may have clinical impor-
tance given the positive correlation reported between marrow adi-
pose content and bone fractures (32).
Further evidence that Wnt signaling increases bone mass 
through the Wnt/β-catenin pathway comes from the results 
of in vivo studies using pharmacological inhibitors of GSK3β. 
For example, administration of LiCl for 4 weeks dramatically 
increased bone formation rate and number of osteoblasts in 
C57BL/6 mice (33). Similar results were obtained in osteope-
nic Lrp5–/– mice, indicating that LiCl acts downstream of LRP5. 
Consistent with the in vitro results described above, inhibition 
of GSK3 reduced the number of marrow adipocytes over this 
period. LiCl influences other signaling pathways besides Wnt, 
and GSK3 regulates many proteins besides β-catenin. However, 
the fact that LiCl stabilizes β-catenin and increases TCF-based 
reporter gene activity and expression of Wnt-responsive genes 




During embryonic development, the level of β-catenin is 
increased in differentiating osteoblasts (34), and pharmacologi-
cal and genetic approaches have indicated that Wnt signaling 
increases bone mass through a number of mechanisms includ-
ing renewal of stem cells (35), stimulation of preosteoblast repli-
cation (13), induction of osteoblastogenesis (13), and inhibition 
of osteoblast and osteocyte apoptosis (Figure 2) (17). These vari-
able results likely arise because Wnt/β-catenin signaling regu-
lates bone development and accrual through different mecha-
nisms at different stages of life. This concept is supported by the 
results of studies using mouse models in which targeted dele-
tion of β-catenin occurs early or late in osteoblastogenesis. For 
example, dermo-Cre mice have a targeted deletion of β-catenin 
in mesenchymal precursors of chondrogenesis and osteogenesis 
(36, 37). These mice show a reduction in all relevant markers of 
osteogenesis and an absence of both endochondral and intra-








upon TNF blockade in human disease suggest that at least part of the
destructive effect of TNF on joints is mediated by DKK-1. On the
other hand, low levels of DKK-1 appear to be crucial for the
emergence of osteophytes, which suggests that Wnt signaling is a
key trigger for bone formation in the joint. Local bone formation i
the form of osteophyte formation is absent in rheumatoid arthritis but
is a hallmark of inflammatory and degenerative joint diseases such as
ankylosing spondylitis and osteoarthritis, respectively (Fig. 6b,c).
Second, blockade of DKK-1 also interfered with local bone resorption
by reducing osteoclast numbers in the joints (Fig. 6b,c). The impact
on local bone resorption is based on the regulation of OPG expression
by canonical Wnt signaling, which is illu-
strated by increased serum levels of OPG
upon DKK-1 inhibition24.
The regulation of systemic bone mass by
means of Wnt signaling is of growing scien-
tific interest. The Wnt coreceptor LRP5 is a
critical regulator of bone mass15. Thus activation of LRP5 affects
bone accrual during growth and regulates the establishment of peak
bone mass25. In particular, the Wnt protein family, which engages the
LRP5/6 receptors on mesenchymal cells, drives new bone formation
and leads to a increase in systemic bone mass. The Wnt pathw y is
therefore considered an interesting target for bone nabolic therapies.
DKK-1 is a Wnt a tagonist that cross-links LRP5/6 with Kremen-1
and prevents its activation by Wnt. Recent data suggest that DKK-1
expression seems to be critical for systemic bone mass, as heterozygous
DKK-1–deficient mice show increased bone formation and bone
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Figure 5 Expression and regulation of DKK-1 in human rheumatoid arthritis.
(a) Immunoblot analysis of synovial tissue extracts from subjects with osteoarthritis
(n ¼ 5) and rheumatoid arthritis (n ¼ 5) for DKK-1 expression. (b) Immuno-
histochemistry of synovial tissue from subjects with rheumatoid arthritis, showing
DKK-1 expression (brown) in spindle-shaped synovial fibroblasts (left, black arrows),
synovial microvessels (middle, black arrows) and chondrocytes (right). Scale bar,
20 mm. (c) Immunohistochemistry for b-catenin in a metacarpophal ngeal joint of an
individual with rheumatoid arthritis. B, bone; BM, bone marrow; C, cartilage; ER,
erosion; JS, joint space. Arrows show nuclear staining of b-catenin. Right image
is an enlarged detail of the left image. Scale bars, 160 mm (left) and 20 mm (right). (d) Measurement of DKK-1 serum levels in healthy controls, subjects
with rheumatoid arthritis (RA) before and 2 and 4 weeks aft r initiation of TNF blockade, and subjects with ankylosing spondylitis (AS). V lues are means ±
s.e.m. * indicates significant (P o 0.05) difference versus healthy controls; ** i dicates significant (P o 0.01) difference versus rheumatoid arthritis
subjects before treatment. Scatter plots show the correlation of DKK-1 level with disease activit in rheumatoid arthritis subjects (DAS28 score) and















Figure 6 DKK-1 is critical for joint remodeling.
(a) In a physiological state, cortical bone
formation and resorption next to joints are in
balance. (b) Inflammatory arthritis such as
rheumatoid arthritis leads to an imbalance
between bone formation and resorption. Bone
formation is hampered by TNF-mediated
expression of DKK-1, which suppresses Wnt
signals, whereas bone resorption is enhanced
by expression of RANKL. (c) Blockade of DKK-1
relieves Wnt signaling from DKK-1–mediated
suppression and induces bone formation mirrored
by the growth of osteophytes. Moreover, Wnt
proteins induce OPG expression, which blocks
RANKL-mediated bone resorption.
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8.2.1.1 Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis 
 
One study by Daoussis et al., has in particular given detailed insight into the role and 
function of Dkk-1 in rheumatological disease [280]. As the findings of that study are so 
pertinent to the Dkk-1 results of this chapter of the thesis, the methods and findings of 
Daoussis et al. will be presented in some detail here, and revisited in the Discussion 
section of this chapter. In 45 AS, 45 RA, 15 PsA, and 50 HC subjects, Daoussis et al. 
measured serum total Dkk-1, serum functional Dkk-1, and performed Dkk-1 function 
assays using Jurkat T cells [280]. Serum total Dkk-1 concentrations were higher in AS 
patients compared with HC (2.73 vs. 2.38 ng/ml; p=0.04), AS compared with PsA (2.73 
vs. 2.44 ng/ml; p=0.05), and AS compared with RA (2.73 vs. 1.85 ng/ml; p=0.02) patients 
(unadjusted for anti-TNF use). Although Dkk-1 concentrations were not associated with 
disease duration, disease activity, erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), or synthetic disease modifying anti-rheumatic drug (DMARD) use in any 
patient group, nor the presence of peripheral arthritis in AS patients, an association with 
anti-TNF use was found. Once adjusted for anti-TNF use, serum total Dkk-1 levels were 
similar between patients with AS, RA, and HC (p=0.62 by one-way analysis of variance). 
AS patients on anti-TNF therapy (n=20) had significantly higher serum Dkk-1 
concentrations compared with AS patients not on anti-TNF (n=25) (3.13 vs. 2.42 ng/ml; 
p=0.01). Disease activity (BASDAI) was not identified as a confounder in this comparison; 
sub-analyses showed that patients on anti-TNF and in clinical remission had similar Dkk-1 
levels to those using anti-TNF and with active disease (BASDAI ≥4). In contrast, RA 
patients on anti-TNF (n=20) had significantly lower serum Dkk-1 levels than those not on 
anti-TNF (1.41 vs. 2.20 ng/ml; p=0.02), again not confounded by disease activity as 
measured by the DAS28. Daoussis et al. showed that in AS, longitudinally-measured Dkk-
1 rises following anti-TNF therapy, the converse relationship was found in RA patients, 
whereby longitudinally-measured Dkk-1 levels decreased following anti-TNF therapy. This 
is contrary to what might be expected given that TNF-alpha is an inducer of Dkk-1 
expression, so one might expect anti-TNF agents to decrease serum Dkk-1 levels. 
 
To evaluate the functional integrity of Dkk-1, Daoussis et al. used ELISA to measure the 
amount of Dkk-1 binding to receptor LRP6 [280]. Microtiter plates were coated with 3 
mcg/ml of human LRP6-Fc chimera, then serum samples were added. The amount of 
serum Dkk-1 that bound to LRP6 was measured using human anti-Dkk-1 antibody, and 
regarded as the amount of functional Dkk-1. Functional Dkk-1 levels were lower in AS 
compared with HC (n=5) (133 vs. 249 pg/ml; p=0.0001), and in AS compared with anti-
TNF-naïve RA patients (133 vs. 390 pg/ml; p=0.0001). In AS patients, the amount of Dkk-
1 bound to LRP6 was no different before or after anti-TNF use (133 vs. 125 pg/ml; 
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p=0.33). Taken together with the study’s other findings, it would seem that whilst serum 
total Dkk-1 levels are no different in AS compared with HC and RA patients (adjusted for 
anti-TNF use), Dkk-1 binds less avidly to LRP6 (as measured by the level of functional 
Dkk-1) in AS compared with both HC and RA. In addition, whilst only tested in 8 AS 
patients, the results indicate that although serum total Dkk-1 rises after anti-TNF therapy, 
the amount of Dkk-1 causing biological consequence (i.e. functional Dkk-1) is unchanged.  
 
Daoussis et al. investigated further by testing the functional capacity of Dkk-1 to directly 
antagonise Wnt signaling using ex-vivo lithium-treated Jurkat T cells (of leukaemic rather 
than osteoblastic origin) by Western immunoblotting [280]. Dephosphorylated beta-catenin 
is the active form of beta-catenin, and is thus a direct marker of the degree of Wnt 
pathway activation. Lithium chloride (LiCl) reduces beta-catenin degradation, thus 
stabilises beta-catenin. Addition of LiCl to Jurkat cells leads to an increase in intracellular 
beta-catenin levels. Addition of HC sera (n=10) to LiCl-treated Jurkat cells had a 
moderate/minimal effect on beta-catenin levels. Whereas the addition of AS serum (n=10) 
led to a significant increase in intracellular active beta-catenin levels (no differences found 
between AS patients on anti-TNF and those not). These experiments indicate that in AS 
serum, despite the increased circulating levels of total Dkk-1 (a Wnt-inhibitor), at an ex-
vivo cellular level, the net effect (stimulatory plus inhibitory) of AS serum on the Wnt 
pathway is stimulatory (abnormal), as compared to inhibitory (normal) in HC serum. One 
explanation as proposed by Daoussis et al., is that in AS serum, Dkk-1 is not mediating 
the induction of Wnt-pathways, instead AS serum contains abnormal levels of other 
soluble molecules e.g. growth factors, that are inducing the Wnt-pathway. A second 
hypothesis proposed is that an autoantibody or a soluble receptor against Dkk-1 is 
present in the serum of AS patients, compromising Dkk-1 function. An alternative 
explanation, proposed by Daoussis et al. is that Dkk-1 is dysfunctional in AS serum and is 
therefore unable to inhibit the Wnt-pathway, which in turn has excessive activity. Higher 
Dkk-1 levels are found in AS patients because the body tries progressively harder to 
inhibit the Wnt-pathway by expressing ever more Dkk-1, in an attempt to compensate for 
the dysfunctional Dkk-1. This hypothesis is fundamental to explaining our own results, as 
will be described later in this chapter. 
 
To directly test the hypothesis that Dkk-1 is dysfunctional in AS patients, a mAb 
specifically blocking the interaction of Dkk-1 with LRP6 was added to sera [280]. This 
addition to HC sera led to an increase in active beta-catenin levels, indicating that Dkk-1 is 
acting physiologically in HC sera, acting an inhibitor of the Wnt pathway. However, the 
addition to sera from AS patients did not increase active beta-catenin levels, suggesting 
that the function of Dkk-1 in patients with AS may be compromised and thus pathological. 
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The authors concluded that in AS patients Dkk-1 is dysfunctional, perhaps with impaired 
Dkk-1 binding to LRP6, resulting in negligible Dkk-1-mediated inhibition of the Wnt 
pathway, and consequent excess activity of bone-formation pathways [280].  
 
8.2.2 Osteoprotegerin (OPG) 
 
Bone formation and resorption are normally tightly coupled, and osteoprotegerin (OPG) 
and receptor activator of nuclear factor kappa-B ligand (RANKL) have key regulatory 
roles. OPG is a 55 kDa glycoprotein and a member of the TNF receptor family [292]. OPG 
is secreted by osteoblasts, and its expression is increased by Wnt-signaling, IL-4, 
interferon-gamma (IFN-gamma), bone morphogenetic protein (BMP) and parathyroid 
hormone (PTH) (Figure 8.1) [295]. Importantly, Wnt-pathway mediated 
osteoblastogenesis creates osteoblasts that in turn express OPG. Through inhibition of 
the Wnt-pathway, Dkk-1 reduces osteoblastogenesis and Dkk-1 is therefore an inhibitor of 
OPG [275]. However, OPG also regulates Dkk-1 through a negative feedback loop (Figure 
8.1) [296].  
 
Receptor activator of nuclear factor kappa-B (RANK) is a receptor present on the surface 
of osteoclasts [292]. Osteoclasts are responsible for physiological, and in the abnormal 
state pathological resorption of bone. The binding of RANK to its ligand, RANKL, leads to 
the promotion of osteoclastogenesis, which in turn increases bone resorption. RANKL is 
mainly produced by osteoblasts and activated T cells, and OPG is predominantly secreted 
by osteoblasts [292]. RANKL expression is increased by TNF, interleukin-1 (IL-1), IL-6, IL-
13 and IL-17, all of which are abnormally up-regulated in inflammatory arthritis and appear 
to have differentially-weighted influence on RANKL [292]. However, OPG is a serum-
soluble decoy receptor to RANKL, preventing the binding of RANKL to RANK. OPG 
therefore inhibits osteoclastogenesis, and ultimately leads to reduced bone resorption 
[292] (Figure 8.1). Fujita, et al. found that Dkk-1 can inhibit OPG secretion, and promotes 
osteolytic lesions in vivo by enhancing RANKL-mediated osteoclastogenesis [297]. 
 
Serum OPG levels have been investigated in PsA [121] and in AS [260, 281, 282, 284, 
285, 295, 298-304]. More details as they relate to our own study findings, are given in the 
Discussion section of this Chapter. Dysregulation of the OPG-RANKL axis has been more 
thoroughly studied in RA, where the excess production of RANKL relative to OPG, by 
activated T cells, likely leads to bone and cartilage destruction [305]. Kim et al. showed 
that whilst OPG levels were no different in AS and HC subjects, RANKL levels were 
increased in AS, resulting in a higher RANKL:OPG ratio in AS compared with HC [302].  
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Synovial tissue from PsA has been shown to express very low quantities of OPG and high 
levels of RANKL, possibly resulting in excessive bone resorption, and providing a 
plausible mechanism for bone erosions in PsA [306]. OPG has shown a role in the 
formation of osteolytic bone lesions in multiple myeloma [307]. Given that mAbs that 
inhibit RANKL (e.g. Denusomab) have shown significant clinical efficacy in the 
management of osteoporosis [308], OPG may also have some utility in the treatment of 
osteoporosis associated with increased osteoclast activity [309]. Since TNF stimulates 
osteoblastic cells to express RANKL and M-CSF, anti-TNF agents may inhibit bone 
resorption [295]. It has not yet been determined if OPG promotes osteoproliferation in the 
form of syndesmophytes or osteophytes. Osteophytes can form independently of the 
OPG-RANKL pathway, through anabolic bone pathways mediated by Dkk-1 [296].  
 
In brief, OPG reduces bone resorption by acting as a decoy receptor in the RANK/RANKL 
pathway (Figure 8.1). OPG expression is reduced by Dkk-1 through inhibition of the Wnt-
pathway. 
 
8.2.3 Macrophage-colony stimulating factor (M-CSF) 
 
Macrophage-colony stimulating factor (M-CSF) is a four-α-helical-bundle cytokine, and 
has several isoforms of varying size. M-CSF is secreted by fibroblasts, activated 
macrophages, bone marrow stromal cells, vitamin D-stimulated osteoblasts, activated 
endothelial cells and endometrial secretory epithelium [310-314]. M-CSF receptor is 
expressed on monocytes and tissue macrophages, and is responsible for mediating M-
CSF endocytosis and transducing the pleotropic effects of M-CSF. M-CSF promotes 
differentiation of several cells, including bone osteoclasts [310-315] and macrophages 
[310]. Parathyroid hormone (PTH) induces the release of M-CSF from osteoblasts, which 
in turn binds to receptors on osteoclasts, and induces osteoclast differentiation, increased 
bone resorption and subsequent increased plasma calcium levels (Figure 8.1). M-CSF 
receptor is also expressed on osteoblasts where it down-regulates RANKL production, 
thus allowing M-CSF to also inhibit osteoclast production [316]. M-CSF is the primary 
regulator of macrophage differentiation, proliferation and survival, and is essential for 
macrophage-related functions such as bone resorption [310]. M-CSF regulates the 
release of cytokines and other inflammatory modulators from macrophages and 
monocytes, and stimulates chemotaxis and pinocytosis, which in-turn cause inflammation 
[310, 312].  
 
A unique characteristic of M-CSF, setting it apart from other pro-inflammatory cytokine in 
rheumatological diseases, it that M-CSF only affects cells of the monocyte lineage [317]. 
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Animal-models deficient in M-CSF are resistant to the development of collagen-induced 
arthritis [318]. M-CSF-deficient mice become deficient in macrophages and subsequently 
develop osteopetrosis (hardening and increased density of bones), and have failure of 
teeth eruption due to insufficient differentiation of bone-resorbing osteoclasts [311-313]. 
Serum M-CSF levels have been investigated in PsA [121] and in AS [295, 317, 319, 320]. 
More details are given in the Discussion section of this Chapter. M-CSF expression has 
shown to be increased in inflammatory bowel disease [310, 311, 313]. The expression of 
M-CSF receptor on cancer cells is thought to facilitate metastasis to the bone by 
chemotaxis toward osteoblast-produced M-CSF, and by promoting osteolysis [321].  
 
8.2.4 Matrix metalloproteinase 3 (MMP-3) 
 
Matrix metalloproteinases (MMPs) are zinc and calcium dependent endopeptidases that 
degrade the extracellular matrix (ECM) of bone and cartilage during normal physiological 
processes such as embryogenesis, morphogenesis, reproduction and tissue remodelling 
[322]. However, MMPs can also degrade extracellular matrix in a pathological manner in 
arthritis, cancer and cardiovascular disease [323]. Most MMPs are secreted as inactive 
pro-proteins, and later activated by extracellular proteinases through cleavage. MMP-3 
has a molecular weight of 54 kDa, and active-MMP-3 can cleave collagen (types III, IV, IX 
and X), aggrecan, fibronectin, laminin, IGFBP-3, serpins, and IL-1β. Active-MMP-3 also 
has a role in activating other MMPs, such proMMP-1, -8, -9, and -13, giving MMP-3 a 
pivotal role in connective tissue remodelling [324]. MMP-1 (aka. interstitial collagenase 1) 
is important in the degradation of articular cartilage, and MMP-9 (aka. gelatinase B) 
digests gelatin and several types of collagens [325]. 
 
The MMP3 gene is part of a cluster of MMP genes which localise to chromosome 
11q22.3. The synthesis of MMP is determined at the level of transcription; whilst the 
proteolytic activity of existing MMP is controlled by the activation of pro-enzymes and the 
inhibition of active enzymes by endogenous inhibitors such as α- tissue inhibitors of 
metalloproteinases. MMP-3 is expressed following stimulus in osteoblasts, fibroblasts, 
chondrocytes, keratinocytes, endothelial cells, macrophages, and vascular smooth muscle 
cells [323]. Stimuli include IL-1, TNF-alpha, epidermal growth factor (EGF), and platelet-
derived growth factor (PDGF) (Figure 8.1). Conversely, glucocorticoids, oestrogen, 
progesterone, tumour derived growth factor-beta (TGF-beta) and retinoic acid inhibit 
MMP-3 synthesis. MMP-3 is a peptide that has several domains, that are cleaved-off at 
various biological stages: a signal peptide cleaved during cellular secretion; a pro-domain 
cleaved during activation; a catalytic domain containing a conserved zinc-binding site, a 
hemopexin domain, and a hinge domain [326]. Pro-MMP-3 is secreted into the ECM in its 
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inactive form, and activated by the removal of the pro-peptide by the action of serine 
proteases, plasmin and trypsin [326]. 
 
Serum levels of MMP-3 have been found to be elevated in RA patients compared with 
osteoarthritis patients [327], shown to correlate with disease progression in RA patients 
[328], and baseline levels have been shown to be prognostic markers of radiographic 
progression in RA [329]. Serum MMP-3 levels have been found to be elevated in PsA 
[121]. Serum MMP-3 levels are elevated in AS and correlate with AS-related outcome 
measures [295, 301, 303, 317, 330-338]. More details are given in the Discussion section 





The bone forming and resorbing phenotypes of PsSpA, pPsA and AS make this group of 
SpAs good candidates to investigate serum-soluble bone-turnover biomarkers. Although 
some research has performed in AS patients, very little had been conducted in PsA and 
PsC, and none in PsSpA or psoriatic arthritis mutilans (PAM) patients. This chapter of the 
thesis aims to do exactly that. Comparisons will be made with the existing literature, to 
either corroborate or challenge the results of previous studies, and where possible explain 
why there may be disparity. Through a better understanding of serum bone-turnover 
biomarkers in SpA, it is hoped that patients can be better classified, monitored and 
managed using the principles of stratified medicine.
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8.3 STUDY OBJECTIVES 
The objectives of this study chapter were to:  
 
(i) investigate four potential serum-soluble bone-turnover biomarkers (Dkk-1, M-CSF, 
MMP-3 and OPG) as predictors of PsSpA occurrence, by comparison with pPsA, AS, 
psoriasis-only (PsC) cases and healthy controls (HC). 
 
(ii) investigate four potential serum-soluble bone-turnover biomarkers (OPG, Dkk-1, MMP-
3 and M-CSF) as predictors of axial radiographic disease severity / morphology in patients 
with PsSpA and AS. 
 
(iii) To investigate four potential serum-soluble bone-turnover biomarkers (OPG, Dkk-1, 
MMP-3 and M-CSF) as predictors of PAM occurrence, by comparison with non-PAM PsA 
cases. 
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8.4 METHODS 
A comprehensive description of general, clinical and radiographic methods, and 
identification of PAM patients are detailed in Chapters 4, 5, 6 and 7 of this thesis, and will 
therefore not be repeated in this chapter. Specific methods for this component of the study 




Cases were enrolled and characterised using the methods described in Chapters 4 to 7. 
Each patient provided a blood sample on the day of clinical assessment for serum-soluble 
biomarker testing and high-sensitivity CRP testing. Serum samples were provided by 201 
AS cases and 200 PsA cases enrolled in the study. One PsA patient had insufficient 
venepuncture to provide serum, and was not willing to reattend. The facilities of the Bath 
Institute for Rheumatic Diseases (BIRD) laboratory were used to process and test 
samples. Blood samples were centrifuged at 2,600 r.p.m. for ten minutes 
to separate the serum and plasma. Four aliquots of serum, each of 1 ml were stored at -
80 degrees Celsius for testing later.  
 
After inception of the original study protocol, it was thought that the study would be further 
strengthened by comparison of serum biomarkers levels with a healthy control (HC) group 
and psoriasis-only (PsC; without clinical evidence of arthritis) cases, as reference groups. 
Fifty HC serum samples were sourced from Health Survey England (HSE) part of the 
Health and Social Care Information Centre (HSIC). These were age, sex and ethnicity 
matched to the 201 PsA cases in this study. Subjects had been screened by the HSIC 
using a questionnaire and deemed to be healthy. A further 200 PsC samples were 
sourced from Professor James Elder (Department of Dermatology, University of Michigan 
Medical School, Michigan, USA). These samples had been collected as part of their on-
going research of psoriasis, stored at -80 degrees Celsius, and had associated clinical 
details including sex, age, disease duration (from psoriasis onset to blood sampling), anti-
TNF or synthetic DMARD use, and Psoriasis Area and Severity Index (PASI). These PsC 
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8.4.2 Biomarkers tested 
 
Commercially available enzyme-linked immunosorbent assay (ELISA) kits were 
purchased to measure the absolute concentration of four biomarkers (MMP-3, M-CSF, 
Dkk-1 and OPG) in 200 PsA, 201 AS cases, 200 PsC and 50 HC cases using the facilities 
of the BIRD laboratory. DJ performed the laboratory work, under the supervision of Dr. 
Juliet Dunphy (Biomedical Scientist and Head of Laboratories), and Professor Mark 
Lindsay. Due to the closure of the BIRD laboratory in October 2014, OPG was tested a 
couple of months later using the Pharmacology Laboratory of the University of Bath, by DJ 
and Ms Hui Lu, under the supervision of Professor Mark Lindsay and Dr. Juliet Dunphy. 
 
Quantikine ELISA kits were sourced from the R&D systems (Abindgon, U.K.) for Dkk-1, 
MMP-3, and M-CSF. ELISA kits were sourced from Biorbyte (Cambridge, U.K.) for OPG. 
All kits have been validated for use in clinical research and have cited use by other 
research groups for these biomarkers. The ELISA kits used in this experiment measured 
serum total MMP-3 (pro-MMP-3 and active-MMP-3), total Dkk-1 (functionally active and 
inactive Dkk-1), total OPG and total M-CSF. For brevity, the methods employed to test 
one biomarker (Dkk-1) are detailed below. The methods were similar for the other three 
biomarkers.  
 
8.4.3 Sample storage and general methods 
 
Serum were stored at -80 degrees Celsius, and to avoid repeated freeze-thaw cycles 
altering biomarkers level [339], each biomarker was tested using a different aliquot, 
thawed on the morning of testing. One biomarker was tested per laboratory day. Four 
plates comprising 96 wells were tested in a semi-automated fashion using a machine to 
distribute samples and reagents, and read the optical density of the wells. Subject serum 
samples were barcoded to minimise the risk of handling error. All cases, standards and 
controls were tested in duplicate. With some variation between biomarker kits, this 
allowed approximately 156 serum samples, one negative standard, five to seven positive 
standards, four inter-plate, and three to six intra-plate samples to be tested. The control 
serum was that used routinely by BIRD laboratory for service and research, and 
comprised pooled serum from cases with known systemic lupus erythematosus.  
 
Data was output as optical density, mean optical density of the duplicate samples, sample 
serum concentration derived from the Standard Curve, mean serum concentration, and 
co-efficient of variation percentage (CV%) between duplicate samples. A CV% of ≤15% 
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was considered acceptable. Case samples not achieving a CV% of ≤15 were repeated 
until the target CV% was attained. 
 
8.4.4 Methods for the Dkk-1 assay 
 
The Quantikine Human Dkk-1 immunoassay is a 4.5 hour solid phase ELISA designed to 
measure human total Dkk-1 in serum, plasma and cell culture supernates. The kit 
contains Sf 21-expressed recombinant human Dkk-1, and has been shown to accurately 
quantify the recombinant factor. The kit has been validated for use to determine relative 
mass values of naturally occurring human Dkk-1. The kits measures serum total Dkk-1 
(both functionally active and inactive Dkk-1). 
 
8.4.4.1 Principle of the assay 
 
A quantitative sandwich enzyme immunoassay technique is employed by the kit. 
Microplates are pre-coated with a monoclonal antibody specific for human Dkk-1. Dkk-1 
present in the standards and samples pipetted into the wells is bound by the immobilised 
antibody. Unbound substances are washed away and an enzyme-linked polyclonal 
antibody specific for Dkk-1 is added to the wells. Unbound antibody-enzyme reagent is 
washed away, a substrate solution is added to the wells and colour develops proportional 
to the amount of Dkk-1 bound in the initial step. Colour development is terminated and the 
intensity of the color indicates the concentration of Dkk-1 in that sample or standard.  
 
8.4.4.2 Procedures followed to optimise the assay 
 
• Foaming was avoided when mixing or reconstituting protein solutions.  
• Pipette tips were changed between additions of each standard level, between sample 
additions, and between reagent additions, to avoid cross-contamination. Separate 
reservoirs for used for each reagent.  
• Plate sealers were used during incubation steps. 
• Since we used an automated plate washer, a 30 second soak period following the 
addition of wash buffer was programmed. 
• Substrate solution was protected from light until the moment of use.  
• Stop solution was added to the plate in the same order as the substrate solution to 
ensure uniformity of incubation time. 
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8.4.4.3 Materials and storage 
 
Dkk-1 Microplate   
96 well polystyrene microplate (12 strips of 8 wells) coated with a mouse 
monoclonal antibody against Dkk-1. Stored at 2-8 oC  in a foil pouch for ≤1 month. 
DKK-1 Standard  
20 ng recombinant human Dkk-1 in a buffered protein solution with preservatives; 
lyophilized. Stored at 2-8 oC for ≤1 month. 
Dkk-1 Conjugate  
21.5 mL of a polyclonal antibody against Dkk-1 conjugated to horseradish 
peroxidase with preservatives. Stored at 2-8 oC for ≤1 month. 
Assay Diluent (RD1W) 
11 mL buffered protein solution with preservatives. Stored at 2-8 oC for ≤1 month. 
Calibrator Diluent (RD5-24) 
21 mL buffered protein solution with preservatives. Stored at 2-8 oC for ≤1 month.  
Wash buffer concentrate  
21 mL 25-fold concentrated solution of buffered surfactant with preservative. 
Stored at 2-8 oC for ≤1 month.  
Color Reagent A  
12 mL stabilised hydrogen peroxide. Stored at 2-8 oC for ≤1 month.  
Color Reagent B  
12 mL stabilised chromogen (tetramethylbenzidine). Stored at 2-8 oC for ≤1 month. 
Stop Solution  
6 mL of 2 N sulfuric acid. Stored at 2-8 oC for ≤1 month.  
Adhesive plate sealers. 
Microplate reader capable of measuring absorbance at 450 nm, with the correction 
wavelength set at 540 nm.   
Pipettes and pipette tips.   
Deionised water.   
Automated microplate washer.   
Horizontal orbital microplate shaker at 500 r.p.m.   
Polypropylene test tubes for dilution of standards and samples.   
 
8.4.4.4 Sample preparation 
 
Serum samples required an eight-fold dilution. 50 µL of sample was added to 350 µL of 
calibrator diluent RD5-24 (1:2).  
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8.4.4.5 Reagent preparation 
 
All reagents were brought to room temperature before use.  
Wash Buffer  
20 mL of wash buffer concentrate was diluted into deionised water to prepare 500 
mL of wash buffer.  
Substrate Solution  
Color reagents A and B were mixed together in equal volumes within 15 minutes of 
use, and protected from light. 200 µL of the resultant mixture was pipetted into 
each well.  
Calibrator Diluent RD5-24 (1:2)  
Calibrator diluent RD5-24 (1:2) was prepared by mixing 6 mL of calibrator diluent 
RD5-24 to 6 mL of deionised water.  
Dkk-1 Standard  
Dkk-1 standard was reconstituted with 1.0 mL of deionised water to produce a 
stock solution of 20,000 pg/mL. The standard was thoroughly mixed to ensure 
complete reconstitution. The standard was allowed to sit for ≥30 minutes with 
gentle agitation prior to making dilutions.  
 
Polypropylene tubes were used to pipette 900 µL of calibrator diluent RD5-24 (1:2) into 
the 2000 pg/mL tube. 500 µL of calibrator diluent RD5-24 (1:2) was pipetted into the 
remaining tubes. The stock solution was used to produce a dilution series (Figure 8.5), 
mixing each tube thoroughly before the next transfer. The 2000 pg/mL standard served as 
the high standard. Calibrator diluent RD5-24 (1:2) served as the zero standard (0 pg/mL).  
 
 
[900 µL of calibrator diluent was added to each of the tubes. 100 µL of standard was then added to 
the first test tube. 500 µL of the resultant mixture was then added to the 2nd tube, and so on. This 
made a series of the required standards from the original Dkk-1 Standard] 
Figure 8.5. Preparation of the standards  
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8.4.4.6 Assay procedure 
 
All reagents and samples were brought to room temperature before use. All standards, 
samples, and controls were assayed in duplicate. The following procedure was performed: 
 
1. 100 µL of assay diluent RD1W was added to each well.   
2. 100 µL of standard, control, or sample was added to each well. The microplate was 
covered with an adhesive strip, and incubated for two hours at room temperature on a 
horizontal orbital microplate shaker set at 500 r.p.m. 
3. Each well was aspirated and washed with wash buffer (400 µL) using an auto-washer; 
repeated three times for a total of four washes. Complete removal of liquid at each step 
was ensured to maintain good assay performance.  
4. 200 µL of Dkk-1 conjugate was added to each well, covered with a new adhesive strip, 
and incubated for two hours at room temperature on the shaker.   
5. The aspiration / wash as in step 5 were repeated.   
6. 200 µL of substrate solution was added to each well, incubated for 30 minutes at room 
temperature on the bench-top and protected from light.   
7. 50 µL of stop solution was added to each well, and gently shaken for 30 seconds to 
ensure thorough mixing.   
8. The optical density of each well was determined immediately using a microplate reader 
set to 450 nm with wavelength correction set to 540 nm to optimise accuracy.   
 
8.4.4.7 Calculation of results 
 
Duplicate readings for each standard, control, and sample were averaged. The average 
zero standard optical density was then subtracted from each of those readings. A 
standard curve was created by reducing the data using Zenit computer software, 
generating a four parameter logistic (4-PL) curve-fit. Since samples were diluted, the 
concentration read from the standard curve was multiplied by the dilution factor of eight.  
 
8.4.4.8 Sensitivity, linearity, calibration and specificity of the Dkk-1 assay 
 
The manufacturer kit insert states that 179 assays were evaluated and the minimum 
detectable dose (MDD) of Dkk-1 ranged from 0.94-15.6 pg/mL. The mean MDD was 4.2 
pg/mL. The MDD was determined by adding two standard deviations to the mean optical 
density value of twenty zero standard replicates and calculating the corresponding 
concentration. To assess the linearity of the assay, samples containing and/or spiked with 
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high concentrations of natural Dkk-1 were serially diluted by the manufacturer with the 
appropriate calibrator diluent to produce samples with values within the dynamic range of 
the assay. Assay sensitivities and ranges according to the manufacturers’ information are 
summarised in Table 8.1. 
 




Dkk-1: Dickkopf 1 OPG: osteoprotegerin   MMP-3: matrix metalloproteinase 3      M-CSF: macrophage colony stimulating factor 
 
The manufacturer states that this immunoassay is calibrated against a highly purified Sf 
21-expressed recombinant human Dkk-1 produced at R&D Systems. The assay 
recognises oligomeric forms of natural and recombinant human Dkk-1. Factors listed 
below were prepared at 50 ng/mL in calibrator diluent and assayed for cross- reactivity. 
Preparations of the following factors at 50 ng/mL in a mid-range recombinant human Dkk-
1 control were assayed for interference. No significant cross-reactivity or interference was 
observed with recombinant human: β-Catenin; Cerberus; Dkk-3; Dkk-4; Kremen-1; 
Kremen-2; LRP-6; Soggy-1; WIF-1.  
 
8.4.4.9 Intra-assay reliability 
 
The concentration of each biomarker was measured in duplicate for 651 samples. The 
coefficient of variation (CV) percentage for each sample was calculated by dividing the 
duplicate standard deviation (SD), by the duplicate mean, then multiplying by 100 [340, 
341]. Any sample with a CV >15% was re-assayed until the CV was ≤15%. The intra-
assay CV% for one experiment was calculated as the mean of the individual CV%s for 
that one experiment. The mean intra-assay CV% for a biomarker was calculated as the 
mean CV% for each experiment [340, 341]. These formulae are summarised below. 
 
CV% for each sample = [ duplicate SD / duplicate mean ] x 100 
 
Intra-assay CV% for one experiment = mean CV% for that experiment 
  
Intra-assay CV% for a biomarker = mean CV% for each experiment 
Biomarker Sensitivity (ng/ml) Assay range (ng/ml) 
Dkk-1 0.015  0.031, 2.000  
M-CSF 0.047 0.078, 5.000  
MMP-3 0.045 0.156, 10.000  
OPG <0.002 0.016, 1.000  
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8.4.4.10 Inter-assay reliability 
 
To monitor plate-to-plate variation, one control sera was used as an internal-control and 
run in duplicate on every plate run for that biomarker. The inter-assay CV was calculated 
using the following formula [340, 341]: 
 
Inter-assay CV = [ (SD of plate means) / (mean of plate means) ] x 100 
 
 
1.1.1 Statistical analysis 
 
A variety of statistical methods were used to analyse the data, determined by the nature of 
the data and the comparison being made. Therefore specific statistical methods are 
detailed at the beginning of each results section. Data are presented as mean, median, 
inter-quartile range (IQR), standard deviation (SD), odds ratio (OR), adjusted OR (ORadj), 
95% confidence interval (95% CI), and p-value, as appropriate to the data. The alpha-
level for statistical significance was set at 0.05.  
 
Data were analysed by Ms. Amelia Jobling (AJ; PhD Research Assistant, Department of 
Pharmacy and Pharmacology, University of Bath) using ‘R’ [252], under the guidance of 
Dr. Gavin Shaddick (GS; Reader, Department of Mathematical Sciences, University of 
Bath). Apart from the multinomial logistic regression, all other analyses were subsequently 
repeated by DJ using STATA 12.1 (2011 Texas, USA) to ensure familiarity with the 





  212 
 
8.5 RESULTS 
Demographic and clinical characteristics of the HC and disease groups are detailed in 
Table 8.2. Statistical comparisons were not made between groups, as these data are for 
descriptive purposes only. The HC group was sex and age-matched to the PsA cohort 
and this is reflected in the data. The parameters varied between the groups, and since the 
literature suggests that some of these parameters can influence biomarker 
concentrations, we proceeded to compare biomarkers concentrations with these 
parameters, to guide our choice of covariates to include in the regression models.  
 
 
Table 8.2. Demographic and clinical characteristics of the healthy control and 
disease groups  
 
 






















































































Male sex 26 (52.00) 102 (51.00) 66 (51.97) 74 (63.25) 118 (75.16) 
Anti-TNF used n/a 26 (13.00) 47 (37.01) 53 (45.30) 59 (37.58) 
HLA-B27 positive n/a n/a 9 (7.09) 47 (40.17) 140 (89.17) 
 
HC: healthy control   PsC: psoriasis without arthritis  PsSpA: psoriatic spondyloarthropathy  
pPsA: peripheral PsA   AS: ankylosing spondylitis  IQR: interquartile range  
n/a: not available / applicable   n: number / proportion   BMI: body mass index   
CRP: C-reactive protein  ASDAS: AS disease activity score  HLA: human leucocyte antigen  
Anti-TNF: anti-tumour necrosis factor drug sDMARD: synthetic disease modifying anti-rheumatic drug   
 
 
All samples (HC and disease) were run in duplicate. The majority of Dkk-1, M-CSF and 
MMP-3 duplicate sample achieved a CV ≤15% on the first run, and very few needed to be 
re-assayed to achieve a CV ≤15%. With the OPG duplicate samples, despite up to four 
runs, a sample CV ≤15% was not achieved in 48 subjects. Therefore OPG serum 
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concentrations were available for analysis in 603/651 subjects (41/50 HC,143/157 AS, 
108/127 pPsA, 117/118 PsSpA, and 194/200 PsC subjects).  
 
8.5.1 Example standard curve for Dkk-1 
 
An example standard curve from one Dkk-1 experiment is shown in Figure 8.6. The curve 
is straight, the duplicate standards show good precision, and the standards used cover 
the range of concentrations expected (based on the literature review) for Dkk-1 in our HC 
and disease samples. These observations support the reliability of the experiment. 
 
Figure 8.6. Standard curve for Dkk-1 in 47 PsA cases 
8.5.2 Intra-assay and inter-assay reliability 
 
Each of the four biomarkers were within the accepted intra-assay CV% of ≤10%, and 
within the accepted inter-assay CV% of ≤15% (Table 8.3) [340, 341].  
 
Table 8.3. Intra- and inter-assay reliability of each biomarker 
Biomarker Intra-plate assay CV% (SD) Inter-plate assay CV% 
Dkk-1 3.22 (0.58) 4.9 
M-CSF 3.88 (1.01) 7.1 
MMP-3 2.17 (0.23) 6.3 
OPG 7.56 (2.11) 9.2 
 
CV%: coefficient of variation percentage SD: standard deviation   Dkk-1: Dickkopf 1    
OPG: osteoprotegerin    MMP-3: matrix metalloproteinase 3  M-CSF: macrophage colony stimulating factor 
 
8.5.3 Biomarker concentrations in the cohort 
 
Serum concentrations of the biomarkers in the HC and disease groups, as well as for the 
entire cohort, as detailed in Table 8.4. Serum concentrations were not normally distributed 
  214 
 
(all positively skewed, at both group and cohort level) (Figure 8.7). Therefore a logarithmic 
transformation was applied prior to comparison of concentrations across groups.  
  
Table 8.4. Biomarker concentrations in the cohort 
 
Group 
Dkk-1 (ng/ml) M-CSF (ng/ml) MMP-3 (ng/ml) OPG (ng/ml) 
Median IQR (range) Median IQR (range) Median IQR (range) Median IQR (range) 
HC 3.52 2.72, 4.460 
(0.24, 9.58) 
0.81 0.41, 0.99 
(0.12, 2.65) 
16.67 9.74, 20.64 
(4.57, 33.19) 
0.153 0.116, 0.173 
(0.063, 0.631) 
PsC 2.50 1.87, 3.42 
(0.37, 23.01) 
0.62 0.25, 0.88 
(0.05, 2.60) 
13.13 9.52, 18.37 
(4.49, 329.55) 
0.165 0.130, 0.211 
(0.042, 2.540) 
pPsA 3.03 1.93, 3.69 
(0.28, 33.37) 
0.29 0.16, 0.68 
(0.05, 2.40) 
16.54 11.77, 26.84 
(4.28, 131.19) 
0.190 0.118, 0.285 
(0.038, 3.882) 
PsSpA 3.34 2.43, 4.44 
(0.57, 12.92) 
0.27 0.17, 0.64 
(0.02, 1.46) 
19.83 11.32, 29.60 
(1.28, 113.62) 
0.165 0.121, 0.244 
(0.038, 1.490) 
AS 3.51 2.92, 4.58 
(1.73, 40.67) 
0.32 0.17, 0.58 
(0.05, 2.21) 
19.73 14.90, 28.02 
(3.01, 1141.27) 
0.165 0.102, 0.221 
(0.038, 0.988)  
Cohort 
  Median 
  IQR 


















HC: healthy control  PsC: psoriasis-only  pPsA: peripheral PsA  AS: ankylosing spondylitis  
PsA: psoriatic arthritis   PsSpA: psoriatic spondyloarthropathy   IQR: interquartile rangeDkk-1: 
Dickkopf 1   OPG: osteoprotegerin   MMP-3: matrix metalloproteinase 3  
M-CSF: macrophage colony stimulating factor   
 
 
DKK-1: Dickkopf 1   M-CSF: macrophage colony stimulating factor  OPG: osteoprotegerin  
MMP-3: matrix metalloproteinase 3 HC: healthy control    PsC: psoriasis-only  
pPsA: peripheral PsA   AS: ankylosing spondylitis    PsA: psoriatic arthritis    
PsSpA: psoriatic spondyloarthropathy 
 
Figure 8.7. Biomarker concentrations across the five groups  
(serum concentrations were not normally distributed; all positively skewed, at both group 
and cohort level) 
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8.5.4 Biomarker levels in healthy controls compared with disease groups  
8.5.4.1 Analysis of covariates 
 
Analyses were performed to determine if the serum concentrations of biomarkers are 
affected by the following covariates: sex, age at blood sampling, disease duration at blood 
sampling, anti-TNF use, body mass index (BMI) and HLA-B27 positivity. Since all serum 
concentrations were positively skewed a logarithmic transformation was applied before 
using linear regression to test the effect of the continuous covariates (e.g. age, disease 
duration and BMI) followed by multiple linear regression to adjust for the other nine 
covariates. Logistic regression was used for binary covariates (e.g. sex and anti-TNF 
use), both unadjusted and adjusted for the other nine potential covariates.  
 
On multivariate analyses, the concentration of MMP-3 (regression coefficient, beta 0.01; 
p=0.04) and OPG (beta 0.01; p<0.0001) increased with each year of age (Table 8.5). M-
CSF and Dkk-1 were not influenced by age at blood sampling. Sex had a significant effect 
on MMP-3 concentrations, with men likely to have lower MMP-3 concentrations than 
women (adjusted OR, ORadj 0.91; 95% CI 0.83, 0.99; p<0.0001) (Table 8.5). No other 
biomarkers were influenced by sex. Disease duration at blood sampling, anti-TNF use (at 
cohort level), and BMI were not associated with serum concentrations of any of the four 
biomarkers (Table 8.5).  
 
A few studies in AS have shown that anti-TNF use influences biomarker concentrations (in 
particular Dkk-1, MMP-3 and M-CSF), both when comparing anti-TNF users to non-users 
cross-sectionally [282, 342], and when comparing patients before and after commencing 
anti-TNF longitudinally [260, 285, 295, 317, 332]. One study showed that the effect of anti-
TNF use can be differential between diseases, e.g. anti-TNF causes Dkk-1 to rise in AS 
patients, but fall in RA patients [280]. Given that these findings have not been consistent 
across studies, we compared concentration of each of the biomarkers in anti-TNF users 
and non-users, separately in the four disease groups. Univariate analyses of each of the 
four disease groups, demonstrated no statistically significant difference in biomarkers 
concentrations in patients using and not-using anti-TNF therapy (Table 8.6).  
 
HLA-B27 status data was available for AS, PsSpA and pPsA cases, but not for PsC or HC 
subjects. HLA-B27 status was not associated with serum concentrations of any of the four 
biomarkers, when analysed for each of the three disease groups separately, using both 
univariate and multivariate analyses (Table 8.7). Therefore, in order to minimise noise and 
as it was not available in all groups, HLA-B27 was not included in the regression models 
comparing HC with disease, or disease with disease. 
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Table 8.5. Association of potential covariates with serum concentrations of the biomarkers  
 
 
Dkk-1 M-CSF MMP-3 OPG 
 


























Age 0.72 (0.27, 10.74) 0.56* 
0.59 
(0.07, 4.73) 0.62** 
4.25 
(1.27, 14.21) 0.02* 
0.94 
(0.22, 3.96) 0.94** 
26.08 
(5.79, 117.44) <0.001 
6.43 
(1.30, 31.89) 0.02** 
289.11 








(0.06, 3.29) 0.42* 
4.45 
(0.54, 36.41) 0.16*** 
44.10 
(11.97, 162.41) <0.001* 
4.64 
(1.13, 18.99) 0.03*** 
3.01 
(0.58, 15.67) 0.19 
3.59 
(0.67, 18.53) 0.14*** 
8.60 
(1.28, 57.77) 0.03 
0.66 
(0.11, 4.08) 0.65*** 
BMI 1.38 (0.54, 3.53) 0.50* 
0.87 
(0.35, 2.18) 0.77**** 
1.58 
(0.85, 2.96) 0.15* 
1.45 
(0.78, 2.70) 0.24**** 
0.76 
(0.37, 1.58) 0.46 
0.61 
(0.30, 1.24) 0.17**** 
1.34 
(0.62, 2.90) 0.46 
1.38 
(0.64, 2.96) 0.41**** 
 
OR (95% CI) p- value OR (95% CI) p-value OR (95% CI) 
p- 
value OR (95% CI) p-value OR (95% CI) 
p- 
value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Sex 0.94 (0.71, 1.25) 0.68^ 
1.07 
(0.78, 1.46) 0.68^ 
0.92 
(0.76, 1.11) 0.38^ 
1.00 
(0.81, 1.23) 0.97^ 
0.14 
(0.10, 0.20) <0.001^ 
0.14 
(0.10, 0.20) <0.001^ 
1.02 
(0.78, 1.33) 0.88^ 
1.18 




(1.01, 1.89) 0.05^ 
1.17 
(0.79, 1.73) 0.43^^ 
0.79 
(0.64, 0.97) 0.02^ 
1.05 
(0.81, 1.36) 0.71^^ 
1.08 
(0.84, 1.39) 0.55^ 
1.04 
(0.77, 1.41) 0.79^^ 
0.82 
(0.61, 1.11) 0.20^ 
0.91 
(0.65, 1.27) 0.58^^ 
 
Beta: regression coefficient  SEM: standard error of mean   anti-TNF: anti-tumour necrosis factor-alpha  BMI: body mass index 
Dkk-1: Dickkopf 1    M-CSF: Macrophage colony stimulating factor  MMP-3: Matrix metalloproteinase 3   OPG: osteoprotegerin 
 
* linear regression model (unadjusted) 
** reverse-stepwise linear regression model (reduced model adjusted for: MMP-3, anti-TNF use, BMI, and disease duration) 
*** reverse-stepwise linear regression model (reduced model adjusted for: age and BMI) 
**** reverse-stepwise linear regression model (reduced model adjusted for: MMP-3, age, disease duration, and ASDAS) 
^ reverse-stepwise logistic regression model (unadjusted) 
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Table 8.6. Biomarker concentrations in anti-TNF non-users vs. users, in each of the 
four disease groups 
 
 


















AS 1.04 (0.95, 1.14) 0.36  
0.71  
(0.28, 1.80) 0.47 
1.00  
(1.00, 1.00) 0.82 
0.07 
(0.01, 2.19) 0.13 
PsSpA 1.14 (0.95, 1.36) 0.17  
0.61 
(0.18 2.03) 0.42 
0.99  
(0.97, 1.02) 0.58 
0.82 
(0.08, 8.51) 0.87 
pPsA 0.84 (0.62, 1.12) 0.23  
1.20 
(0.49 2.97)  0.69 
0.99  
(0.97, 1.01) 0.49 
1.77 
(0.71, 4.38) 0.22 
PsC 0.97  (0.78, 1.22) 0.82  
0.72  
(0.30 1.71) 0.45 
0.98  
(0.93, 1.03) 0.42 
0.74  
(0.05, 10.98) 0.83 
 
Dkk-1: Dickkopf 1    M-CSF: Macrophage colony stimulating factor   
MMP-3: Matrix metalloproteinase 3  OPG: osteoprotegerin 
anti-TNF: anti-tumour necrosis factor-alpha 
 






Table 8.7. Biomarker concentrations in HLA-B27 negative vs. positive cases, in 
each of the three SpA disease groups 
 
 


















AS 0.89 (0.31, 2.58) 0.83 
0.74 
(0.39, 1.42) 0.37 
1.20 
(0.56, 2.55) 0.64 
1.06 
(0.48, 2.38) 0.88 
PsSpA 2.44 (0.85, 5.18) 0.12 
0.96 
(0.61, 1.52) 0.86 
0.97 
(0.56, 1.67) 0.90 
0.57 
(0.29, 1.09) 0.09 
pPsA 1.01 (0.31, 3.32) 0.99 
1.07 
(0.48, 2.41) 0.86 
1.44 
(0.52, 3.99) 0.48 
1.66 




















































pPsA 1.01 (0.31, 3.32) 0.99^ 
1.07 
(0.48, 2.41) 0.86^ 
1.44 
(0.52, 3.99) 0.48^ 
1.66 
(0.78, 3.53) 0.19^ 
 
anti-TNF: anti-tumour necrosis factor-alpha  Dkk-1: Dickkopf 1  OPG: osteoprotegerin 
M-CSF: Macrophage colony stimulating factor   MMP-3: Matrix metalloproteinase 3 
 
* linear regression model (unadjusted)  
** reverse-stepwise linear regression model (reduced model adjusted for disease duration and BMI) 
*** reverse-stepwise linear regression model (reduced model adjusted for sex, age, disease duration, and OPG) 
**** reverse-stepwise linear regression model (reduced model adjusted for sex, age, and disease duration) 
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8.5.4.2 Comparison of biomarkers concentrations with C-reactive protein 
 
Linear regression was performed to determine if C-reactive protein (CRP; a validated 
biomarker of inflammation) correlates with each of the four biomarkers, and should 
therefore be included as a covariate in the regression model. Analyses were performed 
separately for each arthritis disease group (AS, PsSpA and pPsA; CRP was not available 
in the PsC cases) and are shown in Table 8.8, and plotted in Figure 8.8. In AS patients, 
CRP was positively associated with Dkk-1 (beta 1.22; standard error of the mean, SEM 
0.25; p=2x10-6), M-CSF (beta 16.49; SEM 2.92; p=1x10-7), and MMP-3 (beta 0.04; SEM 
0.01; p=1x10-6), and negatively associated with OPG (beta -25.61; SEM 8.74; p=0.004). In 
PsSpA patients, CRP was positively associated with MMP-3 (beta 0.18; SEM 0.05; 
p=0.001) only. In pPsA patients, CRP was positively associated with MMP-3 (beta 0.16; 
SEM 3.51; p=0.001) only. In summary, MMP-3 was the only biomarker associated with 
CRP, across all three arthritis disease groups. Dkk-1, M-CSF, and OPG were associated 
with CRP only in the AS group.  
 
 
Table 8.8. Relationship between biomarker concentration and CRP concentration, in 
each of the three SpA groups 
 










AS 1.22  (0.25) 2x10
-6 16.49 
(2.92) 1x10
-7 0.04 (0.01) 1x10
-6 -25.61 (8.74) 0.004 















beta: regression coefficient   SEM: standard error of the mean  Dkk-1: Dickkopf 1   
M-CSF: Macrophage colony stimulating factor  MMP-3: Matrix metalloproteinase 3 OPG: osteoprotegerin 
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Figure 8.8. Chart showing the relationship between biomarker concentration  
[see legend box on right] and CRP concentration [x-axis] in each of the SpA groups [pPsA 
top-row; PsSpA middle-row; AS bottom-row] 
 
8.5.4.3 Comparison of biomarkers concentrations with ASDAS 
 
Linear regression was performed to determine if the Ankylosing Spondylitis Disease 
Activity Score (ASDAS; a validated measure of axial arthritis disease activity) correlates 
with each of the four biomarkers, and should therefore be included as a covariate in the 
regression model. Analyses were performed separately for each arthritis disease group 
(AS, PsSpA and pPsA; CRP was not available in the PsC cases) and are shown in Table 
8.9, and plotted in Figure 8.9.  
 
In AS patients, ASDAS was positively associated with Dkk-1 (beta 0.07; SEM 0.02; 
p=0.003), M-CSF (beta 0.87; SEM 0.25; p=0.001), and MMP-3 (beta 0.001; SEM 0.001; 
p=0.05), and negatively associated with OPG (beta 1.66; SEM 0.76; p=0.03). In PsSpA 
patients, ASDAS was positively associated with M-CSF (beta 0.61; SEM 0.31; p=0.05) 
only. In pPsA patients, ASDAS was not significantly associated with any of the four 
biomarkers. Since ASDAS is a more encompassing measure of axial disease activity than 
CRP, it was included in the regression model when comparing biomarker concentrations 
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Table 8.9. Relationship between biomarker concentration and axial disease activity 
(ASDAS), in each of the three SpA groups 
 
































beta: regression coefficient   SEM: standard error of the mean  Dkk-1: Dickkopf 1   
M-CSF: Macrophage colony stimulating factor  MMP-3: Matrix metalloproteinase 3 OPG: osteoprotegerin 







Figure 8.9. Chart showing the relationship between biomarker concentration  
[legend box on right] and axial disease activity (ASDAS) [x-axis] in each of the SpA groups 
[pPsA top-row; PsSpA middle-row; AS bottom-row] 
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8.5.4.4 Biomarker concentrations in healthy controls compared with each of the 
four disease groups 
 
Multinomial logistic regression was used to compare each of the disease groups (PsC, 
pPsA, PsSpA and AS) against the reference HC group, in order to test the null hypothesis 
that biomarker concentrations are similar across each group, i.e. there are no differences 
in biomarker concentrations between HC and pPsA cases. All models were adjusted for 
sex, age at blood sampling, and other biomarkers using a reverse-stepwise method. 
Univariate and reduced-multivariate models are show in Table 8.10, and the results are 
summarised in turn below. 
 
Dkk-1 concentrations were significantly lower in PsC cases compared with HC (ORadj 
0.72; 95% CI 0.61, 0.86; p=2x10-4) (Table 8.10). Dkk-1 concentrations were statistically no 
different in HC compared with pPsA, PsSpA or AS cases. 
 
M-CSF concentrations were significantly lower in pPsA (ORadj 0.14; 95% CI 0.06, 0.32; 
p<1x10-5), PsSpA (ORadj 0.07; 95% CI 0.03, 0.17; p<1x10-8), and AS (ORadj 0.37; 95% CI 
0.16, 0.85; p<1x10-7) cases compared with HC. M-CSF concentrations were statistically 
no different in HC compared with PsC cases. 
 
MMP-3 concentrations were significantly higher in pPsA (ORadj 1.06; 95% CI 1.01, 1.10; 
p=0.02), PsSpA (ORadj 1.06; 95% CI 1.01, 1.11; p=0.02), and AS (ORadj 1.06; 95% CI 
1.01, 1.11; p=0.01) cases compared with HC, with a trend approaching statistical 
significance for higher MMP-3 concentrations in PsC (ORadj 1.05; 95% CI 1.00, 1.09; 
p=0.06) compared with HC. 
 
There was a trend approaching statistical significance for higher OPG concentrations in 
pPsA (ORadj 25.77; 95% CI 0.72, 913.42; p=0.07) compared with HC. OPG concentrations 
were statistically no different in HC compared with PsC, PsSpA or AS cases. There was 
high variance in OPG concentrations, and concentrations were not available on several 
HC subjects. This resulted in very wide confidence intervals. These analyses are likely to 
have been underpowered to detect a difference. 
 
Whilst multinomial logistic regression was used to compare each disease group against 
the HC group, in order to determine whether there were any differences in the 
distributions of each biomarker across all five groups the ‘test for homogeneity’ was used. 
The homogeneity p-value indicates whether the biomarkers have significantly different 
effects when modelling the patient groups separately, whilst controlling for the covariates 
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sex, age at blood sampling and the other biomarkers. MMP-3 (homogeneity p-value 4x10-
4) and OPG (homogeneity p-value 5x10-8) concentrations were significantly different 
across the five groups, but Dkk-1 and M-CSF concentrations were not (Table 8.10).  
 
Table 8.10. Serum bone-turnover biomarkers in the four disease groups compared 
with the reference healthy control group 




95% CI p-value OR per 
ng/ml 
increase 
95% CI p-value 
Dkk-1 
(^ Homogeneity p-value = 0.08) 
PsC 0.71 0.61, 0.84 <1x10-4 0.72 0.61, 0.86 2x10-4 
pPsA 0.84  0.72, 0.99 0.03 0.88 0.74, 1.04 0.14 
PsSpA 0.98  0.87, 1.11 0.74 1.00 0.87, 1.15 0.99 
AS 1.04  0.94, 1.16 0.42 1.10 0.97, 1.25 0.13 
  M-CSF 
(^ Homogeneity p-value = 0.26) 
PsC 0.68  0.39, 1.17 0.16  0.59 0.32, 1.08 0.09 
pPsA 0.19 0.09, 0.39 <1x10-5 0.14  0.06, 0.32 <1x10-5 
PsSpA 0.12 0.05, 0.27 <1x10-6 0.07 0.03, 0.17 <1x10-8 
AS 0.17  0.05, 0.27 <1x10-6 0.37  0.16, 0.85 <1x10-7 
  MMP-3 
(^ Homogeneity p-value = 4x10-4) 
PsC 1.02 0.99, 1.06  0.17  1.05  1.00, 1.09 0.06 
pPsA 1.04 1.01, 1.08 0.02  1.06 1.01, 1.10 0.02 
PsSpA 1.04 1.01, 1.08  0.02  1.06 1.01, 1.11 0.02 
AS 1.05 1.01, 1.08  0.01  1.06 1.01, 1.11 0.01 
  OPG 
(^ Homogeneity p-value = 5x10-8) 
PsC 2.85  0.15, 55.08 0.49 8.80 0.25, 309.42 0.23 
pPsA 8.87 0.46, 169.37 0.15  25.77 0.72, 913.42 0.07 
PsSpA 3.17 0.15, 66.27 0.46  8.72  0.23, 334.50 0.24 
AS 1.14 0.05, 26.82 0.94  4.78 0.12, 198.22  0.41 
 
OR: odds ratio per 1 ng/ml increase in concentration 95%CI: 95% confidence interval 
Dkk-1: Dickkopf 1     M-CSF: macrophage colony stimulating factor  
MMP-3: matrix metalloproteinase 3   OPG: osteoprotegerin (n=143 AS, 41 HC, 108 pPsA, 194 PsC, 117 PsSpA) 
AS: ankylosing spondylitis    PsC: psoriasis without arthritis   
pPsA: peripheral-only PsA    PsSpA: psoriatic spondyloarthropathy 
 
^ Multinomial logistic regression: Homogeneity p-value tests for no difference in the concentration of each biomarker across all 5 groups  
   (adjusted for: sex, age at blood sampling, and the other biomarkers)  
* Multinomial logistic regression comparing HC with each of the 4 disease groups (unadjusted) 
** Multinomial logistic regression comparing HC with each of the 4 disease groups (adjusted for: sex, age at blood sampling, and other 
biomarkers) 
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These analyses indicate that Dkk-1, M-CSF and MMP-3 have different concentrations in 
health compared with disease, and may therefore be biomarkers of pathology. OPG 
concentrations were different across the five groups, as determined by the test of 
homogeneity. It is possible that due to our difficulties achieving a CV% ≤15% in some 
OPG samples, thereby reducing the number of HC and cases with OPG results to 41/50 
and 562/601, respectively, that our analyses comparing each of the disease groups with 
HC were underpowered to detect a difference in concentrations. However, taken together 
these data justify proceeding to compare biomarker concentrations in different disease 
states, as is presented below. 
  
8.5.4.5 Biomarker concentrations in PsSpA compared with AS cases  
 
Logistic regression analyses adjusted for covariates (sex, age at blood sampling, disease 
duration from diagnosis to blood sampling, anti-TNF use at blood sampling, most recent 
BMI and ASDAS at blood sampling) were used to compare each of the four biomarker 
concentrations in PsSpA and AS cases, to determine if any of these biomarkers can be 
used to predict if a patient has PsSpA or AS. Univariate and reduced-multivariate results 
are presented in Table 8.11.  
 
PsSpA cases had significantly lower Dkk-1 concentrations than AS cases (ORadj 0.85 per 
ng/ml increase in concentration; 95% CI 0.74, 0.98; p=0.02) (Table 8.11). Expressed 
differently, for every 1 ng/ml increase in Dkk-1 concentration, the probability of a test case 
being classified as having PsSpA decreases by 15%. Concentrations of M-CSF, MMP-3 
and OPG were statistically no different in PsSpA and AS cases (Table 8.11).  
 
 
Table 8.11. Biomarker concentrations in PsSpA vs. AS cases 
 Unadjusted Adjusted * 
  OR per 
ng/ml 
increase 
95% CI p-value OR per 
ng/ml 
increase 
95% CI p-value 
Dkk-1 0.87 0.77, 0.99 0.04 0.85  0.74, 0.98 0.02  
M-CSF 0.86 0.36, 2.02 0.72 0.78 0.31, 1.92 0.59  
MMP-3 1.00 0.99, 1.00 0.24 1.00 0.99, 1.00 0.17 
OPG 4.63 0.65, 33.30 0.13 3.19 0.44, 22.99 0.25 
 
OR: odds ratio per 1 ng/ml increase in biomarker concentration 95% CI: 95% confidence interval 
Dkk-1: Dickkopf 1     M-CSF: macrophage colony stimulating factor   
OPG: osteoprotegerin      MMP-3: matrix metalloproteinase 3 
 
*Multivariate logistic regression (reduced model adjusted for: sex, age, and disease duration)  
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8.5.4.6 Biomarker concentrations in PsSpA compared with pPsA cases  
 
Logistic regression analyses adjusted for covariates (sex, age at blood sampling, disease 
duration from diagnosis to blood sampling, anti-TNF use at blood sampling, most recent 
BMI, and ASDAS at blood sampling) were used to compare each of the four biomarker 
concentrations in PsSpA (PsA with axial disease) and pPsA (PsA without axial disease) 
cases, to determine if any of these biomarkers can be used to predict if a PsA patient has 
axial disease. Univariate and reduced-multivariate results are presented in Table 8.12.  
 
There was a trend approaching statistical significance for M-CSF concentrations to be 
lower in PsSpA compared with pPsA cases (ORadj 0.50 per ng/ml increase in 
concentration; 95% CI 0.22, 1.11; p=0.09) (Table 8.12). There was also a trend 
approaching statistical significance for OPG concentrations to be lower in PsSpA 
compared with pPsA cases (ORadj 0.28 per ng/ml increase in concentration; 95% CI 0.06, 
1.18; p=0.08). Lower M-CSF and OPG concentrations may therefore predict a higher 
likelihood of having axial disease in PsA. Concentrations of Dkk-1, and MMP-3 were 
statistically no different in PsSpA compared with pPsA cases (Table 8.12) 
 
 
Table 8.12. Biomarkers concentrations in PsSpA vs. pPsA cases 




95% CI p-value OR per 
ng/ml 
increase 
95% CI p-value 
Dkk-1 1.08  0.95, 1.23  0.26  1.06 0.95, 1.19 0.28 
M-CSF 0.55 0.25, 1.21 0.14  0.50 0.22, 1.11 0.09 
MMP-3 1.01 0.99, 1.02 0.31 1.00 0.99, 1.02 0.73 
OPG 0.30 0.08, 1.15 0.08 0.28  0.06, 1.18 0.08 
 
OR: odds ratio per 1 ng/ml increase in biomarker concentration 95% CI: 95% confidence interval 
Dkk-1: Dickkopf 1     M-CSF: macrophage colony stimulating factor   
OPG: osteoprotegerin      MMP-3: matrix metalloproteinase 3 
 
*Multivariate logistic regression (reduced model adjusted for: ASDAS)  
 
8.5.4.7 Biomarker concentrations in PsC compared with PsA cases  
 
Biomarker concentrations in PsC and PsA cases were compared, to determine if any of 
these biomarkers can be used to determine if a psoriatic patient has inflammatory arthritis. 
PsSpA (n=117) and pPsA (n=127) cases were combined into one group comprising 
patients with both psoriasis and arthritis (PsA, n=244) and compared with 200 PsC cases 
with psoriasis but no arthritis. Logistic regression analyses adjusted for covariates (sex, 
age at blood sampling, disease duration at blood sampling, anti-TNF use at blood 
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sampling, and PASI at blood sampling; but not BMI as this was not available for the PsC 
cohort) were used to compare concentrations of each of the four biomarkers in PsC and 
PsA cases. As both groups have psoriasis, skin disease should not be a confounder in 
this model. Univariate and reduced-multivariate results are presented in Table 8.13. 
 
MMP-3 concentrations were significantly higher in PsA (median 17.44 ; IQR 11.79, 26.88) 
compared with PsC (median 13.13; IQR 9.52, 18.37) cases (ORadj 1.02 per ng/ml increase 
in concentration; 95% CI 1.01, 1.03; p=0.0004) (Table 8.13). In other words, the 
probability of a test case being classified as PsA rather than PsC increases by 2% for 
every 1 ng/ml increase in MMP-3 concentration. PsA cases (median 0.28; IQR 0.16, 0.67) 
had significantly lower M-CSF concentrations than PsC (median 0.62; IQR 0.25, 0.88) 
cases (ORadj 0.44 per ng/ml increase in concentration; 95% CI 0.24, 0.82; p=0.01). 
PsA cases (median 3.11; IQR 2.02, 3.75) demonstrated a non-significant trend for higher 
Dkk-1 concentrations than PsC (median 2.50; IQR 1.86, 3.42) cases (ORadj 1.14 per ng/ml 
increase in concentration; 95% CI 0.99, 1.31; p=0.07). OPG concentrations were 
statistically no different in PsA compared with PsC cases. 
 
Table 8.13. Biomarker concentrations in PsA vs. PsC cases 




95% CI  p-value OR per 
ng/ml 
increase 
95% CI p-value 
Dkk-1 1.16  1.03, 1.32 0.02 1.14 0.99, 1.31 0.07 
M-CSF 0.23  0.13, 0.39 <1x10-7  0.44 0.24, 0.82 0.01 
MMP-3 1.01 1.00, 1.03 0.03 1.02 1.01, 1.03 4x10-4 
OPG 2.36 0.80, 6.92 0.12 2.51 0.68, 9.28 0.17 
 
OR: odds ratio per 1 ng/ml increase in biomarker concentration 95% CI: 95% confidence interval 
DKK-1: Dickkopf 1     M-CSF: macrophage colony stimulating factor   
OPG: osteoprotegerin      MMP-3: matrix metalloproteinase 3 
 
*Multivariate logistic regression (reduced model adjusted for: age, disease duration, and PASI)  
 
8.5.4.8 Biomarkers of radiographic axial disease, and determination of the 
influence of psoriasis 
 
Biomarker concentrations in cases with and without radiographic axial disease (RAD) 
were compared. The influence of psoriasis (presence or absence) as a covariate in the 
model was also assessed, in order to test the classification system used in this cohort 
(PsSpA: RAD with psoriasis; and AS: RAD without psoriasis). PsSpA (n=117) and AS 
(n=157) cases both have RAD and were therefore combined into one group (RAD; n=274) 
and compared with the 127 pPsA cases without RAD (non-RAD). Logistic regression 
analyses adjusted for covariates (psoriasis, sex, age at blood sampling, disease duration 
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at blood sampling, anti-TNF use at blood sampling, most recent BMI, and ASDAS at blood 
sampling) were used to compare each of the four biomarker concentrations in RAD and 
non-RAD cases. Univariate and reduced-multivariate results are presented in Table 8.14.  
  
Dkk-1 concentrations were significantly higher in RAD (median 3.42; IQR 2.75, 4.49) 
compared with non-RAD (median 3.03; IQR 1.93, 3.69) cases (ORadj 1.22 per 1 ng/ml 
increase in concentration; 95% CI 1.05, 1.42; p=0.01) (Table 8.14). In other words, the 
probability of a test case being classified as RAD increases by 22% for every 1 ng/ml 
increase in Dkk-1 concentration. OPG concentrations were significantly lower in RAD 
(median 0.16; IQR 0.11, 0.22) compared with non-RAD (median 0.19; IQR 0.12, 0.28) 
cases (ORadj 0.20 per 1 ng/ml increase in concentration; 95% CI 0.05, 0.80; p=0.02). The 
concentrations of M-CSF and MMP-3 were statistically no different in RAD compared with 
non-RAD cases. 
 
Of note, cutaneous psoriasis was not a significant covariate in any of these models; 
suggesting that Dkk-1 and OPG are biomarkers of RAD irrespective of whether a patient 
has psoriasis or not, and therefore Dkk-1 and OPG can be used as biomarkers of RAD in 
spondyloarthritis (SpA) as a whole.  
 
 
Table 8.14. Biomarker concentrations in RAD vs. non-RAD cases 




95% CI p-value OR per 
ng/ml 
increase 
95% CI p-value 
Dkk-1 1.23 1.06, 1.44 0.01 1.22 1.05, 1.42 0.01 
M-CSF 0.60 0.31, 1.17 0.13 0.64 0.32, 1.26 0.19 
MMP-3 1.01 1.00, 1.02 0.20 1.00 1.00, 1.01 0.30 
OPG 0.17 0.05, 0.62 0.01 0.20 0.05, 0.80 0.02 
 
OR: odds ratio per 1 ng/ml increase in biomarker concentration 95% CI: 95% confidence interval 
Dkk-1: Dickkopf 1     M-CSF: macrophage colony stimulating factor   
OPG: osteoprotegerin      MMP-3: matrix metalloproteinase 3 
 
* Multivariate logistic regression (reduced model adjusted for: sex, age, and disease duration. Psoriasis, anti-TNF use, ASDAS & BMI were 
not significant covariates in the model) 
 
8.5.4.9 Biomarkers of psoriatic arthritis mutilans 
 
Of the 201 PsA cases in ADIPSA cohort, it is known from Chapter 7 of this thesis that 
19/201 cases have peripheral radiographic evidence of psoriatic arthritis mutilans (PAM) 
and 182/201 do not have PAM (non-PAM). In Chapter 7 it was found that RAD is far more 
common in PAM compared with non-PAM cases. The concentrations of each of the 
biomarkers were therefore compared in cases with PAM and non-PAM, using a logistic 
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regression adjusted for covariates (RAD, sex, age at blood sampling, disease duration at 
blood sampling, anti-TNF use at blood sampling, most recent BMI, and ASDAS at blood 
sampling). Univariate and reduced-multivariate results are presented in Table 8.15. 
 
Concentrations of each of the four biomarkers were statistically no different in PAM 
compared with non-PAM cases (Table 8.15). 
 
 
Table 8.15. Biomarker concentrations in PAM vs. non-PAM cases  




95% CI  p-value OR per 
ng/ml 
increase 
95% CI p-value 
Dkk-1 0.78 0.52, 1.16 0.22 0.71 0.45, 1.13 0.15  
M-CSF 0.96 0.24, 3.84 0.96 0.64 0.13, 3.19 0.58  
MMP-3 1.01 0.98, 1.03 0.68 0.99 0.97, 1.02 0.56  
OPG 0.70 0.11, 4.33 0.70 0.35  0.004, 25.95  0.63  
  
OR: odds ratio per 1 ng/ml increase in biomarker concentration 95% CI: 95% confidence interval 
Dkk-1: Dickkopf 1     M-CSF: macrophage colony stimulating factor    
MMP-3: matrix metalloproteinase 3   OPG: osteoprotegerin 
 
* Multivariate logistic regression (reduced model adjusted for: radiographic axial disease and disease duration)   
 
 
8.5.5 Relationship between biomarker concentration and radiographic axial disease 
severity / morphology 
 
8.5.5.1 Relationship between biomarker concentration and a composite 
radiographic severity index (PASRI) 
 
Analyses were performed to determine if biomarker concentrations correlate with 
radiographic axial disease (RAD) severity, as measured by the composite Psoriatic 
Arthritis Spondylitis Radiology Index (PASRI), which scores for both osteoproliferation 
(new bone formation) and erosion (bone resorption) in the spine and sacroiliac joints. To 
determine this, flexible modelling of the changes in concentrations in relation to disease 
severity was performed using generalised additive models (gam), using penalised splines 
by Ms Amelia Jobling (AJ). Unlike a linear regression model or Spearman rank correlation, 
a GAM model allows for non-linear relationships to be tested, and chooses the best fit 
model (linear, exponential, quadratic etc.). Unadjusted and adjusted (potentially for sex, 
age at blood sampling, disease duration at blood sampling, anti-TNF use at blood 
sampling, most recent BMI, ASDAS at blood sampling, and other biomarkers) analyses 
are presented in Table 8.16.  
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Figure 8.10 show plots of the modelled relationship between the predicted value of the 
PASRI score as a function of OPG, MMP-3 and M-CSF concentrations in PsSpA patients 
(plots created by AJ). The effects of OPG, MMP-3 and M-CSF concentrations in PsSpA 
patients remained significant when considered independently (p=0.03, p=0.01, and 0.02, 
respectively) and when adjusted for other covariates in a reduced model (sex, anti-TNF 
use and ASDAS) (p=0.03, p=0.002, and 0.01, respectively) (Table 8.16). GAMs do not 
indicate the strength of correlation (e.g. like a Spearman rank correlation Rho value) 
because the correlation can be non-linear (Figures 8.10). However, on further inspection 
of these plots, we see that in Figure 8.10 PASRI score increases with increasing OPG 
concentration along a curved line; a correlation pattern that is clinically meaningful and 
therefore useful. However, in Figure 8.10  the relationship between PASRI and MMP-3 is 
initially a sinusoidal line, which in clinical practice is neither meaningful nor clinically useful 
because it predicts that a patient with an OPG of 2 units can have the same PASRI score 
as a patient with an OPG of 3.8 units, but a lower PASRI score than a patient with an 
OPG of either 1 unit or 2.8 units. Similarly, in Figure 8.10  the relationship between PASRI 
and M-CSF is initially a sinusoidal line, which again in clinical practice is neither 
meaningful nor clinically useful. 
 
 
Table 8.16. Relationship between biomarker concentration and radiographic 
severity (PASRI), in PsSpA and AS cases 
 Dkk-1 M-CSF MMP-3 OPG 
 p-value Adjusted  
p-value 
p-value Adjusted  
p-value 
p-value Adjusted  
p-value 
p-value Adjusted  
p-value 
PsSpA 0.10 0.45 * 0.02 0.01 * 0.01 0.002 * 0.03 0.03 * 
AS 0.61 0.33 ** 0.34 0.96 ** 0.11 0.53 ** 0.28 0.99 ** 
 
Dkk-1: Dickkopf 1   M-CSF: macrophage colony stimulating factor  OPG: osteoprotegerin 
MMP-3: matrix metalloproteinase 3 PsSpA: psoriatic spondyloarthritis   AS: ankylosing spondylitis 
 
Generalised additive model (GAM)  
* GAM (reduced model adjusted for: sex, anti-TNF use and ASDAS) 















Multivariate GAM (reduced model adjusted for sex, anti-TNF use and ASDAS) 
PsSpA: psoriatic spondyloarthritis  PASRI: Psoriatic Arthritis Spondylitis Radiology Index  OPG: osteoprotegerin 
MMP-3: matrix metalloproteinase 3 M-CSF: macrophage colony stimulating factor  
 
Figure 8.10. Relationship between radiographic severity and serum biomarker concentration 
GAM output plot of the relationship between radiographic severity (PASRI) score and OPG 




In AS cases, the multivariate GAM demonstrated no correlation between any of the four 
biomarkers and radiographic severity (PASRI) score (Table 8.16). Correlations between 
the PASRI and biomarker concentrations in PsSpA (and AS separately) were also tested 
using a linear regression model. No statistically significant associations were 
demonstrated (data not shown). 
 
8.5.5.2 Bone-formation biomarker correlation with osteoproliferation burden 
 
Analyses were performed to determine if biomarker concentrations correlate with vertebral 
osteoproliferation burden; as measured by the sum of the facet-joint, bridging 
syndesmophyte, and non-bridging syndesmophyte scores of the PASRI. This was 
performed for PsSpA and AS cases separately. Multivariate GAM were used, allowing for 
the possibility of non-linear relationships between biomarker concentrations and 
osteoproliferation score, and adjusted for covariates (sex, age at blood sampling, disease 
  230 
 
duration at blood sampling, anti-TNF use at sampling, most recent BMI, ASDAS at blood 
sampling, and other biomarkers). Figure 8.11 shows plots of the modelled relationship 
between the predicted value of the osteoproliferation burden score as a function of OPG, 
MMP-3 and M-CSF concentrations in PsSpA patients. The effects of OPG, MMP-3 and M-
CSF concentrations in PsSpA patients remained significant when considered 
independently (p=0.01, p=0.01, and 0.08, respectively) and when adjusted for other 
covariates (reduced model adjusted for sex, anti-TNF use and ASDAS; p=0.01, p=0.002, 
and 0.01, respectively) (Table 8.17). However, on further inspection of these plots, it is 
seen that osteoproliferation burden increases with increasing OPG concentration along a 
curved line; a correlation pattern that is clinically meaningful and therefore useful. 
However, in Figure 8.11  the relationship between osteoproliferation burden and MMP-3 is 
initially sinusoidal, which in clinical practice is neither meaningful nor clinically useful. In 
the same Figure, the relationship between osteoproliferation burden and M-CSF is also 
initially sinusoidal, which in clinical practice is neither meaningful nor clinically useful. No 
significant correlation was demonstrated between any of the biomarkers and 
osteoproliferation burden in AS (Table 8.17). 
 
 
Table 8.17. Relationship between biomarker concentration and osteoproliferation 
burden, in PsSpA and AS cases 
 Dkk-1 M-CSF MMP-3 OPG 
 p-value Adjusted  
p-value 
p-value Adjusted  
p-value 
p-value Adjusted  
p-value 
p-value Adjusted  
p-value 
PsSpA 0.77 0.53 * 0.08 0.01 * 0.01 0.002 * 0.01 0.01 * 
AS 0.82 0.39 ** 0.59 0.34 ** 0.07 0.89 ** 0.85 0.99 ** 
 
Dkk-1: Dickkopf 1   M-CSF: macrophage colony stimulating factor  OPG: osteoprotegerin 
MMP-3: matrix metalloproteinase 3 PsSpA: psoriatic spondyloarthritis   AS: ankylosing spondylitis 
 
Generalised additive model (GAM)  
* GAM (reduced model adjusted for: sex, anti-TNF use and ASDAS) 











Multivariate GAM (reduced model adjusted for sex, anti-TNF use and ASDAS) 
PsSpA: psoriatic spondyloarthritis  Osteoproliferation: osteoproliferation severity OPG: osteoprotegerin 
MMP-3: matrix metalloproteinase 3 M-CSF: macrophage colony stimulating factor  
 
Figure 8.11. Relationship between osteoproliferation severity and serum biomarker 
concentrations 
GAM output plot of the relationship between osteoproliferation severity (PASRI-subdomain) 




8.5.5.3 Bone-resorption biomarker correlation with erosion burden 
 
M-CSF, MMP-3 and Dkk-1 are promoters of bone resorption (e.g. erosion). OPG is an 
inhibitor of bone resorption. M-CSF, MMP-3, Dkk-1 and OPG concentrations were 
compared with vertebral erosion burden (as measured by the grade 1-subscore of the 
PASRI) in PsSpA and AS cases separately. Since vertebral erosions were infrequent in 
both PsSpA and AS cases, there were few PASRI-erosion scores >0. PASRI-erosion 
scores were therefore grouped into two categories: 0 (n=112 in PsSpA; n=150 in AS); and 
≥1 (n=6 in PsSpA; n=7 in AS). Logistic regression analyses were used to compare scores 
in PsSpA and then AS cases, adjusted for covariates (sex, age at blood sampling, disease 
duration at blood sampling, anti-TNF use at sampling, most recent BMI, ASDAS at blood 
sampling, and other biomarkers). 
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In PsSpA cases, Dkk-1 concentration was significantly lower in patients with an erosion 
score ≥1 (ORadj 0.28 for every 1 ng/ml increase in concentration; 95% CI 0.10, 0.80; 
p=0.02) (Table 8.17). No significant correlations were demonstrated between Dkk-1, M-
CSF, MMP-3 or OPG and erosion burden AS cases (Table 8.18). 
 
Table 8.18. Biomarker concentration correlation with erosion burden, in PsSpA and 
AS cases 
  PsSpA AS 






















































OR: odds ratio per 1 ng/ml increase in biomarker concentration 95% CI: 95% confidence interval   
PsSpA: psoriatic spondyloarthritis    AS: ankylosing spondylitis  Dkk-1: Dickkopf 1 
M-CSF: macrophage colony stimulating factor   MMP-3: matrix metalloproteinase 3 
* logistic regression model (unadjusted)  
** logistic regression model (reduced model in PsSpA adjusted for: age at blood sampling) 
*** logistic regression model (reduced model in AS did not have any significant covariates) 
 
 
The key results presented so far are summarised below in Figure 8.12. 
 
ORadj: adjusted odds ratio per 1 ng/ml increase in biomarker concentration  
HC: healthy control   PsC: cutaneous psoriasis-only    PsA: psoriatic arthritis  
pPsA: peripheral psoriatic arthritis  PsSpA: psoriatic spondyloarthritis   AS: ankylosing spondylitis  
RAD: radiological axial disease  PASRI: psoriatic arthritis spondylitis radiology index Dkk-1: Dickkopf 1 
OPG: osteoprotegerin   MMP-3: matrix metalloproteinase 3       M-CSF: macrophage colony stimulating factor  
 
Figure 8.12. Summary of serum-soluble bone-turnover biomarkers in psoriatic disease, as 
shown by this study 
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8.6 DISCUSSION & CONCLUSIONS 
8.6.1 Discussion of MMP-3 results 
 
8.6.1.1 Relationship between MMP-3 and disease groups 
 
Compared with HC, MMP-3 concentrations were significantly higher in AS (ORadj 1.06; 
95% CI 1.01, 1.11; p=0.01), PsSpA (ORadj 1.06; 95% CI 1.01, 1.11; p=0.02), pPsA (ORadj 
1.06; 95% CI 1.01, 1.10; p=0.02) groups, and approached statistical significance to be 
higher in the PsC (non-significant trend ORadj 1.05; 95% CI 1.00, 1.09; p=0.06). Further 
investigation showed that MMP-3 concentrations were significantly higher in PsA 
compared with PsC cases (ORadj 1.02; 95% CI 1.01, 1.03; p=0.0004). However, MMP-3 
concentrations were statistically no different in PsSpA compared with AS cases, PsSpA 
compared with pPsA cases, or RAD compared with non-RAD cases. Collectively, these 
results indicate that MMP-3 is a biomarker of disease, perhaps more specific to arthritis 
rather than psoriasis, and therefore could potentially be used to differentiate psoriatic 
patients with and without arthritis. However, MMP-3 appears not to differentiate different 
forms of arthritis, e.g. peripheral versus axial arthritis, or AS versus PsSpA.  
 
Our results are supported by a study by Chandran et al., who also found that MMP-3 
concentrations are higher in PsA compared with HC (ORadj 1.40; 95% CI 1.12, 1.75; 
p=0.003), a trend for MMP-3 concentrations to be higher in PsC compared with HC (ORadj 
1.15; 95% CI 0.98, 1.35; p=0.09), and that MMP-3 concentrations are higher in PsA 
compared with PsC patients (ORadj 1.28; 95% CI 1.02, 1.60; p=0.03) [88]. Two other 
studies have also shown MMP-3 concentrations to be higher in PsA compared with HC 
[147, 148], and one other study has shown higher MMP-3 concentrations in PsA 
compared with HC [148]. Our results are more reliable that those of Shibata et al. as their 
study had very few female PsA patients, and so comparisons were mainly between male 
PsA patients and HC. Of note, we are the first study to compare MMP-3 concentrations in 
PsSpA patients and HC.  
 
Other studies have compared MMP-3 concentrations in AS and HC. Our results are 
consistent with four other studies that have shown MMP-3 levels to be higher in AS 
patients compared with HC [301, 330, 331]. Two studies found no difference in MMP-3 
concentrations in AS patients and HC [147, 317]. However, we feel that our statistical 
analyses are more robust than those by Ribbens et al. and better powered to detect a 
difference, given that they dichotomised MMP-3 concentrations as being normal or 
abnormal using a cut-off based on two standard deviations from the mean in the HC 
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group. We log-transformed the data then performed adjusted multinomial logistic 
regression. The study by Yang et al. may have been underpowered to detect a difference, 
given that they only had 41 AS and 28 HC subjects [317]. 
 
8.6.1.2 Relationship between MMP-3 and radiographic severity 
 
MMP-3 concentrations were significantly and positively associated with radiographic 
severity (PASRI total; adjusted p-value 0.002), and osteoproliferation burden (PASRI 
domain; adjusted p=0.002). However, a plot of the relationship found it to be an initially 
sinusoidal relationship, and therefore not clinically useful. We are the first reported study 
in both AS and PsSpA to compare MMP-3 levels with axial radiographic severity as 
measured by the PASRI, osteoproliferation burden and erosion burden. Almodovar et al. 
used a related axial radiographic severity score, the BASRI-total (spine and hip), and 
found no cross-sectional correlation with MMP-3 levels in AS patients [337]. A longitudinal 
study of 36 AS patients followed over 22 weeks found that baseline MMP-3 concentration 
does not predict either axial radiographic progression as measured by the mSASSS, or 
new syndesmophyte formation [334]. However, an earlier longitudinal study by 
Maksymowych et al. found that baseline MMP-3 level predicted radiographic progression 
as measured by the mSASSS, whilst other clinical parameters such as CRP, sex, age, 
disease duration and baseline mSASSS did not [303]. 
 
8.6.1.3 Relationship between MMP-3 concentration and anti-TNF use 
 
Our exploratory analyses showed that MMP-3 concentrations are not altered by anti-TNF 
therapy use, either when the four disease groups were analysed separately, or when 
analysed together. We are the first study to make this comparison in PsSpA, pPsA and 
PsC patients. Longitudinal studies in PsA show that MMP-3 levels fall after the 
commencement of anti-TNF therapy [125, 343]. Longitudinal studies in AS patients have 
shown that MMP-3 concentrations decrease within a few weeks of anti-TNF therapy 
commencement [295, 317, 336], and in both clinical responders and non-responders 
[332], although not in axial-only AS patients without peripheral arthritis [335]. Our cross-
sectional rather than longitudinal study design likely explains the conflicting results. A 
longitudinal study is the ideal study design, and our exploratory analyses were mainly to 
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8.6.1.4 MMP-3 results in the context of MMP-3 biology 
 
MMP-3 is produced by chondrocytes, macrophages and fibroblasts in synovial tissue, as 
well as some non-articular tissues [326]. MMP-3 levels have been shown to be four times 
higher in synovial fluid compared with serum in the same AS patients with peripheral 
involvement [317], and a thousand times higher in synovial tissue compared with serum 
samples from the same SpA patients with peripheral involvement [344]. MMP-3 may 
therefore be a biomarker more specific to peripheral synovial-based arthritis, than to axial 
non-synovial (fibrocartilage) arthritis. Studies have shown that in axial SpA patients, MMP-
3 levels are higher in those with peripheral arthritis compared with those without 
peripheral arthritis [331, 344, 345]. In peripheral SpA patients, synovial sub-lining MMP-3 
protein expression best differentiated anti-TNF responders from non-responders, and anti-
TNF users from non-users [346].  
 
In AS patients, MMP-3 has been shown to decrease after the use of anti-TNF therapy 
[295, 317, 332, 335, 336]. However, the results of Arends et al. suggested that this 
phenomena may be more specific to mixed axial-peripheral AS patients rather than axial-
only AS patients [336]. In addition, in studies where response criteria were based on axial 
rather than peripheral disease, MMP-3 levels decreased in both anti-TNF clinical 
responders and clinical non-responders [332]. One might surmise that reductions in MMP-
3 levels may reflect improvement in peripheral synovial inflammation, rather than non-
synovial axial disease. Current peripheral arthritis on examination (tender and / or swollen 
joint) was present in 76% of our PsA and 47% of our AS patients. Whilst our data included 
the number of clinically swollen and tender joints, no measure of joint size or degree of 
inflammation was recorded. Higher proportions, may have had a history of peripheral 
arthritis, especially in the PsA group. Therefore, adjusting for peripheral arthritis in 
regression models comparing, for example AS with PsSpA, may be inappropriate and 
misleading. In part, this may also explain why MMP-3 levels did not correlate in a 
meaningful manner with axial radiographic severity or osteoproliferation burden in our AS 
or PsSpA cases. In our study, very few AS and PsSpA cases had axial erosions, and tests 
for correlation with MMP-3 were probably underpowered. 
 
However, it still seems sensible to have investigated MMP-3 as a biomarker of disease in 
axial SpA (AS and PsSpA) since MMP-3 has been shown to be highly expressed in 
fibroblasts of the annulus fibrosus of intervertebral discs, and in macrophages present in 
granulation tissue of herniated discs [347]. Macrophage infiltrates have been 
demonstrated in the subchondral bone marrow of pathological hypervascular spinal facet 
joints in immunohistochemical studies [348]. Axial skeletal tissue obtained at spinal 
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surgery in AS and osteoarthritis patients and analysed using immunohistochemistry, 
showed invasion of bone at entheseal sites by MMP-1-expressing cells, but not by MMP-3 
expressing cells [349]. In murine models, IL-1 and IL-6 induced MMP-3 expression 
appeared to have a role in bone matrix degradation leading to bone resorption [350]. 
 
Disparity of study results may in part be explained by the analysis kit used. For example, 
Ribbens et al. [147] and Yang et al. [317] used kits that measured three components of 
MMP-3 (pro-MMP-3, active-MMP-3 and MMP-3/TIMPs complex), whereas our kit and that 
used by Chen et al. measured two components (pro-MMP-3 and active-MMP-3). Active-
MMP-3 levels may be the best surrogate of MMP-3 activity. As suggested by data from 
Chen et al., the ratio of MMPs and tissue inhibitors of matrix metalloproteinases (TIMPs) 
may determine whether MMPs degrade ECM to cause joint damage, and therefore be 
more informative than total-MMP-3 [330]. Some assays measure activity of MMP-3 using 
a substrate. The cleavage capacity of MMP-3 is regulated by three phases: synthesis, 
activation and inhibition. Since only active-MMP-3 is able to cleave ECM proteins, the 
ability to measure just active-MMP-3 rather than total-MMP-3 may be more informative, 
particularly in terms of imbalance in the latent / active axis, and abnormal binding between 
active-MMP-3 and TIMPs in pathological states [338]. In addition, since pro-MMP-3 levels 
are usually much higher than active-MMP-3 levels, measuring total MMP-3 may not detect 
subtle pathological differences in active-MMP-3 levels. Currently available commercial 
assays cannot distinguish the pro- and active- forms of MMP-3. Sun et al. recently 
reported developing a highly sensitive and reproducible assay for measuring active-MMP-
3 concentrations in human sera [338]. In that cross-sectional study of both AS and RA 
patients, active-MMP-3 levels correlated with CRP and ESR, but not mSASSS or 
BASDAI, and levels of active-MMP-3 significantly decreased after anti-TNF use mirroring 
clinical improvement. One further complicating factor is that active-MMP binds to carrier 
proteins found in high levels in human serum, e.g. TIMPs and alpha-2 macroglobulin 
[351]. Alpha-2 macroglobulin can capture active-MMP and shield it from detection by 
monoclonal antibody assays [352], and so serum active-MMP levels may falsely appear 
lower than reality.  
 
Our results in the context of clinical practice and future research, will be discussed in more 
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8.6.2 Discussion of M-CSF results 
8.6.2.1 Relationship between M-CSF and disease groups 
 
Compared with HC, M-CSF concentrations were significantly lower in pPsA (ORadj 0.14; 
95% CI 0.06, 0.32; p<1x10-5), PsSpA (ORadj 0.07; 95% CI 0.03, 0.17; p<1x10-8), and AS 
(ORadj 0.37; 95% CI 0.16, 0.85; p<1x10-7) cases. These results indicate that M-CSF is a 
biomarker of disease compared with health. Further exploration showed that M-CSF 
concentrations were significantly lower in PsA compared with PsC cases (ORadj 0.44; 95% 
CI 0.24, 0.82; p=0.01), suggesting that M-CSF may be a biomarker of arthritis in patients 
with psoriasis. M-CSF concentrations were statistically no different in PsSpA compared 
with pPsA, PsSpA compared with AS cases, or RAD compared with non-RAD cases; 
indicating that whilst M-CSF is a biomarker of arthritis, it does not differentiate different 
forms of SpA, e.g. peripheral (pPsA) from axial PsA (PsSpA), or PsSpA from AS. M-CSF 
may not differentiate these diseases because it is in fact a biomarker of a pathological 
process common to these three forms of arthritis, e.g. entheseal disease or bone 
resorption. 
 
Generally in our study, M-CSF concentrations were lower in disease than in HC, and in 
PsA compared with PsC. Along with other covariates, our analyses were adjusted for age 
and disease duration at blood sampling which should have adjusted for patients being in 
different phases (early, middle, or late) of their disease, and adjusted for anti-TNF use 
given that TNF is a known inducer of M-CSF release by osteoblasts. SpA, especially AS, 
is characterised by increased bone resorption in trabecular bone resulting in osteoporosis, 
and one might therefore expect higher M-CSF levels in SpA. However, in SpA paradoxical 
abnormal new bone formation at entheseal sites resulting in syndesmophytes and SIJ 
ankylosis is also observed. The latter phenomena might be explained by an imbalance in 
the metabolic bone axis, with either less bone resorption, more bone formation, or both 
pathological processes simultaneously. Lower M-CSF levels in our SpA patients 
compared with HC and PsC subjects, suggest SpA patients have less M-CSF-related 
bone resorption. This may translate into the typical bone-forming phenotype of SpA. We 
did not measure bone mineral density as a surrogate for osteoporosis in our study, and so 
cannot test the effect of low M-CSF on trabecular bone in our cohort. It is possible that in 
SpA, M-CSF is a less important mediator of trabecular bone resorption than other 
molecules such as OPG and RANKL, and therefore serum M-CSF concentration is not a 
biomarker of trabecular bone resorption. 
 
Few data have been published on M-CSF concentrations in PsA compared with HC. 
Using the same R&D ELISA kits, Dalbeth et al. found higher concentrations of M-CSF in 
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PsA compared with HC (p<0.01), and PsA compared with PsC (p<0.01), but no difference 
in concentrations between PsC and HC [126]. They did not sub-categorise PsA into pPsA 
and PsSpA. Whilst Dalbeth et al. argued that their data suggests M-CSF-induced bone 
loss at peripheral joint sites (M-CSF is a promoter of osteoclast-mediated bone 
resorption), no association was found between M-CSF concentration and the extent of 
systemic bone loss in PsA as measured by bone mineral density. Their results therefore 
do not follow-through on their biological hypothesis. Another hypothesis proposed by 
Dalbeth et al. was that serum M-CSF might promote the survival or release of circulating 
osteoclast precursor cells, rather than differentiation or activity of osteoclasts.  
 
In AS patients, data on serum M-CSF is conflicting; one study showed higher M-CSF 
concentrations in AS compared with HC [319], and another study showed no difference 
[317]. A study from the University of California by C. Yang et al. found no difference in M-
CSF levels in 41 AS and 28 HC subjects [317]. They used the same ELISA kits as we did, 
but their AS cohort was quite different to ours: all AS cases were anti-TNF-naïve; had 
lower mean age than ours (mean 25 vs. median 53 years, respectively); had shorter 
disease duration than ours (mean 6 vs. median 22 years, respectively); and had higher 
disease activity than ours (median BASDAI 5.25 vs. 3.20, respectively). Overall their 
cases appear to have been recent-onset younger AS cases in the initial active stage of 
their disease, compared with our more established cases with a spectrum of disease 
activity and anti-TNF use. Compared with our study, C.Yang et al. had a smaller sample 
size for both cases and HC, and their range of measured M-CSF concentrations in AS 
cases was larger (0.40 to 3.83 ng/ml). Both factors increase the likelihood that their 
analyses had higher statistical error and lower power to detect a difference, than our 
study. Data published in the form of a letter in Annals of the Rheumatic Diseases by P-T. 
Yang et al. from China, showed M-CSF concentrations to be higher in AS compared with 
HC (2.89 vs. 0.18 ng/ml) as part of a secondary sub-analysis [319]. The primary objective 
of the pilot study was determine if M-CSF levels differed in active AS patients taking 
thalidomide or not. The study had a very small sample size (29 AS cases, 10 HC 
subjects), AS patients were male, of young age (approximately 23 years) and of low 
disease duration (approximately 1.8 years). AS patient sampling was selective (all were 
required to have active disease, BASDAI ≥3), and the allocation of thalidomide to patients 
was determined by a desire not to have children, rather than being randomised. All HCs 
were male (age-matched to AS cases) and sampling methods not detailed. Overall, it 
therefore seems inappropriate to compare the results of these studies with ours. 
 
Koths reported that M-CSF has several isoforms, and so ELISA kits using different target 
sites may be prone to interaction with other molecules [353]. The M-CSF ELISA kits we 
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used (R&D Systems, Minnesota, USA) are reported to have no significant cross-reactivity 
with other molecules. This may in part explain disparity between some of our results and 
those of some other studies. 
 
8.6.2.2 Relationship between M-CSF and radiographic severity 
 
We are the first study to compare M-CSF levels with radiographic axial radiographic 
severity, osteoproliferation burden and erosion burden, in PsSpA and AS. Whilst there 
was a statistically significant correlation in PsSpA cases between M-CSF concentrations 
and radiographic severity (PASRI; p=0.01) and osteoproliferation burden (PASRI 
subdomain; p=0.01), plots of these relationships showed them not to be clinically useful. 
Instead of using a generalised additive model (GAM), when forced into a more linear 
model using linear regression, these associations were no longer evident. We found no 
association between M-CSF and erosion burden (PASRI subdomain), in either PsSpA or 
AS cases.  
 
8.6.2.3 Relationship between M-CSF concentration and anti-TNF use 
 
Our exploratory analyses showed that M-CSF concentrations are not altered by anti-TNF 
therapy use, either when the four disease groups were analysed separately, or when 
analysed together. We are the first study to make this comparison in PsSpA, pPsA and 
PsC patients. In AS patients, one longitudinal study testing M-CSF concentrations before 
and after anti-TNF therapy commencement supports our findings [317], but one similarly 
designed study found that M-CSF concentrations decreased after 12 weeks of anti-TNF 
therapy [295]. 
 
Our results in the context of clinical practice and future research, will be discussed in more 
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8.6.3 Discussion of OPG results 
8.6.3.1 Relationship between OPG and disease groups 
 
OPG concentrations were not significantly different in HC compared with the four disease 
groups. Our findings of no difference in OPG concentrations in HC compared with pPsA is 
supported by the results of Dalbeth et al. [126], although different to two studies that found 
higher levels in PsA (not sub-categorised into pPsA and PsSpA) compared with HC [88, 
141]. Just as we found, two other studies also found no difference in OPG concentrations 
in PsC compared with HC [126]. Our findings of no significant difference in OPG 
concentrations in AS compared with HC, is consistent with two other studies [281, 302]. 
Other studies show very mixed results, with three studies showing lower OPG 
concentrations in AS compared with HC [282, 299, 342], and four studies showing higher 
OPG concentration in AS compared with HC [141, 285, 298, 300, 301]. It is possible that 
our OPG analyses were underpowered to detect a difference between HC and disease 
groups. The 95% confidence intervals for comparisons were wide, indicating high 
statistical uncertainty, most likely related to our small sample of HC subjects (n=41); lower 
than the other biomarkers due to some difficulty obtaining satisfactory CV% in duplicate 
samples. 
 
In our study, OPG concentrations were lower in RAD compared with non-RAD cases 
(ORadj 0.20; 95% CI 0.05, 0.80; p=0.02), and on the same spectrum a trend approaching 
statistical significance for OPG levels to be lower in PsSpA compared with pPsA cases 
(ORadj 0.28; 95% CI 0.06, 1.18; p=0.08). To our knowledge, we are the first study to make 
these comparisons. In our study, OPG concentrations were no different in PsSpA 
compared with AS cases, or PsA compared with PsC cases. The latter finding is 
supported by the results of Dalbeth et al. [126]. The general direction of OPG levels being 
lower in patients with axial SpA (RAD vs. non-RAD, and PsSpA vs. pPsA), is in keeping 
with the broad theme demonstrated by three studies showing significantly lower OPG 
levels in AS compared with HC, in particular the well-designed large sample-size (264 AS 
cases and 240 age-matched HC) study by Franck et al. [282, 299, 342]. Franck et al. also 
found evidence that bone loss (e.g. osteoporosis as measured by low bone mineral 
density) in AS patients was associated with low serum levels of OPG, sex steroid 
hormones, and inflammatory activity; with and lack of compensatory age-related increase 
of OPG serum levels. Their results, were consistent with data from studies of RA patients, 
where low serum OPG levels were considered inappropriately low to counteract enhanced 
bone resorption [354].  
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8.6.3.2 Biology of the OPG results 
 
Our results showing OPG concentrations to be lower in RAD compared with non-RAD 
cases, and in PsSpA compared with pPsA cases make biological sense. Bone resorption 
in SpA occurs at several different sites: axial and peripheral articular sites in the form of 
erosion and osteolysis; and the general skeleton in the form of bone mineral density loss 
resulting in osteoporosis. Compared with the general population, there is an excess 
burden of osteoporosis in both AS patients [264-266], and PsA patients [267, 268], with 
similar prevalence between disease groups. Through the inhibition of RANKL-mediated 
osteoclastogenesis, high OPG levels would reduce bone resorption. If OPG levels are 
low, osteoclastogenesis would be less impeded, and result in more bone resorption in 
trabecular bone (i.e. osteoporosis) and possibly at entheseal insertions into cortical bone 
(e.g. entheseal erosions and / or vertebral corner erosions). The lower levels of OPG we 
found in axial SpA patients (RAD compared with non-RAD, and PsSpA compared with 
pPsA) might manifest as osteoporosis and increasing entheseal-erosions characteristic of 
SpA. In fact, synovial tissue from PsA patients has been shown to express very low 
quantities of OPG and high levels of RANKL, and therefore increased OPG/RANKL-
mediated osteoclastogenesis has been proposed as a possible mechanism for bone 
erosions in PsA [306]. In our study, this translated as would be expected to lower 
circulating serum concentration of OPG. A study of synovial tissue from RA and AS 
patients found higher RANKL expression in tissues with active synovitis than normal 
tissues, and lower OPG expression in RA patients (although not in AS patients) with 
active synovitis than normal tissues [355]. The authors therefore proposed RANKL-
mediated osteoclastogenesis as a mechanism for synovial-based erosions.  
 
Some authors argue that OPG should be higher in diseases characterised by axial and / 
or peripheral osteoproliferation and / or periostitis [88]. The counter-argument is that 
although OPG inhibits bone resorption, this does not necessarily mean that OPG’s effects 
translate further to cause increased entheseal and articular bone formation in the form of 
osteoproliferative syndesmophytes and SIJ ankylosis. High OPG levels may simply lead 
to increased trabecular bone density and subsequent high bone mass. Whilst Grisar et al. 
found elevated levels of OPG in AS and PsA cases compared with HC, they could not 
convincingly explain the biological mechanism for these results [141]. They cited 
osteoblast-upregulation as a reaction to increased bone resorption, and / or reactive TNF-
mediated induction of OPG in inflammatory arthritis as possible explanations. Their own 
uncertainty was evidenced by their comment to interpret their results with caution. 
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Unfortunately, we were unable to measure serum RANKL, as currently available assays 
are not sufficiently reliable. Our study might have been improved had we also measured 
serum RANKL levels, as there is some evidence that the ratio of RANKL:OPG is more 
indicative of axis dysregulation than either biomarker alone [300, 302, 342]. Kim et al. 
showed that whilst OPG is no different in AS compared with HC subjects, the ratio of 
RANKL:OPG was higher in AS due to higher RANKL in AS patients [302]. The imbalance 
of OPG and RANKL, rather than the absolute serum level of each biomarker, may be 
pathogenic in SpA. In addition, we may have found a stronger association between OPG 
and radiographic progression had we tested for correlation using the ratio of OPG:RANKL. 
In a study of RA patients, peripheral radiographic progression was weakly associated with 
RANKL concentrations, not associated with OPG concentrations, but strongly associated 
with the ratio of OPG:RANKL [356]. 
 
8.6.3.3 Relationship between OPG and radiographic severity 
 
We found a statistically significant and clinically meaningful positive correlation in PsSpA 
cases, whereby OPG levels increased with increasing radiographic severity as measured 
by the PASRI (GAM p=0.03), and with increasing osteoproliferation burden as measured 
by the PASRI (GAM p=0.01). Such correlations were not demonstrated in AS cases. We 
are the first study to test for correlation between OPG levels and radiographic severity in 
PsSpA cases, and the first to do so using the PASRI total, osteoproliferation burden 
domain of the PASRI and erosion burden domain of the PASRI. We are the first study to 
use the PASRI for this purpose in AS patients. Maksymowych et al. used the related 
radiographic severity score, mSASSS, in AS patients and found no correlation between 
OPG and two-year radiographic progression in a multivariate model [303].  
 
However, from a biological perspective our results are somewhat difficult to explain. 
Firstly, when comparing HC with disease groups it was concluded that OPG might be a 
biomarker of increased trabecular bone resorption in axial SpA, rather than entheseal / 
articular osteoproliferation. Consequently, there seems to be no biological reason for 
circulating serum OPG to correlate with axial radiographic severity (PASRI total) or 
osteoproliferation burden. As mentioned before, there was limited axial bone erosion, for 
that to be confounding the apparent correlation with radiographic severity (PASRI total). 
Other than the pathogenesis of AS and PsSpA being differentially mediated by OPG, 
which seems unlikely, there appears little reason for a correlation to be seen in PsSpA but 
not in AS. Collectively, this suggests that the correlation of OPG with radiographic severity 
in PsSpA may simply be a chance finding. 
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8.6.3.4 Relationship between OPG concentration and anti-TNF use 
 
Our exploratory analyses showed that OPG concentrations are not altered by anti-TNF 
use, either when the four disease groups were analysed separately, or when analysed 
together. This is somewhat surprising given that TNF-alpha induces Dkk-1, which 
indirectly inhibits osteoblastogenesis-related OPG expression (Figure 8.1). In addition, 
TNF-alpha induces osteoblast expression of RANKL, and one might therefore expect a 
reactive down-regulation of OPG expression in anti-TNF users. We are the first study to 
make this comparison in PsSpA, pPsA and PsC. Our results are supported by Chandran 
et al. who demonstrated no longitudinal change in OPG levels after the commencement of 
anti-TNF in PsA patients [343]. The AS literature is conflicting with some reports of OPG 
levels being lower in anti-TNF-treated patients [282, 285, 342], and other studies reporting 
no difference [295, 304]. The disparity in study findings is likely related to both cross-
sectional and longitudinal study designs being used, and a variety of statistical methods 
used to test for correlation and / or association. Many studies did not adjust for 
confounders as analyses were secondary objectives. 
 
Given the negative feedback loop between OPG and Dkk-1 (Figure 8.1), we performed 
exploratory analyses but found no correlation between OPG and Dkk-1 concentrations in 
either AS, PsSpA or pPsA cases (results not shown; tested using univariate and 
multivariate linear regression, and Spearman rank correlation). 
 
Our results in the context of clinical practice and future research, will be discussed in more 
detail in the next chapter of this thesis, Discussion of Thesis. 
 
 
8.6.4 Discussion of Dkk-1 results 
8.6.4.1 Dkk-1 levels in healthy controls compared with disease groups 
 
Compared with HC, the odds ratios (ORs) for Dkk-1 concentrations steadily increased 
from PsC, to pPsA, to PsSpA to AS following the clinical characteristic of progressively 
increasing axial disease. There was no statistically significant difference in Dkk-1 
concentrations in HC compared with either PsSpA or pPsA cases, but there was a trend 
approaching statistical significance for Dkk-1 to be higher in AS compared with HC (ORadj 
1.10; 95% CI 0.97, 1.25; p=0.13). This latter finding is consistent with the results of three 
other studies, also using R&D ELISA kits, that showed higher Dkk-1 levels in AS 
compared with HC: Daoussis et al. (2.73 vs. 2.38 ng/ml; p=0.04) [280]; Klingberg et al. 
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(2.89 vs. 2.66 ng/ml; p=0.06) [281]; and Wang et al. (4.04 vs. 3.20 ng/ml; p=0.13) [260]; 
and also potentially by a further study that compared 52 SpA cases (number of AS cases 
not stated) with 26 HC (5.79 vs. 3.09 ng/ml; p<0.0001) [282]. Two studies challenge our 
results. Firstly, Taylan et al. showed Dkk-1 concentrations to be no different in AS cases 
and HC, although their Dkk-1 concentrations were very low compared with all other 
reports (median 0.01 ng/ml in AS, and 0.12 ng/ml in HC); and contrary to other studies 
they found that Dkk-1 concentrations were higher in AS patients using synthetic 
DMARD(s) compared with non-users, but no different in AS patients using anti-TNF 
compared with non-users [342]. Both issues question the reliability of the Taylan et al. 
results. A second paper, by Kwon et al. found Dkk-1 concentrations to be lower in AS 
compared with HC (12.31 vs. 20.81 ng/ml; p<0.0001) [285]; although that study had fewer 
AS (n=56) and HC (n=40) cases, and the disease duration of their AS patients was much 
lower than in our study (median 7 vs. 22 years, respectively).  
 
We measured serum total Dkk-1, rather than serum functional Dkk-1 (a measure of the 
amount of serum Dkk-1 binding to its receptor LRP6). In a cross-sectional study, Yucong 
et al. found no difference in serum total Dkk-1 in AS compared with HC, but did find a 
lower concentration of serum functional Dkk-1 in AS compared with HC (9.15 vs. 17.24 
pg/ml; p<0.001) [283].  
 
Our findings of no difference in Dkk-1 concentration in pPsA cases compared with HC, is 
broadly supported by Daoussis et al. who compared PsA with HC [280]. Dalbeth et al. 
found higher Dkk-1 concentrations in the PsA cases compared with HC, but were unable 
to explain the differential direction of Dkk-1 concentrations in PsC (lower) and PsA 
(higher) cases compared with HC, when one might expect the same direction in these two 
related diseases. Several factors might explain the disparity between our results and 
those of Dalbeth et al. Dalbeth et al. did not subcategorise their 38 PsA cases into pPsA 
and PsSpA cases (n=127 and n=118 in our study, respectively), and they had only 12 HC 
compared with our 50 HC. Dalbeth et al. used the less validated R&D Duoset kits which 
requires coating wells with Dkk-1 antibody in-house, compared with the more validated 
R&D Quantikine kits that we used, that had pre-coated wells. In addition, Dalbeth et al. 
stored serum at -20 degrees Celsius, rather than the standard procedure of storing at -80 
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8.6.4.2 Dkk-1 levels across disease groups 
 
RAD cases had significantly higher Dkk-1 than non-RAD cases (ORadj 1.22; 95% CI 1.05, 
1.42; p=0.01). Similarly, a general pattern was seen for Dkk-1 to progressively higher 
along a spectrum of increasing axial disease, for example: AS cases had significantly 
higher Dkk-1 than PsSpA cases (ORadj 1.18; 95% CI 1.02, 1.35; p=0.02); PsSpA cases 
showed a trend for higher Dkk-1 than pPsA cases (ORadj 1.06; 95% CI 0.95, 1.19; 
p=0.28); and PsA cases showed a trend for higher Dkk-1 than PsC cases (ORadj 1.14; 
95% CI 0.99, 1.31; p=0.07). Collectively these results suggest that Dkk-1 concentrations 
increase with progressively increasing axial SpA. Daoussis et al. found higher Dkk-1 
concentrations in AS compared with PsA cases (2.73 vs. 2.44 ng/ml; p=0.05) [280]. We 
are the first study to compare Dkk-1 concentrations in PsSpA and AS, and RAD and non-
RAD cases. Alongside clinical history, examination and imaging, these results indicate 
that Dkk-1 levels could potentially be used in a clinical setting to help differentiate PsSpA 
from AS, SpA cases with and without RAD, and possibly PsA from PsC. Of note, 
cutaneous psoriasis was not a significant covariate in the regression model that showed 
Dkk-1 levels to be higher in RAD compared with non-RAD cases. This indicates that Dkk-
1 may be a biomarker specific to RAD in SpA, independently of cutaneous psoriasis, and 
therefore gives Dkk-1 more clinical utility.  
 
It seems unlikely that significant baseline temporal fluctuations in serum Dkk-1 levels may 
explain the disparity between the results of different studies. Heiland et al, found that 
serum functional Dkk-1 levels were relatively stable over the three time-points spanning a 
three-year period [286]. If found to be a useful biomarker, this characteristic would add to 
the utility of Dkk-1 as a biomarker. 
 
8.6.4.3 Biological explanation of results showing higher Dkk-1 levels in axial-SpA 
 
Given that induction of the Wnt pathway promotes osteoblastogenesis, resulting in 
increased new bone formation, and since Dkk-1 is an inhibitor of the Wnt pathway, one 
might expect Dkk-1 concentrations to be progressively lower along a spectrum of 
diseases with increasing new bone formation (e.g. from PsC, to pPsA, to PsSpA to AS). 
Whilst our Dkk-1 results are contrary to what we might expect from a simple 
understanding of biological pathways, our results are mostly consistent with the results of 
studies in AS and one study in PsA.  
 
As described in detail in the Introduction section of this chapter, Dkk-1 levels may be 
higher in SpA, particularly AS, because Dkk-1 is pathologically dysfunctional. Daoussis et 
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al. found that whilst serum total Dkk-1 levels are higher in AS compared with HC and PsA 
subjects (unadjusted for anti-TNF use), Dkk-1 binds less avidly to LRP6 (as measured by 
the level of functional Dkk-1) in AS compared with both HC and RA [280]. Their 
experiments also showed that in AS serum, despite the increased circulating levels of total 
Dkk-1, at an ex-vivo cellular level, the net effect (stimulatory plus inhibitory) of AS serum 
on the Wnt pathway is stimulatory (abnormal), as compared to inhibitory (normal) in HC 
serum. Daoussis et al. also showed that the addition of an anti-Dkk-1 monoclonal antibody 
to sera from HC led to an increase in active beta-catenin levels, indicating that Dkk-1 is 
acting physiologically to inhibit the Wnt pathway. The same increase in beta-catenin was 
not observed in AS sera, suggesting that the function of Dkk-1 in AS patients may be 
compromised and thus pathological. The authors concluded that Dkk-1 is dysfunctional in 
AS serum, and is therefore unable to inhibit the Wnt-pathway, which in turn has excessive 
bone-forming activity. Their study conclusions explain the progressively higher Dkk-1 
levels along our spectrum patients with increasing axial-SpA. Our AS compared with HC 
subjects, RAD compared with non-RAD cases, and PsSpA compared with pPsA cases 
appear to be expressing more Dkk-1 in an attempt to compensate for the dysfunctional 
Dkk-1. Dysfunctional Dkk-1 is not inhibiting Wnt-pathways as it should, allowing Wnt-
related bone-forming pathways to flourish unimpeded, possibly translating to the 
osteoproliferative phenotype of AS and RAD characterised by axial syndesmophytes and 
ankylosis. 
 
In mouse-models, increased Dkk-1 levels have been associated with increased bone 
resorption in terms of osteopaenia [357], decreased levels with new bone formation in 
terms of trabecular number / thickness and cortical thickness [279], and anti-Dkk-1 
monoclonal antibodies (mAbs) have been shown to induce fusion of sacroiliac joints in 
mice transgenic for TNF [89]. Diarra et al. used a mAb to inhibit Dkk-1, thereby reversing 
the bone-destructive pattern of a mouse model of RA to the bone-forming pattern of 
osteoarthritis. Bone erosion was halted and bony growths (osteophytes) typical of 
osteoarthritis formed. They identified TNF as a key inducer of Dkk-1 in their mouse 
inflammatory arthritis model. These data give further credence to the hypothesis that 
serum Dkk-1 is dysfunctional in our SpA patients, thereby explaining the reactive 
abnormally high serum total Dkk-1 levels detected by our study.  
 
8.6.4.4 Dkk-1 levels in PsC  
 
In our study, Dkk-1 concentrations were significantly lower in PsC compared with HC 
(ORadj 0.72; 95% CI 0.61, 0.86; p=0.0002), which is consistent with the results of Dalbeth 
et al. who found a trend for the same [126], but different to results by Seifert et al. who 
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found Dkk-1 to be no different in PsC and HC [358]. Seifert et al. had much fewer PsC 
(n=46) and HC (n=25) cases than our study and may therefore have been underpowered 
to detect a difference.  
 
We also found a non-significant trend for higher Dkk-1 concentrations in PsA compared 
with PsC cases (ORadj 1.14; 95% CI 0.99, 1.31; p=0.07), which is consistent with the 
findings of Dalbeth et al. (p<0.001) [126]. Dkk-1 levels may be higher in PsA compared 
with PsC, because Dkk-1 is dysfunctional in PsA but not in PsC, and therefore the body 
reacts by increasing expression of serum total Dkk-1 in attempt to compensate for 
biologically-inactive dysfunctional Dkk-1. 
 
As has been presented so far, Wnt-proteins are regulators of cell proliferation / 
differentiation and potentially have a role in innate immune pathway signaling. For this 
reason it may be hypothesised that Wnt-pathways may be involved in non-bone 
pathways, particularly in diseases such as psoriasis, characterised by keratinocytes 
hyperproliferation and altered innate immunity. There is emerging evidence that Wnt-
related beta-catenin is increased in lesional suprabasal psoriatic epidermis [359], and that 
Wnt16B has a role in mediating keratinocyte proliferation [360]. As mentioned earlier, Dkk-
1 through Wnt-pathways regulates skin pigmentation and thickness [277]. Studies have 
demonstrated increased expression of Wnt5a mRNA and Wnt-5a protein psoriatic skin 
lesions [361, 362]. Given that Wnt pathways are known to induce angiogenesis by 
increased synthesis of vascular endothelial growth factor (VEGF) [363], Seifert et al. 
hypothesised that increased Dkk-1 expression in non-lesional psoriatic skin may inhibit 
angiogenesis by antagonising Wnt signaling thus preventing psoriatic plaque formation 
[358]. The Dkk-1 gene is pro-apoptotic, and it has therefore been hypothesised that 
altered Dkk-1 gene expression may lead to lower Dkk-1 levels in psoriatic lesions, 
resulting in less cellular apoptosis and keratinocyte hyperproliferation [358]. 
 
8.6.4.5 Relationship between Dkk-1 and radiographic severity 
 
In PsSpA cases we found that Dkk-1 concentrations were lower in patients with vertebral 
erosions than those without erosions (ORadj 0.28; 95% CI 0.10, 0.80; p=0.02). No 
association was found in AS cases. Vascular proliferation in the form of pannus extension 
into articular cartilage and bone, is a critical part of erosion formation in inflammatory 
arthritis. In human embryonic stems cells, Dkk-1 has been shown to play an important role 
in the promotion of synovial angiogenesis, that could potentially lead to inflammatory 
pannus formation, and subsequent erosion [364] . 
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We did not find a correlation in either PsSpA or AS cases, between Dkk-1 concentrations 
and radiographic severity as measured by the PASRI-total, or between Dkk-1 
concentrations and osteoproliferation burden severity as measured by the PASRI-
osteoproliferation domain. These results are unsurprising given that the PASRI-total 
encompasses diametrically opposite pathologies; both osteoproliferation and erosion. 
When analysed separately, a signal was detected for Dkk-1 to be lower in PsSpA cases 
with vertebral erosions than without. However, that result must be taken with caution given 
the low frequency of vertebral erosion in both PsSpA and AS cases. 
 
No other studies have investigated PsSpA cases in terms of  Dkk-1 correlation with axial 
radiographic severity, axial osteoproliferation burden or axial erosion burden. Dalbeth et 
al. compared Dkk-1 concentrations with peripheral radiographic severity in PsA patients; 
finding no correlation between Dkk-1 concentrations and the van Heijde composite score, 
joint space narrowing score, peripheral erosion score, number of joint with 
osteoproliferation, or number of joints with osteolysis [126].  
 
Supporting our results in AS patients, Daoussis et al. found no correlation between Dkk-1 
concentrations and axial radiographic severity using the mSASSS, nor did they find a 
correlation with a peripheral radiographic severity score (the modified Sharp score) [280]. 
Klingberg et al. found significantly lower Dkk-1 concentration (2.78 vs. 3.27 ng/ml; 
p=0.003) in the fourth quartile (mSASSS ≥20) compared with the first quartile (mSASSS = 
0) of the mSASSS severity score [281]. This statistical difference was only found by 
categorising the mSASSS into quartiles, rather than treating it as continuous variable, as 
we did for the PASRI. There are no validated severity categories for the mSASSS or 
PASRI, so the use of quartiles was simply for the purpose of statistical modeling, rather 
then being clinically meaningful. We would therefore stand by our decision to compare 
Dkk-1 with PASRI as a continuous variable. 
 
We measured serum total Dkk-1, rather than serum functional Dkk-1. Yucong et al. found 
that serum functional Dkk-1 levels in AS were significantly and negatively associated with 
the mSASSS (r = -0.39; p=0.03), and the New York grading score for sacroiliitis (r = -0.24; 
p=0.04), i.e. Dkk-1 concentration was lower in AS cases with higher mSASSS and higher 
sacroiliitis score [283]. In a longitudinal study by Heiland et al. of 65 TNF-naïve AS cases 
from the German Spondyloarthritis Inception Cohort (GESPIC) cohort, followed with axial 
radiographs at baseline, 1 and 2 years, reported that functional Dkk-1 concentration 
(mean of the three time-points) was significantly lower in patients with syndesmophyte 
growth (n=12) than in patients without (n=37) syndesmophyte growth (4.13 vs. 6.78 pg/ml; 
p=0.03) [286]. Serum total Dkk-1 was no different in patient with and without 
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syndesmophyte growth. The authors proposed that patients with lower baseline functional 
Dkk-1 have less inhibition of the Wnt pathway, and therefore more osteoproliferation in the 
form of syndesmophytes.  
 
8.6.4.6 Relationship between Dkk-1 concentration and anti-TNF use 
 
Given that TNF-alpha is an inducer of Dkk-1 expression by fibroblastic synovial cells and 
neighboring chondrocytes (Figure 8.1), one might predict that anti-TNF agents would 
reduce serum Dkk-1 levels in patients using these agents. However, our exploratory 
analyses showed that DKk-1 concentrations are not altered by anti-TNF use, either when 
the four disease groups were analysed separately, or when analysed together. One might 
surmise that dysfunctional Dkk-1 in SpA does not decrease following anti-TNF therapy, 
like it does in RA, because its dysfunctional structure responds differently to attempted 
induction by TNF-alpha. The published literature has conflicting results. Daoussis et al. 
showed that in AS, cross-sectionally measured Dkk-1 is higher in anti-TNF treated than 
non-treated cases, and when measured longitudinally, Dkk-1 rises following anti-TNF 
therapy [280]. Both findings are contrary to what one might expect given that TNF is an 
inducer of Dkk-1 expression. In the same study, the converse relationship was found in 
PsA and RA patients, whereby Dkk-1 was lower in anti-TNF treated cases, and Dkk-1 
levels decreased following anti-TNF therapy in RA patients [280]. Daoussis et al. 
attempted to explain their Dkk-1 results in AS as being a “counter-balancing mechanism 
to attenuate Wnt signaling, which is turned on following resolution of inflammation in AS”. 
No difference in Dkk-1 concentrations in anti-TNF users and non-users was found in two 
other cross-sectional studies [282, 342], and one longitudinal study [285] of AS cases. 
The role of TNF-alpha in the pathogenesis of AS is not yet understood. Whilst patients 
with AS and PsSpA patients do respond to anti-TNF in terms of pain, stiffness and fatigue, 
data on the effects of anti-TNF therapy on radiographic progression in AS is conflicting, 
with some indicating inhibition of syndesmophyte progression over five years [236], and 
some data suggesting no effect over a shorter period of two years [237, 238]. Perhaps this 
is because the TNF-related Dkk-1 / Wnt pathway is one of several independent pathways 
mediating the pathogenesis of SpA. Pathways such as the transforming growth factor-
beta (TGF-beta) [365] and bone morphogenetic protein (BMP) [281, 366] pathways have 
also been implicated in the pathogenesis of SpA. Lories et al. reported evidence for 
uncoupling of inflammation and joint remodeling in SpA, where anti-TNF did not affect the 
severity or incidence of joint ankylosis in a mouse model of SpA [367]. They proposed 
therefore that the process of entheseal osteoproliferation may be independent of TNF. 
The ‘TNF-alpha brake hypothesis’ proposes that TNF-alpha may act as a molecular 
brake, perhaps through the Wnt-pathway, to inhibit new bone formation [368]. Therefore 
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anti-TNF therapy may actually lead to induction of Wnt signaling in AS. However, in 
humans it has not yet been robustly tested or proven clinically that anti-TNF therapy 
translates to progression of osteoproliferation in SpA.  
 
 
8.6.5 Biomarkers of PAM 
 
None of the four biomarkers had different concentrations in PsA cases with (n=19) and 
without (n=182) psoriatic arthritis mutilans (PAM). This is the first reliable reported study to 
compare serum soluble bone and cartilage-turnover biomarkers in cases with and without 
PAM. Given the severe and extensive bone-remodelling observed in PAM, characterised 
by peripheral articular deep bone resorption resulting in osteolysis, and by extensive 
osteoproliferation (as described in Chapter 7), one might expect bone biomarker 
concentrations to be different in PAM compared with non-PAM. This was not found to be 
the case. This may be explained by one or both of the following reasons. One explanation 
is that the amount of bone remodelling taking place in the relatively small articular joints of 
the hands and feet is insufficient to alter circulating serum levels of bone biomarkers. 
Another explanation is that these patients were sampled during the refractory phase of 
PAM, when the destruction of PAM had passed, and only small-scale remodelling in 
keeping with general PsA was happening. Serum biomarker concentrations were 
therefore in keeping with general PsA. The results from Chapter 7, showing rapidly 
progressive osteolysis soon after the onset of PAM, followed by a tapering of activity, 
would certainly support the second hypothesis. One final, albeit less likely explanation, is 
that the PAM is mediated by metabolic bone pathways not involving Dkk-1, M-CSF, OPG 
or MMP-3. 
 
Only one other study has reported on serum biomarkers in PAM, but their data seem 
unreliable [126]. In a cohort of 38 PsA cases Dalbeth et al. identified some cases that had 
pencil-in-cup deformity on plain radiographs of the hands and feet. Pencil-in-cup deformity 
is a radiographic marker of PAM, and is formed by the combination of osteolysis and 
osteoproliferation either side of an articular surface. Dalbeth et al. reported that M-CSF 
(Spearman r=0.36; p<0.05) and RANKL (Spearman r=0.41; p<0.05) concentrations 
positively correlated with the number of joints affected by pencil-in-cup deformity. 
Concentrations of Dkk-1 and OPG were not found to correlate with the number of joints 
affected by pencil-in-cup deformity. They did not report the number of cases with PAM. 
Given that PAM has an estimated prevalence of 5-6% in PsA cohorts (see Chapter 7), 
one would estimate that only two of their PsA cases had PAM; unless their cohort was 
unselected, and would therefore add bias to their data. In addition, since PAM cases have 
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on average 1-4 osteolytic joints (see Chapter 7), and with such low numbers of PAM 
cases, it is unclear how Dalbeth et al. were able to meaningfully correlate the number of 
joints affected by pencil-in-cup deformity with serum biomarkers concentrations. These 
observations question the reliability of their results. 
 
8.6.6 General discussion of serum biomarkers in SpA 
8.6.6.1 Reasons for disparity in study findings 
 
Disparity between study findings will likely be explained by differences in study cohorts, 
design, and analysis methods. Most studies were cross-sectional which is appropriate for 
HC comparisons with disease groups, and other studies were longitudinal which is more 
appropriate for assessment of biomarker correlation with disease activity. Most studies 
had patients with recent-onset disease, rather than a mixture of both newly diagnosed and 
established disease patients as we did. Almost all of our SpA patients were blood 
sampled in the morning, which may influence some biomarker levels, whilst other studies 
did not state the timing of their venepuncture. We stored samples at -80 degrees Celsius 
and minimised the number of free-thaw cycles, whereas other studies did not. Studies 
used different ELISA kits used, some less validated, and there was varying stringency for 
assay quality control.  
 
Disparity in study findings may in part be explained by a lack of multivariate analyses 
adjusted for potential confounders such as sex, age, disease duration, disease activity, 
pathological phase of disease, medication use, and body mass index. The prospective 
nature of our study allowed us to collect parameters thought to be relevant to biomarker 
testing, and significantly strengthened our analyses. The majority of studies never stated a 
power calculation for their primary analysis, and were likely underpowered to detect a 
difference, particularly for their secondary analyses. Through clinical and biological driven 
a priori hypotheses, we limited the number of comparisons that we made, and therefore 
did not adjust for multiple testing. Many studies have performed a lot of statistical 
comparisons without an a priori hypothesis, and made no adjustment for this. This may 
explain some of the false positive associations in the literature, that we did not 
corroborate. 
 
The concentrations of biomarkers in our large study were not normally distributed. 
However, several studies, even very small studies such as that by Chandran et al. [88], 
reported means and standard deviations for their biomarker concentrations, and 
proceeded to perform parametric tests. Had the authors stated the distribution of their 
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concentrations, then the appropriateness of using parametric tests would have been 
confirmed. A further difference is that we compared biomarker concentrations as a 
continuous variable in different groups. Other studies dichotomised biomarkers as being 
normal or abnormal, on the basis of being two standard deviations from the mean in the 
healthy control group [143, 147]. This approach does not seem robust given that the HC 
sample was often small and perhaps not reflective of the general population. To use such 
a method requires a normally distributed HC sample, which seems unlikely especially if 
small. In addition, dichotomising data in such a way reduces the power of analyses to 
detect a difference between groups, compared with using data in its original continuous 
form. 
 
The phase of disease when serum biomarkers are measured is a potential important 
consideration. Considering AS as a predominantly bone-forming disease, RA as a 
predominantly bone-resorbing disease, and PsA (both pPsA and PsSpA) as having both 
bone-forming and bone-resorbing characteristics, may be over-simplifying the situation 
and not taking into consideration different stages of disease, or concurrent processes in 
the musculoskeletal system. In AS vertebrae, the erosive process at vertebral corners 
(Romanus lesions) can be followed by osteoproliferative events such as vertebral 
sclerosis, vertebral squaring and syndesmophyte formation. In the SIJs, sclerotic changes 
are followed by erosive changes, and then osteoproliferation in the form of SIJ ankylosis. 
Heiland et al. found higher Dkk-1 levels in AS patients with progressive syndesmophytes 
compared with those non-progressive syndesmophytes over a two-year period [286]. 
Research has not yet established whether the syndesmophyte-forming phase happens at 
the same point after disease onset in all AS patients, at multiple time-points, or even 
whether it can be detected by changes in ASDAS or CRP. Our AS and PsSpA cases 
generally had high disease activity, as measured by the ASDAS, BASDAI and PaGA. AS 
patients in other studies had lower, similar and higher disease activity than those in other 
studies. This may explain some of the disparity in study results. It is yet to be established 
whether these activity indices reflect erosive disease, osteoproliferative disease, or both. If 
erosion is the first step in the formation of osteoproliferation, then perhaps ASDAS is 
reflecting global-burden of erosive processes, that will ultimately lead to osteoproliferation. 
Therefore statistical modelling adjusted for these covariates can never completely adjust 
for phase in axial pathology, such as syndesmophyte formation. 
 
In AS and PsSpA there exists a paradox of both osteoproliferation in the axial spine, and 
bone resorption characterised by vertebral erosions, and osteoporosis. Bone loss can 
occur soon after AS onset, with even young AS patients experiencing osteoporotic fragility 
fractures [369]. Therefore, measuring some circulating serum biomarkers e.g. Dkk-1 and 
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M-CSF, may not be sufficiently tissue-specific to indicate pathology at axial tissue-level. 
This may explain why some serum biomarker results do not appear to align with 
anticipated biological pathways.  
 
8.6.6.2 Study critique 
 
This study has several strengths, in particular: the very large sample size compared with 
previously reported studies in PsA and in particular for PAM; the robust case classification 
system employed; no missing data for three of the biomarkers, albeit some missing data 
for OPG; HC samples being age and sex-matched to the PsA cohort; and the quality 
control and rigour of our laboratory experiments. These aspects have improved the 
study’s power, and the reliability of the results. All PsA and AS clinic attendees were 
invited to participate in the study, thereby minimising selection bias, and giving us a broad 
spectrum of recent-onset / established-disease patients, clinically active / inactive 
patients, and younger / older patients. In addition, our hospital is a secondary referral 
centre, rather than a centre receiving high volumes of specialist tertiary-centre referrals. 
This makes our study results more generalisable to SpA patients in other centres, and our 
findings translatable to real-world clinical practice. This is an important tenant for 
biomarker research, especially if intended to be used in clinical practice, rather than just 
for research. 
 
This study has its limitations. The cross-sectional design of this study limits the 
interpretation of our analyses correlating  biomarker concentrations with outcomes such 
as CRP and ASDAS. This would have been better investigated through a longitudinal 
study with biomarkers and outcomes indices measured at several time-points and then 
tested for correlation. However, doing so would have been more time-consuming, costly, 
and enrolment of patients to a study requiring multiple attendance for venepuncture and 
clinical assessment would have hampered recruitment. 
 
Our fifty HC samples were obtained from Health Survey England, and whilst subjects 
contributing these samples were screened for disease and medication use, the reliability 
of these screening methods can not be verified. A higher proportion of our HC samples 
(18%), compared with our disease samples (1-15%) had missing OPG data because 
intra-sample variation (CV%) of ≤15% was difficult to attain. This meant that comparisons 
of OPG levels in HC compared with disease groups may have been less well-powered 
than for other biomarkers. Reassuringly, missing OPG data was relatively proportional 
across the disease groups, likely resulting in similar magnitude and direction of 
confounding. Some of our analyses e.g. comparison of biomarker levels with axial erosion 
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burden, had too few patients with erosions to make robust comparisons, especially 
adjusted comparisons. Caution when interpreting those results is therefore recommended. 
 
Our pPsA, PsSpA and AS samples were only subject to one cycle of freeze-thaw between 
venepuncture and ELISA testing, and were always stored at -80 degrees Celsius. 
However, as HC and PsC samples were sourced from other centres, it is possible that 
they may have been subject to several freeze-thaw cycles, and not always stored at -80 
degrees. This may have resulted in some biomarker degradation in the HC and PsC 
samples. 
 
One must also consider the presence of uncontrolled confounding. As mentioned in 
Chapter 5, despite our best attempts with the data collected, time-varying variables such 
as disease activity (ASDAS), BMI and medications can not been fully adjusted for in 
cross-sectional studies such as this. BMI and medication use change over time. It is not 
known how long these factors impact on biomarker levels, if there is a differential effect 
once certain thresholds of BMI are reached, or if certain anti-TNF agents differentially 
affect some biomarkers. On balance, for these two time-varying variables, the direction 
and magnitude of their confounding is unlikely to be significantly different across the four 
disease groups, and therefore their effect on the results of this study may be minimal.  
 
We also acknowledge that there are unmeasured confounders, of which some we may not 
even be aware. For example, corticosteroid medications have been reported to alter 
MMP-3 levels [147]. We did not collect data on corticosteroid use, as it is difficult to 
comprehensively do so because it is time-varying variable with a variety of doses, modes 
of administration and durations of therapy used. Corticosteroids are less likely to have 
been used in HC, PsC and AS patients compared with pPsA and PsSpA patients. This 
may have confounded the comparisons of MMP-3 levels in these groups. Similarly, oral 
contraceptive pill use, phase of menstrual cycle, diet / meal composition, and timing of 
sample after ingestion have been shown to alter some serum biomarkers [150, 339]. We 
did not collect these parameters. The AS and HC subjects were generally younger than 
the other three groups, so the females in the AS and HC groups may have been more 
likely to have used the oral contraceptive pill, or still be menstruating. This may have 
resulted in differences both within and between groups. The PsC samples were collected 
from patients living in Michigan, who may have had a different diet and / or lifestyle to the 
SpA patients living in south-west England. This may have confounded our comparisons of 
biomarker levels in PsC versus HC, and PsC versus PsA. 
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As mentioned earlier in the Discussion, our results would have been strengthened and 
provided more biological insight had we also measured active-MMP-3 rather than total 
MMP-3, measured functional Dkk-1 and  / or Dkk-1 biological activity rather than just total 
Dkk-1, and measured bone mineral density. 
 
 
8.6.7. Conclusions  
 
We have compared a large cohort of well-characterised PsSpA, pPsA, AS and PsC cases 
with a group of matched HC to determine biomarkers of axial / peripheral inflammatory 
arthritis occurrence, and radiographic severity. OPG appears to be a biomarker of axial 
disease in patients with SpA (pPsA, PsSpA and AS). It can therefore be used to 
differentiate PsSpA from pPsA, and axial-SpA from peripheral-only SpA patients 
independently of psoriasis status. Dkk-1 appears to be a biomarker of axial disease in 
SpA; with a pattern for increasing concentrations along a spectrum of increasing axial 
involvement. It can therefore be used to differentiate PsSpA from AS patients, axial-SpA 
from peripheral-only SpA patients irrespective of psoriasis status, and potentially PsSpA 
from pPsA patients. Both M-CSF and MMP-3 appear to be biomarkers of arthritis, 
differentiating SpA (PsSpA, pPsA and AS) from HC and PsC. However, neither M-CSF 
nor MMP-3 appear to differentiate various forms of SpA, i.e. pPsA, PsSpA and AS. Only 
OPG has shown signals to be a biomarker of radiographic severity and osteoproliferation 
burden, although only in PsSpA, and the clinical significance of this remains be 
determined. No biomarkers for the occurrence of PAM in PsA cases were found. The high 
concentration of Dkk-1 in AS and PsSpA compared with HC, supports previous reports 
that Dkk-1 may be dysfunctional in SpA. Since bone mineral density was not measured, it 
is difficult to determine if these serum biomarkers are reflecting SpA-related pathology in 
trabecular bone, or vertebral corners and sacroiliac joints. In the next chapter, ‘Discussion 
of Thesis’, the wider implications of our results in the context of clinical practice and future 
biomarkers research, will be discussed in greater detail.
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8.7 PUBLICATIONS ARISING FROM THE WORK OF THIS THESIS 
CHAPTER 
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9 CHAPTER IX: DISCUSSION OF THE THESIS 
 
The aims of this thesis were to determine the prevalence and characteristics of psoriatic 
spondyloarthritis (PsSpA) and psoriatic arthritis mutilans (PAM) in a cohort of psoriatic 
arthritis (PsA) patients, and to determine biomarkers of these PsA phenotypes. In the 
order that they relate to the ‘Aims and Objectives’ of this thesis, the key findings of the 
studies comprising this thesis will now be highlighted and discussed, in particular their 
wider meaning in the context of clinical practice and how they may inform future research. 
The Discussion section of each of the earlier chapters have already critiqued the studies 
in this thesis and compared our results with the published literature. Those discussions 
will therefore not be repeated unless specifically relating to a particular theme. 
 
9.1 DISCUSSION OF THESIS OBJECTIVE 1: Prevalence and 
characteristics of psoriatic spondyloarthritis, and a 
comparison with ankylosing spondylitis 
Objective 1(a) of this thesis was to determine the prevalence and characteristics of axial 
involvement (PsSpA) in a PsA cohort, using patient reported outcome measures 
(PROMs), clinical examination and radiographic indices. Objective 1(b) was to compare 
the pattern of axial involvement in PsSpA with that of an ankylosing spondylitis (AS) 
cohort, using PROMs, clinical examination and radiographic indices. A prospective single-
centre cross-sectional study was conducted to achieve these objectives. The key findings 
of the study comparing the clinical characteristics of PsSpA, AS and peripheral-only PsA 
(pPsA) are summarised and discussed below.  
 
• A significant proportion of SpA patients had PsSpA (48.16%). PsSpA therefore 
represents a common and important PsA phenotype to diagnose and manage. The 
robust radiographic and clinical classification system employed in this study 
strengthens the reliability of our estimate of the prevalence of PsSpA in SpA, 
especially when compared with the varied estimates in the published literature. 
 
• PsSpA was often symptomatically-silent but radiographically-evident (25.42%). This  
finding may prompt and justify the baseline and interval screening of PsA patients for 
PsSpA as part of routine clinical care. A prospective longitudinal study investigating 
the natural clinical and radiographic history of such patients is needed, especially to 
determine if there is progression to axial symptoms, restricted metrology, function and 
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/ or disability. This clinical approach would be further justified if future research 
demonstrates that pharmacological and physical therapies halt or temper the 
progression of asymptomatic but radiographically-evident PsSpA.     
 
• A significant proportion of SpA patients fulfilled diagnostic / classification criteria for 
two diseases. The modified New York (mNY) diagnostic criteria for AS were fulfilled by 
48/201 (23.88%) of PsA cases, and the Classification of Psoriatic Arthritis (CASPAR) 
criteria were fulfilled by 49/201 (24.38%) of AS cases. These results question the 
validity of the CASPAR and mNY criteria for use in PsSpA. To prevent the 
misclassification of PsSpA cases as PsA or AS, thereby altering their course of 
management and eligibility for more specialist biological therapies, the inception of 
PsSpA-specific classification criteria should be a high research and clinical priority. As 
discussed in previous chapters, the variety of classification systems used for PsSpA 
has led to varied and conflicting results when comparing the clinical, radiographic and 
genetic characteristics of PsSpA with pPsA and AS. An international consensus 
classification system for PsSpA can only serve to improve clinical care and future 
research efforts. As discussed in chapter 5, the establishment of a ‘SpA clinic’, rather 
than separate PsA, AS and general rheumatology clinics, may improve the ‘patient 
journey’, facilitating correct diagnosis, and both appropriate and timely instigation of 
specialist therapies. Our data does not detail exactly how the PsSpA cases accessed 
anti-TNF therapy, and whether their original diagnoses were reconsidered according 
to clinical need. 
 
• Clinical predictors for a PsA patient developing axial disease (i.e. having PsSpA rather 
than pPsA) included: HLA-B27 positivity, presence of inflammatory bowel disease 
(IBD), younger age at arthritis symptom onset, and higher psoriatic nail disease 
severity as measured by the mNAPSI, in particular nail onycholysis severity. Male PsA 
cases were no more likely to be classified as PsSpA than female patients. As 
discussed in chapter 5, these clinical predictors are biologically plausible, thereby 
adding to the credence of these results. HLA-B27 testing is readily available and 
inexpensive in most hospitals in the U.K.. The other clinical parameters are easily 
determined through history taking and clinical examination. The clinical predictors of 
PsSpA occurrence identified by this study are therefore attainable and feasible in 
clinical practice, and should prompt the identification of PsSpA in symptomatic 
patients and / or screening of asymptomatic patients. The positive predictive value of 
these clinical predictors should be tested during any future inception of a classification 
system for PsSpA. The high prevalence of IBD in PsSpA compared with pPsA patients 
should trigger the investigation and early management of PsA patients with compatible 
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gastrointestinal symptoms. The markedly different prevalence of HLA-B27 positivity in 
PsSpA, pPsA and AS cases does imply that this class I receptor has a pathogenic role 
in PsSpA, but not in pPsA, and perhaps a slightly different pathogenic role in AS. 
Further investigation is warranted, and as will be discussed later in this chapter, the 
role of HLA- and non-HLA genetic variants in PsSpA will be studied as part of post-
doctoral research. 
 
• Function as measured by the BASFI, was poorer in AS compared with PsSpA cases. 
However, AS and PsSpA cases had similarly high disease activity (as measured by 
the ASDAS, BASDAI, and PaGA), similarly poor metrology (as measured by the 
BASMI), and similar disability (as measured by the HAQ). Collectively, these results 
indicate that PsSpA has just as significant a clinical impact on patients as does AS. 
The management of AS has been the focus of much research over the last few 
decades. There has been a dearth of clinical trials for PsSpA. Much has therefore 
been borrowed from AS, in terms of pharmacological and physical therapies, to 
manage PsSpA. This may not be entirely appropriate in light of the clinical, 
radiographic, genetic and serum biomarker differences this thesis has shown exist 
between the two conditions. The clinical impact of PsSpA on patients that we have 
demonstrated, will hopefully serve to emphasise the need and prompt clinical trials 
specifically investigating PsSpA. These results also underline the pressing clinical 
need of PsSpA patients for more intensive therapies, such as biologics, at a level on 
par with AS. The health economics of using such costly agents needs further 
investigation, but will likely be similarly justified. 
 
PsSpA and AS patients were compared in terms of axial radiographic features and 
severity. The specific objectives were to compare: (i) the pattern of radiographic axial 
disease in PsSpA and AS; (ii) the morphological (osteoproliferation and erosion) features 
of radiographic axial disease in PsSpA and AS; (iii) axial radiographic severity in PsSpA 
and AS. The key findings of this radiographic comparison, and their wider impact on the 
clinical care and research of PsSpA are detailed below. 
 
• A significant proportion of PsSpA cases had spondylitis without sacroiliitis (33.05%), 
whilst 38.14% had sacroiliitis with spondylitis, and 28.81% had sacroiliitis without 
spondylitis. The majority of PsSpA cases with spondylitis-alone were symptomatic 
(56.41%); although were less likely to be symptomatic than PsSpA cases with 
sacroiliitis with / without spondylitis. These results are important in the broader context 
of PsA for several reasons. Firstly, spondylitis without sacroiliitis is important clinically 
if the majority of such patients are symptomatic; it is not an incidental finding with no 
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clinical consequence. Secondly, this may indicate that even within PsSpA, axial 
disease can have varying degrees of expression radiographically and in terms of 
symptoms. A prospective longitudinal study with interval radiographs and PROMs is 
needed to clarify if patients with spondylitis-alone, develop sacroiliitis and / or become 
symptomatic. Perhaps most importantly, any international consensus classification 
system for PsSpA developed in the future would need to capture PsSpA patients with 
spondylitis alone. Our results indicate that only classifying PsA patients with sacroiliitis 
as having PsSpA would overlook a significant proportion of symptomatic individuals 
with genuine inflammatory spinal disease. 
  
• HLA-B27 positivity was significantly more likely in PsSpA cases with both sacroiliitis 
and spondylitis, compared with PsSpA cases with spondylitis-alone. Broadly this 
suggests that HLA-B27 has a differential pathogenic role in PsSpA, and may be more 
involved in pathways leading to sacroiliitis rather than spondylitis. As will be discussed 
later in this chapter, I will investigate the role of HLA- and non-HLA genetic variants on 
the radiographic and clinical phenotype expression of PsSpA as part of post-doctoral 
research. 
 
• AS cases were more likely than PsSpA cases to have complete ankylosis of the SIJs, 
and vertebral bridging syndesmophytes. These radiographic features may be more 
useful than paramarginal syndesmophytes, in both clinical and research settings to 
distinguish PsSpA from AS cases [59, 191]. As was discussed in chapter 6, 
subsequent studies [58] found paramarginal syndesmophytes to not be uncommon in 
AS. In addition, paramarginal syndesmophytes can be difficult to distinguish from the 
degenerative osteophytes of osteoarthritis. Our study therefore offers two unique and 
morphologically distinct radiographic features to differentiate PsSpA from AS. These 
findings along with the results on radiographic severity below, give a unique insight 
suggesting that PsSpA does not have the same degree of osteoproliferation as AS; 
with PsSpA-related osteoproliferation less likely to completely bridge the SIJ or 
intervertebral disc space. 
 
• Both PsSpA and AS cases tended to have bilateral symmetrical-grade sacroiliitis, with 
no difference between the two groups in the occurrence of SIJ sclerosis, erosion or 
partial ankylosis, or in terms of cervical vertebrae spondylitis, lumbar vertebrae 
spondylitis, or cervical facet joint fusion. Unlike several previous studies [58, 59, 191], 
our analyses adjusted for both disease duration and age, which allowed us to 
accommodate for potentially different ages at onset of radiographic axial disease in 
PsSpA and AS cases. Previous studies have proposed that unilateral grade 2 
  261 
 
sacroiliitis is common in PsSpA and can therefore be used to classify SpA patients as 
PsSpA. Our results would challenge that position, and favour using a definition of 
sacroiliitis in PsSpA that is consistent with AS (i.e. bilateral sacroiliitis of grade ≥2, or 
unilateral sacroiliitis of grade ≥3). Our results could therefore inform the radiographic 
criteria of any future classification systems for PsSpA. 
 
• Radiographic axial disease was more severe in AS compared with PsSpA, as 
measured by the Psoriatic Arthritis Spondylitis Radiology Index (PASRI), modified 
Stoke Ankylosing Spondylitis Spinal Score (mSASSS), and osteoproliferative burden, 
although not erosion burden. Despite the differences, radiographic axial disease 
severity in PsSpA was not mild; it was clinically important and should be actively 
treated. This is the first study to compare radiographic severity in PsSpA and AS using 
the more PsA-specific PASRI score, and the mSASSS. Our exploratory analyses 
showing moderate-to-good correlation between metrology (BASMI) and axial 
radiographic indices (PASRI and mSASSS) both globally and regionally. However, it is 
notable that this difference in radiographic severity between the two conditions did not 
translate into worse metrology (BASMI), disability (HAQ) or disease activity (ASDAS, 
BASDAI, or PaGA) in AS compared with PsSpA patients. As has been shown to be 
the case in osteoarthritis of the hip and knee [370-372], in PsSpA and AS there also 
appears to be some disassociation between radiographic severity and clinical impact. 
This may in part be explained by the differential impact of pharmacological and 
physical therapies on clinical symptoms compared with radiographic structural 
damage. Unlike magnetic resonance imaging (MRI), plain radiographs do not indicate 
new or active structural damage. As has been discussed in previous chapters, 
patients also have differing degrees of physical, psychological and pain-management 
adaptations to their disease, thereby differentially circumventing their radiographic 
structural damage. In clinical practice, these study results should remind the clinician 
to modify clinical care in PsSpA and AS patients according to clinical symptoms and 
examination, rather than necessarily on the basis of radiographic severity.  
 
9.1.1 Clinical and radiographic research of spondyloarthritis 
 
Correct classification of cohorts is important for research, particularly for biomarker and 
prognosis research. Unlike rheumatoid arthritis which has a more homogenous 
phenotype, PsA is a heterogenous disease, with several distinct phenotypic expressions. 
Given the diversity of diseases under the umbrella term of SpA, further insight into SpA 
will only be learnt if cohorts are carefully characterised clinically, and through imaging and 
biomarkers. The Classification for Psoriatic Arthritis (CASPAR) criteria are a notable 
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example whereby the introduction and uptake of a classification system for PsA, has 
homogenised cohorts and improved the quality of international research. Much has been 
published debating whether clinicians and researchers should be ‘combining’ or ‘splitting’ 
cohorts. Grouping SpAs in a simple manner such as peripheral-SpA and axial-SpA, can 
only impede research of this complex collection of overlapping but distinct diseases. 
‘Combining’ may be appropriate for management pathways where there is much overlap 
in treatment strategies, and homogenising cohorts allows more uniform access to 
treatments, and diagnostic nomenclature is more interpretable for patients and non-
specialists. However, for biomarker and prognosis research I would advocate ‘splitting’ 
and refining cohorts into phenotypes and subphenotypes. When investigating specific 
metabolic bone pathways relating to new bone formation, it would seem sensible not to 
‘combine’ patients who are bone formers with those who are bone resorbers into one 
category, and have a mixed group of quite different subphenotypes.  
 
It could be argued that studies to date have not clinically characterised cohorts well 
enough, and have therefore had limited success in biomarker research. Therein lies the 
strength of this current study, with a highly clinically- and radiographically-characterised 
cohort. Four decades ago, HLA-B27 variants were found to be more common in PsSpA 
compared with pPsA [110]. The results of this thesis, and of two other recent studies 
suggest that the phenotypic expression of PsSpA itself, may be determined by HLA- 
variants and / or their haplotypes [102, 106]. However, relatively little is still known on how 
HLA-B27 variants translate biologically into the phenotype of PsSpA. Such research 
would be impeded by combining SpA cohorts with different phenotype and genotype 
expressions. 
 
An interesting concept that should guide future research of PsA, in particular PsSpA 
research, was proposed by Chandran et al. [61]. Chandran et al. proposed that 
radiographic damage, nail dystrophy, and periostitis might indicate severity of the disease, 
instead of being markers of pathogenic events. As disease severity increased, more 
structures were involved, and so in fact, patients with peripheral arthritis plus axial 
arthritis, periostitis, and nail dystrophy represented the complete PsA disease spectrum, 
whilst patients with a few manifestation represented incomplete PsA [61]. 
 
The knowledge gained from the clinical experience of looking after SpA cases 
longitudinally should not be underestimated, as many characteristics and end-points do 
not lend themselves well to observational medical research. Gladman et al. demonstrated 
disparity between patient-reported (such axial stiffness / pain) and clinician-
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measured clinical indices (such as axial range of movement), and their potential limitation 
for reliability when used in longitudinal studies of PsSpA [34]. 
 
9.2 DISCUSSION OF THESIS OBJECTIVE 2: Prevalence, 
characteristics and natural radiographic history of psoriatic 
arthritis mutilans  
 
Objective 2 of this thesis had three key aims: (i) to determine the prevalence of psoriatic 
arthritis mutilans (PAM) in a cohort of PsA cases; (ii) to compare the clinical 
characteristics of PAM and non-PAM cases in a cohort of PsA cases using PROMs, 
clinical history and radiographic indices; (iii) to determine the natural radiographic history 
of PAM. These objectives were met through the performance of a retrospective cohort 
study of all PsA patients attending a single centre, with a review of all PsA patients’ hands 
and feet radiographs, followed by scoring of sequential radiographs of PAM cases. The 
key study findings are described below. 
• Of 610 PsA cases, 36/610 (5.9%) had PAM.  
• PAM was more likely in PsA cases with psoriatic nail dystrophy, and younger age at 
diagnosis of PsA. Nail dystrophy also predicted more severe osteolysis. 
• Compared with non-PAM cases, PAM cases had more disability (as measured by the 
HAQ), and radiographic axial disease, especially radiographic sacroiliitis.  
• PAM cases were more likely than non-PAM cases to have used a synthetic DMARD, 
but not an anti-TNF agent. Given that 29/33 PAM cases had initiated a synthetic 
DMARD and 4/13 had initiated anti-TNF prior to first demonstration of PAM, within the 
constraints of this study’s design and this being a secondary analyses, it appears 
neither agent prevents the onset of PAM. 
• During follow-up, PAM tended to be progressive from monoarticular to polyarticular 
involvement. Certain joints were more frequently affected. 
• The majority of PAM-related damage occurs soon after the onset of osteolysis, with a 
monophasic pattern of activity. Osteolysis was initially rapid and progressive in the 
hands and feet, tapering later during disease course.  
 
These results in the context of previous research, have already been discussed in chapter 
7 and will therefore not be repeated here. Further research is needed to investigate 
particular aspects of this rare but severely destructive subphenotype of PsA. In particular, 
little is known of the pathogenesis of PAM, serum-soluble and genetic biomarkers of PAM, 
and whether anti-TNF or anti-resorptive agents may offer therapeutic efficacy. Serum 
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soluble bone-biomarkers of PAM have been investigated in chapter 8 of this thesis, and 
the results are summarised below. Genetic biomarkers of PAM and the chronology of 
pathological events leading to PAM have yet to be determined, and I plan to undertake 
this as part of post-doctoral research (see below under heading 9.5). The efficacy of anti-
TNF or anti-resorptive agents for PAM can only be reliably determined through a clinical 
trial. However, given the rarity of PAM and it relatively narrow monophasic period of 
activity, much research may initially need to performed in proof-of-concept animal models 
of PAM. Knowledge of abnormal immune pathways involved in the pathogenesis of PAM, 
through serum and genetic biomarker studies, as provided by this thesis, would certainly 
guide and facilitate that research. 
 
 
9.3 DISCUSSION OF THESIS OBJECTIVE 3: Serum-soluble bone-
turnover biomarkers of psoriatic spondyloarthritis  
9.3.1 Systematic review of the literature on serum-soluble bone and cartilage-turnover 
biomarkers in PsA and PsSpA 
 
A systematic review of the literature on serum-soluble bone and cartilage-turnover 
biomarkers in PsA and PsSpA was performed. The key findings of the systematic review 
are described below. 
• No studies have investigated serum bone and cartilage-turnover biomarkers in PsSpA; 
either as a primary objective, or as part of secondary analyses. Only ten studies have 
directly compared serum bone and cartilage-turnover biomarkers in PsA and healthy 
controls (HC). Some of these studies proceeded to compare the same biomarkers in 
PsA and psoriasis-only patients without arthritis (PsC).  
• These studies have used a variety of study designs, classification systems for PsA 
patients, patient selection methods, laboratory methods, clinical end-points, and 
analysis techniques. Meta-analysis of the study results was therefore not possible. 
The majority of studies have had small sample size, and have likely been 
underpowered to detect a difference.  
• Several serum bone and cartilage-turnover biomarkers have shown signals for being 
able to differentiate PsA from HC, PsA from PsC, and PsC from HC. Some biomarkers 
have shown signals for association with demographic, clinical, radiographic and 
laboratory parameters (Figure 2.2).  
• The systematic review identified four candidate biomarkers that warrant further 
investigation for association with PsA and PsSpA in the first instance, and 
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subsequently for association with hard end-points such as radiographic outcome. 
These included: Dickopff 1 (Dkk-1), macrophage colony-stimulating factor (M-CSF), 
osteoprotegerin (OPG), and matrix metalloproteinase-3 (MMP-3).  
 
The results of this systematic literature review guided our methods and choice to 
investigate four candidate biomarkers in subjects (AS, PsSpA, pPsA, PsC and HC) 
enrolled in our study, as detailed in chapter 8 of this thesis. The systematic literature 
review has been published in a high-impact peer-reviewed journal, and it is hoped that this 
synthesis of the existing canon of knowledge and identification of areas of limited 
evidence, will inform and promote future serum biomarker research in the broader SpA 
research community. 
 
9.3.2 OBJECTIVE 3a: To investigate four candidate serum-soluble bone-turnover 
biomarkers as predictors of PsSpA occurrence, by comparison with PsA, AS, PsC 
cases and HC subjects  
 
Chapters 5 and 6 of this thesis showed that PsSpA is characterised by pathological new 
bone formation (osteoproliferation) and bone loss (resorption), with a differing pattern and 
magnitude to that seen in pPsA and AS. We hypothesised that this may be reflected by 
differing levels of serum-soluble bone-turnover biomarkers in PsSpA, pPsA, AS, PsC and 
HC. We therefore compared a large cohort of 651 well-characterised PsSpA, pPsA, AS 
and PsC cases with a group of matched HC to determine biomarkers of axial / peripheral 
inflammatory arthritis occurrence, and radiographic severity. The key findings of this study 
are listed below. 
• OPG appears to be a biomarker of axial disease in patients with SpA (pPsA, PsSpA 
and AS). It can therefore potentially be used to differentiate PsSpA from pPsA, and 
axial-SpA from peripheral-only SpA patients irrespective of psoriasis status.  
• Dkk-1 appears to be a biomarker of axial disease in SpA; with a pattern for increasing 
concentrations along a spectrum of increasing axial involvement. It can therefore 
potentially be used to differentiate PsSpA from AS patients, axial-SpA from peripheral-
only SpA patients irrespective of psoriasis status, and potentially PsSpA from pPsA 
patients.  
• Both M-CSF and MMP-3 appear to be biomarkers of arthritis, differentiating SpA 
(PsSpA, pPsA and AS) from HC and PsC. However, neither M-CSF nor MMP-3 
appear to differentiate various forms of SpA, i.e. pPsA, PsSpA and AS. 
 
These results in the context of clinical practice and future research will now be discussed. 
The results of this study indicate that Dkk-1 and OPG are biomarkers of axial disease in 
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SpA. In a clinical setting this may be useful for several purposes: to identify asymptomatic 
PsA patients with PsSpA; and to risk-stratify PsA patients with non-specific but suggestive 
inflammatory axial symptoms and / or subtle axial radiographic changes, who are likely to 
develop more florid PsSpA. Of note, in statistical models demonstrating these 
associations, cutaneous psoriasis was not found to be a significant covariate, indicating 
that the association of OPG and Dkk-1 with axial disease in SpA, is independent of 
cutaneous psoriasis.  
 
Dkk-1 also appears to differentiate PsSpA from AS, with Dkk-1 levels being higher in AS 
patients. Following the establishment of sensitivities and specificities for different 
concentrations, this may be helpful to differentiate patients with PsSpA from those with AS 
and coincidental psoriasis. These data also fuel the debate on whether PsSpA and AS are 
separate clinical entities determined by different pathological pathways, or the same 
disease determined by the same pathological pathway, with an altered phenotype 
expression due to genetic and / or environmental factors. 
 
Both M-CSF and MMP-3 appear to be biomarkers of arthritis. In a clinical setting this may 
be useful in several situations. Firstly, it not uncommon for PsA patients to initially present 
with non-specific symptoms, limited clinical signs of inflammatory arthritis, normal plain 
radiographs and / or normal acute-phase response. M-CSF and MMP-3 may help 
differentiate individuals with and without inflammatory arthritis in keeping with PsA. 
Secondly, if testing for these two laboratory biomarkers were readily available and 
inexpensive, they may be more appealing for use in clinical practice than further imaging 
with Magnetic Resonance Imaging (MRI) or ultrasound, which can be less readily 
available and dearer. Thirdly, M-CSF and MMP-3 could be investigated further in terms of 
their sensitivity and specificity for detecting subclinical arthritis in PsC patients; either in 
PsC patients with suggestive but non-specific symptoms, or as a wider screening tool for 
arthritis in all PsC patients. The early detection of subclinical arthritis in PsC patients, and 
potential for intervention to halt the full expression of PsA, is currently very topical in the 
SpA research community. In fact, this forms a component of one work-stream of 
investigation in the National Institute for Health Programme Grant ‘PROMPT’ study being 
led by the Royal National Hospital for Rheumatic Diseases in Bath. 
 
As reviewed in the Discussion section of chapter 8, some of the directions of associations 
were surprising at first glance. In particular, the higher concentration of serum total Dkk-1 
along the spectrum of increasing axial disease. One might expect serum Dkk-1 levels to 
be lower in AS and PsSpA, since both are diseases characterised by osteoproliferative 
changes, and a mouse model has shown that blockade of Dkk-1 results in sacroiliac joint 
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fusion [89]. However, my review of the AS literature, which is more extensive than the PsA 
literature, showed that serum total Dkk-1 levels are in fact higher in AS than HC, PsA and 
RA subjects. Our results can be explained from a biological perspective by the findings of 
a study by Daoussis et al. who found that Dkk-1 is dysfunctional in AS, in terms of its 
binding to the LRP6 receptor and its induction of beta-catenin-mediated intracellular 
events, that would normally have led to inhibited osteoblastogenesis and decreased bone 
formation. Unfortunately, corroborating this hypothesis by measuring functional Dkk-1 
levels and downstream effects of Dkk-1 using cell-cultures is beyond the remit of this 
thesis. However, this would certainly be a highly interesting avenue of further research. 
 
Similarly, from a biological perspective one might have expected OPG to be higher in 
axial-SpA, due to the osteoproliferative characteristics of these conditions. We found the 
converse to be true, with low OPG levels in axial-SpA compared with peripheral-only-SpA 
patients. The low serum OPG levels may be allowing unimpeded RANKL-mediated 
trabecular bone resorption. The circulating serum OPG measured in this study therefore 
likely reflects the more large-scale processes leading to bone mineral density loss (i.e. 
osteoporosis) often seen in AS, rather then smaller-scale osteoproliferative changes in the 
relatively small axial joints. 
 
9.3.3 OBJECTIVE 3b: To investigate four potential serum-soluble bone-turnover 
biomarkers as predictors of disease severity in patients with PsSpA  
 
Objective 3(a) of this thesis was to investigate four potential serum-soluble bone-turnover 
biomarkers (OPG, Dkk-1, MMP-3 and M-CSF) as predictors of disease severity in patients 
with PsSpA. Axial radiographs of the PsSpA and AS patients were scored using the 
PASRI, and compared with serum concentrations of each of the four biomarkers, 
separately for PsSpA and AS. The results of this comparison are summarised below. 
• Only OPG showed signals to be a biomarker of radiographic severity as measured by 
the PASRI-total score, and osteoproliferation burden as measured by the PASRI-
osteoproliferation domain score. However, this correlation was only demonstrated in 
PsSpA, and not in AS cases.  
• Levels of Dkk-1, M-CSF, and MMP-3 did not correlate with axial radiographic severity 
or morphology. 
 
The clinical significance and biological plausibility of these results remains to be 
determined, particularly since OPG showed correlation only in PsSpA patients, and 
because OPG levels were lower in patients with axial disease compared to those without 
axial disease and HC. 
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A biomarker of axial radiographic severity would be particularly useful. As discussed in the 
Introduction chapter of this thesis, a few clinical, laboratory and genetic prognostic 
markers of disease severity have been identified in PsA. Radiographic severity is a hard 
end-point, and therefore a good surrogate of overall disease severity. Patients with poor 
prognostic biomarkers could be targeted for more intensive pharmacological therapy in 
the form of biologics (e.g. anti-TNF), and closer clinical and radiographic monitoring for 
disease progression. Patients with few poor prognostic biomarkers could be saved the 
inconvenience and potential side-effects of intensive therapies. From a public health 
perspective, the use of dearer biologic therapies and more frequent healthcare utilisation, 
is more justified in patients with poor prognostic biomarkers, if these interventions are 
ultimately shown to alter disease course.  
 
Correlation of a serum biomarker with disease severity, but in particular a morphological 
feature such as osteoproliferation or erosion, may indicate the pathway leading to that 
pathology. For example, this may give insight into the biological pathways leading to 
osteoproliferation, and thus potential candidates within that pathway that may be 
amenable to pharmacological alteration, in order to correct the pathological imbalance in 
that axis. Just as when anti-TNF therapy was first introduced for the treatment of 
inflammatory arthritis, caution must be taken with this approach, as not to inadvertently 
cause side-effects such as cancer or tuberculosis. Altering one cytokine or chemokine in a 
complex biological pathway with multiple mediators, could have unwanted downstream 
effects. For example, altering the OPG-RANKL axis to inhibit osteoporosis, could 
inadvertently cause pathological high bone mass elsewhere.  
 
9.3.4 OBJECTIVE 3c: To investigate four potential serum-soluble bone-turnover 
biomarkers as predictors of PAM occurrence, by comparison with non-PAM PsA 
cases 
 
Given the severe and extensive bone-remodelling observed in PAM, characterised by 
peripheral articular severe deep bone resorption resulting in osteolysis, and by extensive 
osteoproliferation, one might expect bone biomarker concentrations to be different in PAM 
compared with non-PAM. We tested this hypothesis, and found that: 
• None of the four biomarkers tested were predictors for the occurrence of PAM in the 
PsA cases.  
 
As discussed in more detail in chapter 8, this is most likely explained by a combination of 
two reasons. Firstly, the amount of PAM-related bone remodelling taking place in the 
relatively small articular joints of the hands / feet is insufficient to alter circulating serum 
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levels of bone biomarkers. Secondly, the PAM patients had blood sampling performed 
during the refractory phase of PAM, once the monophasic destruction of PAM had 
passed, and only small-scale remodelling in keeping with general PsA was active. Our 
results from chapter 7, showing rapidly progressive osteolysis soon after the onset of 
PAM, followed by a tapering of activity, would certainly support this reasoning. The search 
for a biomarker of PAM occurrence would have been improved by a longitudinal rather 
than cross-sectional study design. However, given the rarity and natural history of PAM as 
determined in chapter 7 of this thesis, such a study would require two-yearly interval 
serum biomarker testing and imaging over a period spanning 20-40 years. This is certainly 
beyond the remit of the current thesis, and such a study would be logistically challenging 
and costly to perform. However, this observation does underline the importance of our 
serum biomarker study in PAM. Few other centres have as many well-characterised 
robustly-classified PAM cases as in this study, and therefore no other study has compared 
serum bone-biomarker levels in PAM and non-PAM PsA cases. Unlike time-varying 
variables such as serum biomarkers, genetic variants do not change over time and 
therefore do not necessarily require a longitudinal study to investigate them as biomarkers 
for PAM occurrence. Haroon et al. took advantage of this fact and showed an association 
between osteolysis, a radiographic surrogate of PAM, and a variant of the HLA- 
C*02:02:02 locus [106]. As will be discussed under subheading 9.5 of this thesis chapter, 
we also plan to compare both HLA- and non-HLA variants in our PAM and non-PAM PsA 
cases. Compared with our serum analyses that comprised 19 PAM  and 182 non-PAM 
cases, our genetic analyses will comprise up to 38 PAM cases, and up to 480 non-PAM 
PsA. The analyses will therefore be better powered to detect differences. 
 
Given the ferocity of destruction resulting in hand / feet deformity and disability, as shown 
in chapter 7, the identification of a biomarker of PAM occurrence in PsA would have been 
particularly useful clinically. PsA patients with serum biomarker levels heralding the onset 
of PAM could be targeted for more intensive therapies to either halt or impede PAM 
progression. Biomarkers could also prompt the need for closer clinical and radiographic 
monitoring. Although not designed to address the specific question, the results of chapter 
7 indicate that anti-TNF therapy does not prevent the onset of PAM. Given the rarity of 
PAM, few clinical trials have robustly reported the clinical efficacy of pharmacological 
therapies in PAM. As discussed in chapter 7, the pathogenesis of PAM has yet to be 
determined. A serum biomarker of PAM occurrence may give insight into the pathology of 
PAM, inform proof-of-concept pharmaceutical trials for PAM, and potentially serve as a 
biomarker for disease monitoring in clinical practice and / or clinical trials.  
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9.3.5 The importance of biomarker research in spondyloarthritis 
 
During the process of testing potential covariates to include in the regression models 
comparing serum biomarker levels in the different groups, our exploratory analyses 
demonstrated that concentrations of some of the four serum biomarkers correlated with 
axial disease activity as measured by the ASDAS. The conclusions that can be drawn 
from these exploratory analyses are limited by the cross-sectional nature of this study. 
The best way to explore the relationship would be through a longitudinal study with 
biomarker concentrations and ASDAS measured at several time-points, both during a 
period of no treatment alteration, and also perhaps before and after the commencement of 
anti-TNF therapy. This would give insight into three other potential utilities of biomarkers: 
monitoring disease, monitoring treatment response, and predicting response to treatment. 
The identification of biomarker predictors of treatment response is currently an important 
research agenda in SpA and rheumatology in general. Up to 30-40% of PsA and AS 
patients do not respond to biological therapies [25, 26, 334, 373], and even the six-month 
period trialing a biologic-therapy before assessing efficacy, can be costly. C-reactive 
protein (CRP) does not hold the same value for monitoring disease activity in PsA and AS, 
as it does in rheumatoid arthritis (RA). In PsA and AS it is often within the normal range, 
and is less responsive to change in axial disease activity [48]. An alternative serum 
biomarker to CRP to monitor disease activity, progression, and treatment response would 
therefore be very valuable in both clinical and research settings. Such a serum biomarker 
would hopefully be more available and cheaper than magnetic resonance imaging, and be 
more sensitive to change than plain radiographic progression which can take several 
years. 
 
Our analyses of covariates to include in the regression model for the primary analyses 
indicate that there is: a significant and positive correlation between ASDAS and M-CSF in 
AS and PsSpA; a significant and positive correlation between ASDAS and both MMP-3 
and Dkk-1 in AS; and a significant and negative correlation between ASDAS and OPG in 
AS. In addition, our analysis of covariates also found that there is: a significant and 
positive correlation between CRP and MMP-3 in pPsA, PsSpA and AS; a significant and 
positive correlation between CRP and both M-CSF and Dkk-1 in AS; and a significant and 
negative correlation between CRP and OPG in AS. Whilst these exploratory analyses 
suggest that some of these biomarkers are promising biomarkers of axial disease activity, 
more investigation is required to estimate the clinical usefulness of these biomarkers. 
Correlation expressed as a regression coefficient (beta) or correlation coefficient 
(Spearman rho) is not a measurement of the clinical usefulness of a candidate biomarker. 
The same patients would need to be tested longitudinally at multiple time-points with 
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paired serum biomarker and ASDAS measurements, and an estimation made of the 
sensitivity, specificity, and positive and negative predictive values of the test. Since CRP 
comprises one domain of the ASDAS and is already used as a biomarker for SpA, any 
new biomarker must be compared against CRP using standard receiver operating 
characteristic (ROC) plots. The area under the curve (AUC) of these plots is a measure of 
the information provided by the candidate biomarker. Since four of the five domains 
comprising the ASDAS, are completed by the patient and therefore subjective, 
characteristics of patient populations is an important consideration. Therefore, to validate 
the new biomarker test for use in other centres or countries, the same study methods 
would need to be repeated in independent cohorts nationally and internationally. 
 
Chen et al. assessed correlation between MMP-3 and axial disease activity as measured 
by the BASDAI [330]. Rather than using MMP-3 concentrations from healthy controls as 
threshold cut-offs in AS patients, they used the cut-off value selected by ROC analysis 
and the median value as the threshold. Their statistical modeling was based on methods 
used in large-scale epidemiology studies in cardiology, showing that subjects with high-
sensitivity CRP levels, previously thought to be normal based on thresholds in the general 
population, can also pose an excess risk of cardiovascular disease [374]. 
 
Even if the concentration of a biomarker is no different in the diseased compared with 
healthy state, the biomarker can still have utility in clinical practice. For example, serum 
CRP concentrations in apparently healthy individuals, are used as a prognostic marker for 
future ischaemic heart disease [375]. Our results showing no difference in M-CSF 
concentrations in HC and PsC cases, but difference in concentrations in PsC compared 
with PsA, gives M-CSF clinical utility in PsC. Similarly, M-CSF could still be used to 
monitor response to anti-TNF therapy in a longitudinal study with serial M-CSF 
measurements before and after the commencement of anti-TNF therapy. 
 
9.3.6 Other promising serum-soluble biomarkers in PsSpA 
 
Several other biomarkers warrant further investigation in PsSpA. Once reliable 
commercially available assays for RANKL are available, serum RANKL levels, as well as 
the ratio of RANKL:OPG may be more indicative of axis dysregulation than either 
biomarker alone [300, 302, 342]. Neoepitopes of type 2 collagen formation (CPII) and 
degradation (C2C), and in particular the ratio of  CPII:C2C have shown promise as useful 
biomarkers in PsA [88] and AS [376]. Sclerostin is another Wnt antagonist, and its 
expression is closely linked to Dkk-1 expression. In AS patients, low levels of sclerostin 
have been shown to be associated with syndesmophyte formation and progression [86, 
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293, 377]. During the systematic literature review of serum bone and cartilage-turnover 
biomarkers, it was noted that sclerostin has never been investigated in PsA or PsSpA. R-
Spondin 1 is a Wnt agonist, and has been shown to protect against inflammatory bone 
damage by modulating the Wnt pathway in a mouse model of arthritis [294]. In vivo, R-
Spondin 1 promoted osteoblast differentiation and bone formation while blocking 
osteoclast development, thereby contributing to the integrity of joints during inflammatory 
arthritis. Both sclerostin and R-Spondin 1 therefore warrant further investigation as 
biomarkers in PsSpA. TGF-β is involved in bone and matrix turnover as well as new bone 
formation in AS, and has shown some utility in the assessment of treatment efficacy in AS 
[376, 378], and may also be a useful biomarker in PsSpA. 
 
9.3.7 Systemic-circulating versus tissue-specific biomarkers 
 
The measurement of circulating serum-soluble biomarkers, may be too simplistic an 
approach for biomarker research, and not sufficiently take into consideration the complex 
downstream interplay of signaling molecules such as cytokines and chemokines. Tissue-
specific biomarkers levels may be far more informative than circulating serum biomarker 
levels. For example, serum OPG may primarily be a surrogate of OPG levels in large 
bones, rather than small-scale OPG-mediated pathology in the entheses and vertebral 
corners. Therefore, OPG levels in entheseal structures may be far more useful to 
measure. In SpA, elevated serum MMP-3 may primarily be a consequence of peripheral 
arthritis, rather than axial arthritis. Therefore any comparison between diseases, e.g. AS 
with PsSpA, may need adjustment for the presence and degree of peripheral arthritis. 
Adjusting for the degree (severity) of peripheral arthritis is difficult and may not even be 
possible due to the varying sizes of joints and grades of arthritis activity. However, without 
such adjustment MMP-3 levels may falsely appear no different in AS and PsSpA cases. 
The measurement of MMP-3 levels in axial tissue would circumvent the need to adjust for 
peripheral arthritis presence and severity. In addition, the influence of a biomarker on 
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9.4 SUMMARY OF THE KEY FINDINGS OF THIS THESIS 
The work of this thesis has found differences and similarities between PsSpA, AS and 
pPsA patients, as well as between PAM and non-PAM patients. These are summarised 









Figure 9.2. The similarities and differences between PsSpA and pPsA  
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9.5 CURRENT DEVELOPMENTS & FUTURE RESEARCH WORK 
Experts on serum biomarker research suggest that either a panel of biomarkers or the 
ratio of biologically-related biomarkers, rather than a single biomarker, may be most 
informative [379-381]. The regression models used in chapter 8 did test for interaction 
between serum biomarkers, and some signals were detected. However, the ability of a 
panel of biomarkers to differentiate between the five subject groups was not formally 
tested. I plan to do this after seeking advice on the mathematical methods to achieve this.  
  
Receiver operating characteristic (ROC) curves were used by Chandran et al. to 
determine the serum concentration cut-off for optimal sensitivity and specificity to 
differentiate PsA from PsC [88]. I plan to do the same. For example, to determine the best 
concentration cut-off for Dkk-1 / M-CSF to differentiate PsSpA from AS, and M-CSF / 
MMP-3 to differentiate PsA from PsC. 
 
As discussed above, the measurement of tissue-specific biomarkers appears to offer 
several significant advantages over systemic-circulating biomarkers. My longer-term 
research strategy is therefore to investigate tissue-specific biomarkers as predictors of 
SpA-subphenotype occurrence, severity and disease activity. I have made some progress 
in this research through the acquisition of skills in musculoskeletal ultrasound, taking 
ultrasound-guided synovial biopsy, and involvement in international multi-centre studies 
investigating synovial tissue biomarkers in rheumatoid arthritis. I intend to apply these 
research skills and principles to synovial and / or entheseal tissue biomarker research in 
SpA. 
 
This thesis has focused on axial disease in SpA. Almost all the PsA cases also have 
peripheral arthritis. This period of research towards a PhD was part funded by an 
Investigator Initiated Research Grant (iCRP-2013) from Pfizer Limited. Part of the remit of 
that research grant was to investigate serum-soluble bone-biomarkers of peripheral 
radiographic disease. During the last year I have therefore scored the most recent hands 
and feet radiographs of the 201 PsA patients enrolled in the ADIPSA1 study, using the 
modified van der Heijde scoring tool [145] and Ratingen scoring tool [249], both of which 
have been validated for use in PsA. I will therefore investigate the relationship between 
Dkk-1, OPG, M-CSF, MMP-3 and these peripheral radiographic scores in terms of overall 
severity, as well as severity of erosion, osteoproliferation, and joint-space narrowing.  
 
As mentioned earlier, a key unknown aspect of PAM is the chronology of pathological 
events leading to the osteolysis of PAM. The radiographic scoring conducted in the study 
  276 
 
included domains for osteolysis, erosion, joint space narrowing, osteoproliferation, 
periostitis, osteopaenia and tuft resorption. Chapter 7 only reports the natural history of 
PAM based on change in osteolysis score. Within the constraints of this study design and 
data available, I plan to investigate the type of pathological changes that occur before the 
onset of osteolysis in a particular joint. My anecdotal observations having read the 
radiographs longitudinally, is that there is progressive joint space narrowing before onset 
of osteolysis, and perhaps no progressive erosion or osteopaenia. However, after onset of 
osteolysis bone remodelling does appear to occur in the form of osteoproliferation, 
perhaps as a compensatory mechanism to correct abnormal joint loading and movement. 
Periostitis seemed very rare in the PAM cases. This will need to be tested mathematically. 
 
A review of the literature on the genetics of PsSpA and PsA is detailed in the Introduction 
chapter of this thesis. Apart from variants of HLA-B27, other genetic biomarkers have not 
been reported in this thesis. This will be undertaken as part of my post-doctoral research. 
The 402 patients enrolled in the ADIPSA1 study were consented for DNA collection and 
testing. As mentioned in chapter 4, these patients’ DNA has been sequenced for HLA-B 
and HLA-C variants, in more detail than the HLA-B27 data presented in this thesis. Over 
the forthcoming year, this genetic sequencing data of these 118 PsSpA, 127 pPsA and 
157 AS cases will be compared to determine if specific HLA- genotypes or haplotypes 
associate with PsSpA, or its radiographic and / or clinical phenotype expression. 
Comparison of our results will be made with two recently published investigating the same 
[106, 382]. In addition, 35 of the 36 PAM patients identified in chapter 7 of this thesis, also 
consented through the LOPAS1 [38] study to have their DNA sequenced for HLA-B and 
HLA-C variants. A recent study showed an association between osteolysis (a marker of 
PAM) and HLA-C02:02:02 [106]. HLA- genotypes and haplotypes will therefore be tested 
for association with PAM in our cohort. 
 
As mentioned above, this period of research towards a PhD was part funded by the iCRP-
2013 grant from Pfizer Limited, as part of the ADIPSA2 study. Part of the remit of that 
research grant was to investigate genetic biomarkers of axial and peripheral radiographic 
disease. During the last year I have therefore scored the most recent axial, hands and feet 
radiographs of 515 PsA patients (201 PsA patients enrolled in the ADIPSA1 study and 
314 PsA patients enrolled in the LOPAS1 study) using the PASRI (for axial disease), 
mSASSS (for axial disease), modified van der Heijde scoring tool (for peripheral disease) 
[145] and Ratingen scoring tool (for peripheral disease) [249]. Patients enrolled in 
ADIPSA2 study consented (through ADIPSA1 and LOPAS1) to have their DNA 
genotyped. This was performed in November 2014 by Professor Anne Barton’s team at 
the Arthritis Research U.K. Epidemiology Unit in Manchester (U.K.) using the Illumina 
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Infinium HumanCoreExome BeadChip, which genotypes 500,000 single nucleotide 
polymorphisms (SNPs) in the exome and inter-genic regions. Informed by the published 
literature, a candidate gene approach will be used to identify genetic loci associated with 
PsSpA, radiographic axial disease severity, peripheral radiographic morphology (erosion 
and osteoproliferation) and peripheral radiographic severity. Some preliminary analyses 
have already been undertaken, and will continue in the forthcoming year as part of post-
doctoral research. An abstract of some of this work has been accepted for poster 
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9.6 FINAL CONCLUSIONS 
To conclude, the work of this thesis has identified several clinical biomarkers, imaging 
biomarkers, serum-soluble biomarkers and genetic biomarkers that differentiate PsSpA 
from pPsA and AS. Given that PsSpA has its own discrete clinical and biomarker 
signature, its clinical management and research should be tailored from that of pPsA and 
AS. PsSpA affects a significant proportion of PsA patients. PsSpA is not simply AS with 
coincidental psoriasis, nor is PsSpA a milder version of AS. This thesis has shown that 
PsSpA involvement is as disabling and clinically impactful as AS; perhaps in part because 
PsSpA progresses for a long time period, and brings with it a burden of peripheral arthritis 
[201]. PAM was found to be associated with PsSpA, and in addition, this thesis identified 
clinical biomarkers of PAM occurrence and radiographic progression. Taken together, this 
thesis indicates that PsSpA is on a spectrum of musculoskeletal disease, in between 
pPsA and AS; with PsSpA comprising a continuum itself, and with a phenotype 
expression related to disease duration. It is hoped that recognition of these facts will 
prompt the inception of an international consensus classification system for PsSpA, for 
which there is burning need. The advent of new imaging techniques, laboratory markers, 
and epidemiological studies on PsSpA should facilitate this process. Ultimately this may 
further the effort for stratified and personalised medicine. Gaps in the current canon of 
knowledge on PsSpA and PAM have been identified by this body of work and will 
hopefully inform future research. Some of these will be addressed in my future post-
doctoral research as described above. Other identified topics will hopefully be investigated 
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 10 APPENDICES 







Please place patient label here
ADIPSA Outcome Measures
Please place an "X" in the box to indicate your answer to each question relating to the past 1 week.
1. How would you describe the overall level of fatigue/tiredness you have experienced?
0 1 2 3 4 5 6 7 8 9 10
NONE VERY SEVERE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0hr 2 or
more hrs
0 1 2 3 4 5 6 7 8 9 10
2. How would you describe the overall level of neck, back or hip pain you have had?
3. How would you describe the overall level of pain/swelling in joints other than neck, back or hips you have had?
4. How would you describe the overall level of discomfort you have had from any areas tender to touch or pressure?
5. How would you describe the overall level of morning stiffness you have had from the time you wake up?
6. How long does your morning stiffness last from the time you wake up?
1 hr
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
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Please place a "X" in the box to indicate your level of ability with each of the following activities during the
LAST 1 WEEK.
1. Putting on your socks or tights without help or aids (e.g. sock aid).
2. Bending forward from the waist to pick up a pen from the floor without an aid.
3 Reaching up to a high shelf without help or aids (e.g. helping hand).
4. Getting up out of an armless dining room chair without using your hands or any other help.
5. Getting up off the floor without help from lying on your back.
6. Standing unsupported for 10 minutes without discomfort.
7 Climbing 12-15 steps without using a handrail or walking aid.
8. Looking over your shoulder without turning your body.
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
BASFI
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5858467395








9. Doing physically demanding activities (e.g. physiotherapy exercises, gardening or sports).
10. Doing a full day's activities, whether it be at home or at work.
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
EASY IMPOSSIBLE
0 1 2 3 4 5 6 7 8 9 10
1. Based on your assessment, please place a "X" in the box to indicate what is the amount of back pain at night
that     you experienced during the last week?
2. Based on your assessment, please place an "X" in the box to indicate what is the amount of back pain at any
time that you experienced during the last week?
0 1 2 3 4 5 6 7 8 9 10
NO PAIN MOST SEVERE PAIN
0 1 2 3 4 5 6 7 8 9 10
0 1 2 3 4 5 6 7 8 9 10
NO PAIN MOST SEVERE PAIN
0 1 2 3 4 5 6 7 8 9 10
1. Please place an 'X' in the box  to indicate your overall assessment of your disease activity over the last week.
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Section 1 – Health Assessment questionnaire
We are interested in learning how your illness affects your ability to function in daily life. Please feel free to
add any comments at the end of this form.
Please tick the one response which best describes your usual abilities over the past week.
1)    Dressing and Grooming
Are you able to:
- Dress yourself including shoelaces and doing buttons?
- Shampoo your hair?
2)    Rising
Are you able to:
- Stand up from an armless straight chair?
- Get in and out of bed?
3)    Eating
Are you able to:
- Cut your meat?
- Lift a full cup or glass to your mouth?
- Open a new carton of milk (or soap powder)?
4)     Walking
Are you able to:
- Walk outdoors on flat ground?














Devices used for dressing (button hook, zipper pull, long handled shoe horn etc)
Built-up or special utensils
Special or built-up chair
Other (specify)




HAQ     (Health Assessment Questionnaire)
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Please tick the one response which best describes your usual abilities over the past week.
1)    Hygiene
Are you able to:
- Wash and dry your entire body?
- Take a bath?
- Get on and off the toilet?
2)    Reach
Are you able to:
- Reach and get down a 5lb object (e.g. bag of 
potatoes) from just above your head?
- Bend down to pick clothing from the floor?
3)    Grip
Are you able to:
- Open car doors?
- Open jars which have previously opened?
- Turn taps on and off?
4)     Activities
Are you able to:
- Run errands and shop?
- Get in and out of a car?












Jar opener (for jars 
Previously opened)
Bath Rail
Long-handled appliances for reach
Other (specify)
Please tick any categories for which you usually need HELP FROM ANOTHER PERSON:
Hygiene
Please tick any AIDS or DEVICES that you usually use for any of these activities:
Reach Gripping and opening things Activities
Dressing & grooming Rising Eating Walking
Hygiene Reach Grip Activity
For office use only
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LEI     (Leeds Enthesitis Index)
 
THE FOLLOWING WILL BE PERFORMED
WITH THE RESEARCHER







1. Tragus to wall distance
2. Lateral spinal flexion







Please place a 'X' for any site  that is  tender. Right     Left
Lateral epicondyle humerus
Medial femoral condyle
Achilles tendon insertion Score
.
.
Left        Degrees Right        Degrees













1st                       2nd
RIGHT


























































































































mNAPSI         (modified Nail Psoriasis Severity Index)
R1    R2     R3      R4       R5             L1        L2      L3        L4       L5
CUMULATIVE TOTAL (Range 0-140)
Onycholysis     (0-3)
Pitting         (0-3)
Crumbling       (0-3)
Leukonychia     (0-1)
Splinter haem   (0-1)
Hyperkeratosis  (0-1)
Red spot Lunula (0-1)
Global assessment of nails - PATIENT
Global assessment of nails - RESEARCHER
0 100
0 100





















x 0.1 =   + +  =
x 0.2 =   + +  =
x 0.3 =   + +  =
x 0.4 =   + +  =
Extent          Total            {            SEVERITY                   }             Total         Total Extent x





.PASI (PsA Skin Index)=extent x severity
                       (max 72)
PASI     (Psoriasis Area Severity Index)
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1.25mm elevationVery thick scaleDeep red or purple4 – very severe
1mm elevationThick white scaleVery red3 – severe
0-0.75mm elevationModerate scaleDarker pink or red2 – moderate
0-0.5mm elevationFine white scalePink or light red1 – slight































Crohn's / Ulcerative Colitis
Family History of SpA
(Ank Spond, PsA or uSpA)
Has the patient experienced any of the following?
Having excluded spinal fracture, intervertebral disc disease & fibromyalgia; complete  the following:
Clinical criterion
1. Inflammatory low back pain & stiffness    3m that 
          -improves with exercise
          -not relieved by rest
End of researcher completed Proforma
2. Reduced motion of the lumbar-spine in both sagittal & frontal planes
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Inflammatory pain = Pain with stiffness that is worse first thing after waking or after sitting down for an hour; it
improves later in the day with some activity / exercise. Lasts for >30 min each time.
Chest wall pain = Pain / swelling either side of the breast bone
Enthesitis = Pain / swelling where ligaments join bone e.g. tennis elbow, golfer's elbow, Achilles tendon, front
of knee cap
Plantar fasciitis = Pain on the sole of the foot near the heel base
Dactylitis = When a finger / toe swells up along its entire length "like a sausage", with a shiny stretched skin
appearance
Iritis = Red painful eye that affects vision. Lasts for a week or more. Often needs steroid eyedrops to settle.
Crohn's / Ulcerative colitis = Bloody diarrhoea and weight loss for several weeks / months.
ASIN:
2170467399








PASRI     (Psoriatic Arthritis Spondylitis Radiology Index)
Scoring Key for PASRI & mSASSS 
   SIJ                          Vertebrae     Posterior elements 
   0 = Normal         0 = No abnormality     0 = No fusion 
   1 = Suspicion of sacroiliitis        1 = Erosions, sclerosis, or squaring              1 = Fusion 
   2 = Sclerosis either side of joint                        2 = Non-bridging syndesmophyte 
   3 = Joint space widening, erosions or partial ankylosis     3 = Bridging syndesmophyte 
   4 = Complete joint ankylosis 
ASIN:
Please place patient label here
SI joints (0-4)









(CS) TOTAL      (range 0-24)





TOTAL    (range 0-4)
Right     Left     Total Lumbar spine (0-3 each, using AP & lateral views)
Lower T12











TOTAL               (range 0-36)
Posterior Lumbar elements 







TOTAL    (range 0-6)
FINAL SCORE                       (range: 0-78)
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mSASSS     (modified Stoke Ankylosing Spondylitis Spinal Score)
Cervical spine (0-3 each anterior site, lateral views only)
        Lower C6
        Upper C7
        Lower C7
        Upper T1
THIS TOTAL                      (range 0-12)
(CS) TOTAL (from PASRI)                     (range0-24)
TOTAL               (range 0-36)
Lumbar spine
Use score from PASRI; from Lower T12 - Upper S1
TOTAL                (range 0-36)
FINAL SCORE       (range: 0-72)
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Does patient fulfill N.Y. criteria for A.S.?
(Radiological criterion     1 clinical criterion) Yes No
Radiological criterion
Has radiographic sacroiliitis                        No
 
                                                                                 Grade    2 bilaterally 
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PATIENT INFORMATION SHEET 
 
Study Title: 




You are being invited to participate in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information and ask for anything that is unclear to be explained. 
 
• Part 1 tells you the purpose of the study and what will happen to you if you take part. 




What is the purpose of the study? 
Individuals with Psoriatic Arthritis or Ankylosing Spondylitis can experience spinal symptoms and 
damage. Although the study title refers to ‘Psoriatic Arthritis’, we are also studying patients with 
Ankylosing Spondylitis so that we can compare and contrast. 
• Firstly, the ADIPSA study will investigate if people with Psoriatic Arthritis or Ankylosing 
Spondylitis have similar / different symptoms, X-ray changes, altered spinal movement, impact 
on lifestyle or damage to the nails, skin or joints of the hands and feet. 
• The second aim of the ADIPSA study is to investigate how proteins dissolved in the blood 
(soluble serum biomarkers) or genes (molecules contained in all the body’s cells that help 
determine how we look or if we will develop certain diseases) contribute to this. 
Overall, this study will help us understand the similarites and differences between Psoriatic Arthritis 
and Ankylosing Spondylitis, so that we may care for patients in the best possible way.  
 
Why have I been chosen? 
You have been chosen to participate as you have a diagnosis of either Psoriatic Arthritis or 
Ankylosing Spondylitis. 
 
Do I have to take part? 
It is up to you to decide. You do not have to take part. If you do not want to take part, it will not affect 
the care you receive now or in the future. However, if you do decide to take part, you can keep this 
sheet and will be asked to sign a consent form. You are still free to withdraw at any time without 
giving a reason. Your participation will not interfere with the standard of care you receive.  
 
What will happen to me if I take part? 
Your participation will involve the following: 
(i) Agreement to have routine measurements of your spine, hands, feet & skin performed. 
(ii) Agreement to complete four questionnaires about how your arthritis affects you. 
(iii) Agreement to have a blood sample taken for further testing. 
(iv) Agreement for a member of the ADIPSA research team to look at your medical notes or X-
rays that you have had previously, to look for evidence of damage to your joints.  
It will take approximately 30-45 minutes to complete these tasks, immediately before your next 
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What do I have to do? 
• If you agree to take part in the study, a member of the ADIPSA research team (Doctor, Nurse or 
Physiotherapist) will ask you to sign a consent form, perform the measurements, give you the 
questionnaires and arrange for a blood sample to be taken. 
• Most of these tests would be performed as part of the treatment that you would receive anyway, 
regardless of whether or not you choose to participate in this study.  
• No extra X-rays will be taken. 
 
What will the blood sample be tested for? 
The blood sample will be tested for markers of inflammation in the blood (soluble serum biomarkers), 
which are sometimes present in patients with Psoriatic Arthritis or Ankylosing Spondylitis. The blood 
sample will also be tested for genes that may make you more / less likely to experience particular 
symptoms, for example inflammatory back pain. 
 
What are the possible benefits of taking part? 
We cannot promise that the results of the study will help you directly, but the information we get 
might improve the treatment of people with Psoriatic Arthritis and Ankylosing Spondylitis. 
 
Will the research influence the treatment I receive? 
The research does not alter the treatment you receive. Your specialist will start and stop treatments 
as determined by your clinical condition. 
 
Will my taking part in the study be kept confidential? 
Yes. We follow ethical and legal practices and all the information about your participation in this 
study will be kept confidential. The details are included in Part 2. 
 
Who is organising and co-ordinating the study? 
The study is being co-ordinated by Professor. Neil McHugh, Dr Raj Sengupta and Dr Ellie 
Korendowych. 
 
Who is funding the study? 
Pfizer Limited are funding this study. Pfizer do not have any commercial interest in the study 
outcome. 
  
This completes Part 1 of the information sheet. 
If the information in Part 1 has interested you and you are considering participation, please continue 




What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, we will destroy all of your identifiable samples, but we will need to 
use the data collected up until your withdrawal. 
 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential. You will be assigned a unique ADIPSA study number (ASIN), so that your name is kept 
confidential and separate from the tests, measurement or questionnaires you complete. 
 
Clinical information about you will be collected and compared with genetic data. The individuals 
performing the genetic tests at the Arthritis Research U.K. centre in Manchester, will have no access 
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What will happen to the blood sample I give? 
The blood sample will be tested either immediately or stored in the Bath Institute for Rheuamtic 
Diseases for further testing as part of this study.  
• DNA (a molecule that contains your genes) will be extracted and sent to the Arthritis Research 
U.K. centre in Manchester for further genetic testing. The DNA will be analysed but the tests 
conducted will not produce results with clinical or familial significance. Samples will be stored 
with a code, so that they will be anonymous to researchers conducting the DNA analysis. 
However, we know which code belongs to which participant, so that they can be linked if needed. 
• The blood sample with be tested on-site for proteins (soluble serum biomarkers) that may affect 
the type of disease you have. 
 
What physical measurements wil be taken? 
The researcher will count the number of tender / swollen joints you have, if some of the sites where 
tendons attach to your bone are tender, look to see if your nails / skin are affected and perform 
measurements of your back. The back measurements include the distance between your ear and a 
wall, how far you can bend forward / side-ways, how far you can turn your head, how deep you can 
breath in and the distance between your ankles when spread apart.  
 
What will happen to the results of the research study? 
Results of the ADIPSA study will be published in scientific journals and presented at national and 
international rheumatology / genetics meetings. You will never be identified. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
the Frenchay Research Ethics Committee. 
 
 
For more information please contact: 
 
The study co-ordinator:  
Dr Deepak Jadon  
on 07870522111 or 01225 465941 ext 269 
or email: Deepak.Jadon@rnhrd.nhs.uk 
 
Professor. Neil McHugh on 01225 465941  
Dr Raj Sengupta on 01225 473442 
Dr Ellie Korendowych on 01225 465941 
 
Thank you for taking time to read the information sheet,  
which you should keep for future reference. 


























     
     
 
  
     
     






















________________________            _______________________           _______________ 




________________________            _______________________        _______________ 
Name of researcher taking consent  Signature         Date       
1. I confirm that I have read and understand the Patient Information Sheet dated 
24/04/2012 (version 2) for the ADIPSA study. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time up to the point at which my data is anonymised without my medical care 
or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected during 
the study, may be looked at by regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records, but understand that strict confidentiality 




4. I agree to having a blood sample taken. 
 
 
5. I agree to having my blood sample stored at the Bath Institute for Rheumatic 




6. I agree for my blood sample to undergo DNA analysis. 
 
 
7. I agree to take part in the ADIPSA study. 
































Please place patient label here
RNHRD:Date Of Xray / /
Bath Radiographic Arthritis Mutilans Score " BRAMS"
Date Of Birth / /
































































































































































































































RNHRD:Date Of Xray / /4860036906
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